var images_info;if (!images_info) images_info =[]; images_info["104"]={"104000":{"type":"graphic_picture","displayName":"Lateral shoulder abduction to 90 degrees","title":"Lateral shoulder abduction to 90 degrees","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral shoulder abduction to 90 degrees</div><div class=\"cntnt\"><img style=\"width:314px; height:723px;\" src=\"images/SM/104000_Lat_shldr_abdctn_90_dgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used to strengthen the muscles involved in shoulder abduction. The patient stands with their arm at their side, elbow straight, and palm against their lateral thigh. The patient raises their arm laterally, keeping the palm down, until it reaches 90 degrees of lateral shoulder abduction (shoulder height) and then returns it to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104000 Version 1.0</div></div></div>"},"104001":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph lymphangitic carcinomatosis","title":"Chest radiograph of a patient with lymphangitic carcinomatosis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a patient with lymphangitic carcinomatosis</div><div class=\"cntnt\"><img style=\"width:567px; height:654px;\" src=\"images/PALC/104001_Chst_rdgrph_lmphng_crcnmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This frontal chest radiograph from a 53-year-old woman with lymphangitic carcinomatosis due to malignant melanoma demonstrates characteristic findings of diffuse reticular and nodular opacities with mediastinal (aortopulmonary window, arrow) and right hilar (arrowhead) lymphadenopathy. Small bilateral pleural effusions are also present.</div><div class=\"graphic_reference\">Reproduced from: Biswas A, Sriram PS. Getting the whole picture: Lymphangitis carcinomatosis. Am J Med 2015; 128:837. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104001 Version 2.0</div></div></div>"},"104002":{"type":"graphic_picture","displayName":"Shoulder scaption exercises in external rotation","title":"Shoulder scaption exercises in external rotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder scaption exercises in external rotation</div><div class=\"cntnt\"><img style=\"width:433px; height:769px;\" src=\"images/SM/104002_Shldr_scptn_exrcs_extr_rtt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown&nbsp;can be used as&nbsp;part of an exercise program for throwers and other overhead athletes. To perform the exercise, the patient stands with their elbow straight and thumb up (ie, extended like a hitchhiker) and then raises their arm to shoulder level and no further. Movement occurs in the scapular plane, about 30 degrees anterior to the frontal plane. The patient maintains the arm at shoulder height for 2 seconds and the slowly lowers it to the starting position. Resistance may be added as strength increases.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104002 Version 1.0</div></div></div>"},"104003":{"type":"graphic_diagnosticimage","displayName":"CT scan of lymphangitic carcinomatosis","title":"Computed tomography imagesÂ of a patient with lymphangitic carcinomatosis (Images A&B)","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Computed tomography images&nbsp;of a patient with lymphangitic carcinomatosis (Images A&amp;B)</div><div class=\"cntnt\"><img style=\"width:471px; height:629px;\" src=\"images/PALC/104003_CT_scn_lmphngtc_crcnmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These axial images of a contrast-enhanced CT scan of the chest are from a 53-year old woman with lymphangitic carcinomatosis due to malignant melanoma. Image (A) shows extensive reticular markings (interlobular septal thickening) and diffuse ground glass opacities in the lung parenchyma in a pattern known as \"crazy-paving\". Mediastinal adenopathy (precarinal) and small bilateral pleural effusions are also noted. Image (B) shows a similar \"crazy-paving\" appearance with denser consolidative opacities in the dependent lower lobes. Hilar and mediastinal adenopathy and bilateral pleural effusions are also present.</div><div class=\"graphic_reference\">Reproduced from: Biswas A, Sriram PS. Getting the whole picture: Lymphangitis carcinomatosis. Am J Med 2015; 128:837. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104003 Version 1.0</div></div></div>"},"104005":{"type":"graphic_picture","displayName":"Side-lying shoulder external rotation","title":"Side-lying shoulder external rotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Side-lying shoulder external rotation</div><div class=\"cntnt\"><img style=\"width:438px; height:726px;\" src=\"images/SM/104005_Side_lyng_shldr_extrnl_rttn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used to strengthen the rotator cuff muscles involved in shoulder external rotation. To perform the exercise, the patient lies on their uninvolved, or non-throwing, side. The throwing arm begins at the side of the body with the elbow bent to 90 degrees. While keeping the elbow of throwing arm fixed to their side, the patient externally rotates their shoulder, holds the rotated position for two seconds, and then slowly lowers the arm to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104005 Version 1.0</div></div></div>"},"104008":{"type":"graphic_picture","displayName":"Prone shoulder abduction with external rotation at 100 degrees","title":"Prone shoulder abduction with external rotation at 100 degrees","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prone shoulder abduction with external rotation at 100 degrees</div><div class=\"cntnt\"><img style=\"width:436px; height:743px;\" src=\"images/SM/104008_Prn_shldr_abdct_extrn_100_deg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. To perform the exercise, the patient begins the exercise laying face down with their throwing arm hanging straight towards the floor and thumb up (ie, extended like a hitchhiker). The patient raises their arm to the side in a plane slightly superior to the shoulder until the arm is parallel to the floor. This position is held for two seconds, and then slowly lowered back to the starting position. As strength increases, resistance is added.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104008 Version 1.0</div></div></div>"},"104010":{"type":"graphic_picture","displayName":"Prone rowing exercise","title":"Prone rowing exercise","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Prone rowing exercise</div><div class=\"cntnt\"><img style=\"width:479px; height:722px;\" src=\"images/SM/104010_Prn_rwng_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. To perform the exercise, the patient begins the exercise laying face down with their throwing arm hanging straight towards the floor, holding an appropriate dumbbell. Using a steady pace, the patient raises the dumbbell to their chest, holds the position at the top for two seconds, and then gradually lowers the weight back to the starting position. Resistance is increased as strength develops.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104010 Version 1.0</div></div></div>"},"104013":{"type":"graphic_picture","displayName":"Prone rowing into external rotation","title":"Prone rowing into external rotation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prone rowing into external rotation</div><div class=\"cntnt\"><img style=\"width:432px; height:738px;\" src=\"images/SM/104013_Prn_rwng_extrnl_rttn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. To perform the exercise, the patient&nbsp;lays face down with their throwing arm hanging straight towards the floor, holding an appropriate dumbbell. The patient gradually raises their arm, while simultaneously bending their elbow, until the arm is at the level of the table and parallel to the floor (this is a prone row). The forearm remains pointed towards the floor. After pausing for one second in this position, the patient externally rotates their shoulder until the dumbbell is as the height of the table, while maintaining elbow flexion at 90 degrees. This position is held for 2 seconds, then the shoulder is gradually internally rotated, and the arm lowered back to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104013 Version 1.0</div></div></div>"},"104014":{"type":"graphic_picture","displayName":"Press-up exercise","title":"Press-up exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Press-up exercise</div><div class=\"cntnt\"><img style=\"width:403px; height:785px;\" src=\"images/SM/104014_Press_up_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. While seated, the patient firmly grasps both sides of the chair or table with their palms down. The hands should be directly below the shoulders. The patient then slowly pushes downward through their hands to elevate their body off the chair or table, holds the elevated position for two seconds, and slowly lowers their body back to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104014 Version 1.0</div></div></div>"},"104016":{"type":"graphic_picture","displayName":"Push-up exercise","title":"Push-up exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Push-up exercise</div><div class=\"cntnt\"><img style=\"width:425px; height:590px;\" src=\"images/SM/104016_Push_up_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When performed correctly, the push-up is a useful exercise for developing strength in the muscles that push and those that stabilize the torso (core). The patient assumes a standard push-up position, with their hands below the level of their shoulders (ie, caudad) and no more than shoulder width apart. They then&nbsp;lower their body to the floor in a controlled fashion, and then push back up to the starting position. For additional emphasis on the scapular stabilizers, the patient pushes up as high as possible at the&nbsp;top of the push-up, rolling their shoulders forward (maximal scapular protraction) after the elbows are straight.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104016 Version 1.0</div></div></div>"},"104017":{"type":"graphic_picture","displayName":"Push-up exercise against wall","title":"Push-up exercise against wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Push-up exercise against wall</div><div class=\"cntnt\"><img style=\"width:339px; height:722px;\" src=\"images/SM/104017_Psh_up_exrcs_agnst_wll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If a standard push-up is included in a rehabilitation or strength program&nbsp;but&nbsp;is too difficult or causes pain in the shoulder or elbow,&nbsp;a patient may start with push-ups against a wall. As strength improves, the patient&nbsp;gradually transitions to performing the exercise on increasingly lower surfaces (eg, chair, step), until it can be performed on the floor.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104017 Version 1.0</div></div></div>"},"104018":{"type":"graphic_picture","displayName":"Elbow flexion exercise (dumbbell curl)","title":"Elbow flexion exercise (dumbbell curl)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow flexion exercise (dumbbell curl)</div><div class=\"cntnt\"><img style=\"width:273px; height:722px;\" src=\"images/SM/104018_Elbw_flxn_exrcs_dmbl_crl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used to strengthen the biceps muscles. From a standing position with their arm against their side and palm facing inward while holding an appropriate dumbbell, the patient flexes their elbow, while gradually turning the palm upward. The top position is held for two seconds, and then the arm is lowered back to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104018 Version 1.0</div></div></div>"},"104019":{"type":"graphic_picture","displayName":"Elbow extension exercise","title":"Elbow extension exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow extension exercise</div><div class=\"cntnt\"><img style=\"width:308px; height:782px;\" src=\"images/SM/104019_Elbow_extnsn_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used to strengthen the triceps muscles. From a standing position, the patient holds an appropriate dumbbell, raises their throwing arm overhead, and flexes their elbow so it points directly upward. The opposite hand supports the elbow. The patient then extends their elbow until the arm is straight overhead. The top position is held for two seconds, and then the arm is lowered back to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104019 Version 1.0</div></div></div>"},"104020":{"type":"graphic_picture","displayName":"Wrist extension exercise","title":"Wrist extension exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wrist extension exercise</div><div class=\"cntnt\"><img style=\"width:332px; height:726px;\" src=\"images/SM/104020_Wrist_extension_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is intended to strengthen the wrist extensor muscles. While holding an appropriate dumbbell with their palm facing downward, the patient extends their wrist as far as possible, holds the position for two seconds, and then slowly lowers it to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104020 Version 1.0</div></div></div>"},"104021":{"type":"graphic_picture","displayName":"Wrist flexion exercise","title":"Wrist flexion exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wrist flexion exercise</div><div class=\"cntnt\"><img style=\"width:359px; height:765px;\" src=\"images/SM/104021_Wrist_flexion_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is intended to strengthen the wrist flexor muscles. While holding an appropriate dumbbell with their palm facing upward, the patient flexes their wrist as much as possible, holds the position for two seconds, and then slowly lowers it to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104021 Version 1.0</div></div></div>"},"104022":{"type":"graphic_picture","displayName":"Bridge with leg extension exercise","title":"Bridge with leg extension exercise","html":"<div class=\"graphic\"><div style=\"width: 872px\" class=\"figure\"><div class=\"ttl\">Bridge with leg extension exercise</div><div class=\"cntnt\"><img style=\"width:852px; height:617px;\" src=\"images/SM/104022_Brdg_leg_extnsn_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used to develop core strength and stability. The patient lies on their back with knees bent and feet flat on the floor. The patient then lifts their buttocks off the floor (bridge) by moving at the hips. Maintaining this position, the patient raises one leg and extends their knee until the leg is straight, while keeping the abdominal muscles tight, and then flexes the knee and returns the foot to the floor. The patient then performs the same maneuver using the opposite leg.&nbsp; </div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104022 Version 1.0</div></div></div>"},"104023":{"type":"graphic_picture","displayName":"Draw-in with leg extension exercise","title":"Draw-in with leg extension exercise","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Draw-in with leg extension exercise</div><div class=\"cntnt\"><img style=\"width:706px; height:496px;\" src=\"images/SM/104023_Drw_in_leg_extnsn_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown helps to develop core strength. The patient lays supine with their hips and knees flexed to 90 degrees. Next, the patient tightens their abdominal muscles and slowly extends one leg while maintaining the pelvis in a neutral position (ie, not allowing the lumbar spine to fall into lordosis). This position is held for 3 seconds, and then the leg is returned to the starting position. The exercise continues as&nbsp;the&nbsp;patient alternates between extending legs.&nbsp;</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104023 Version 2.0</div></div></div>"},"104024":{"type":"graphic_picture","displayName":"Superman shoulder and scapular exercise","title":"Superman shoulder and scapular exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superman shoulder and scapular exercise</div><div class=\"cntnt\"><img style=\"width:314px; height:869px;\" src=\"images/SM/104024_Sprmn_shldr_scplr_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used to strengthen the rotator cuff and scapular stabilizing muscles. While holding a&nbsp;light dumbbell in each hand, the patient places their belly on a physio-ball in a prone position. Next, the patient braces their abdominal muscles and brings their arms to a position of 90 degrees of shoulder abduction and external rotation, with the elbows flexed to 90 degrees, as if they were performing an overhead press. The patient then presses the dumbbells by fully extending their arms outward, ending in a position resembling Superman's flying position. Return to the initial position by retracing the arm-path.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104024 Version 1.0</div></div></div>"},"104025":{"type":"graphic_picture","displayName":"Square steps exercise with resistance band","title":"Square steps exercise with resistance band","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Square steps exercise with resistance band</div><div class=\"cntnt\"><img style=\"width:688px; height:750px;\" src=\"images/SM/104025_Sqr_stp_exrcs_rsstnc_bnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is&nbsp;used in&nbsp;exercise programs for a range of athletes. With an elastic band (eg, TheraBand) encircling both knees, stand in a half-squat position with toes pointing forward and a neutral spine. Take steps to the left, forward, right, and backward, making a square, while maintaining continuous tension in the band.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104025 Version 1.0</div></div></div>"},"104027":{"type":"graphic_picture","displayName":"Shoulder external rotation plyometric exercise","title":"Shoulder external rotation plyometric exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation plyometric exercise</div><div class=\"cntnt\"><img style=\"width:319px; height:759px;\" src=\"images/SM/104027_Shldr_extrnl_rtt_plymtrc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. With their elbow against their side and hand against their abdomen, the patient grips elastic tubing attached about waist height to a fixed object. The patient stands perpendicular to the attachment point. With moderate to fast speed, the patient externally rotates their shoulder to approximately 30 degrees past neutral, then gradually allows the band to pull the hand back to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104027 Version 1.0</div></div></div>"},"104029":{"type":"graphic_picture","displayName":"Shoulder external rotation while abducted plyometric exercise","title":"Shoulder external rotation while abducted plyometric exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation while abducted plyometric exercise</div><div class=\"cntnt\"><img style=\"width:315px; height:757px;\" src=\"images/SM/104029_Shldr_extrnl_rttn_abdc_plymtrc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. The patient begins exercise with arm abducted to 90 degrees and elbow bent to 90 degrees, while holding elastic tubing attached to a fixed object at about waist height. The patient stands facing this object. With moderate to fast speed, the patient externally rotates their shoulder to 90 degrees of external rotation, then gradually allows the band to pull the hand back to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104029 Version 1.0</div></div></div>"},"104030":{"type":"graphic_table","displayName":"PHQ-9 modified for teens","title":"PHQ-9: Modified for teens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PHQ-9: Modified for teens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <p><strong>Name:</strong></p> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"> <p><strong>Clinician:</strong></p> </td> <td colspan=\"2\"> <p><strong>Date:</strong></p> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Instructions:</strong> How often have you been bothered by each of the following symptoms during the past two weeks? For each symptom put an <strong>\"X\"</strong> in the box beneath the answer that best describes how you have been feeling.</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Not at all</td> <td class=\"subtitle1\">Several days</td> <td class=\"subtitle1\">More than half the days</td> <td class=\"subtitle1\">Nearly every day</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Score</strong></td> <td class=\"centered\"><strong>(0)</strong></td> <td class=\"centered\"><strong>(1)</strong></td> <td class=\"centered\"><strong>(2)</strong></td> <td class=\"centered\"><strong>(3)</strong></td> </tr> <tr> <td> <ol> <li>Feeling down, depressed, irritable, or hopeless? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"2\"> <li>Little interest or pleasure in doing things? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"3\"> <li>Trouble falling asleep, staying asleep, or sleeping too much? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"4\"> <li>Poor appetite, weight loss, or overeating? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"5\"> <li>Feeling tired, or having little energy? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"6\"> <li>Feeling bad about yourself &#8212; or feeling that you are a failure, or that you have let yourself or your family down? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"7\"> <li>Trouble concentrating on things like school work, reading, or watching TV? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"8\"> <li>Moving or speaking so slowly that other people could have noticed?<br /> Or the opposite &#8212; being so fidgety or restless that you were moving around a lot more than usual? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td> <ol start=\"9\"> <li>Thoughts that you would be better off dead, or of hurting yourself in some way? </li> </ol> </td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Total ___ =</strong></td> <td class=\"centered\"><strong>___</strong></td> <td class=\"centered\"><strong>+ ___</strong></td> <td class=\"centered\"><strong>+ ___</strong></td> <td class=\"centered\"><strong>+ ___</strong></td> </tr> <tr> <td colspan=\"5\"><strong>PHQ-9 score &#8805;10: Likely major depression</strong></td> </tr> <tr> <td colspan=\"5\"><strong>Depression score ranges:</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">0 to 4: No or minimal depression</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">5 to 9: Mild</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">10 to 14: Moderate</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">15 to 19: Moderately severe</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\">&#8805;20: Severe</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text sublist1\" colspan=\"5\">&nbsp;</td> </tr> <tr> <td colspan=\"5\">In the <em><strong>past year</strong></em> have you felt depressed or sad most days, even if you felt okay sometimes?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\"> <p><span class=\"primarybox_left\">&nbsp;</span>Yes</p> <span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td colspan=\"5\">If you are experiencing any of the problems on this form, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\"> <p><span class=\"primarybox_left\">&nbsp;</span>Not difficult at all</p> <p><span class=\"primarybox_left\">&nbsp;</span>Somewhat difficult</p> <p><span class=\"primarybox_left\">&nbsp;</span>Very difficult</p> <p><span class=\"primarybox_left\">&nbsp;</span>Extremely difficult</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text sublist1\" colspan=\"5\">&nbsp;</td> </tr> <tr> <td colspan=\"5\">Has there been a time in the past month when you have had serious thoughts about ending your life?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\"> <p><span class=\"primarybox_left\">&nbsp;</span>Yes</p> <span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td colspan=\"5\">Have you <em><strong>ever</strong></em>, in your <em><strong>whole life</strong></em>, tried to kill yourself or made a suicide attempt?</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\"> <p><span class=\"primarybox_left\">&nbsp;</span>Yes</p> <span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"highlight_gray_text\" colspan=\"2\">&nbsp;</td> <td class=\"highlight_blue_text centered\" colspan=\"2\"><strong>FOR OFFICE USE ONLY</strong></td> <td class=\"highlight_blue_text\"> <p><strong>Score:</strong></p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PHQ: Patient Health Questionnaire.</div><div class=\"graphic_reference\">Modified from PHQ developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc.</div><div id=\"graphicVersion\">Graphic 104030 Version 1.0</div></div></div>"},"104031":{"type":"graphic_picture","displayName":"Shoulder external rotation plyometric throwing exercise","title":"Shoulder external rotation plyometric throwing exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation plyometric throwing exercise</div><div class=\"cntnt\"><img style=\"width:306px; height:709px;\" src=\"images/SM/104031_Shldr_extrn_rtt_plymtrc_thrw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. To perform the exercise, the patient stands with shoulder flexed to 90 degrees and elbow bent to 90 degrees holding a small Plyoball. The patient then externally rotates their shoulder rapidly, throwing the Plyoball to a partner or against a wall. The partner throws the ball back and the thrower catches the ball as it crosses their body, decelerating their arm and returning it to the starting position, and then quickly repeating the motion.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104031 Version 1.0</div></div></div>"},"104032":{"type":"graphic_picture","displayName":"Kneeling deceleration throwing exercise","title":"Kneeling deceleration throwing exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kneeling deceleration throwing exercise</div><div class=\"cntnt\"><img style=\"width:304px; height:776px;\" src=\"images/SM/104032_Kneel_dclr_thrw_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. To perform the exercise, the patient begins in a half kneeling position, with their shoulder abducted to 90 degrees and externally rotated to 90 degrees, and facing away from their partner. Their partner throws a Plyoball over the thrower's shoulder and into the path of the throwing arm. The patient catches the ball and decelerates their arm through the entire path of the deceleration phase, and then quickly reverses their arm motion along the same path and throws the ball back to their partner.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104032 Version 1.0</div></div></div>"},"104033":{"type":"graphic_picture","displayName":"Kneeling throwing exercises","title":"Kneeling throwing exercises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kneeling throwing exercises</div><div class=\"cntnt\"><img style=\"width:316px; height:751px;\" src=\"images/SM/104033_Kneel_throw_exrcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is part of an exercise program for throwers. To perform the exercise,&nbsp;a partner throws a small Plyoball to the patient, who is in a standing or half kneeling position, facing the partner. With their shoulder at 90 degrees of abduction and 90 degrees of external rotation, the patient catches the ball, decelerates their arm, and returns it to the starting position. The patient then throws the Plyoball back to their partner using sound mechanics.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104033 Version 1.0</div></div></div>"},"104034":{"type":"graphic_picture","displayName":"Tinea imbricata","title":"Tinea imbricata","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Tinea imbricata</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/104034_Tinea_imbricata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly eruption in a concentric pattern on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104034 Version 1.0</div></div></div>"},"104036":{"type":"graphic_picture","displayName":"Tinea imbricata on arm","title":"Tinea imbricata","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea imbricata</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104036_Tn_imbrct_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patterned,&nbsp;scaly eruption on the extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104036 Version 2.0</div></div></div>"},"104041":{"type":"graphic_algorithm","displayName":"Etiology and mechanisms of precocious puberty","title":"Etiology and mechanisms of precocious puberty","html":"<div class=\"graphic\"><div style=\"width: 836px\" class=\"figure\"><div class=\"ttl\">Etiology and mechanisms of precocious puberty</div><div class=\"cntnt\"><img style=\"width:816px; height:291px;\" src=\"images/PEDS/104041_Eilgy_mchn_prcc_pbrty.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone.</div><div class=\"graphic_reference\">From: Harrington J, Palmert MR, Hamilton J. Use of local data to enhance uptake of published recommendations: an example from the diagnostic evaluation of precocious puberty. Arch Dis Child 2014; 99:15. Reproduced with permission from BMJ Publishing Group Ltd. Copyright Â© 2014.</div><div id=\"graphicVersion\">Graphic 104041 Version 2.0</div></div></div>"},"104043":{"type":"graphic_movie","displayName":"Shoulder external rotation plyometric exercise with tubing","title":"Shoulder external rotation plyometric exercise with tubing","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation plyometric exercise with tubing</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/104043_Shldextrotattubingvid.mp4\" style=\"width:432px;height:704px\"></div><img style=\"width:533px; height:532px;\" src=\"images/SM/104043_Shldextrotattubingimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">External rotation performed at moderate to high speed against the resistance provided by elastic tubing helps to develop power and endurance in the rotator cuff, which is of great importance for throwers.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104043 Version 1.0</div></div></div>"},"104045":{"type":"graphic_movie","displayName":"Shoulder external rotation in abduction plyometric exercise","title":"Shoulder external rotation in abduction plyometric exercise with elastic tubing","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder external rotation in abduction plyometric exercise with elastic tubing</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/104045_Shldextrotatabdplyovid.mp4\" style=\"width:432px;height:704px\"></div><img style=\"width:466px; height:582px;\" src=\"images/SM/104045_Shldextrotatabdplyoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shoulder external rotation performed in an explosive manner against resistance helps to develop power and endurance in the rotator cuff muscles, which is important for throwers.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104045 Version 1.0</div></div></div>"},"104047":{"type":"graphic_movie","displayName":"Overhead medicine ball throw","title":"Overhead medicine ball throw","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Overhead medicine ball throw</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/104047_Overheadmedballthrwvid.mp4\" style=\"width:448px;height:688px\"></div><img style=\"width:449px; height:561px;\" src=\"images/SM/104047_Overheadmedballthrwimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overhead medicine ball throws are used to develop power and endurance in throwers and other overhead athletes.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104047 Version 1.0</div></div></div>"},"104050":{"type":"graphic_movie","displayName":"Kneeling deceleration throwing plyometric exercise","title":"Kneeling deceleration throwing plyometric exercise","html":"<div class=\"graphic normal\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Kneeling deceleration throwing plyometric exercise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/104050_Kneeldeceleratthrplyvid.mp4\" style=\"width:464px;height:704px\"></div><img style=\"width:563px; height:704px;\" src=\"images/SM/104050_Kneeldeceleratthrplyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The deceleration throwing exercise shown in the video may be used as part of a plyometric training program to help throwers increase power and endurance.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104050 Version 1.0</div></div></div>"},"104052":{"type":"graphic_movie","displayName":"Kneeling throwing plyometric exercise","title":"Kneeling throwing plyometric exercise","html":"<div class=\"graphic normal\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Kneeling throwing plyometric exercise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/104052_Kneelthrowplyovid.mp4\" style=\"width:544px;height:656px\"></div><img style=\"width:354px; height:443px;\" src=\"images/SM/104052_Kneelthrowplyoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used as part of a plyometric training program to help throwers develop power and endurance.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104052 Version 1.0</div></div></div>"},"104053":{"type":"graphic_movie","displayName":"Kneeling external rotation throwing plyometric exercise","title":"Kneeling external rotation throwing plyometric exercise","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Kneeling external rotation throwing plyometric exercise</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/104053_Kneelextrotthrwplyovid.mp4\" style=\"width:496px;height:704px\"></div><img style=\"width:531px; height:580px;\" src=\"images/SM/104053_Kneelextrotthrwplyoimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The exercise shown is used as part of a plyometric training program to help throwers develop power and endurance.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104053 Version 1.0</div></div></div>"},"104055":{"type":"graphic_table","displayName":"Positive and negative PV for cfDNA and combined test","title":"Positive and negative predictive values for selected outcomes for cell-free DNA and combined test in various populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Positive and negative predictive values for selected outcomes for cell-free DNA and combined test in various populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Disorder</td> <td class=\"subtitle1\" rowspan=\"3\">Test</td> <td class=\"subtitle1\" colspan=\"4\">Test setting</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">General population</td> <td class=\"subtitle2\" colspan=\"2\">High-risk (women age &#8805;35)</td> </tr> <tr> <td class=\"subtitle3\">PPV</td> <td class=\"subtitle3\">NPV</td> <td class=\"subtitle3\">PPV</td> <td class=\"subtitle3\">NPV</td> </tr> <tr> <td>Trisomy 21*</td> <td>Combined<sup>&#182;</sup></td> <td>5% (1:19)</td> <td>99.9% (2500:1)</td> <td>12% (1:9)</td> <td>99.9% (943:1)</td> </tr> <tr> <td>Trisomy 21</td> <td>cfDNA</td> <td>71% (2:1)</td> <td>99.9% (&#62;50,000:1)</td> <td>87% (7:1)</td> <td>99.9% (25,000:1)</td> </tr> <tr> <td>Trisomy 18<sup>&#916;</sup></td> <td>cfDNA</td> <td>36% (1:2)</td> <td>99.9% (&#62;50,000:1)</td> <td>63% (1:1)</td> <td>99.9% (26,000:1)</td> </tr> <tr> <td>Monosomy X<sup>&#9674;</sup></td> <td>cfDNA</td> <td>12% (1:8)</td> <td>99.9% (2400:1)</td> <td>12% (1:8)</td> <td>99.9% (2400:1)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PPV&nbsp;is the probably that a positive test is associated with an affected pregnancy (also expressed as odds). NPV is the probability that a negative test is associated with an unaffected pregnancy (also expressed as odds).</div><div class=\"graphic_footnotes\">PPV: positive predictive value; NPV: negative predictive value.<br />*&nbsp; The first-trimester prevalence in the general and high-risk populations are taken to be 1 in 400 and 1 in 150, respectively.<br />Â¶ The first-trimester combined test include nuchal translucency measurements along with several serum markers.&nbsp;Detection and false-positive rates are 85% and 5%, respectively.<br />Î The first-trimester prevalence in the general and high-risk populations are taken to be 1 in 1800 and 1 in 600, respectively.<br />â The first-trimester prevalence in the two populations are both taken to be 1 in 250.</div><div id=\"graphicVersion\">Graphic 104055 Version 4.0</div></div></div>"},"104056":{"type":"graphic_figure","displayName":"Distribution of material classes used in fittings and refittings","title":"Distribution of material classes used in fittings and refittings","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Distribution of material classes used in fittings and refittings</div><div class=\"cntnt\"><img style=\"width:652px; height:462px;\" src=\"images/PC/104056_Distrib_material_classes.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PMMA: polymethyl methacrylate.</div><div class=\"graphic_reference\">Reproduced with permission from: Nichols JJ. 2014 Annual report: Contact lenses 2014. Contact Lens Spectrum 2015; 30:22. Copyright &copy; 2015 PentaVision LLC.</div><div id=\"graphicVersion\">Graphic 104056 Version 2.0</div></div></div>"},"104057":{"type":"graphic_figure","displayName":"Distribution of lens modalities used in fittings and refittings","title":"Distribution of lens modalities used in fittings and refittings","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Distribution of lens modalities used in fittings and refittings</div><div class=\"cntnt\"><img style=\"width:710px; height:352px;\" src=\"images/PC/104057_Distrib_lens_modalities.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GP: gas permeable.</div><div class=\"graphic_reference\">Reproduced with permission from: Nichols JJ. 2014 Annual report: Contact lenses 2014. Contact Lens Spectrum 2015; 30:22. Copyright &copy; 2015 PentaVision LLC.</div><div id=\"graphicVersion\">Graphic 104057 Version 1.0</div></div></div>"},"104058":{"type":"graphic_figure","displayName":"Diagnostic peritoneal lavage","title":"Diagnostic peritoneal lavage","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Diagnostic peritoneal lavage</div><div class=\"cntnt\"><img style=\"width:508px; height:467px;\" src=\"images/SURG/104058_Dgnstc_prtnl_lvg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagram shows the correct positioning of the peritoneal lavage catheter with its tip (arrow) deep in the pelvis.</div><div class=\"graphic_reference\">From: Whitehouse JS, Weigelt JA. Diagnostic peritoneal lavage: a review of indications, technique, and interpretation. Scand J Trauma Resusc Emerg Med 2009; 17:13. Copyright &copy; 2009 Whitehouse and Weigelt. This graphic has been reproduced under the <a href=\"http://creativecommons.org/licenses/by/2.0/\" spellcheck=\"true\" target=\"_blank\">Creative Commons Attribution License (2.0)</a>.</div><div id=\"graphicVersion\">Graphic 104058 Version 1.0</div></div></div>"},"104061":{"type":"graphic_algorithm","displayName":"Management of chronic nociceptive pain in patients with CKD","title":"Management of chronic nociceptive pain in patients with chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of chronic nociceptive pain in patients with chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:384px; height:288px;\" src=\"images/NEPH/104061_Mngmnt_chrnc_nociceptv_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Many clinicians favor adding an opioid (ie, tier 3) rather than tramadol for pain that is unresponsive to acetaminophen.</div><div id=\"graphicVersion\">Graphic 104061 Version 2.0</div></div></div>"},"104062":{"type":"graphic_algorithm","displayName":"Management of chronic neuropathic pain in patients with CKD","title":"Management of chronic neuropathic pain in patients with chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Management of chronic neuropathic pain in patients with chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:518px; height:468px;\" src=\"images/NEPH/104062_Mngmnt_chrnc_neuropath_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Many clinicians favor adding an opioid rather than tramadol for pain that is unresponsive to the addition of acetaminophen.</div><div id=\"graphicVersion\">Graphic 104062 Version 2.0</div></div></div>"},"104063":{"type":"graphic_algorithm","displayName":"Management of chronic mixed pain in patients with CKD","title":"Management of chronic mixed pain in patients with chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of chronic mixed pain in patients with chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:334px; height:288px;\" src=\"images/NEPH/104063_Mngmnt_chronic_mixed_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Many clinicians favor adding an opioid rather than tramadol for pain that is unresponsive to acetaminophen plus gabapentin/pregabalin.</div><div id=\"graphicVersion\">Graphic 104063 Version 2.0</div></div></div>"},"104064":{"type":"graphic_diagnosticimage","displayName":"MRI of fatty lesions and erosions of SIJ","title":"Fatty lesions and erosions on MRI of the sacroiliac joint","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Fatty lesions and erosions on MRI of the sacroiliac joint</div><div class=\"cntnt\"><img style=\"width:600px; height:240px;\" src=\"images/RHEUM/104064_Exmpl_ftty_lsn_ersn_MRI_SIJ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal oblique MRI views of sacroiliac joints.<br />(A) T1-weighted image: arrows indicate fatty lesions; arrowheads indicate erosions.<br />(B) T2 fat-suppression image: arrows indicate changes of bone marrow edema.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Dr. Zheng Zhao, PLA Hospital, Beijing, China.</div><div id=\"graphicVersion\">Graphic 104064 Version 2.0</div></div></div>"},"104072":{"type":"graphic_figure","displayName":"Arm bar test for olecranon apophysitis or stress fracture","title":"Arm bar test for suspected olecranon apophysitis, stress fracture, or posterolateral impingement","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Arm bar test for suspected olecranon apophysitis, stress fracture, or posterolateral impingement</div><div class=\"cntnt\"><img style=\"width:517px; height:316px;\" src=\"images/SM/104072_Armbartest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pronated hand is placed on the clinician's shoulder with the elbow extended. The clinician pushes down on the upper and lower arm. Pain at the olecranon indicates a positive test. </div><div id=\"graphicVersion\">Graphic 104072 Version 3.0</div></div></div>"},"104075":{"type":"graphic_algorithm","displayName":"Overview of approach to treatment of GIST","title":"Overview of the approach to treatment of gastrointestinal stromal tumors (GIST)","html":"<div class=\"graphic\"><div style=\"width: 1624px\" class=\"figure\"><div class=\"ttl\">Overview of the approach to treatment of gastrointestinal stromal tumors (GIST)</div><div class=\"cntnt\"><img style=\"width:1604px; height:1186px;\" src=\"images/ONC/104075_Overview_appr_tx_GIST.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NF: neurofibromatosis; SDH: succinate dehydrogenase.<br />* Situations where preoperative (neoadjuvant) imatinib might be considered include a rectal primary site, locally advanced unresectable but nonmetastatic tumor, and a localized tumor for which surgical morbidity could be reduced by downstaging tumor preoperatively.<br />Â¶ Irregular border, cystic spaces, ulceration, echogenic foci, heterogeneity.<br />Î Risk stratification based upon mitotic rate, size, tumor site, and presence or absence of tumor rupture.</div><div id=\"graphicVersion\">Graphic 104075 Version 2.0</div></div></div>"},"104076":{"type":"graphic_figure","displayName":"Tracheobronchial anatomy","title":"Anatomy of the tracheobronchial tree","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Anatomy of the tracheobronchial tree</div><div class=\"cntnt\"><img style=\"width:495px; height:643px;\" src=\"images/PULM/104076_Tracheobronchial_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulmonary artery and its branches follow the same course as the tracheobronchial tree.</div><div id=\"graphicVersion\">Graphic 104076 Version 2.0</div></div></div>"},"104077":{"type":"graphic_picture","displayName":"Fluidic reservoir cannula","title":"Fluidic reservoir cannula","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Fluidic reservoir cannula</div><div class=\"cntnt\"><img style=\"width:583px; height:780px;\" src=\"images/PULM/104077_Fluidic_rssvr_cnnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fluidic reservoir cannula is designed to be oxygen conserving across a range of oxygen flow rates. Unlike the Oxymizer mustache cannula, the device does not have an inner membrane.</div><div id=\"graphicVersion\">Graphic 104077 Version 1.0</div></div></div>"},"104080":{"type":"graphic_figure","displayName":"Testicular volume","title":"Reference chart for testicular volume","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Reference chart for testicular volume</div><div class=\"cntnt\"><img style=\"width:568px; height:828px;\" src=\"images/PEDS/104080_Testicular_volume.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reference chart of testicular volume measured with an orchidometer, based upon data from 769 healthy Dutch boys aged 6 months to 19 years.<sup>[1]</sup></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>âJoustra S, van der Plas E, Goede J, et al. New reference charts for testicular volume in Dutch children and adolescents allow calculation of standard deviation scores. Acta Paediatrica 2015; 104:e271.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission. Copyright &copy;2015 TNO.</div><div id=\"graphicVersion\">Graphic 104080 Version 1.0</div></div></div>"},"104081":{"type":"graphic_algorithm","displayName":"Diagnosis of primary hyperparathyroidism","title":"Diagnosis of primary hyperparathyroidism","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Diagnosis of primary hyperparathyroidism</div><div class=\"cntnt\"><img style=\"width:763px; height:876px;\" src=\"images/ENDO/104081_Diagprimaryhyperprthyrdsm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; PHPT: primary hyperparathyroidism; FHH: familial hypocalciuric hypercalcemia; Ca/Cr: calcium/creatinine ratio; CaSR: calcium-sensing receptor.<br />* Inappropriately normal given hypercalcemia<br />Â¶ Assess for a family history of asymptomatic hypercalcemia, especially in young children.<br />Î Refer to UpToDate topic on hyperparathyroidism for details.</div><div id=\"graphicVersion\">Graphic 104081 Version 4.0</div></div></div>"},"104093":{"type":"graphic_table","displayName":"Pediatric Daytime Sleepiness Scale","title":"Pediatric Daytime Sleepiness Scale (PDSS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric Daytime Sleepiness Scale (PDSS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Please answer the following questions as honestly as you can by circling one answer only:</td> </tr> <tr> <td colspan=\"6\"> <ol> <li>How often do you fall asleep or get drowsy during class periods? </li> </ol> </td> </tr> <tr> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Always</p> </td> <td class=\"centered\"> <p>Frequently</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td colspan=\"6\"> <ol start=\"2\"> <li>How often do you get sleepy or drowsy while doing your homework? </li> </ol> </td> </tr> <tr> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Always</p> </td> <td class=\"centered\"> <p>Frequently</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td colspan=\"6\"> <ol start=\"3\"> <li>Are you usually alert most of the day?* </li> </ol> </td> </tr> <tr> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Always</p> </td> <td class=\"centered\"> <p>Frequently</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td colspan=\"6\"> <ol start=\"4\"> <li>How often are you ever tired and grumpy during the day? </li> </ol> </td> </tr> <tr> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Always</p> </td> <td class=\"centered\"> <p>Frequently</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td colspan=\"6\"> <ol start=\"5\"> <li>How often do you have trouble getting out of bed in the morning? </li> </ol> </td> </tr> <tr> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Always</p> </td> <td class=\"centered\"> <p>Frequently</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td colspan=\"6\"> <ol start=\"6\"> <li>How often do you fall back to sleep after being awakened in the morning? </li> </ol> </td> </tr> <tr> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Very often</p> </td> <td class=\"centered\"> <p>Often</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td colspan=\"6\"> <ol start=\"7\"> <li>How often do you need someone to awaken you in the morning? </li> </ol> </td> </tr> <tr> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Always</p> </td> <td class=\"centered\"> <p>Frequently</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td colspan=\"6\"> <ol start=\"8\"> <li>How often do you think that you need more sleep? </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>&nbsp;</p> </td> <td class=\"centered\"> <p>Very often</p> </td> <td class=\"centered\"> <p>Often</p> </td> <td class=\"centered\"> <p>Sometimes</p> </td> <td class=\"centered\"> <p>Seldom</p> </td> <td class=\"centered\"> <p>Never</p> </td> </tr> <tr> <td><strong>Scoring</strong></td> <td class=\"centered\"><strong>4</strong></td> <td class=\"centered\"><strong>3</strong></td> <td class=\"centered\"><strong>2</strong></td> <td class=\"centered\"><strong>1</strong></td> <td class=\"centered\"><strong>0</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Reverse score this item.</div><div class=\"graphic_reference\">Republished with permission of the American Academy of Sleep Medicine, from Drake C, Nickel C, Burduvali E, et al. The Pediatric Daytime Sleepiness Scale (PDSS): Sleep habits and school outcomes in middle-school children. Sleep 2003; 26:455; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 104093 Version 1.0</div></div></div>"},"104097":{"type":"graphic_form","displayName":"24-hour sleep log","title":"24-hour sleep log","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">24-hour sleep log</div><div class=\"cntnt\"><img style=\"width:752px; height:529px;\" src=\"images/SLEEP/104097_24_hour_slp_log.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 104097 Version 1.0</div></div></div>"},"104099":{"type":"graphic_figure","displayName":"Rigid dilation","title":"Rigid dilator for central airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Rigid dilator for central airway obstruction</div><div class=\"cntnt\"><img style=\"width:538px; height:227px;\" src=\"images/PULM/104099_Rigid_dilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pictorial graphic image representing a rigid dilator (arrow). Dilators of incremental size are sequentially pushed through the obstructing lesion to improve airway patency.</div><div id=\"graphicVersion\">Graphic 104099 Version 1.0</div></div></div>"},"104100":{"type":"graphic_diagnosticimage","displayName":"The Golden S sign","title":"Computed tomography of tracheal collapse in tracheobronchomalacia","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Computed tomography of tracheal collapse in tracheobronchomalacia</div><div class=\"cntnt\"><img style=\"width:491px; height:404px;\" src=\"images/PULM/104100_The_gldn_S_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic image of tracheal collapse during expiration, also known as the Golden S sign (arrow).</div><div id=\"graphicVersion\">Graphic 104100 Version 1.0</div></div></div>"},"104102":{"type":"graphic_table","displayName":"ENMC IBM research diagnostic criteria 2011","title":"ENMC IBM research diagnostic criteria 2011","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ENMC IBM research diagnostic criteria 2011</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Clinical and laboratory features</td> <td class=\"subtitle1\">Pathological features</td> </tr> <tr> <td>&nbsp;</td> <td>Required for all: <ul class=\"decimal_heading\"> <li>Duration &#62;12 months </li> <li>Age at onset &#62;45 years </li> <li>sCK no greater than 15xULN </li> </ul> </td> <td> <ul> <li>Endomysial inflammatory infiltrate </li> <li>Rimmed vacuoles </li> <li>Protein accumulation* or 15 to 18 nm filaments </li> </ul> </td> </tr> <tr> <td><strong>Clinico-pathologically defined IBM</strong></td> <td> <p>Knee extension weakness &#8805; hip flexion weakness</p> <p><strong>and/or</strong></p> Finger flexion weakness &#62; shoulder abduction weakness</td> <td>All of the above features</td> </tr> <tr> <td><strong>Clinically defined IBM</strong></td> <td> <p>Knee extension weakness &#8805; hip flexion weakness</p> <p><strong>and</strong></p> Finger flexion weakness &#62; shoulder abduction weakness</td> <td>One or more of above features</td> </tr> <tr> <td><strong>Probable IBM</strong></td> <td> <p>Knee extension weakness &#8805; hip flexion weakness</p> <p><strong>or</strong></p> Finger flexion weakness &#62; shoulder abduction weakness</td> <td>One or more of above features</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ENMC: European Neuromuscular Centre; IBM: inclusion body myositis.<br />* Demonstration of amyloid or other protein accumulation by established methods (eg, for amyloid Congo red, crystal violet, thioflavin T/S; for other proteins p62, SMI-31, TDP-43). Current evidence favors p62 in terms of sensitivity and specificity but the literature is limited and further work required.</div><div class=\"graphic_reference\">Original figure modified for this publication. Rose MR, ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion body myositis, 2-4 December 2011, Naarden, the Netherlands. Neuromuscul Disord 2013; 23:1044. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104102 Version 2.0</div></div></div>"},"104103":{"type":"graphic_diagnosticimage","displayName":"TEE view of aortic dissection and severe aortic regurgitation","title":"Aortic dissection and severe aortic regurgitation seen on TEE midesophageal long-axis view","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Aortic dissection and severe aortic regurgitation seen on TEE midesophageal long-axis view</div><div class=\"cntnt\"><img style=\"width:467px; height:708px;\" src=\"images/ANEST/104103_Artc_dssct_artc_rgrg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midesophageal aortic valve long-axis image in a patient with acute Stanford type A aortic dissection associated with severe aortic regurgitation. TEE two-dimensional imaging demonstrates an intimal flap within the aortic root (A). Color-flow Doppler imaging demonstrates severe aortic regurgitation with a regurgitant jet occupying the entire width of the LV outflow tract in diastole (B). (Aortic dissection is classified as Stanford type A when it involves the ascending aorta and Stanford type B when it is confined to the descending aorta.)</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104103 Version 3.0</div></div></div>"},"104112":{"type":"graphic_figure","displayName":"LV perfusion territories","title":"LV perfusion territories","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">LV perfusion territories</div><div class=\"cntnt\"><img style=\"width:521px; height:567px;\" src=\"images/ANEST/104112_LV_perfusion_territories.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The regional distribution of LV segmental wall motion abnormalities detected by TEE can be used to help determine the location of disease within the coronary arteries. The diagram displays the typical territories of myocardium perfused by each of the major coronary arteries supplying the LV in the TEE mid-esophageal four-chamber view, TEE mid-esophageal two-chamber view, TEE mid-esophageal long-axis view, and TEE transgastric LV short-axis view. Anatomic variations and coronary collateral flow may produce different patterns of coronary perfusion in individual patients.</div><div class=\"graphic_footnotes\">LV: left ventricle/left ventricular; TEE: transesophageal echocardiography; LAD: left anterior descending; Cx: circumflex; RCA: right coronary artery.</div><div class=\"graphic_reference\">Modified from: Shanewise JS, Cheung AT, Aronson S, et al. ASE/SCA guidelines for performing a comprehensive intraoperative multiplane transesophageal echocardiography examination: recommendations of the American Society of Echocardiography Council for Intraoperative Echocardiography and the Society of Cardiovascular Anesthesiologists Task Force for Certification in Perioperative Transesophageal Echocardiography. J Am Soc Echocardiogr 1999; 12:884.</div><div id=\"graphicVersion\">Graphic 104112 Version 2.0</div></div></div>"},"104113":{"type":"graphic_figure","displayName":"LV segmental anatomy","title":"LV segmental anatomy","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">LV segmental anatomy</div><div class=\"cntnt\"><img style=\"width:516px; height:608px;\" src=\"images/ANEST/104113_LV_segmental_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The regional distribution of myocardial ischemia can be detected as segmental LV wall motion abnormalities by TEE. The entire LV in the 17-segment model can be imaged in long-axis using a combination of the TEE mid-esophageal four-chamber view (a), TEE mid-esophageal two-chamber view (b), and TEE mid-esophageal long-axis view (c). Alternatively, all 17 LV wall segments can be imaged using the TEE transgastric LV short-axis views at the levels of the LV base (d), papillary muscles (e), and apex (not shown). Alternatively, an earlier version of a 16-segment LV model that excludes the apical cap is often used for TEE studies.</div><div class=\"graphic_footnotes\">LV: left ventricle/left ventricular; TEE: transesophageal echocardiography.</div><div class=\"graphic_reference\">Modified from: Shanewise JS, Cheung AT, Aronson S, et al. ASE/SCA guidelines for performing a comprehensive intraoperative multiplane transesophageal echocardiography examination: recommendations of the American Society of Echocardiography Council for Intraoperative Echocardiography and the Society of Cardiovascular Anesthesiologists Task Force for Certification in Perioperative Transesophageal Echocardiography. J Am Soc Echocardiogr 1999; 12:884.</div><div id=\"graphicVersion\">Graphic 104113 Version 2.0</div></div></div>"},"104116":{"type":"graphic_diagnosticimage","displayName":"Measurement of LV end-diastolic diameter (LV dilation present)","title":"TEE measurement of LV end-diastolic diameter inÂ theÂ transgastric mid-papillary view in a patient with severe cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">TEE measurement of LV end-diastolic diameter in&nbsp;the&nbsp;transgastric mid-papillary view in a patient with severe cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:710px; height:514px;\" src=\"images/ANEST/104116_TEE_TG_LV_SAX_8_cm_dm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transgastric mid-papillary short-axis view of the LV in a patient with cardiomyopathy demonstrating severe LV enlargement (end-diastolic diameter 8 cm). In a patient with this baseline LV dilation, it is difficult to diagnose hypovolemia based on a single TEE measurement of LV cavity size.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; LV: left ventricle/left ventricular.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104116 Version 3.0</div></div></div>"},"104117":{"type":"graphic_diagnosticimage","displayName":"TEE view of severe aortic stenosis","title":"TEE view of severe aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">TEE view of severe aortic stenosis</div><div class=\"cntnt\"><img style=\"width:479px; height:702px;\" src=\"images/ANEST/104117_Aortic_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midesophageal aortic valve long-axis image at mid-systole in a patient with severe aortic stenosis (A). Anatomic characteristics of severe aortic stenosis include calcification and decreased separation of aortic valve cusps during ventricular systole. The functional severity of aortic stenosis was quantified using continuous-wave Doppler echocardiography in the transgastric long-axis view of the aortic valve (B) that demonstrates a peak velocity across the aortic valve of 441 cm/second.&nbsp;Using the simplified Bernoulli equation, this equals a peak instantaneous pressure gradient of 78 mmHg and a mean pressure gradient of 52 mmHg.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104117 Version 2.0</div></div></div>"},"104118":{"type":"graphic_table","displayName":"Initiating a palliative care discussion","title":"Initiating a discussion about palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initiating a discussion about palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Begin discussion when patient is feeling relatively well</td> </tr> <tr> <td class=\"indent1\">This is a discussion that I have with all my patients who have this type of lung disease and I'm not raising it because I am particularly worried about you. Have you thought about the type of care you would want if you were to get sicker?</td> </tr> <tr> <td class=\"subtitle1_single\">Focus on a recent hospitalization or emergency department visit</td> </tr> <tr> <td class=\"indent1\">I understand that you were in the hospital recently; how did that go? It makes me wonder whether you would always want to go to the hospital when your breathing is worse. Have you thought about staying at home instead and how your shortness of breath might be managed?</td> </tr> <tr> <td class=\"indent1\">I notice that you have been to the emergency room three times in the past year. This is sometimes a sign that your lung disease is getting more serious. I'd like to spend some time talking about where your disease is headed and make sure I know what types of care you would like to have or avoid in the future.</td> </tr> <tr> <td class=\"subtitle1_single\">Focus on uncontrolled symptoms such as dyspnea</td> </tr> <tr> <td class=\"indent1\">It seems your shortness of breath is getting worse. Feeling short of breath can be frightening. How are you feeling about this? Do you have any questions or concerns that you would like to talk about?</td> </tr> <tr> <td class=\"indent1\">I notice that you were breathing heavily when you walked in. How has your breathing been feeling lately? Have you thought about the care you would want if your breathing gets worse suddenly?</td> </tr> <tr> <td class=\"subtitle1_single\">Focus on a change in oxygen requirement or pulmonary function tests</td> </tr> <tr> <td class=\"indent1\">Your pulmonary function tests show that your lung disease is gradually getting worse. As we have talked about in the past, this is a feature of \"X\" disease. Would you like to take a few minutes to talk about how this decline may impact your future?</td> </tr> <tr> <td class=\"indent1\">I see that you are requiring more oxygen to feel comfortable and maintain your blood oxygen levels. I suspect you may be wondering what will happen as you need more and more oxygen.</td> </tr> <tr> <td class=\"subtitle1_single\">Focus on independence/dependence on others</td> </tr> <tr> <td class=\"indent1\">I wonder, with your shortness of breath, whether you are able to take care of things at home or do you need help? Do you have someone who can help you with shopping and making meals?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 104118 Version 1.0</div></div></div>"},"104119":{"type":"graphic_algorithm","displayName":"Nutrition support protocol in burn patients","title":"Nutrition support protocol in burn patients","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Nutrition support protocol in burn patients</div><div class=\"cntnt\"><img style=\"width:584px; height:574px;\" src=\"images/SURG/104119_Nutr_supp_protocol_burn_pts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TBSA: total body surface area; TENS: toxic epidermal necrolysis syndrome; SJS: Stevens-Johnson syndrome; FT: feeding tube (nasoenteral, nasogastric).<br />* Indirect calorimetry performed every Monday, Wednesday, and Friday.<br />Â¶ If patient has emesis/abdominal pain, hold tube feeds and notify physician. Ongoing assessment of nutritional goals. Other nutritional supplementation (eg, protein shakes) may be needed to meet nutritional goals.</div><div class=\"graphic_reference\">Based on: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009; 33:277.</LI></OL>Adapted from the University of Utah Burn Center Nutrition Support Protocol.</div><div id=\"graphicVersion\">Graphic 104119 Version 3.0</div></div></div>"},"104120":{"type":"graphic_picture","displayName":"Prone shoulder horizontal abduction exercise","title":"Prone shoulder horizontal abduction exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prone shoulder horizontal abduction exercise</div><div class=\"cntnt\"><img style=\"width:380px; height:793px;\" src=\"images/SM/104120_Prn_shldr_hrzn_abdct_exrc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal shoulder abduction performed as pictured above is an important exercise for throwers and overhead athletes. The patient begins the exercise laying face down with their throwing arm hanging straight towards the floor. The patient raises their arm to the side in a plane slightly superior to the shoulder until the arm is parallel to the floor, with palms facing down. This position is held for two seconds, and then slowly lowered back to the starting position.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 104120 Version 1.0</div></div></div>"},"104121":{"type":"graphic_table","displayName":"Primary palliative care education","title":"Primary palliative care educational offerings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary palliative care educational offerings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Center for Advancement of Palliative Care (CAPC)</strong></td> <td>CAPC is a national membership based organization offering tools, training, and technical assistance to front-line clinicians. <a href=\"https://www.capc.org/\" target=\"_blank\">www.capc.org</a></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vitaltalk</strong></td> <td>Vitaltalk is an online resource to teach clinicians end-of-life communication skills. <a href=\"http://www.vitaltalk.org/\" target=\"_blank\">www.vitaltalk.org</a></td> </tr> <tr class=\"divider_bottom\"> <td><strong>End of Life Nursing Education Consortium (ELNEC)</strong></td> <td>ELNEC is offered worldwide to nurses of all levels. Classroom courses and online modules are available on basic palliative care and specialty topics. <a href=\"http://www.aacn.nche.edu/elnec\" target=\"_blank\">www.aacn.nche.edu/elnec</a></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Palliative Care Education and Practice (PCEP)</strong></td> <td>Training for nurse educators and physicians. <a href=\"http://www.hms.harvard.edu/pallcare/PCEP/PCEP.htm\" target=\"_blank\">www.hms.harvard.edu/pallcare/PCEP</a></td> </tr> <tr class=\"divider_bottom\"> <td><strong>MJHS Institute for Innovation in Palliative Care</strong></td> <td>Online palliative care webinars for health care professionals. <a href=\"https://www.mjhspalliativeinstitute.org/e-learning/\" target=\"_blank\">www.mjhspalliativeinstitute.org/e-learning</a></td> </tr> <tr> <td colspan=\"2\"><strong>Professional Societies</strong> <ul class=\"decimal_heading\"> <li>The American Academy of Hospice and Palliative Care Medicine. <a href=\"http://aahpm.org/\" target=\"_blank\">www.aahpm.org</a> </li> <li>Hospice and Palliative Nurses Association. <a href=\"http://hpna.advancingexpertcare.org/\" target=\"_blank\">www.hpna.org</a> </li> <li>The National Hospice and Palliative Care Organization. <a href=\"http://www.nhpco.org/education-online-learning/e-ol-courses-and-webcasts\" target=\"_blank\">www.nhpco.org/eol</a> </li> <li>The European Association of Palliative Care (EAPC). Identifies 10 core competencies for health and social care professionals delivering basic palliative care. <a href=\"http://www.eapcnet.eu/Themes/AbouttheEAPC/EAPCPublications/EAPCRecommendations/tabid/1616/Articleid/566/mod/3090/Default.aspx\" spellcheck=\"true\" target=\"_blank\">http://www.eapcnet.eu/Themes/AbouttheEAPC/EAPCPublications/EAPCRecommendations/tabid/1616/Articleid/566/mod/3090/Default.aspx</a> </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 104121 Version 2.0</div></div></div>"},"104122":{"type":"graphic_table","displayName":"Dyspnea crisis management","title":"Dyspnea crisis management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dyspnea crisis management</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">What can clinicians do about dyspnea crisis?</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Educate patients, families, caregivers, and health care professionals </li> <li>Develop a tailored \"action plan\" before a crisis and reinforce it at every visit </li> <li>Incorporate developing an action plan into pulmonary rehabilitation programs, videos, or web-based educational tools </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Approaches to help patients and caregivers manage dyspnea crisis</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Develop and practice a \"ritual\" to decrease fears and sense of panic and to increase sense of control. </li> <li>Try approaches that have worked before, eg, inhaler or nebulizer treatment. </li> <li>Change positions. Find a position that helps ease breathing, eg, elevate the head of the bed, use extra pillows, or sit upright or in a \"tripod position.\" </li> <li>Pursed lip breathing. </li> <li>Develop a hand sign or signal that means, \"I need help!\" </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 104122 Version 1.0</div></div></div>"},"104123":{"type":"graphic_figure","displayName":"Dyspnea crisis guide for caregivers","title":"Sudden breathlessness crisis guide for caregivers","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Sudden breathlessness crisis guide for caregivers</div><div class=\"cntnt\"><img style=\"width:770px; height:428px;\" src=\"images/PULM/104123_Dyspnea_crisis_guide_crgvrs.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2015 American Thoracic Society. Schneidman A, Reinke L, Donesky D, Carrieri-Kohlman V. Patient information series. Sudden breathlessness crisis. Am J Respir Crit Care Med 2014; 189:P9. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 104123 Version 1.0</div></div></div>"},"104125":{"type":"graphic_table","displayName":"Two-question screen for alcohol use in adolescents","title":"Two-question screen for alcohol use in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Two-question screen for alcohol use in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Screening questions</td> <td class=\"subtitle1\">Risk assessment*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">9 to 11 years</td> <td>\"Do you have any friends who drank beer, wine, or any drink containing alcohol in the <strong>past year</strong>?\"</td> <td>Any drinking by friends heightens concern<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>\"How about you <span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash; </span>have you <strong>ever</strong> had more than a few sips of beer, wine, or any drink containing alcohol?\"</td> <td>Any drinking indicates highest risk<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">11 to 14 years</td> <td>\"Do you have any friends who drank beer, wine, or any drink containing alcohol in the <strong>past year</strong>?\"</td> <td>Any drinking by friends heightens concern<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">\"How about you&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash; </span>in the <strong>past year, on how many days</strong> have you had more than a few sips of beer, wine, or any drink containing alcohol?\"</td> <td>11 years: Any drinking: Highest risk<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>12 to 14 years: <ul class=\"decimal_heading\"> <li>1 to 5 days: Moderate risk<sup>&#916;</sup> </li> <li>&#62;5 days: Highest risk<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td rowspan=\"5\">14 to 18 years</td> <td rowspan=\"4\">\"In the <strong>past year, on how many days</strong> have you had more than a few sips of beer, wine, or any drink containing alcohol?\"</td> <td>14 through 15: <ul class=\"decimal_heading\"> <li>1 to 5 days: Moderate risk<sup>&#916;</sup> </li> <li>&#62;5 days: Highest risk<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td>16 years: <ul class=\"decimal_heading\"> <li>1 to 5 days: Lower risk </li> <li>6 to 11 days: Moderate risk<sup>&#916;</sup> </li> <li>&#62;11 days: Highest risk<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td>17 years: <ul class=\"decimal_heading\"> <li>1 to 5 days: Lower risk </li> <li>6 to 23 days: Moderate risk<sup>&#916;</sup> </li> <li>&#62;23 days: Highest risk<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td>18 years: <ul class=\"decimal_heading\"> <li>1 to 11 days: Lower risk </li> <li>12 to 51 days: Moderate risk<sup>&#916;</sup> </li> <li>&#62;51 days: Highest risk<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td>\"If your friends drink, <strong>how many drinks</strong> do they usually drink on an occasion?\"</td> <td>Binge drinking<sup>&#9674;</sup> by friends heightens concern<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Use in conjunction with what you already know about the patient's physical and psychosocial development, level of family support, drinking and smoking habits of parents and siblings, school functioning, or trouble with authority figures to provide advice and assistance. Refer to the practitioner's guide for details.<br />Â¶ If the patient does not drink, but friends do, explore the patient's views about friends' drinking and ask about his or her plans to stay alcohol free.<br />Î For patients at moderate or higher risk, obtain additional information about drinking pattern, drinking-related problems or risk-taking, and other substance use.<br /><FONT class=lozenge>â</FONT> Binge drinking: â¥3 drinks for girls (all ages) and boys ages 9 to 13 years; â¥4 drinks for boys 14 through 15 years; â¥5 drinks for boys age â¥16 years.</div><div class=\"graphic_reference\">Adapted from: National Institute on Alcohol Abuse and Alcoholism. Alcohol screening and brief intervention for youth: A practitioner's guide. Available at: <A spellcheck=true href=\"https://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/alcohol-screening-and-brief-intervention-youth\" target=_blank>https://www.niaaa.nih.gov/publications/clinical-guides-and-manuals/alcohol-screening-and-brief-intervention-youth</A> (Accessed on June 20, 2017).</div><div id=\"graphicVersion\">Graphic 104125 Version 2.0</div></div></div>"},"104126":{"type":"graphic_table","displayName":"Diff dx ACTH-dependent mineralocorticoid excess","title":"Differential diagnosis of ACTH-dependent mineralocorticoid excess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of ACTH-dependent mineralocorticoid excess</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Abnormal steroids</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Defective gene</td> </tr> <tr class=\"divider_bottom\"> <td>17-hydroxylase deficiency</td> <td> <p>&#8593; DOC, corticosterone</p> <p>&#8595; 17OH-steroids, cortisol</p> <p>&#8595; aldosterone</p> &#8595; androgens and estrogens</td> <td> <p>Sexual ambiguity or infantilism</p> Autosomal recessive</td> <td><em>CYP17A1</em></td> </tr> <tr class=\"divider_bottom\"> <td>11-beta-hydroxylase deficiency</td> <td> <p>&#8593; DOC, 11-deoxycortisol</p> <p>&#8595; corticosterone, cortisol</p> <p>&#8595; aldosterone</p> &#8593; androgens</td> <td> <p>Androgen excess</p> Autosomal recessive</td> <td><em>CYP11B1</em></td> </tr> <tr class=\"divider_bottom\"> <td>Syndrome of apparent mineralocorticoid excess</td> <td> <p>&#8593; cortisol/cortisone ratios</p> <p>&#8595; aldosterone</p> Normal androgens</td> <td> <p>Mimicked by licorice ingestion</p> Autosomal recessive</td> <td><em>HSD11B2</em></td> </tr> <tr class=\"divider_bottom\"> <td>Glucocorticoid-remediable aldosteronism</td> <td> <p>&#8593; 18OH- &#38; 18-oxo-cortisol</p> <p>&#8593; aldosterone</p> <p>Normal cortisol</p> Normal androgens</td> <td> <p>Strokes common</p> Autosomal dominant</td> <td> <p>Chimeric gene</p> <em>CYP11B1/CYP11B2</em></td> </tr> <tr class=\"divider_bottom\"> <td>Glucocorticoid resistance</td> <td> <p>Moderate &#8593; DOC, cortisol</p> <p>&#8593; androgens</p> Variable estrogens</td> <td> <p>Compensated adrenal insufficiency</p> <p>Androgen excess</p> Autosomal recessive</td> <td> <p><em>NR3C1</em> (glucocorticoid receptor)</p> Other</td> </tr> <tr> <td>Cushing's disease</td> <td> <p>&#8593; cortisol &#38; metabolites</p> Variable other steroids</td> <td> <p>Cushingoid features</p> Variable mineralocorticoid excess</td> <td> <p>Various tumor syndromes</p> Also sporadic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: corticotropin; DOC: 11-deoxycorticosterone; 17OH: 17-hydroxy; 18OH: 18-hydroxy.</div><div id=\"graphicVersion\">Graphic 104126 Version 3.0</div></div></div>"},"104127":{"type":"graphic_picture","displayName":"X-linked ichthyosis histo 1","title":"Histologic features of recessive X-linked ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic features of recessive X-linked ichthyosis</div><div class=\"cntnt\"><img style=\"width:431px; height:431px;\" src=\"images/DERM/104127_X_lnk_ichthys_hst_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic picture of X-linked ichthyosis exhibiting subtle hyperkeratosis and hypergranulosis with mild dermal perivascular inflammation (H&amp;E stain; original magnification: x100).</div><div class=\"graphic_reference\">Reproduced from: Fernandes NF, Janniger CK, Schwartz RA. X-linked ichthyosis: an oculocutaneous genodermatosis. J Am Acad Dermatol 2010: 62:480. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104127 Version 1.0</div></div></div>"},"104128":{"type":"graphic_picture","displayName":"X-linked ichthyosis histo 2","title":"Histologic features of recessive X-linked ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Histologic features of recessive X-linked ichthyosis</div><div class=\"cntnt\"><img style=\"width:518px; height:444px;\" src=\"images/DERM/104128_X_lnkd_ichthys_hst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This slide demonstrates a normal granular layer in a patient with recessive X-linked ichthyosis (H&amp;E stain; original magnification: x100).</div><div class=\"graphic_reference\">Reproduced from: Hand JL, Runke CK, Hodge JC. The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray. J Am Acad Dermatol 2015; 72:617. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104128 Version 1.0</div></div></div>"},"104129":{"type":"graphic_picture","displayName":"X-linked ichthyosis histo 3","title":"Histologic features of recessive X-linked ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Histologic features of recessive X-linked ichthyosis</div><div class=\"cntnt\"><img style=\"width:519px; height:449px;\" src=\"images/DERM/104129_X_lnk_ichthys_hst_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This slide demonstrates an absent granular layer (arrow) in a patient with recessive X-linked ichthyosis (H&amp;E stain, original magnification: x100).</div><div class=\"graphic_reference\">Reproduced from: Hand JL, Runke CK, Hodge JC. The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray. J Am Acad Dermatol 2015; 72:617. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104129 Version 1.0</div></div></div>"},"104130":{"type":"graphic_table","displayName":"Oxygen conserving systems","title":"Characteristics of oxygen conserving systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of oxygen conserving systems</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Reservoir</td> <td class=\"subtitle1\">Demand pulse</td> <td class=\"subtitle1\">Noninvasive open ventilator with oxygen<sup>[1]</sup></td> <td class=\"subtitle1\">Transtracheal catheter (placed surgically)</td> </tr> <tr> <td><strong>Mechanism</strong></td> <td>Stores <strong>oxygen</strong>&nbsp;during exhalation</td> <td>Delivery during early inspiration</td> <td>Delivers 50 to 250 mL pulses</td> <td>Store, bypass dead-space</td> </tr> <tr> <td><strong>Efficiency</strong></td> <td>2:1 to 4:1</td> <td>3:1 to 7:1</td> <td>Not available</td> <td>2:1 to 3:1</td> </tr> <tr> <td><strong>High-flow</strong></td> <td>16 L/m</td> <td>Not applicable</td> <td>Larger pulses</td> <td>16 L/m</td> </tr> <tr> <td><strong>Comfort</strong></td> <td>Adequate</td> <td>Adequate</td> <td>Adequate</td> <td>Good after insertion; requires daily cleaning</td> </tr> <tr> <td><strong>Cosmetics</strong></td> <td>Obtrusive</td> <td>Adequate</td> <td>Adequate</td> <td>Excellent</td> </tr> <tr> <td><strong>Complications</strong></td> <td>Rare</td> <td>Mechanical failure</td> <td>Mechanical failure</td> <td>Mucous plug, bleeding, malposition</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>âPorszasz J, Cao R, Morishige R, et al. Physiologic effects of an ambulatory ventilation system in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:334.</LI></OL></div><div id=\"graphicVersion\">Graphic 104130 Version 1.0</div></div></div>"},"104131":{"type":"graphic_diagnosticimage","displayName":"MRI femoral neck stress fracture (compression side)","title":"MRI femoral neck stress fracture (compression side)","html":"<div class=\"graphic\"><div style=\"width: 856px\" class=\"figure\"><div class=\"ttl\">MRI femoral neck stress fracture (compression side)</div><div class=\"cntnt\"><img style=\"width:836px; height:460px;\" src=\"images/SM/104131_MRI_fmrl_nck_strss_frct_cmp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The magnetic resonance imaging (MRI) studies above show a stress fracture of femoral neck (arrows) along the inferior aspect. These are commonly referred to as compression side fractures.</div><div class=\"graphic_reference\">Courtesy of Rob Johnson, MD.</div><div id=\"graphicVersion\">Graphic 104131 Version 2.0</div></div></div>"},"104133":{"type":"graphic_diagnosticimage","displayName":"False profile view of hip on plain radiography","title":"False profile view of hip on plain radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">False profile view of hip on plain radiography</div><div class=\"cntnt\"><img style=\"width:214px; height:229px;\" src=\"images/SM/104133_Fls_prfl_vw_hp_pln_rdgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A false profile view of the hip using plain radiographs as pictured above provides a good view of the posterior femoroacetabular joint (arrows).</div><div class=\"graphic_reference\">Courtesy of Rob Johnson, MD.</div><div id=\"graphicVersion\">Graphic 104133 Version 2.0</div></div></div>"},"104136":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph of crossover sign for femoroacetabular impingem","title":"Plain radiograph of crossover sign for femoroacetabular impingement","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of crossover sign for femoroacetabular impingement</div><div class=\"cntnt\"><img style=\"width:531px; height:712px;\" src=\"images/SM/104136_Pln_rdgrph_crssvr_fmrctblr_impngm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">AP view of the right hip. The anterior (open dots) and posterior (solid dots) rim of the acetabulum are marked. The superior portion of the anterior rim lies lateral to the posterior rim (arrow) indicating overcoverage of the acetabulum. Anteriorly, it assumes a more normal medial position, creating the crossover sign (arrowhead), which is an indicator of a pincer-type femoroacetabular impingement.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Originally published in: Byrd JWT. Femoroacetabular impingement. In: Operative Arthroscopy, 4th Edition, Johnson DH (ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Reprinted with permission from J.W. Thomas Byrd. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 104136 Version 2.0</div></div></div>"},"104138":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph mixed cam-pincer femoroacetabular impingement","title":"Plain radiograph of mixed cam-pincer femoroacetabular impingement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of mixed cam-pincer femoroacetabular impingement</div><div class=\"cntnt\"><img style=\"width:447px; height:756px;\" src=\"images/SM/104138_Xray_mixed_cam-pincer_FAI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is a portion of an anteroposterior pelvic radiograph showing a left hip with acetabular retroversion.&nbsp;In addition,&nbsp;a pistol grip deformity of the proximal femur is present. Femoroacetabular impingement is, therefore, of the mixed cam-pincer type.</div><div class=\"graphic_reference\">Reproduced with permission from: Beck M, Schoeniger R. FAI-acetabular retroversion. In: The Adult Hip: Hip Preservation Surgery, Clohisy JC, BeaulÃ© PE, Della Valle CJ, et al (Eds), Wolters Kluwer, Philadelphia 2015. Copyright Â© 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 104138 Version 1.0</div></div></div>"},"104139":{"type":"graphic_diagnosticimage","displayName":"Plain radiographs of cam type femoroacetabular impingement","title":"Plain radiographs of cam type femoroacetabular impingement","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Plain radiographs of cam type femoroacetabular impingement</div><div class=\"cntnt\"><img style=\"width:727px; height:412px;\" src=\"images/SM/104139_Cam_typ_femoroactblr_imping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This anteroposterior (AP) plain&nbsp;radiograph of the right hip of a 39-year-old woman shows excessive bone buildup at the femoral head/neck junction (arrow), known as a cam deformity. There are signs of secondary osteoarthritis of the hip joint.<br />(B)&nbsp;This AP&nbsp;hip radiograph of&nbsp;a 41-year-old man demonstrates&nbsp;the&nbsp;tubular appearance of the proximal right femur and the osseous prominence at the femoral head-neck junction, known as&nbsp;a&nbsp;\"pistol grip\" deformity. Also evident is osteoarthritis of the hip joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Greenspan A, Beltran J. Orthopedic Imaging: A Practical Approach, 6th Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 104139 Version 2.0</div></div></div>"},"104140":{"type":"graphic_diagnosticimage","displayName":"TEE view of cardiac tamponade","title":"TEE view of cardiac tamponade","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">TEE view of cardiac tamponade</div><div class=\"cntnt\"><img style=\"width:840px; height:641px;\" src=\"images/ANEST/104140_Crdc_tmpnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transgastric mid-papillary short-axis image obtained in a patient with intraoperative hypotension caused by cardiac tamponade. A large pericardial effusion is identified by the echolucent spaces anterior and posterior to the LV.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; LV: left ventricular.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104140 Version 3.0</div></div></div>"},"104141":{"type":"graphic_diagnosticimage","displayName":"TEE view of severe mitral stenosis","title":"TEE view of severe mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">TEE view of severe mitral stenosis</div><div class=\"cntnt\"><img style=\"width:501px; height:726px;\" src=\"images/ANEST/104141_TEE_vw_svr_mtrl_stns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midesophageal four-chamber view of the mitral valve (A) at mid-diastole in a patient with severe mitral stenosis. Echocardiographic features of mitral stenosis include thickened or calcified mitral valve leaflets, commissural fusion causing decreased separation of the leaflets in diastole, and an enlarged left atrium with spontaneous echo contrast. The severity of mitral stenosis was quantified by continuous-wave Doppler measurement demonstrating a peak transvalvular pressure gradient of 18 mmHg (4 x Vmax<SUP>2</SUP> = 4 x 2.142). The pressure half-time was measured at 254 ms, resulting in a calculated pressure half time of 0.87 cm<SUP>2</SUP>.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; bpm: beats/minute; Vmax: maximum velocity; P1/2t: pressure half time; MVA: mitral valve area.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104141 Version 4.0</div></div></div>"},"104142":{"type":"graphic_figure","displayName":"Nerves of the gluteal region","title":"Nerves of the gluteal region","html":"<div class=\"graphic\"><div style=\"width: 739px\" class=\"figure\"><div class=\"ttl\">Nerves of the gluteal region</div><div class=\"cntnt\"><img style=\"width:719px; height:693px;\" src=\"images/SM/104142_Nerves_gluteal_region.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Lippincott Williams &amp; Wilkins Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 104142 Version 1.0</div></div></div>"},"104143":{"type":"graphic_diagnosticimage","displayName":"TEE view of severe mitral regurgitation","title":"TEE view of severe mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 721px\" class=\"figure\"><div class=\"ttl\">TEE view of severe mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:701px; height:495px;\" src=\"images/ANEST/104143_Severe_mitral_rgrgttn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midesophageal four-chamber view in a patient with severe mitral regurgitation. Doppler color-flow imaging demonstrated a large mitral regurgitant jet that occupied approximately 50% of the left atrial area. The vena contracta or width of the regurgitant jet at the level of the mitral valve coaptation was measured to be 1.2 cm, consistent with severe mitral regurgitation.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104143 Version 2.0</div></div></div>"},"104144":{"type":"graphic_movie","displayName":"TEE (ME 4CV view) of normal and abnormal LV systolic function","title":"TEE (midesophaeal 4-chamber view) of normal and abnormal LV systolic function","html":"<div class=\"graphic normal\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">TEE (midesophaeal 4-chamber view) of normal and abnormal LV systolic function</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/104144_TEEnormabnrmlLVsystvid.mp4\" style=\"width:656px;height:304px\"></div><img style=\"width:584px; height:250px;\" src=\"images/ANEST/104144_TEEnormabnrmlLVsystimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midesophageal four-chamber views of a patient with normal LV systolic function (left panel) and a patient with cardiomyopathy and severe global LV systolic dysfunction (right panel). The LV ejection fraction was measured to be 60% in the patient with normal ventricular function (left panel) and 20% in the patient with cardiomyopathy (right panel).</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal: 4CV: 4-chamber view; LV: left ventricular.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104144 Version 3.0</div></div></div>"},"104149":{"type":"graphic_movie","displayName":"TEE (TG LV SAX view) showing normovolemia vs hypovolemia","title":"TEE (transgastric LV short-axisÂ view)Â showing normovolemia versus hypovolemia","html":"<div class=\"graphic normal\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">TEE (transgastric LV short-axis&nbsp;view)&nbsp;showing normovolemia versus hypovolemia</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/104149_TEEhypovolemiavid.mp4\" style=\"width:656px;height:336px\"></div><img style=\"width:583px; height:231px;\" src=\"images/ANEST/104149_TEEhypovolemiaimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative TEE transgastric LV short-axis images in a patient at baseline (left panel) and after acute blood loss of approximately 10 mL/kg (right panel). Hypovolemia caused by acute blood loss decreased TEE LV short-axis cross-sectional area and diameter at both end-diastole and end-systole. Each 1.75 mL/kg blood loss will acutely decrease LV end-diastolic area by 0.8 cm<SUP>2</SUP> and LV end-diastolic diameter by 0.1 cm<SUP>[1]</SUP>.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; TG: transgastric; LV: left ventricular; SAX: short-axis.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cheung AT, Savino JS, Weiss SJ, et al.&nbsp; Echocardiographic and hemodynamic indexes of left ventricular preload in patients with normal and abnormal ventricular function.&nbsp;Anesthesiology 1994; 81:376.</LI></OL>Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104149 Version 4.0</div></div></div>"},"104150":{"type":"graphic_movie","displayName":"TEE views in a patient with anaphylaxis","title":"TEE views in a patient with anaphylaxis (distributive shock)","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">TEE views in a patient with anaphylaxis (distributive shock)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/104150_TEEanaphylaxisvid.mp4\" style=\"width:640px;height:304px\"></div><img style=\"width:583px; height:252px;\" src=\"images/ANEST/104150_TEEanaphylaxisimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transgastric LV short-axis (left panel) and midesophageal four-chamber view (right panel) in a patient with intraoperative hypotension caused by anaphylaxis treated with intravenous epinephrine. The decreased LV end-systolic cavity size seen in both views resulted from increased myocardial contractility and decreased LV afterload.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; LV: left ventricular.</div><div class=\"graphic_reference\">Reproduced with permission from Albert T. Cheung, MD, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 104150 Version 3.0</div></div></div>"},"104152":{"type":"graphic_table","displayName":"FLEP scale","title":"The Frontal Lobe Epilepsy and Parasomnias (FLEP) scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Frontal Lobe Epilepsy and Parasomnias (FLEP) scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Clinical feature</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Age at onset</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">At what age did the patient have their first clinical event?</td> <td>&#60;55 years</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;55 years</td> <td class=\"centered\">&ndash;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Duration</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">What is the duration of a typical event?</td> <td>&#60;2 minutes</td> <td class=\"centered\">+1</td> </tr> <tr> <td>2 to 10 minutes</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;10 minutes</td> <td class=\"centered\">&ndash;2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Clustering</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">What is the typical number of events to occur in a single night?</td> <td>1 or 2</td> <td class=\"centered\">0</td> </tr> <tr> <td>3 to 5</td> <td class=\"centered\">+1</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;5</td> <td class=\"centered\">+2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Timing</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">At what time of night do the events most commonly occur?</td> <td>Within 30 minutes of sleep onset</td> <td class=\"centered\">+1</td> </tr> <tr class=\"divider_bottom\"> <td>Other times (including if no clear pattern identified)</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Symptoms</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Are the events associated with a definite aura?</td> <td>Yes</td> <td class=\"centered\">+2</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Does the patient ever wander outside the bedroom during the events?</td> <td>Yes</td> <td class=\"centered\">&ndash;2</td> </tr> <tr class=\"divider_bottom\"> <td>No (or certain)</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Does the patient perform complex, directed behaviors (eg, picking up objects, dressing) during events?</td> <td>Yes</td> <td class=\"centered\">&ndash;2</td> </tr> <tr class=\"divider_bottom\"> <td>No (or uncertain)</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Is there a clear history of prominent dystonic posturing, tonic limb extension, or cramping during events?</td> <td>Yes</td> <td class=\"centered\">+1</td> </tr> <tr class=\"divider_bottom\"> <td>No (or uncertain)</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Stereotypy</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Are the events highly stereotyped or variable in nature?</td> <td>Highly stereotyped</td> <td class=\"centered\">+1</td> </tr> <tr> <td>Some variability/uncertain</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td>Highly variable</td> <td class=\"centered\">&ndash;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Recall</td> </tr> <t /> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Does the patient recall the events?</td> <td>Yes, lucid recall</td> <td class=\"centered\">+1</td> </tr> <tr class=\"divider_bottom\"> <td>No or vague recollection only</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vocalization</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Does the patient speak during the events and, if so, is there subsequent recollection of this speech?</td> <td>No</td> <td class=\"centered\">0</td> </tr> <tr> <td>Yes, sounds only or single words</td> <td class=\"centered\">0</td> </tr> <tr> <td>Yes, coherent speech with incomplete or no recall</td> <td class=\"centered\">&ndash;2</td> </tr> <tr class=\"divider_bottom\"> <td>Yes, coherent speech with recall</td> <td class=\"centered\">+2</td> </tr> <tr> <td colspan=\"2\"><strong>Total score</strong></td> <td class=\"centered\"><strong>&nbsp;</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A score of zero or less is very suggestive of a parasomnia, while scores &gt;3&nbsp;are suggestive of nocturnal frontal lobe epilepsy. Scores of 1 to 3 are indeterminate, and further investigation may be required in these patients. Refer to the UpToDate topic on the approach to abnormal movements and behaviors during sleep for more details.</div><div class=\"graphic_reference\">Reproduced with permission from: Derry CP, Davey M, Johns M, et al. Distinguishing sleep disorders from seizures. Arch Neurol 2006; 63:705. Copyright &copy; 2006 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104152 Version 4.0</div></div></div>"},"104154":{"type":"graphic_table","displayName":"Pretreatment evaluation for the use of cyclophosphamide","title":"Pretreatment evaluation for the use of cyclophosphamide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pretreatment evaluation for the use of cyclophosphamide</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Assessment for drug interactions.</td> </tr> <tr> <td>Counseling on infertility risk, based on the patient's age, gender, and anticipated cumulative dose of CYC.</td> </tr> <tr> <td>Counseling on the importance of flawless contraception.</td> </tr> <tr> <td>Age-appropriate screening for cervical cancer and HPV infection in women, followed by close monitoring by a gynecologist if HPV-related disease is present.</td> </tr> <tr> <td>Baseline laboratory testing (CBC with differential, serum creatinine levels, urinalysis, liver function tests, hepatitis B and C serologies).</td> </tr> <tr> <td>Latent tuberculosis testing (tuberculin skin test and/or interferon gamma release assay).</td> </tr> <tr> <td>Prophylaxis for <em>Pneumocystis jirovecii</em><em>.</em></td> </tr> <tr> <td>Review of immunization status. Immunization with killed vaccines including influenza, Tdap, 13 valent, and 23 valent pneumococcal vaccines may safely be undertaken, albeit with possibly reduced efficacy in the setting of immunosuppression (recognizing that the two pneumococcal vaccines must be given at different times).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYC: cyclophosphamide; HPV: human papillomavirus; CBC: complete blood count.</div><div id=\"graphicVersion\">Graphic 104154 Version 3.0</div></div></div>"},"104155":{"type":"graphic_figure","displayName":"Vertex waves and SEM of NREM 1 sleep","title":"Vertex waves and slow eye movement of non-rapid eye movement (NREM) 1 sleep","html":"<div class=\"graphic\"><div style=\"width: 1116px\" class=\"figure\"><div class=\"ttl\">Vertex waves and slow eye movement of non-rapid eye movement (NREM) 1 sleep</div><div class=\"cntnt\"><img style=\"width:1096px; height:336px;\" src=\"images/SLEEP/104155_Vrtx_wv_SEM_NREM_1_slp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">30-second epoch of polysomnography (PSG) showing vertex waves maximal over the central regions typically first seen in later NREM 1 sleep, common in NREM 2.</div><div id=\"graphicVersion\">Graphic 104155 Version 1.0</div></div></div>"},"104164":{"type":"graphic_table","displayName":"Excimer laser protocol psoriasis","title":"Excimer laser treatment protocol for psoriasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Excimer laser treatment protocol for psoriasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"5\">Initial dose for psoriasis</td> </tr> <tr> <td class=\"subtitle2\">Plaque thickness</td> <td class=\"subtitle2\">Induration score</td> <td class=\"subtitle2\">Fitzpatrick skin type I-III (dose in mJ/cm<sup>2</sup>)</td> <td class=\"subtitle2\" colspan=\"2\">Fitzpatrick skin type IV-VI (dose in mJ/cm<sup>2</sup>)</td> </tr> <tr> <td>None</td> <td>0</td> <td>&nbsp;</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td>Mild</td> <td>1</td> <td>300</td> <td colspan=\"2\">400</td> </tr> <tr> <td>Moderate</td> <td>2</td> <td>500</td> <td colspan=\"2\">600</td> </tr> <tr> <td>Severe</td> <td>3</td> <td>700</td> <td colspan=\"2\">900</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"5\">Dose for subsequent treatments</td> </tr> <tr> <td class=\"subtitle2\">No effect</td> <td class=\"subtitle2\">Minimal effect</td> <td class=\"subtitle2\">Good effect</td> <td class=\"subtitle2\">Considerable improvement</td> <td class=\"subtitle2\">Moderate/severe erythema</td> </tr> <tr> <td>No erythema at 12 to 24 hours and no plaque improvement</td> <td>Slight erythema at 12 to 24 hours but no significant improvement</td> <td>Mild to moderate erythema response 12 to 24 hours</td> <td>Significant improvement with plaque thinning or reduced scaliness or pigmentation occurred</td> <td>With or without blistering</td> </tr> <tr> <td>Increase dose by 25%</td> <td>Increase dose by 15%</td> <td>Maintain dose</td> <td>Maintain dose or reduce dose by 15%</td> <td>Reduce dose by 25% (treat around blistered area, do not treat blistered area until it heals or crust disappears)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduce with permission from: XTRAC Psoriasis and Vitiligo Laminated Guideline Cards, 12-95359-01, Rev F. Copyright &copy; 2015 MELA Sciences, Inc.</div><div id=\"graphicVersion\">Graphic 104164 Version 1.0</div></div></div>"},"104165":{"type":"graphic_figure","displayName":"PSG showing saw-tooth waves of REM sleep","title":"Polysomnography showing saw-tooth waves of REM sleep","html":"<div class=\"graphic\"><div style=\"width: 1115px\" class=\"figure\"><div class=\"ttl\">Polysomnography showing saw-tooth waves of REM sleep</div><div class=\"cntnt\"><img style=\"width:1095px; height:339px;\" src=\"images/SLEEP/104165_PSG_shw_sw_tth_REM_slp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">30-second epoch of PSG showing saw-tooth waves of REM sleep that are best seen over central regions typically accompanied by rapid eye movements, a low voltage mixed frequency EEG and chin EMG atonia.</div><div class=\"graphic_footnotes\">PSG: polysomnography; REM: rapid eye movement; EEG: electroencephalography; chin EMG: submentalis electromyography.</div><div id=\"graphicVersion\">Graphic 104165 Version 1.0</div></div></div>"},"104166":{"type":"graphic_figure","displayName":"High voltage slow wave activity of NREM 3 sleep","title":"High voltage slow wave activity of NREM 3 sleep","html":"<div class=\"graphic\"><div style=\"width: 1116px\" class=\"figure\"><div class=\"ttl\">High voltage slow wave activity of NREM 3 sleep</div><div class=\"cntnt\"><img style=\"width:1096px; height:338px;\" src=\"images/SLEEP/104166_Hgh_vlt_lw_actv_NREM_3_slp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">30-second epoch of PSG showing high voltage slow wave activity of NREM 3 sleep, which is often of highest amplitude over the frontal regions.</div><div class=\"graphic_footnotes\">PSG: polysomnography; NREM: non-rapid eye movement.</div><div id=\"graphicVersion\">Graphic 104166 Version 1.0</div></div></div>"},"104167":{"type":"graphic_figure","displayName":"Sleep spindles of NREM 2 sleep","title":"Sleep spindles of NREM 2 sleep","html":"<div class=\"graphic\"><div style=\"width: 1117px\" class=\"figure\"><div class=\"ttl\">Sleep spindles of NREM 2 sleep</div><div class=\"cntnt\"><img style=\"width:1097px; height:340px;\" src=\"images/SLEEP/104167_Slp_spndl_NREM_2_slp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">30-second epoch of PSG showing sleep spindles of NREM 2 sleep (which may linger into early NREM 3) may be more prominent over the frontal, central, or occur independently over the frontal and central regions in children younger than 13 years.</div><div class=\"graphic_footnotes\">PSG: polysomnography; NREM: non-rapid eye movement.</div><div id=\"graphicVersion\">Graphic 104167 Version 1.0</div></div></div>"},"104168":{"type":"graphic_table","displayName":"Diagnostic cardiac catheterization findings and implications","title":"Diagnostic cardiac catheterization findings and implications for anesthesiologists","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic cardiac catheterization findings and implications for anesthesiologists</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cardiac catheterization finding</td> <td class=\"subtitle1\">Implications for the anesthesiologist</td> </tr> <tr> <td>Coronary anatomy</td> <td>Knowledge of the coronary anatomy (right versus left dominance or codominance) and stenotic coronary lesions allows the anesthesiologist to better interpret intraoperative events such as ischemic ST-segment changes detected with ECG monitoring or LV RWMAs detected with TEE monitoring.</td> </tr> <tr> <td>Pulmonary artery pressure</td> <td>The presence and severity of&nbsp;pulmonary hypertension&nbsp;and the resultant degree of RV compromise influence decisions regarding whether a PAC should be inserted to monitor PAP and cardiac output and whether pulmonary vasodilator agents should be prepared, and also influence preparation of specific inotropic agents.</td> </tr> <tr> <td>Right atrial pressure&nbsp;and cardiac output</td> <td>An elevated RAP with reduced&nbsp;cardiac output&nbsp;indicates severe RV dysfunction and increased risk of intraoperative RV failure (eg, due to direct myocardial depressant effects of anesthetic agents; RV ischemia caused by systemic hypotension; or increased RV impedance caused by acute increases in PAP due to pain, hypoxemia, or hypercarbia).</td> </tr> <tr> <td>Hemoglobin saturation \"step-up\"</td> <td>A hemoglobin saturation \"step-up\" indicates a left-to-right heart shunt, with possible volume overload of the right heart chambers and&nbsp;associated complications (eg, tricuspid regurgitation, RA enlargement and supraventricular arrhythmias, RV dysfunction, and hepatic and venous congestion). (Refer to UpToDate topics on pathophysiology of left-to-right shunts.)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; LV: left ventricular; RWMA: regional wall motion abnormality; TEE: transesophageal echocardiography; PAP: pulmonary artery pressure; RV: right ventricular; PAC: pulmonary artery catheter; RAP: right atrial pressure;&nbsp;RA: right atrial.</div><div id=\"graphicVersion\">Graphic 104168 Version 2.0</div></div></div>"},"104169":{"type":"graphic_table","displayName":"Echocardiographic findings - implications for anesthesiologis","title":"Echocardiographic findingsÂ andÂ implications for anesthesiologists","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic findings&nbsp;and&nbsp;implications for anesthesiologists</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Echocardiographic finding</td> <td class=\"subtitle1\">Implications for the anesthesiologist</td> </tr> <tr> <td>LV and RV systolic function</td> <td>Use this information to plan: <ul class=\"decimal_heading\"> <li>Monitoring strategies (eg, whether to use TEE and/or a PAC) </li> <li>Choices of anesthetic and inotropic agents </li> <li>Potential need for perioperative mechanical circulatory support </li> </ul> </td> </tr> <tr> <td>LV diastolic function</td> <td> <ul> <li>Patients with milder degrees of LV diastolic dysfunction (ie, impaired relaxation) may benefit from enhanced preload and a longer diastolic time to allow more time for ventricular relaxation and filling. Thus, a slow heart rate (eg, 55 to 70 bpm) may be beneficial in these patients. </li> <li>Patients with more advanced degrees of diastolic dysfunction (ie, restrictive filling) have poor ventricular compliance and a fixed stroke volume. These patients typically need a normal heart rate (eg, 70 to 85 bpm) to generate an adequate cardiac output<sup>[1]</sup>. </li> </ul> </td> </tr> <tr> <td>RWMAs</td> <td> <ul> <li>Necessary for assessment of new RWMAs that may develop during surgery, as detected with TEE monitoring. Although new intraoperative RWMAs are not predictive of early graft failure<sup>[2]</sup>, they are associated with increased risk for adverse cardiac events in the long term<sup>[3]</sup>. </li> </ul> </td> </tr> <tr> <td>Ventricular dimensions</td> <td> <ul> <li><span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">The failing left or right ventricle&nbsp;undergoes compensatory chamber dilatation (ie, above-normal values for ventricular internal diameter and/or area measurements<sup>[4]</sup>) in order to maintain stroke volume.</span> Chamber dilatation leads to increased systolic wall stress. These patients are less sensitive to preload than those without chamber dilatation but are exquisitely sensitive to increases in afterload. </li> </ul> </td> </tr> <tr> <td>Valvular lesions</td> <td> <ul> <li>The presence and severity of valvular lesions (eg, mitral regurgitation, aortic stenosis) affects intraoperative hemodynamic goals and resultant anesthetic management. </li> </ul> </td> </tr> <tr> <td>Aortic atheroma</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>The presence of large or mobile atheroma in the ascending or descending aorta has been associated with a higher incidence of postoperative stroke.</li> </ul> </td> </tr> <tr> <td>Pericardial disease or effusion</td> <td> <ul> <li>While small pericardial effusions are generally well tolerated, a large effusion may indicate pericardial tamponade. Induction of anesthesia in a patient with cardiac tamponade may cause life-threatening cardiovascular collapse due to effects of anesthetic agents (eg, systemic vasodilation, decreased preload, and direct myocardial depression).&nbsp;Necessary planning requires communication&nbsp;among team members&nbsp;and preparation of induction agents with minimal myocardial depressant effects (eg, etomidate) and inotropic and/or vasopressor drugs. </li> <li>Cardiac surgery in patients with pericarditis or pericardial constriction typically results in significant blood loss. </li> </ul> </td> </tr> <tr> <td>Anatomic defects (eg, ASD or VSD)</td> <td> <ul> <li>A large ASD and/or VSD typically results in RV volume overload and increased PAP, with resultant reduced pulmonary compliance and increased work of breathing. Patients may be asymptomatic or may exhibit varying degrees of heart failure and/or pulmonary edema. </li> <li>Presence of a septal defect should prompt thorough intraoperative TEE evaluation for associated congenital cardiac anomalies (eg, coronary sinus defects, partial anomalous venous connection, or cleft anterior mitral valve leaflet). </li> </ul> </td> </tr> <tr> <td>Atrial or mural thrombi</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>The presence of thrombus in the left atrial appendage or apex of the&nbsp;left ventricle&nbsp;may alter the surgical plan (eg, thrombectomy or ligation of left atrial appendage). Intraoperative TEE is necessary to confirm whether the thrombus is still present before, during, and after surgery. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LV: left ventricular; RV: right ventricular; TEE: transesophageal echocardiography; PAC: pulmonary artery catheter; bpm: beats per minute; RWMA: regional wall motion abnormality; ASD: atrial septal defect; VSD: ventricular septal defect; PAP: pulmonary artery pressure.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>âNicoara A, Swaminathan M. Diastolic dysfunction, diagnostic and perioperative management in cardiac surgery. Curr Opin Anaesthesiol 2015; 28:60.</LI>&#xD;&#xA;<LI>De Mey N, Couture P, Laflamme M, et al. Intraoperative changes in regional wall motion: can postoperative coronary artery bypass graft failure be predicted? J Cardiothorac Vasc Anesth 2012; 26:371.</LI>&#xD;&#xA;<LI>Swaminathan M, Morris RW, De Meyts DD, et al. Deterioration of regional wall motion immediately after coronary artery bypass graft surgery is associated with long-term major adverse cardiac events. Anesthesiology 2007; 107:739.</LI>&#xD;&#xA;<LI>Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.</LI></OL></div><div id=\"graphicVersion\">Graphic 104169 Version 3.0</div></div></div>"},"104170":{"type":"graphic_algorithm","displayName":"Management of gallstones","title":"Management of gallstones in an outpatient who is currently asymptomatic*","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Management of gallstones in an outpatient who is currently asymptomatic*</div><div class=\"cntnt\"><img style=\"width:596px; height:552px;\" src=\"images/GAST/104170_Management_of_gallstones.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on the management of gallstones for a discussion of gallstone management in patients with active hemolytic disorders.<br />&para; Risk factors for gallbladder cancer include anomalous pancreatic ductal drainage, gallbladder adenomas, large gallstones (particularly &gt;3 cm), and porcelain gallbladder.<br />&Delta; Typical biliary colic is an intense, dull pain that is located in the right upper quadrant or epigastric area. It is often associated with diaphoresis, nausea, and vomiting, and lasts between 30 minutes and 6 hours (typically plateauing within an hour). Atypical symptoms include dyspepsia, nausea or vomiting without typical biliary pain, chest pain, nonspecific abdominal pain, and bloating.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate topics on the nonsurgical treatment of gallstones.</div><div id=\"graphicVersion\">Graphic 104170 Version 1.0</div></div></div>"},"104172":{"type":"graphic_table","displayName":"Choice of systemic therapy for renal clear-cell carcinoma","title":"Choice of systemic therapy for clear-cell renal cell carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choice of systemic therapy for clear-cell renal cell carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical setting</td> <td class=\"subtitle1\">Options</td> <td class=\"subtitle1\">Phase III results/comments</td> </tr> <tr class=\"divider_bottom\"> <td>No prior systemic therapy</td> <td>HD-IL-2*<sup>&#182;</sup></td> <td> <p>No survival advantage in a randomized trial</p> In retrospective studies, curative in a minority of carefully selected, favorable-risk patients</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">No prior systemic therapy, not a candidate for HD-IL-2</td> <td>Pazopanib*</td> <td> <p>Superior PFS to placebo</p> Good- and intermediate-risk patients: Efficacy similar to sunitinib, better quality of life, and less toxicity</td> </tr> <tr> <td>Sunitinib*</td> <td> <p>PFS superior to IFNa; efficacy similar to pazopanib</p> PFS superior to everolimus</td> </tr> <tr> <td>Cabozantinib</td> <td>PFS superior to sunitinib with similar toxicity; not yet approved for first-line treatment</td> </tr> <tr> <td>Temsirolimus</td> <td>Poor-prognosis patients: OS superior to IFNa</td> </tr> <tr> <td>Axitinib</td> <td>PFS marginally superior to sorafenib</td> </tr> <tr class=\"divider_bottom\"> <td>Bevacizumab plus IFNa</td> <td>PFS superior to placebo plus IFNa; option for patients without access to HD-IL-2, pazopanib, or sunitinib</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Prior immunotherapy (HD-IL-2), no prior targeted therapy</td> <td>Pazopanib or sunitinib (good or intermediate prognosis)*</td> <td>No randomized trials; recommendation based upon results in patients with no prior systemic therapy</td> </tr> <tr> <td>Axitinib*</td> <td>PFS superior to sorafenib</td> </tr> <tr class=\"divider_bottom\"> <td>Sorafenib</td> <td>PFS superior to placebo</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Prior targeted therapy, no prior immunotherapy</td> <td>Nivolumab*</td> <td>OS superior to everolimus; less toxicity than cabozantinib</td> </tr> <tr> <td>Cabozantinib</td> <td>PFS superior to everolimus; preferred where nivolumab not available</td> </tr> <tr> <td>Axitinib</td> <td>PFS superior to sorafenib</td> </tr> <tr class=\"divider_bottom\"> <td>Everolimus</td> <td>PFS ssuperior to placebo</td> </tr> <tr> <td rowspan=\"2\">Prior targeted therapy and prior PD-1 blocker</td> <td>Cabozantinib*</td> <td>No randomized trials; recommendation based upon results in patients with prior targeted therapy but no prior immunotherapy</td> </tr> <tr> <td>Axitinib</td> <td>PFS superior to sorafenib</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HD-IL-2: high-dose interleukin-2; PFS: progression-free survival; IFNa: interferon-alfa; OS: overall survival PD-1: programmed cell death protein 1.<br />* Preferred options.<br />Â¶ Bolus HD-IL-2 is an option for patients with good performance status, no significant comorbidity, and access to a&nbsp;center with experience managing the toxicities associated with this regimen.</div><div id=\"graphicVersion\">Graphic 104172 Version 2.0</div></div></div>"},"104173":{"type":"graphic_picture","displayName":"Stasis dermatitis and ulcer","title":"Stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104173_Stasis_drmtts_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stasis dermatitis surrounding venous insufficiency ulcers.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104173 Version 2.0</div></div></div>"},"104174":{"type":"graphic_picture","displayName":"Ischemic ulcer","title":"Ischemic ulcer","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ischemic ulcer</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104174_Ischemic_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated, \"punched-out\" ulcers with eschar on the lower extremity.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104174 Version 2.0</div></div></div>"},"104175":{"type":"graphic_picture","displayName":"Neuropathic ulcer on heel","title":"Neuropathic ulcer","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neuropathic ulcer</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104175_Nrpthc_ulcer_heel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Punched-out\" ulcer with surrounding callus on the heel.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104175 Version 1.0</div></div></div>"},"104176":{"type":"graphic_picture","displayName":"Pressure ulcer on leg","title":"Pressure ulcer","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pressure ulcer</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104176_Pressure_ulcer_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure ulcer overlying a bony prominence on the distal leg.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104176 Version 1.0</div></div></div>"},"104182":{"type":"graphic_picture","displayName":"Gummatous syphilis","title":"Gummatous syphilis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Gummatous syphilis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104182_Gummatous_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gumma on the leg of a patient with tertiary syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104182 Version 1.0</div></div></div>"},"104186":{"type":"graphic_table","displayName":"Maternal early warning criteria","title":"Maternal early warning criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal early warning criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td>Systolic BP (mm Hg)</td> <td>&#60;90 or &#62;160</td> </tr> <tr> <td>Diastolic BP (mm Hg)</td> <td>&#62;100</td> </tr> <tr> <td>Heart rate (beats per min)</td> <td>&#60;50 or &#62;120</td> </tr> <tr> <td>Respiratory rate (breaths per min)</td> <td>&#60;10 or &#62;30</td> </tr> <tr> <td>Oxygen saturation on room air, at sea level, %</td> <td>&#60;95</td> </tr> <tr> <td>Oliguria, mL/hr for &#8805;2 hours</td> <td>&#60;35</td> </tr> <tr> <td colspan=\"2\">Maternal agitation, confusion, or unresponsiveness; patient with preeclampsia reporting a non-remitting headache or shortness of breath</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These triggers cannot address every possible clinical scenario that could be faced by an obstetric clinician and must not replace clinical judgment. As a core safety principle, bedside nurses should always feel comfortable to escalate their concerns at any point.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">From: Mhyre JM, D'Oria R, Hameed AB, et al. The maternal early warning criteria: A proposal from the national partnership for maternal safety. Obstet Gynecol 2014; 124:782. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=10000&amp;article=00019&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/AOG.0000000000000480</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American College of Obstetricians and Gynecologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104186 Version 1.0</div></div></div>"},"104187":{"type":"graphic_picture","displayName":"Cryoprobe","title":"Flexible cryoprobe","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Flexible cryoprobe</div><div class=\"cntnt\"><img style=\"width:666px; height:324px;\" src=\"images/PULM/104187_Cryoprobe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexible cryoprobe with dimensions of 1.9 mm by 900 mm. This probe can be easily passed through the working channel of a flexible bronchoscope.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Erbe USA, Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104187 Version 1.0</div></div></div>"},"104188":{"type":"graphic_picture","displayName":"Thromboangiitis obliterans","title":"Thromboangiitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Thromboangiitis obliterans</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/104188_Thrmbngts_obltrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital ulcers in a patient with thromboangiitis obliterans (Buerger's disease).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104188 Version 1.0</div></div></div>"},"104189":{"type":"graphic_picture","displayName":"Cryoglobulinemia","title":"Cryoglobulinemia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104189_Cryoglobulinemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower extremity ulcers in cryoglobulinemia.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104189 Version 1.0</div></div></div>"},"104190":{"type":"graphic_picture","displayName":"Recluse spider bite ulcer","title":"Recluse spider bite","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Recluse spider bite</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104190_Recluse_spdr_bite_ulcr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic ulcer at the site of a recluse spider bite.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104190 Version 1.0</div></div></div>"},"104201":{"type":"graphic_table","displayName":"Targeted phototherapy indications","title":"Indications for targeted phototherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for targeted phototherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical indications</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"indent1\">Vitiligo</td> </tr> <tr> <td class=\"indent1\">Mycosis fungoides</td> </tr> <tr> <td class=\"indent1\">Atopic dermatitis </td> </tr> <tr> <td class=\"indent1\">Pityriasis lichenoides</td> </tr> <tr> <td class=\"indent1\">Urticaria pigmentosa</td> </tr> <tr> <td class=\"indent1\">Morphea</td> </tr> <tr> <td class=\"indent1\">Scleroderma</td> </tr> <tr> <td class=\"indent1\">Granuloma annulare</td> </tr> <tr> <td class=\"indent1\">Lichen planus</td> </tr> <tr> <td class=\"indent1\">Lichen simplex chronicus</td> </tr> <tr> <td class=\"indent1\">Alopecia areata</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Mehraban S, Feily A. 308nm excimer laser in dermatology. J Lasers Med Sci 2014; 5:8.</div><div id=\"graphicVersion\">Graphic 104201 Version 1.0</div></div></div>"},"104206":{"type":"graphic_table","displayName":"DSM-5 diagnostic criteria for illness anxiety disorder","title":"DSM-5 diagnostic criteria for illness anxiety disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-5 diagnostic criteria for illness anxiety disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>A.</strong> Preoccupation with having or acquiring a serious illness.</td> </tr> <tr> <td><strong>B.</strong> Somatic symptoms are not present or, if present, are only mild in intensity. If another medical condition is present or there is a high risk for developing a medical condition (eg, strong family history is present), the preoccupation is clearly excessive or disproportionate.</td> </tr> <tr> <td><strong>C.</strong> There is a high level of anxiety about health, and the individual is easily alarmed about personal health status.</td> </tr> <tr> <td><strong>D.</strong> The individual performs excessive health-related behaviors (eg, repeatedly checks his or her body for signs of illness) or exhibits maladaptive avoidance (eg, avoids doctor appointments and hospitals).</td> </tr> <tr> <td><strong>E.</strong> Illness preoccupation has been present for at least six months, but the specific illness that is feared may change over that period of time.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>F.</strong> The illness-related preoccupation is not better explained by another mental disorder, such as somatic symptom disorder, panic disorder, generalized anxiety disorder, body dysmorphic disorder, obsessive-compulsive disorder, or delusional disorder, somatic type.</td> </tr> <tr> <td><em>Specify</em> whether:</td> </tr> <tr> <td class=\"indent1\"><strong>Care-seeking type:</strong> Medical care, including physician visits or undergoing tests and procedures, is frequently used.</td> </tr> <tr> <td class=\"indent1\"><strong>Care-avoidant type:</strong> Medical care is rarely used.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright &copy; 2013). American Psychiatric Association. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 104206 Version 2.0</div></div></div>"},"104207":{"type":"graphic_table","displayName":"7 item Whiteley Index","title":"7 item Whiteley Index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">7 item Whiteley Index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Circle \"yes\" or \"no\" for each question.</td> </tr> <tr> <td class=\"subtitle2_single\">1. Do you think there is something seriously wrong with your body?</td> </tr> <tr> <td class=\"indent2\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">No</td> </tr> <tr> <td class=\"subtitle2_single\">2. Do you worry a lot about your health?</td> </tr> <tr> <td class=\"indent2\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">No</td> </tr> <tr> <td class=\"subtitle2_single\">3. Is it hard for you to believe the doctor when he tells you there is nothing to worry about?</td> </tr> <tr> <td class=\"indent2\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">No</td> </tr> <tr> <td class=\"subtitle2_single\">4. Do you often worry about the possibility that you have a serious illness?</td> </tr> <tr> <td class=\"indent2\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">No</td> </tr> <tr> <td class=\"subtitle2_single\">5. Are you bothered by many different pains or aches?</td> </tr> <tr> <td class=\"indent2\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">No</td> </tr> <tr> <td class=\"subtitle2_single\">6. If a disease is brought to your attention (eg, on TV, radio, the newspapers, or by someone you know), do you worry about getting it yourself?</td> </tr> <tr> <td class=\"indent2\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">No</td> </tr> <tr> <td class=\"subtitle2_single\">7. Do you find that you are bothered by many different symptoms?</td> </tr> <tr> <td class=\"indent2\">Yes</td> </tr> <tr> <td class=\"indent2\">No</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Fink P, Ewald H, Jensen J, et al. Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatization. J Psychosom Res 1999; 46:261.</div><div id=\"graphicVersion\">Graphic 104207 Version 1.0</div></div></div>"},"104208":{"type":"graphic_table","displayName":"Type of BCG infection in 282 patients","title":"Type of BCG infection in 282 patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Type of BCG infection in 282 patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of complication</td> <td class=\"subtitle1\">Number of patients (%)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic</td> </tr> <tr> <td class=\"indent1\">Disseminated BCG infection</td> <td class=\"centered\">97 (34.4)</td> </tr> <tr> <td class=\"indent1\">Persistent fever (as isolated manifestation)</td> <td class=\"centered\">4 (1.4)</td> </tr> <tr> <td class=\"indent1\">Osteomuscular</td> <td class=\"centered\">56 (19.9)</td> </tr> <tr> <td class=\"indent2\">Arthritis</td> <td class=\"centered\">20 (7.1)</td> </tr> <tr> <td class=\"indent2\">Reactive arthritis</td> <td class=\"centered\">16 (5.7)</td> </tr> <tr> <td class=\"indent2\">Spondylodiscitis</td> <td class=\"centered\">10 (3.5)</td> </tr> <tr> <td class=\"indent2\">Prosthetic joint infection</td> <td class=\"centered\">5 (1.8)</td> </tr> <tr> <td class=\"indent2\">Muscle abscess (as isolated manifestation)*</td> <td class=\"centered\">5 (1.8)</td> </tr> <tr> <td class=\"indent1\">Vascular</td> <td class=\"centered\">19 (6.7)</td> </tr> <tr> <td class=\"indent2\">Mycotic aneurysm or pseudoaneurysm<sup>&#182;</sup></td> <td class=\"centered\">13 (4.6)</td> </tr> <tr> <td class=\"indent2\">Mycotic aneurysm with fistulization</td> <td class=\"centered\">2 (0.7)</td> </tr> <tr> <td class=\"indent2\">Aorto-enteric fistula</td> <td class=\"centered\">2 (0.7)</td> </tr> <tr> <td class=\"indent2\">Infection of vascular bypass graft</td> <td class=\"centered\">2 (0.7)</td> </tr> <tr> <td class=\"indent1\">Ocular (with no articular involvement)</td> <td class=\"centered\">9 (3.2)</td> </tr> <tr> <td class=\"indent2\">Uveitis</td> <td class=\"centered\">7 (2.4)</td> </tr> <tr> <td class=\"indent2\">Endophthalmitis</td> <td class=\"centered\">1 (0.4)</td> </tr> <tr> <td class=\"indent2\">Autoimmune retinopathy</td> <td class=\"centered\">1 (0.4)</td> </tr> <tr> <td class=\"indent1\">Hepatitis (as isolated manifestation)</td> <td class=\"centered\">16 (5.7)</td> </tr> <tr> <td class=\"indent1\">Cutaneous<sup>&#916;</sup></td> <td class=\"centered\">4 (1.4)</td> </tr> <tr> <td class=\"indent1\">Pulmonary (other than miliary tuberculosis)</td> <td class=\"centered\">2 (0.7)</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> <td class=\"centered\">1 (0.4)</td> </tr> <tr> <td class=\"indent1\">Other<sup>&#9674;</sup></td> <td class=\"centered\">6 (2.1)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mixed complications<sup>&#167;</sup></td> <td class=\"centered\">2 (0.7)</td> </tr> <tr> <td class=\"subtitle2_left\">Local (genitourinary)</td> <td class=\"subtitle2_left centered\">66 (23.4)</td> </tr> <tr> <td class=\"indent1\">Bladder involvement</td> <td class=\"centered\">17 (5.9)</td> </tr> <tr> <td class=\"indent1\">Penile lesions</td> <td class=\"centered\">17 (5.9)</td> </tr> <tr> <td class=\"indent1\">Prostatitis</td> <td class=\"centered\">11 (3.5)</td> </tr> <tr> <td class=\"indent1\">Kidney parenchymal involvement</td> <td class=\"centered\">10 (3.5)</td> </tr> <tr> <td class=\"indent1\">Epididymo-orchitis</td> <td class=\"centered\">10 (3.5)</td> </tr> <tr> <td class=\"indent1\">Pyeloureteral stenosis</td> <td class=\"centered\">1 (0.35)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BCG: Bacillus Calmette-Guerin.<br />* Overall, 11 patients (3.9%) were diagnosed with muscle abscess: three additional cases were secondary to spondylodiscitis; two were secondary to mycotic aneurysm or pseudoaneurysm; and one was secondary to infection of hip prosthesis.<br />&para; Overall, 16 patients (5.7%) were diagnosed with mycotic aneurysm: one additional case was secondary to spondylodiscitis.<br />&Delta; Includes subcutaneous nodules (two cases), plaque and abscess (one case each).<br /><span class=\"lozenge\">&loz;</span> Includes peritoneal tuberculosis (two cases), parotid gland tuberculosis, enteritis, rhabdomyolysis, and prevesical abscess (one case each).<br />&sect; Includes one case of pleuropericardic effusion with arthritis and penile lesion, and one case of cold abscess of the chest wall with rash and penile lesion.</div><div class=\"graphic_reference\">From: P&eacute;rez-Jacoiste As&iacute;n MA, Fern&aacute;ndez-Ruiz M, L&oacute;pez-Medrano F, et al. Bacillus Calmette-Gu&eacute;rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 2014; 93:236. DOI: <a href=\"http://journals.lww.com/md-journal/pages/articleviewer.aspx?year=2014&amp;issue=10030&amp;article=00001&amp;type=abstract\" target=\"_blank\">10.1097/MD.0000000000000119</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104208 Version 1.0</div></div></div>"},"104209":{"type":"graphic_algorithm","displayName":"Intravesical BCG instillation","title":"Intravesical BCG instillation","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Intravesical BCG instillation</div><div class=\"cntnt\"><img style=\"width:706px; height:502px;\" src=\"images/ONC/104209_Intravesical_BCG_instillatn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposal of a diagnostic and therapeutic algorithm for patients with suspected BCG infection following BCG instillation. The terms \"low-grade\" and \"high-grade fever\" refer to body temperature &lt;37.9Â°C and â¥38Â°C, respectively.</div><div class=\"graphic_footnotes\">BCG: Bacillus Calmette-GuÃ©rin; NSAIDs: non-steroidal anti-inflammatory drugs; TB: tuberculosis; INH: isoniazid; RIF: rifampin; EMB: ethambutol.<br />* Antituberculosis treatment should include INH, RIF, and EMB for 2 months, and INH and RIF for 4 more months.<br />Â¶ Continuation of BCG instillations could be considered in patients with persistent fever and no miliary pattern on chest imaging, once antituberculosis treatment has been completed, and only if the expected benefits of BCG therapy clearly exceed the risks (that is, high-grade carcinoma).</div><div class=\"graphic_reference\">From: P&eacute;rez-Jacoiste As&iacute;n MA, Fern&aacute;ndez-Ruiz M, L&oacute;pez-Medrano F, et al. Bacillus Calmette-Gu&eacute;rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 2014; 93:236. DOI: <a href=\"http://journals.lww.com/md-journal/pages/articleviewer.aspx?year=2014&amp;issue=10030&amp;article=00001&amp;type=abstract\" target=\"_blank\">10.1097/MD.0000000000000119</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104209 Version 1.0</div></div></div>"},"104210":{"type":"graphic_figure","displayName":"Timing of sleep-related movements and behaviors","title":"Timing of sleep-related movements and behaviors throughout the sleep period","html":"<div class=\"graphic\"><div style=\"width: 940px\" class=\"figure\"><div class=\"ttl\">Timing of sleep-related movements and behaviors throughout the sleep period</div><div class=\"cntnt\"><img style=\"width:920px; height:417px;\" src=\"images/SLEEP/104210_Time_sleep-rltd_mvmnts_bhvr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">REM: rapid eye movement.<br />* Examples include hypnic jerks, hypnagogic foot tremor, periodic limb movements, and sleep-related rhythmic movement disorder.<br />Â¶ Disorders of arousal from non-REM sleep include confusional arousals, sleep-related abnormal sexual behavior, sleep terrors, sleepwalking, and sleep-related eating disorder.</div><div id=\"graphicVersion\">Graphic 104210 Version 2.0</div></div></div>"},"104212":{"type":"graphic_figure","displayName":"CPAP studies forest plot","title":"CPAP studies forest plot","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">CPAP studies forest plot</div><div class=\"cntnt\"><img style=\"width:604px; height:537px;\" src=\"images/PC/104212_CPAP_stdy_frst_plt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data were calculated by a random effects model. Studies were stratified by baseline depression score. Boxes are SMDs, and lines are 95% CIs. The vertical solid line represents no difference between CPAP and control. Values to the right of the solid line favor CPAP benefit. Pooled SMDs and 95% CIs are represented by the diamond shapes.</div><div class=\"graphic_footnotes\">SMD: standardized mean difference; CPAP: continuous positive airway pressure.</div><div class=\"graphic_reference\">Reproduced from: Povitz M, Bolo CE, Heitman SJ. Effect of treatment of obstructive sleep apnea on depressive symptoms: systematic review and meta-analysis. PLoS Med 2014; 11:e1001762. Copyright &copy; 2014 Povitz et al. This graphic has been reproduced under the terms of the <a href=\"http://creativecommons.org/licenses/by/4.0/\" spellcheck=\"true\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 104212 Version 1.0</div></div></div>"},"104213":{"type":"graphic_table","displayName":"Meta-regression analysis for effect of CPAP","title":"Meta-regression analysis for effect of CPAP on depressive symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Meta-regression analysis for effect of CPAP on depressive symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CPAP treatment</td> <td class=\"subtitle1\">Pooled SMD (95% CI)</td> <td class=\"subtitle1\">p-Statistic (95% CI)</td> <td class=\"subtitle1\">p-Value from meta-regression</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Overall</strong></td> <td><strong>0.312 (0.099, 0.525)</strong></td> <td><strong>71 (54, 82)</strong></td> <td><strong>&ndash;</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">RCT design</td> </tr> <tr> <td class=\"indent1\">Parallel</td> <td>0.506 (0.196, 0.817)</td> <td>78 (62, 87)</td> <td>0.076</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Crossover</td> <td>0.063 (&ndash;0.116, 0.243)</td> <td>0 (0, 71)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Depression measurement tool</td> </tr> <tr> <td class=\"indent1\">SF-36 MH or SF-36 MCS</td> <td>0.259 (0.01, 0.509)</td> <td>61 (19, 81)</td> <td>0.725</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other depression scale</td> <td>0.373 (0.001, 0.745)</td> <td>79 (61, 88)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">OSA severity*</td> </tr> <tr> <td class=\"indent1\">Mild to moderate</td> <td>0.457 (0.063, 0.85)</td> <td>84 (70, 91)</td> <td>0.408</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Severe</td> <td>0.228 (&ndash;0.002, 0.458)</td> <td>48 (0, 74)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Blinding</td> </tr> <tr> <td class=\"indent1\">No</td> <td>0.389 (0.093, 0.686)</td> <td>76 (57, 87)</td> <td>0.508</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Yes</td> <td>0.214 (&ndash;0.112, 0.54)</td> <td>67 (29, 84)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Trial length</td> </tr> <tr> <td class=\"indent1\">&#60;4 weeks</td> <td>0.31 (&ndash;0.107, 0.728)</td> <td>58 (0, 83)</td> <td>0.708</td> </tr> <tr> <td class=\"indent1\">4 to 8 weeks</td> <td>0.385 (&ndash;0.038, 0.807)</td> <td>83 (70, 91)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">8+ weeks</td> <td>0.202 (0.042, 0.363)</td> <td>0 (0, 85)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Mean adherence</td> </tr> <tr> <td class=\"indent1\">&#60;4 hours/night</td> <td>0.472 (0.131, 0.813)</td> <td>80 (65, 88)</td> <td>0.213</td> </tr> <tr> <td class=\"indent1\">4+ hours/night</td> <td>0.161 (&ndash;0.001, 0.323)</td> <td>0 (0, 75)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Not reported</td> <td>0.086 (&ndash;0.451, 0.623)</td> <td>&ndash;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Baseline depression</td> </tr> <tr> <td class=\"indent1\">No</td> <td>0.197 (0.059, 0.334)</td> <td>30 (0, 61)</td> <td>&#60;0.001</td> </tr> <tr> <td class=\"indent1\">Yes</td> <td>2.004 (1.387, 2.621)</td> <td>12 (&ndash;)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Meta-regression was performed to explore heterogeneity of pooled SMDs in depression scores for CPAP treatment versus control. Positive values indicate a greater improvement in depression symptoms with CPAP treatment than control. I2 statistic provides a measure of heterogeneity, with lower values indicating less heterogeneity. p-Values were considered significant with an alpha of 0.10. Dashes indicate values that could not be calculated.</div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; SMD: standardized mean difference; RCT: randomized controlled trial; MH: mental health; MDC: mental component summary; OSA: obstructive sleep apnea; AHI: Apnea&ndash;Hypopnea Index; RDI: respiratory disturbance index.<br />* Mild to moderate OSA defined as AHI/RDI &lt;30 or ODI &lt;20. Severe OSA defined as AHI/RDI &gt;30 or ODI &gt;20.</div><div class=\"graphic_reference\">Reproduced from: Povitz M, Bolo CE, Heitman SJ. Effect of treatment of obstructive sleep apnea on depressive symptoms: systematic review and meta-analysis. PLoS Med 2014; 11:e1001762. Copyright &copy; 2014 Povitz et al. This table has been reproduced under the terms of the <a href=\"http://creativecommons.org/licenses/by/4.0/\" spellcheck=\"true\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 104213 Version 1.0</div></div></div>"},"104216":{"type":"graphic_algorithm","displayName":"Treatment of essential tremor","title":"Treatment of essential tremor","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Treatment of essential tremor</div><div class=\"cntnt\"><img style=\"width:656px; height:628px;\" src=\"images/NEURO/104216_Treatment_essential_tremor.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Rajput AH, Rajput A. Medical treatment of essential tremor. J Cent Nerv Syst Dis 2014; 6:29.</div><div id=\"graphicVersion\">Graphic 104216 Version 1.0</div></div></div>"},"104220":{"type":"graphic_algorithm","displayName":"Diagnosis of AAT deficiency","title":"Algorithm for the diagnosis of alpha-1 antitrypsin deficiency","html":"<div class=\"graphic\"><div style=\"width: 858px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of alpha-1 antitrypsin deficiency</div><div class=\"cntnt\"><img style=\"width:838px; height:388px;\" src=\"images/PULM/104220_Diagnosis_AAT_deficiency.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AAT: alpha-1 antitrypsin; PCR: polymerase chain reaction (looks for specific AAT alleles); IEF: isoelectric focusing (assesses protein migration).<br />* Alternatively, in patients with a high clinical suspicion of AAT deficiency, such as those with neonatal cholestasis or childhood cirrhosis, a genotype PCR test may be the first step.<br />Â¶ Either IEF or genotype PCR is acceptable for diagnosis of AAT deficiency; no need to confirm with alternative test if result is clear and consistent with AAT level.<br />Î AAT is an acute phase reactant, so a low AAT may increase into the normal range during acute illness.</div><div id=\"graphicVersion\">Graphic 104220 Version 3.0</div></div></div>"},"104224":{"type":"graphic_algorithm","displayName":"Management of iliac artery aneurysm","title":"Management of iliac artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of iliac artery aneurysm</div><div class=\"cntnt\"><img style=\"width:434px; height:422px;\" src=\"images/SURG/104224_Mng_ilc_artry_anrysm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IAA: iliac artery aneurysm; AAA: abdominal aortic aneurysm.<br />* Indications for AAA include: symptomatic or ruptured AAA; or asymptomatic AAA with diameter &gt;5.5 cm or rapid expansion &gt;0.5 cm/year or associated with other peripheral artery aneurysm or peripheral artery disease requiring repair.<br />Â¶ Imaging every six months after diagnosis, then if stable, annual surveillance.<br />Î More than 1.0 cm/year or 0.7 cm in six months.<br /><FONT class=lozenge>â</FONT> Endovascular repair is generally preferred; open repair may be appropriate if decompressing the aneurysm sac is necessary to relieve symptoms, or if preserving internal iliac artery flow is critical and endovascular means are not feasible.<br />Â§ Method of repair determined by aortoiliac anatomy and pelvic circulation. Endovascular coil embolization of the hypogastric artery may be needed to achieve a proper seal of the endovascular graft components. Bilateral coil embolization for bilateral iliac aneurysm associated with AAA is less desirable, and if necessary, is better performed as a staged endovascular procedure.</div><div id=\"graphicVersion\">Graphic 104224 Version 2.0</div></div></div>"},"104227":{"type":"graphic_diagnosticimage","displayName":"Thoracic vertebral burst fracture CT and MRI","title":"Thoracic vertebral burst fracture CT and MRI","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Thoracic vertebral burst fracture CT and MRI</div><div class=\"cntnt\"><img style=\"width:574px; height:654px;\" src=\"images/EM/104227_Spinal_column_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These computed tomography (CT) and magnetic resonance&nbsp;images&nbsp;show a thoracic injury&nbsp;sustained by&nbsp;a 30-year-old man who was a restrained passenger in a high-speed, head-on motor vehicle collision. The patient was neurologically intact.<br /><br />(A) A sagittal reconstruction of the thoracic&nbsp;spine demonstrates a flexion distraction type injury with a burst component that involves the T5 and T6 vertebral bodies. Also evident are fractures of the spinous processes of T3, T4, and T6.<br /><br />(B) The axial CT image of the T6 vertebral body shows fractures of the anterior, middle, and posterior columns (ie, lamina fracture), but no evidence of retropulsion of bone into the spinal canal.<br /><br />(C) A sagittal T2-weighted magnetic resonance image demonstrates fracture of the T5 and T6 vertebral bodies as well as probable disruption of the posterior ligamentous complex at this level.</div><div class=\"graphic_reference\">Reproduced with permission from: Kim DH, Rihn JA, Albert TJ. Anterior and posterior instrumentation techniques used in the thoracic spine for treatment of fractures. In: The Textbook of Spinal Surgery, 3rd Ed, Bridwell KH, DeWald RL, Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 104227 Version 2.0</div></div></div>"},"104279":{"type":"graphic_algorithm","displayName":"Pathogenesis of rheumatic MV disease","title":"Pathogenesis of rheumatic mitral valve disease","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of rheumatic mitral valve disease</div><div class=\"cntnt\"><img style=\"width:622px; height:446px;\" src=\"images/CARD/104279_First_episode_of_ARC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the theoretical pathway for the various phenotypic manifestations of rheumatic MV disease. The initial inflammatory response following the first episode of ARC determines the degree and extent of structural involvement of the MV apparatus. Severe inflammation of the chordal structures and MV leaflets often lead to severe MR in the very young, whereas moderate inflammation followed by repeated bouts of ARC is more likely to cause mixed MV disease (MR and MS) later in life. Isolated MS is usually the consequence of milder or even subclinical forms of ARC followed by episodes of recurrent carditis. In developing countries where the risk of recurrent ARC is high, MS presents at a younger age and the valve leaflets are more likely to be pliable and not calcified. In Western societies where the risk of recurrent ARC is low, MS presents later in life, and the MV leaflets are more likely to be rigid and calcified.</div><div class=\"graphic_footnotes\">ARC: acute rheumatic carditis; MS: mitral stenosis; MV: mitral valve; MR: mitral regurgitation.</div><div class=\"graphic_reference\">Courtesy of Theo Meyer, MD, PhD.</div><div id=\"graphicVersion\">Graphic 104279 Version 3.0</div></div></div>"},"104280":{"type":"graphic_figure","displayName":"Transmitral gradients with varying MVA and HR","title":"Transmitral gradients with varying mitral valve area, heart rate, and cardiac output","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Transmitral gradients with varying mitral valve area, heart rate, and cardiac output</div><div class=\"cntnt\"><img style=\"width:548px; height:418px;\" src=\"images/CARD/104280_Gorlinformula.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using the Gorlin formula, the relationship between heart rate, mean transmitral gradient, and four different MVAs (2, 1.5, 1, and 0.7 cm<SUP>2</SUP>) are shown at a cardiac output of 5 liters/min. For each decrement in MVA, there is steeper rise in mean transmitral gradient with increasing heart rates (shorter diastolic filling times).<br />In a patient with an MVA of 1.5 cm<SUP>2</SUP>, the impact of an increase in cardiac output (9 liters/min) at heart rate of 100 beats/min is shown in the arrowed black box; this scenario is often encountered during exertion and in pregnant women. The mean transmitral gradient is similar to that seen in a patient with severe mitral stenosis (MVA of 0.7 cm<SUP>2</SUP>) at heart rate of 88 beats/min.</div><div class=\"graphic_footnotes\">MVA: mitral valve area.</div><div class=\"graphic_reference\">Courtesy of Theo Meyer, MD, PhD.</div><div id=\"graphicVersion\">Graphic 104280 Version 5.0</div></div></div>"},"104283":{"type":"graphic_algorithm","displayName":"Hemodynamic and structural sequelae of MS","title":"Hemodynamic alterations and structural sequelae of mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Hemodynamic alterations and structural sequelae of mitral stenosis</div><div class=\"cntnt\"><img style=\"width:596px; height:556px;\" src=\"images/CARD/104283_Hmdyn_alt_strct_sequelae_MS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the progressive hemodynamic alterations and structural sequelae of mitral stenosis. Obstruction to flow through the stenotic valve leads to chronic LA pressure overload, which over time results in PVH and LA enlargement. Remodeling of the LA is the substrate of atrial fibrillation and in-situ thrombi. An enlarged LA may cause left recurrent laryngeal nerve compression. PVH promotes broncho-pulmonary venous anastomoses and passively increases pulmonary arterial pressures. In another group of patients with mitral stenosis, PAH bears little relationship to the LA pressure. This type of reactive PAH is due to vasoconstriction and pathological remodeling of the pulmonary vasculature (medial hypertrophy and intimal hyperplasia). The vascular remodeling and in-situ arteriolar thrombosis promote progressive PAH, RV pressure overload, RV dilation, and TR.</div><div class=\"graphic_footnotes\">RV: right ventricular; TR: tricuspid regurgitation; PAH: pulmonary arterial hypertension; PVH: pulmonary venous hypertension; LA: left atrial.</div><div class=\"graphic_reference\">Courtesy of Theo Meyer, MD, PhD.</div><div id=\"graphicVersion\">Graphic 104283 Version 3.0</div></div></div>"},"104381":{"type":"graphic_diagnosticimage","displayName":"Proximal interphalangeal joint dislocation in a child","title":"Proximal interphalangeal joint dislocation in a child","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Proximal interphalangeal joint dislocation in a child</div><div class=\"cntnt\"><img style=\"width:646px; height:722px;\" src=\"images/EM/104381_Prx_intrphlng_jnt_dslct_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This child sustained a proximal interphalangeal joint dislocation of the little finger (fifth digit). Note that the portion of the finger&nbsp;distal to&nbsp;the dislocation is dorsally displaced and pulled back towards the hand.<br />(B) Post reduction radiograph shows return of normal alignment and no fracture. The child was also able to flex the finger which excluded a volar plate dislocation.</div><div class=\"graphic_reference\">Courtesy of Samir Joshi, MD.</div><div id=\"graphicVersion\">Graphic 104381 Version 1.0</div></div></div>"},"104383":{"type":"graphic_diagnosticimage","displayName":"Incomplete dislocation of the thumb","title":"Incomplete dislocation of the thumb","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Incomplete dislocation of the thumb</div><div class=\"cntnt\"><img style=\"width:571px; height:719px;\" src=\"images/EM/104383_Incmplt_dslct_thmb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The position of thumb at approximately 45 degrees of displacement relative to the thumb metacarpal phalanx indicates volar plate ligament disruption with some preservation of collateral ligament function.<br />(B) The post-reduction film shows normal alignment and no fracture. This patient received a thumb spica splint and subsequently did well.</div><div class=\"graphic_reference\">Courtesy of Samir Joshi, MD.</div><div id=\"graphicVersion\">Graphic 104383 Version 1.0</div></div></div>"},"104385":{"type":"graphic_diagnosticimage","displayName":"Lateral dislocation of the fifth PIP joint","title":"Lateral dislocation of the fifth proximal interphalangeal joint","html":"<div class=\"graphic\"><div style=\"width: 841px\" class=\"figure\"><div class=\"ttl\">Lateral dislocation of the fifth proximal interphalangeal joint</div><div class=\"cntnt\"><img style=\"width:821px; height:477px;\" src=\"images/EM/104385_Ltr_dslct_ffth_PIP_jnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral dislocation of the fifth PIP (little finger) was caused by a medial force that disrupted the collateral ligament.</div><div class=\"graphic_footnotes\">PIP: proximal interphalangeal.</div><div class=\"graphic_reference\">Courtesy of Samir Joshi, MD.</div><div id=\"graphicVersion\">Graphic 104385 Version 1.0</div></div></div>"},"104402":{"type":"graphic_algorithm","displayName":"Vertebral osteomyelitis algorithm","title":"Clinical approach to vertebral osteomyelitis in adults","html":"<div class=\"graphic\"><div style=\"width: 1172px\" class=\"figure\"><div class=\"ttl\">Clinical approach to vertebral osteomyelitis in adults</div><div class=\"cntnt\"><img style=\"width:1152px; height:1088px;\" src=\"images/ID/104402_Vertebral_osteo_clin_appr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MRI: magnetic resonance imaging; CT: computed tomography.<br />* Additional diagnostic testing may be warranted based on epidemiologic factors (eg, to evaluate for infection due to brucellosis or tuberculosis); refer to UpToDate topic on vertebral osteomyelitis and discitis in adults for discussion.<br />&para; Refer to UpToDate topic on vertebral osteomyelitis and discitis in adults for discussion of characteristic radiographic findings, differential diagnosis, and approach to antibiotic selection.<br />&Delta; A needle biopsy may not be necessary in patients with clinical and radiographic findings typical of vertebral osteomyelitis and positive blood cultures with a likely pathogen; refer to UpToDate topic on vertebral osteomyelitis and discitis in adults for further discussion.<br /><span class=\"lozenge\">&loz;</span> Biopsy material should be sent for bacterial (aerobic and anaerobic) culture, fungal culture, and mycobacterial culture in addition to histologic examination.</div><div id=\"graphicVersion\">Graphic 104402 Version 1.0</div></div></div>"},"104410":{"type":"graphic_figure","displayName":"Comparison of pharmacokinetics for IVIG, fSCIG, and SCIG","title":"Comparison of pharmacokinetics for intravenous and subcutaneous immune globulin","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Comparison of pharmacokinetics for intravenous and subcutaneous immune globulin</div><div class=\"cntnt\"><img style=\"width:608px; height:438px;\" src=\"images/ALLRG/104410_Pharmacokintcs_IVIG_vs_SCIG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immune globulin pharmacokinetics for IVIG, SCIG, and fSCIG administration. The graph shows an illustration of the differences in the levels of IgG in the blood following IVIG (red-dotted) and fSCIG infusion (blue-solid), both given as a first infusion, compared with traditional SCIG (gray-dashed), shown at a steady-state over a 28-day time period. The differences in the pharmacokinetics of the three delivery modalities show the loss of the IVIG peak level with fSCIG, followed by a similar gradual decline in IgG levels over the dosing cycle. Traditional SCIG at steady-state is characterized by very stable levels and a higher \"trough\" IgG level than IVIG or fSCIG.&nbsp;Levels of IgG&nbsp;on the y-axis are given in g/L. Equivalent values in mg/dL are 0 to 2500 mg/dL.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IVIG: intravenous immune globulin; fSCIG: facilitated subcutaneous immune globulin; SCIG: subcutaneous immune globulin.</div><div class=\"graphic_reference\">Republished with permission of Dove Medical Press Ltd., from Jolles S, Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency, ImmunoTargets and Therapy 2013; Vol. 2: Pg. 125; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 104410 Version 2.0</div></div></div>"},"104413":{"type":"graphic_figure","displayName":"Anatomic relationships during mediastinoscopy","title":"Anatomic relationships during mediastinoscopy","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Anatomic relationships during mediastinoscopy</div><div class=\"cntnt\"><img style=\"width:624px; height:522px;\" src=\"images/ANEST/104413_Antmc_rltnshps_mediastnscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Ehrenwerth J, Brull S. Anesthesia for thoracic diagnostic procedures. In: Thoracic Anesthesia, 3rd ed, Kaplan JA, Slinger PD (Eds), Elsevier 2003. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104413 Version 2.0</div></div></div>"},"104414":{"type":"graphic_picture","displayName":"Anesthesia machine circuit with nasal cannula tubing adaptor","title":"Standard anesthesia machine breathing circuit with adaptor to fit nasal cannula tubing","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Standard anesthesia machine breathing circuit with adaptor to fit nasal cannula tubing</div><div class=\"cntnt\"><img style=\"width:684px; height:513px;\" src=\"images/ANEST/104414_Ansths_nasal_cannula_tubing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For anesthesia machines without a common gas outlet, adjustment of oxygen concentration during open delivery of oxygen via a nasal cannula (or facemask) can be accomplished by using the universal airway connector from a #6 endotracheal tube with the standard breathing circuit.</div><div id=\"graphicVersion\">Graphic 104414 Version 2.0</div></div></div>"},"104420":{"type":"graphic_figure","displayName":"Twenty-year breast cancer-specific survival after DCIS by race","title":"Twenty-year breast cancer-specific survival after ductal carcinoma in situ (DCIS) by race/ethnicity","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Twenty-year breast cancer-specific survival after ductal carcinoma in situ (DCIS) by race/ethnicity</div><div class=\"cntnt\"><img style=\"width:722px; height:600px;\" src=\"images/ONC/104420_Twnty_yr_br_cncr_DCIS_race.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Death occurred by 20 years after a diagnosis of DCIS for 623 of 76,188 whites, 59 of 8839 Hispanic whites, 185 of 10,943 blacks, and 61 of 10,036 Asians.</div><div class=\"graphic_reference\">Reproduced with permission from: Narod SA, Iqbal J, Giannakeas V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015; 1:888. Copyright Â© 2015 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104420 Version 4.0</div></div></div>"},"104422":{"type":"graphic_figure","displayName":"Twenty-year breast cancer-specific survival after DCIS by ER","title":"Twenty-year breast cancer-specific survival after ductal carcinoma in situ (DCIS) by estrogen receptor (ER) status","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Twenty-year breast cancer-specific survival after ductal carcinoma in situ (DCIS) by estrogen receptor (ER) status</div><div class=\"cntnt\"><img style=\"width:744px; height:594px;\" src=\"images/ONC/104422_Twnty_yr_br_cncr_DCIS_ER.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Death occurred by 20 years after a diagnosis of DCIS for 82 of 8908 patients with ER-negative disease and 157 of 46,002 patients with ER-positive disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Narod SA, Iqbal J, Giannakeas V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015; 1:888. Copyright Â© 2015 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104422 Version 3.0</div></div></div>"},"104426":{"type":"graphic_algorithm","displayName":"Approach to metastatic GINET","title":"Algorithmic approach to management of metastatic gastrointestinal neuroendocrine tumors (GINET)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to management of metastatic gastrointestinal neuroendocrine tumors (GINET)</div><div class=\"cntnt\"><img style=\"width:443px; height:896px;\" src=\"images/ONC/104426_Apprch_mtsttc_GINET.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 104426 Version 2.0</div></div></div>"},"104429":{"type":"graphic_figure","displayName":"Severe combined chronic venous insufficiency and lymphedema","title":"Severe combined chronic venous insufficiency and lymphedema","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Severe combined chronic venous insufficiency and lymphedema</div><div class=\"cntnt\"><img style=\"width:782px; height:679px;\" src=\"images/SURG/104429_Svr_cmb_chrn_vns_insffcy_lmphdm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient had recurrent episodes of cellulitis requiring inpatient treatment. The mass on the medial aspect of the leg represents a focal form of lymphedema that is related to obesity. Surgical excision may be required in the setting of persistent or recurrent infection.</div><div id=\"graphicVersion\">Graphic 104429 Version 2.0</div></div></div>"},"104430":{"type":"graphic_figure","displayName":"DIPSS Plus for primary myelofibrosis","title":"Dynamic International Prognostic Scoring System (DIPSS) Plus for primary myelofibrosis","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Dynamic International Prognostic Scoring System (DIPSS) Plus for primary myelofibrosis</div><div class=\"cntnt\"><img style=\"width:559px; height:377px;\" src=\"images/HEME/104430_DIPSS_pls_prmr_mlfbrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival data of 428 patients with primary myelofibrosis evaluated within one year of their diagnosis and stratified by their Dynamic International Prognostic Scoring System (DIPSS) + karyotype + platelet count + transfusion status prognostic scores. Low risk, zero adverse points; n = 46; median survival, approximately 180 months. Intermediate-1 risk, one adverse point; n = 114; median survival, approximately 80 months. Intermediate-2 risk, two or three adverse points; n = 177; median survival, approximately 35 months. High risk, four to six adverse points; n = 91; median survival, approximately 16 months. </div><div class=\"graphic_reference\">From: Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29(4):392-7. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104430 Version 2.0</div></div></div>"},"104432":{"type":"graphic_figure","displayName":"Plasma epinephrine and norepinephrine concentrations","title":"Plasma epinephrine and norepinephrine concentrations during laparoscopic adrenalectomy for pheochromocytoma","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Plasma epinephrine and norepinephrine concentrations during laparoscopic adrenalectomy for pheochromocytoma</div><div class=\"cntnt\"><img style=\"width:512px; height:747px;\" src=\"images/ANEST/104432_Plsm_epnphrn_nrpnp_cncnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plasma epinephrine and norepinephrine concentrations during laparoscopic adrenalectomy (n = 8) for pheochromocytoma. Individual data (dashed lines) and mean (open circle and solid line). Normal values for epinephrine and norepinephrine plasma concentrations were 0 to 100 ng/L and 0 to 500 ng/L, respectively. Catecholamine concentrations were measured before the induction of anesthesia (PREOP); after induction of anesthesia (POST IND); 5 minutes after tilting the patient to the lateral position (LAT POSIT); 5 (PNP-5), 15 (PNP-15), and 30 minutes (PNP-30) after peritoneal insufflation; during adrenal manipulation (MANIP); after adrenal vein clamping (CLAMP); 5 minutes after tumor removal (TUMORECT); and at the end of surgery in supine position (END). Epinephrine:&nbsp;p&lt;0.05 PREOP and POST-IND versus PNP-5, PNP-15, PNP-30, MANIP, and CLAMP; LAT POSIT versus PNP-30, MANIP, and CLAMP; PNP-5 versus MANIP; MANIP and CLAMP versus TUMORECT and END. Norepinephrine: p&lt;0.05 PREOP and POST-IND versus PNP-30, MANIP, and CLAMP; LAT POSIT versus MANIP; MANIP and CLAMP versus END. Symbols for statistically significant differences have been omitted for clarity.</div><div class=\"graphic_reference\">From: Joris JL, Hamoir EE, Hartstein GM, et al. Hemodynamic Changes and Catecholamine Release During Laparoscopic Adrenalectomy for Pheochromocytoma. Anesth Analg 1999; 88:16. DOI: <a href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=1999&amp;issue=01000&amp;article=00004&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1213/00000539-199901000-00004</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 1999 International Anesthesia Research Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104432 Version 4.0</div></div></div>"},"104435":{"type":"graphic_algorithm","displayName":"Diagnostic approach to eye injuries","title":"Diagnostic approach to eye injuries*","html":"<div class=\"graphic\"><div style=\"width: 956px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to eye injuries*</div><div class=\"cntnt\"><img style=\"width:936px; height:1134px;\" src=\"images/EM/104435_Diag_approach_eye_injuries.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FB: foreign body; rAPD: relative afferent pupillary defect; IOFB: intraocular foreign body.<br />* Eye trauma frequently results in more than one injury to the eye.<br />&para; Vision-threatening condition, emergency treatment and urgent consultation with an ophthalmologist is needed. Refer to UpToDate topics on eye injuries for management of the specific condition.<br />&Delta; Tight eyelids are \"rock hard\" and cannot be opened. A tight globe resists attempts to push it deeper in the orbit (decreased retropulsion). Refer to UpToDate topics on the overview of eye injuries.<br /><span class=\"lozenge\">&loz;</span> Perform orbital CT to evaluate for orbital fracture or globe disruption and consult ophthalmologist for detailed eye examination, including indirect ophthalmoscopy. Other surgical subspecialists may also need to be consulted eg, neurosurgery if CT shows orbital roof fracture or otolarygnology if the fracture extends into a sinus cavity.<br />&sect; For patients with normal vision, visual acuity of 20/40 (6/12) or worse after injury. For patients who do not have normal vision at baseline, a decrease of one line or more on the vision chart.<br />&yen; Consult ophthalmologist for detailed eye examination, including indirect ophthalmoscopy.<br />&Dagger; Consult ophthalmology or plastic surgery for repair.</div><div id=\"graphicVersion\">Graphic 104435 Version 2.0</div></div></div>"},"104437":{"type":"graphic_diagnosticimage","displayName":"Retinal fundus photographs of hypertensive retinopathy","title":"Retinal fundus photographs of hypertensive retinopathy","html":"<div class=\"graphic\"><div style=\"width: 693px\" class=\"figure\"><div class=\"ttl\">Retinal fundus photographs of hypertensive retinopathy</div><div class=\"cntnt\"><img style=\"width:673px; height:786px;\" src=\"images/NEPH/104437_Rtnl_fnd_pht_hprtnsv_rtnpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative digital retinal fundus photographs of mild (A,B), moderate (C,D), and severe (E,F) hypertensive retinopathy, as graded with the simplified classification:<br />(A) Mild hypertensive retinopathy is indicated by the presence of generalized arteriolar narrowing, arteriovenous (AV) nicking, and opacification of the arteriolar wall (\"copper wiring\").<br />(B) Mild hypertensive retinopathy with focal arteriolar narrowing.<br />(C,D) Moderate hypertensive retinopathy with multiple retinal hemorrhages and cotton wool patches.<br />(E,F) Severe hypertensive retinopathy with swelling of the optic disk, retinal hemorrhages, hard exudates, and cotton wool patches.</div><div class=\"graphic_reference\">From: Downie LE, Hodgson LA, Dsylva C, et al. Hypertensive retinopathy: Comparing the Keith-Wagener-Barker to a simplified classification. J Hypertens 2013; 31:960. DOI: <a href=\"http://journals.lww.com/jhypertension/pages/articleviewer.aspx?year=2013&amp;issue=05000&amp;article=00019&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/HJH.0b013e32835efea3</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2013 International Society of Hypertension and European Society of Hypertension. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104437 Version 1.0</div></div></div>"},"104439":{"type":"graphic_table","displayName":"CIDP Disease Activity Status (CDAS)","title":"CDAS classification scheme and proportion of CIDP patients within each category","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CDAS classification scheme and proportion of CIDP patients within each category</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Patients (n = 106)</td> </tr> <tr> <td><strong>1. Cure: &#8805;5 years off treatment</strong></td> <td class=\"centered\"><strong>11% cure</strong></td> </tr> <tr> <td class=\"indent1\">A. Normal examination</td> <td class=\"centered\">6 (6%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B. Abnormal examination, stable/improving</td> <td class=\"centered\">5 (5%)</td> </tr> <tr> <td><strong>2. Remission: &#60;5 years off treatment</strong></td> <td class=\"centered\"><strong>20% remission</strong></td> </tr> <tr> <td class=\"indent1\">A. Normal examination</td> <td class=\"centered\">12 (11%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B. Abnormal examination, stable/improving</td> <td class=\"centered\">10 (9%)</td> </tr> <tr> <td><strong>3. Stable active disease: &#8805;1 year, on treatment</strong></td> <td class=\"centered\"><strong>44% stable disease</strong></td> </tr> <tr> <td class=\"indent1\">A. Normal examination</td> <td class=\"centered\">18 (17%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B. Abnormal examination, stable/improving</td> <td class=\"centered\">29 (27%)</td> </tr> <tr> <td><strong>4. Improvement: &#8805;3 months &#60;1 year, on treatment</strong></td> <td class=\"centered\"><strong>7% improving</strong></td> </tr> <tr> <td class=\"indent1\">A. Normal examination</td> <td class=\"centered\">0 (0%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B. Abnormal examination, stable/improving</td> <td class=\"centered\">8 (7%)</td> </tr> <tr> <td><strong>5. Unstable active disease: Abnormal examination with progressive or relapsing course</strong>*</td> <td class=\"centered\"><strong>18% active disease</strong></td> </tr> <tr> <td class=\"indent1\">A. Treatment na&#239;ve or &#60;3 months</td> <td class=\"centered\">6 (6%)</td> </tr> <tr> <td class=\"indent1\">B. Off treatment</td> <td class=\"centered\">7 (7%)</td> </tr> <tr> <td class=\"indent1\">C. On treatment</td> <td class=\"centered\">5 (5%)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The classification is based upon the clinical assessment of the treating physician at the time of last evaluation.</div><div class=\"graphic_footnotes\">CIDP: chronic inflammatory demyelinating polyneuropathy; CDAS: CIDP Disease Activity Status.<br />* 5B and 5C refer to patients who were treatment refractory from prior therapy or worsening despite ongoing therapy.</div><div class=\"graphic_reference\">From: Gorson KC, van Schaik IN, Merkies IS, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15:326. DOI: <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1529-8027.2010.00284.x/abstract\" target=\"_blank\">10.1111/j.1529-8027.2010.00284.x</a>. Copyright &copy; 2010 Peripheral Nerve Society. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 104439 Version 1.0</div></div></div>"},"104443":{"type":"graphic_table","displayName":"Key clinical features of sleep terrors versus nightmares","title":"Key clinical features of sleep terrorsÂ versus nightmares","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key clinical features of sleep terrors&nbsp;versus nightmares</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Sleep terror</td> <td class=\"subtitle1\">Nightmare</td> </tr> <tr> <td><strong>Timing during the night</strong></td> <td>First third (deep slow wave sleep)</td> <td>Last third (REM sleep)</td> </tr> <tr> <td><strong>Presentation of fear behaviors</strong></td> <td>During the event</td> <td>After the event</td> </tr> <tr> <td><strong>Movements</strong></td> <td>Common</td> <td>Rare</td> </tr> <tr> <td><strong>Severity</strong></td> <td>Severe</td> <td>Mild</td> </tr> <tr> <td><strong>Vocalizations</strong></td> <td>Common</td> <td>Rare</td> </tr> <tr> <td><strong>Autonomic (sympathetic) output</strong></td> <td>Severe and intense</td> <td>Mild</td> </tr> <tr> <td><strong>Amnesia</strong></td> <td>Present</td> <td>Absent</td> </tr> <tr> <td><strong>State on waking</strong></td> <td>Confused/disoriented</td> <td>Normal</td> </tr> <tr> <td><strong>Injuries or violence</strong></td> <td>Common</td> <td>Rare</td> </tr> <tr> <td><strong>Displacement from bed</strong></td> <td>Common</td> <td>Very rare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REM: rapid eye movement.</div><div id=\"graphicVersion\">Graphic 104443 Version 1.0</div></div></div>"},"104444":{"type":"graphic_picture","displayName":"Plantar ecchymosis from tarsometatarsal (Lisfranc) injury","title":"Plantar ecchymosis from tarsometatarsal (Lisfranc) injury","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Plantar ecchymosis from tarsometatarsal (Lisfranc) injury</div><div class=\"cntnt\"><img style=\"width:708px; height:528px;\" src=\"images/SM/104444_Plnt_ecchyms_trsmt_lsfrnc_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows distinct ecchymosis at the plantar surface of the midfoot in a patient who sustained a tarsometatarsal, or Lisfranc, injury.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Cole Taylor, MD.</div><div id=\"graphicVersion\">Graphic 104444 Version 1.0</div></div></div>"},"104445":{"type":"graphic_diagnosticimage","displayName":"Bilateral comparison of tarsometatarsal (Lisfranc) injury","title":"Bilateral comparison of tarsometatarsal (Lisfranc) injury","html":"<div class=\"graphic\"><div style=\"width: 721px\" class=\"figure\"><div class=\"ttl\">Bilateral comparison of tarsometatarsal (Lisfranc) injury</div><div class=\"cntnt\"><img style=\"width:701px; height:617px;\" src=\"images/SM/104445_Bltrl_cmpr_trsmt_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain radiographs shown above are weight-bearing views of both feet of a patient who has sustained a left tarsometatarsal injury. Note the abnormal widening in the left foot at the region of the first and second metatarsals. The right foot is uninjured and shows normal spacing and alignment.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Cole Taylor, MD.</div><div id=\"graphicVersion\">Graphic 104445 Version 1.0</div></div></div>"},"104447":{"type":"graphic_diagnosticimage","displayName":"Fleck sign of tarsometatarsal (Lisfranc) injury","title":"Fleck sign of tarsometatarsal (Lisfranc) injury","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Fleck sign of tarsometatarsal (Lisfranc) injury</div><div class=\"cntnt\"><img style=\"width:674px; height:713px;\" src=\"images/SM/104447_Flck_sgn_trsmtt_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small avulsion fractures at the origin or insertion of the Lisfranc ligament, as shown in the plain radiograph above, may occur with a tarsometatarsal injury. Such fractures are referred to as the Fleck sign.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Cole Taylor, MD.</div><div id=\"graphicVersion\">Graphic 104447 Version 1.0</div></div></div>"},"104448":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph proximal second metatarsal fracture","title":"Plain radiograph proximal second metatarsal fracture","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Plain radiograph proximal second metatarsal fracture</div><div class=\"cntnt\"><img style=\"width:519px; height:706px;\" src=\"images/SM/104448_Pln_rdgr_prx_snd_mttr_frct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fractures of the proximal first or second metatarsal, such as the one shown in the plain radiograph above, are often associated with an injury to the tarsometatarsal joint complex (Lisfranc injury).</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Cole Taylor, MD.</div><div id=\"graphicVersion\">Graphic 104448 Version 1.0</div></div></div>"},"104449":{"type":"graphic_diagnosticimage","displayName":"MRI of tarsometatarsal joint complex (Lisfranc) injury","title":"MRI of tarsometatarsal joint complex (Lisfranc) injury","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">MRI of tarsometatarsal joint complex (Lisfranc) injury</div><div class=\"cntnt\"><img style=\"width:703px; height:400px;\" src=\"images/SM/104449_MRI_trsmttr_jnt_cmplx_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The magnetic resonance images (MRI) above show edema and a near complete tear of the interosseous Lisfranc ligament (arrow), and edema within the Lisfranc joint and the inter-metatarsal space (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Cole Taylor, MD.</div><div id=\"graphicVersion\">Graphic 104449 Version 1.0</div></div></div>"},"104450":{"type":"graphic_diagnosticimage","displayName":"CT of tarsometatarsal joint complex (Lisfranc) injury","title":"CT of tarsometatarsal joint complex (Lisfranc) injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of tarsometatarsal joint complex (Lisfranc) injury</div><div class=\"cntnt\"><img style=\"width:436px; height:339px;\" src=\"images/SM/104450_CT_trsmttrsl_jnt_cmpl_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The computed tomography (CT) images above reveal 6.9 mm of diastasis between the medial and intermediate cuneiforms, suggestive of tarsometatarsal joint injury, and a fracture involving the second tarsometatarsal joint. The arrow in image B points to a small fracture fragment.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Cole Taylor, MD.</div><div id=\"graphicVersion\">Graphic 104450 Version 1.0</div></div></div>"},"104452":{"type":"graphic_picture","displayName":"Argon plasma coagulation probe","title":"Argon plasma coagulation probe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Argon plasma coagulation probe</div><div class=\"cntnt\"><img style=\"width:211px; height:212px;\" src=\"images/PULM/104452_Argn_plsm_coagl_prb.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 CONMED Corporation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104452 Version 1.0</div></div></div>"},"104453":{"type":"graphic_table","displayName":"Autoimmunity and immune dysregulation in PID disorders","title":"Autoimmunity and immune dysregulation in primary immunodeficiency disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Autoimmunity and immune dysregulation in primary immunodeficiency disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">PID/syndrome (in approximate order of prevalence)</td> <td class=\"subtitle1\">Estimated prevalence</td> <td class=\"subtitle1\">PID classification<sup>[1]</sup></td> <td class=\"subtitle1\">&nbsp;Hallmarks (of the PID disorder)</td> <td class=\"subtitle1\">Immunodeficiency features</td> <td class=\"subtitle1\">Possible manifestations of autoimmunity and/or immune dysregulation</td> <td class=\"subtitle1\">Suspected predominant mechanism(s) of autoimmunity or immune&nbsp;dysregulation<sup>[2-5]</sup>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Selective IgA deficiency</strong>&nbsp;</td> <td>1 to 3:1000&nbsp;</td> <td>Predominantly antibody deficiency&nbsp;</td> <td>Allergies; may precede CVID or have positive family history</td> <td>Asymptomatic or recurrent sinopulmonary bacterial infections</td> <td>Endocrinopathies, cytopenia, SLE</td> <td>Lacking clearance of antigens from mucosal surfaces, autoreactive B cells due to impaired negative selection and regulation, reduced T regulatory function; reduced debris clearance</td> </tr> <tr class=\"divider_bottom\"> <td><strong>22q11 deletion syndrome (DiGeorge)</strong></td> <td>2 to 5:10,000</td> <td>CID with syndromic features</td> <td>Cardiac, abnormal facies, thymic hypoplasia, cleft palate, hypoparathyroidism, cognitive and speech problems</td> <td>Variable, opportunistic infections</td> <td>Cytopenia, endocrinopathies, arthritis</td> <td>Impaired T regulatory cell function and diversity, oligoclonal TCR repertoire, residual autoreactive T cells</td> </tr> <tr class=\"divider_bottom\"> <td><strong><strong>Wiskott-Aldrich syndrome (WAS)</strong></strong></td> <td>1:20,000</td> <td>CID with syndromic features</td> <td>Microthrombocytopenia, eczema</td> <td>Severe, viral, and bacterial opportunistic infections</td> <td>Skin (eczema, atopic dermatitis), cytopenia, vasculitis, kidney disease (nephritis, IgA nephropathy, glomerulonephritis), arthritis, IBD</td> <td>Defective T regulatory cell function, impaired lymphocyte migration and activation, loss of inhibitory signaling</td> </tr> <tr class=\"divider_bottom\"> <td><strong><strong>Common variable immunodeficiency (CVID)</strong></strong></td> <td>1 to 10:100,000</td> <td>Predominantly antibody deficiency</td> <td>Hypogammaglobulinemia</td> <td>Recurrent infections</td> <td>Cytopenia, endocrinopathies, IBD, SLE, arthritis, pneumonitis, lymphoproliferation, lymphoma, granuloma formation</td> <td>BCR editing checkpoint and B cell maturation defects leading to residual autoreactive B cell clones, loss of inhibitory signaling, reduced T regulatory cell function, impaired T helper cell activity</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Familial hemophagocytic lymphohistiocytosis (FHL), hemophagocytic lymphohistiocytosis (HLH)</strong></td> <td>Unknown, estimated 1:50,000</td> <td>Diseases of immune dysregulation</td> <td>Hemophagocytosis, fever, hyperferritinemia, syndromes with or without hypopigmentation</td> <td>EBV or other herpes viruses may be trigger</td> <td>Cytopenia, lymphoproliferation, hemophagocytosis, neurologic symptoms (CNS infiltration)</td> <td>Uncontrolled cytokine and interferon-mediated macrophage activation due to impaired cellular cytotoxicity of T and NK cells, apoptosis defects</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Combined immunodeficiencies (CID)*</strong></td> <td>Unknown, estimated 1 to 5:100,000</td> <td>CID</td> <td>Depending on subtype/genetic cause</td> <td>Combined, variable severity</td> <td>Cytopenia, endocrinopathies, IBD, skin (eczema, rash, other), lymphoproliferation, lymphoma</td> <td>Impaired T and T regulatory cell function and diversity, oligoclonal TCR repertoire, residual autoreactive T cells, hypersensitivity to persisting viral antigens</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Autoimmune lymphoproliferative syndrome (ALPS)</strong></td> <td>Unknown, estimated &#62;1 to 5:100,000</td> <td>Diseases of immune dysregulation</td> <td>Increased T cell receptor alpha/beta-positive CD4-CD8- double-negative T (DNT) cells</td> <td>Rare</td> <td>Cytopenia, endocrinopathies, kidney disease (glomerulonephritis), lymphoproliferation, lymphoma</td> <td>Apoptosis defect, immature and senescent T cell phenotype, resulting in autoreactive T and B cells, impaired debris clearance</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>X-linked agammaglobulinemia</strong></p> <p><strong>(XLA)</strong></p> </td> <td>1:200,000</td> <td>Predominantly antibody deficiency</td> <td>Agammaglobulinemia</td> <td>Bacterial, enteroviral</td> <td>Cytopenia, endocrinopathies, skin (eczema, rash, vitiligo, alopecia, oral ulcerations, mucocutaneous candidiasis), IBD</td> <td>Unknown</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Chronic granulomatous disease (CGD)</strong></td> <td>1 to 5:500,000</td> <td>Congenital defects of phagocyte function, number, or both</td> <td>May mimic Crohn disease or lymphoproliferative disorders, HLH</td> <td>Bacterial (<em>Staphylococci</em>), fungal</td> <td>Granuloma formation, IBD, lymphoproliferation</td> <td>Ineffective and deregulated phagocyte activation, chemoattraction, impaired T regulatory function, defective clearance of apoptotic cells, hypersensitivity to bacterial antigens (neutrophil, NK-mediated)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hyperimmunoglobulin M syndromes (HIGM)</strong></td> <td>1 to 2:500,000</td> <td>CID</td> <td><em>Cryptosporidium</em> infection, <em>Pneumocystis</em> pneumonia, sclerosing cholangitis</td> <td>Bacterial and opportunistic infections</td> <td>Cytopenia, IBD, primary biliary cirrhosis, sclerosing cholangitis</td> <td>Disturbed T-B cell interaction, residual autoreactive B cells, T cell-mediated hypersensitivity to parasitic antigens (<em>Cryptosporidium, Pneumocystis</em>)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Complement deficiencies<sup>&#182;</sup></strong></td> <td>1 to 5:500,000</td> <td>Complement deficiencies</td> <td>&nbsp;</td> <td>Some have increased&nbsp;risk of neisserial infections</td> <td>SLE, vasculitis</td> <td>Ineffective clearance of immune complexes, apoptotic cells, and debris</td> </tr> <tr class=\"divider_bottom\"> <td><strong>APECED</strong></td> <td>1 to 10:1,000,000</td> <td>Diseases of immune dysregulation</td> <td>Ectodermal dystrophy, 21-hydroxylase autoantibodies</td> <td>Candidiasis</td> <td>Endocrinopathies, skin (eczema, rash, vitiligo, alopecia, oral ulcerations, mucocutaneous candidiasis)</td> <td>Central tolerance defect, anticytokine, enzyme- and tissue-directed autoantibodies</td> </tr> <tr class=\"divider_bottom\"> <td><strong>IPEX and IPEX-like syndromes</strong></td> <td>Unknown, estimated &#60;1:1,000,000</td> <td>Diseases of immune dysregulation</td> <td>Early-onset enteropathy, type 1 diabetes mellitus</td> <td>Combined, variable severity</td> <td>IBD, endocrinopathies, cytopenia, skin (eczema, rash, vitiligo), autoimmune hepatitis</td> <td>T regulatory cell deficiency or loss-of-function</td> </tr> <tr class=\"divider_bottom\"> <td><strong>LRBA deficiency</strong></td> <td>Unknown, estimated &#60;1:1,000,000</td> <td>Diseases of immune dysregulation, predominantly antibody deficiency</td> <td>Enteropathy, ALPS/CVID-overlap syndrome</td> <td>Bacterial and opportunistic infections</td> <td>IBD, cytopenia, arthritis, myasthenia gravis, neurologic disease (encephalitis, cerebellitis,&nbsp;CNS lymphoma), lymphoproliferation</td> <td>CTLA4-dependent T regulatory cell defect, impaired autophagy, autoreactive B cells</td> </tr> <tr class=\"divider_bottom\"> <td><strong>CTLA4 haploinsufficiency (ALPSV)</strong></td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td>Progressive loss of B cells, hypogammaglobulinemia</td> <td>Upper and lower respiratory infections</td> <td>IBD, granuloma formation, pneumonitis, cytopenia, SLE, endocrinopathies, (arthritis, neurologic disease [encephalitis, cerebellitis, CNS lymphoma]), lymphoproliferation, organ infiltration</td> <td>T regulatory cell defect, impaired T cell help for B cells</td> </tr> <tr class=\"divider_bottom\"> <td><strong>CD27 deficiency</strong></td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td>Hypogammaglobulinemia, lymphoma</td> <td>EBV may be a trigger</td> <td>Lymphoproliferation, hemophagocytosis, lymphoma, cytopenia&nbsp;</td> <td>Impaired antigen-activated T and B cell expansion and memory development, impaired NK function</td> </tr> <tr class=\"divider_bottom\"> <td><strong>ITK deficiency</strong></td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td>Hodgkin (and rarer non-Hodgkin) lymphoma</td> <td>EBV may be trigger</td> <td>Lymphoproliferation, lymphoma, cytopenia</td> <td>Skewed CD4 T cell differentiation</td> </tr> <tr class=\"divider_bottom\"> <td><strong>XLP1 (SH2D1A deficiency)</strong></td> <td>1 to 5:1,000,000</td> <td>Diseases of immune dysregulation</td> <td>Lymphoproliferation, hypo- or agammaglobulinemia, HLH, lymphoma</td> <td>EBV may be trigger</td> <td>Lymphoproliferation, hemophagocytosis,&nbsp;lymphoma, cytopenia</td> <td>Disturbed T-B cell cross-talk, impaired T and NK cytotoxicity</td> </tr> <tr class=\"divider_bottom\"> <td><strong>XLP2 (XIAP deficiency)</strong></td> <td>Unknown, estimated &#60;1:1,000,000</td> <td>Diseases of immune dysregulation</td> <td>Lymphoproliferation, IBD, HLH</td> <td>EBV may be trigger</td> <td>IBD, autoimmune hepatitis, lymphoproliferation, cytopenia</td> <td>T cell apoptosis and activation-induced cell death</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Activated PI3K-d syndrome</strong></td> <td>Unknown</td> <td>Predominantly antibody deficiency</td> <td>T and B lymphoid nodules, bronchiectasis, CVID-like</td> <td>Respiratory tract infections, chronic EBV and CMV infection</td> <td>Pneumonitis, cytopenia, lymphoproliferation</td> <td>Immature and terminal effector T cell phenotype, transitional B cells increased, lymphocyte sensitivity to activation-induced death</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Type 1 interferonopathies</strong></td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td>Progressive encephalopathy</td> <td>&nbsp;</td> <td>SLE, cytopenia</td> <td>Impaired cellular nucleic debris clearance</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Early-onset inflammatory bowel disease syndromes</strong></td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td>&nbsp;</td> <td>Respiratory infections</td> <td>IBD, arthritis, lymphoma</td> <td>Lacking responses to immune regulatory interleukins</td> </tr> <tr class=\"divider_bottom\"> <td><strong>CMC/STAT1 gain-of-function</strong></td> <td>Unknown</td> <td>Defects in innate immunity</td> <td>CMC</td> <td>Fungal, bacterial, mycobacterial, herpesvirus infections</td> <td>Endocrinopathies, cytopenia</td> <td>Impaired development of interleukin-17-producing T cells</td> </tr> <tr> <td><strong>STAT3 gain-of-function</strong></td> <td>Unknown</td> <td>Diseases of immune dysregulation</td> <td>Early-onset, IPEX-like</td> <td>&nbsp;</td> <td>IBD, endocrinopathies, cytopenia, pneumonitis, autoimmune hepatitis, lymphoproliferation</td> <td>Increased T cell differentiation towards interleukin-17 production, perturbed T regulatory cell function</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PID: primary immunodeficiency; IgA: immunoglobulin A; CVID: common variable immunodeficiency; SLE: systemic lupus erythematosus; CID: combined immunodeficiencies; <FONT color=black>TCR: T cell receptor</FONT><FONT color=black>;</FONT> IBD: inflammatory bowel disease; <FONT color=black>BCR:</FONT>&nbsp;B cell receptor; EBV: Epstein-Barr virus; CNS: central nervous system; NK: natural killer; APECED: autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;&nbsp;IPEX: immune dysregulation, polyendocrinopathy, and enteropathy, X-linked; LRBA: lipopolysaccharide (LPS)-responsive beige-like anchor; CTLA4: cytotoxic T lymphocyte-associated protein 4; <FONT color=red><SPAN style=\"COLOR: black\">ALPSV: autoimmune lymphoproliferative syndrome type 5</SPAN><FONT color=black>; </FONT></FONT>ITK: interleukin-2 (IL-2)-inducible T cell kinase; XLP: X-linked lymphoproliferative disorder; SH2D1A: SH2 domain protein-1A; XIAP: X-linked inhibitor of apoptosis protein; PI3K-d: phosphoinositide-3 kinases delta; CMV: cytomegalovirus; CMC: chronic mucocutaneous candidiasis; STAT: signal transducer and activator of transcription. <br /><FONT color=black>* Including Omenn syndrome, leaky or hypomorphic severe combined immunodeficiency (SCID), and defects in various&nbsp;T cell surface receptors, lymphocyte structural, or T-B cell activation or signaling, which are usually less severe than SCID. Some of these disorders are also listed separately in this table because they belong to multiple categories of PID.</FONT><br />Â¶ Excluding hereditary angioedema.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: An update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol 2015; 35:696.</LI>&#xD;&#xA;<LI>Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002; 99:2694.</LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Todoric K, Koontz JM, Mattox D, Tarrant TK. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep 2013; 13:361.</SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Grimbacher B, Warnatz K, Yong PF, et al. The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects. J Allergy Clin Immunol 2016; 137:3. </SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Fischer A, Provot J, Jais JP, et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol 2017; 140:1388.</SPAN></LI></OL></div><div id=\"graphicVersion\">Graphic 104453 Version 2.0</div></div></div>"},"104454":{"type":"graphic_table","displayName":"Omalizumab in various disorders","title":"Omalizumab: Evidence for clinical benefits in different disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Omalizumab: Evidence for clinical benefits in different disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Excellent evidence:</td> </tr> <tr> <td class=\"indent1\">Allergic asthma</td> </tr> <tr> <td class=\"indent1\">Chronic spontaneous urticaria</td> </tr> <tr> <td class=\"subtitle1_single\">Good evidence:</td> </tr> <tr> <td class=\"indent1\">Allergic rhinitis</td> </tr> <tr> <td class=\"indent1\">Nonallergic asthma</td> </tr> <tr> <td class=\"indent1\">Protective during&nbsp;allergen immunotherapy and desensitization</td> </tr> <tr> <td class=\"subtitle1_single\">Fair evidence:</td> </tr> <tr> <td class=\"indent1\">Atopic dermatitis</td> </tr> <tr> <td class=\"indent1\">Physical urticaria</td> </tr> <tr> <td class=\"indent1\">Mast cell activation disorders</td> </tr> <tr> <td class=\"indent1\">Food allergy </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 104454 Version 2.0</div></div></div>"},"104459":{"type":"graphic_algorithm","displayName":"Management and evaluation of spondylolysis in adolescents","title":"Management and evaluation of spondylolysis in older children and adolescents","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Management and evaluation of spondylolysis in older children and adolescents</div><div class=\"cntnt\"><img style=\"width:748px; height:748px;\" src=\"images/SM/104459_Mngmnt_eval_spondylolysis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HPI: history of present illness; MRI: magnetic resonance imaging; Sx: symptoms.</div><div id=\"graphicVersion\">Graphic 104459 Version 1.0</div></div></div>"},"104502":{"type":"graphic_algorithm","displayName":"Management BD-IPMN","title":"Management of branch-duct IPMN","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Management of branch-duct IPMN</div><div class=\"cntnt\"><img style=\"width:556px; height:720px;\" src=\"images/GAST/104502_Management_BD_IPMN.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IPMN: intraductal pancreatic mucinous neoplasm; MRCP: magnetic resonance cholangiopancreatography; CT: computed tomography; EUS: endoscopic ultrasound; FNA: fine-needle aspiration.<br />* For patients with multiple cysts, each lesion is managed as it would be if it were the only lesion. Published guidelines on the management of pancreatic cystic neoplasms are variable. This algorithm reflects the authors' approach, which is largely consistent with published guidelines. Refer to UpToDate topic reviews on IPMN management for additional details.<br />&para; The decision to recommend surgery should take into account factors such as the patient's age and general health, the malignant risk of the specific lesion, and the suspicion for malignancy.<br />&Delta; Surveillance recommendations will depend on the size of the cyst, whether the patient is a good surgical candidate, and whether the cyst is stable on repeat imaging. Refer to UpToDate topics on the management of IPMN for details.</div><div id=\"graphicVersion\">Graphic 104502 Version 1.0</div></div></div>"},"104503":{"type":"graphic_diagnosticimage","displayName":"Measurement of LV end-diastolic area","title":"TEE measurement of LV end-diastolic area in the transgastric mid-papillary view in a patient with normal ventricular size","html":"<div class=\"graphic\"><div style=\"width: 791px\" class=\"figure\"><div class=\"ttl\">TEE measurement of LV end-diastolic area in the transgastric mid-papillary view in a patient with normal ventricular size</div><div class=\"cntnt\"><img style=\"width:771px; height:582px;\" src=\"images/ANEST/104503_Msr_LV_end_dstlc_area.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transgastric mid-papillary short-axis end-diastolic view of the LV in a patient with normal ventricular function demonstrating quantitative measurement of end-diastolic area. Note that when measuring end-diastolic area, the papillary muscles should be excluded from the tracing.</div><div class=\"graphic_footnotes\">LV: left ventricular; TEE: transesophageal echocardiography; bpm: beats/minute.</div><div id=\"graphicVersion\">Graphic 104503 Version 6.0</div></div></div>"},"104512":{"type":"graphic_algorithm","displayName":"Management MD-IPMN","title":"Management of main-duct IPMN","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Management of main-duct IPMN</div><div class=\"cntnt\"><img style=\"width:644px; height:644px;\" src=\"images/GAST/104512_Management_MD_IPMN.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IPMN: intraductal pancreatic mucinous neoplasm; MRCP: magnetic resonance cholangiopancreatography; CT: computed tomography; EUS: endoscopic ultrasound; FNA: fine-needle aspiration.<br />* For patients with multiple cysts, each lesion is managed as it would be if it were the only lesion. This algorithm reflects the authors' approach to management, which is generally consistent with published guidelines. Refer to UpToDate topic reviews on IPMN management for additional details.<br />Â¶ The decision to recommend surgery should take into account factors such as the patient's age and general health, the malignant risk of the specific lesion, and the suspicion for malignancy.<br />Î Provided the patient remains a good surgical candidate.</div><div id=\"graphicVersion\">Graphic 104512 Version 1.0</div></div></div>"},"104523":{"type":"graphic_picture","displayName":"Boston bowel preparation scale","title":"Boston bowel preparation scale","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Boston bowel preparation scale</div><div class=\"cntnt\"><img style=\"width:721px; height:627px;\" src=\"images/GAST/104523_Bstn_bwl_prp_scl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The BBPS. A: Segment score 0, unprepared colon segment with mucosa not seen because of solid stool that cannot be cleared. B: Segment score 1, portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen because of staining, residual stool, and/or opaque liquid. C: Segment score 2, minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well. D: Segment score 3, entire mucosa of colon segment seen well with no residual staining, small fragments of stool and/or opaque liquid.</div><div class=\"graphic_reference\">Reproduced from: Lai EJ, Calderwood AH, Doros G, et al. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc 2009; 69:620. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104523 Version 1.0</div></div></div>"},"104531":{"type":"graphic_movie","displayName":"TEE (TG LV SAX view) showing normal LV systolic function","title":"TEE (transgastric LV short-axis view)Â showing normal LV systolic function","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">TEE (transgastric LV short-axis view)&nbsp;showing normal LV systolic function</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/104531_TEEtrnsgstrcmidppllryvidSRC.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:468px; height:349px;\" src=\"images/ANEST/104531_TEEtrnsgstrcmidppllryimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transgastric mid-papillary short-axis view is typically used to qualitatively evaluate LV systolic function, as well as to estimate LV EF. This patient has normal systolic ventricular function.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; LV: left ventricular; EF: ejection fraction.</div><div id=\"graphicVersion\">Graphic 104531 Version 3.0</div></div></div>"},"104549":{"type":"graphic_picture","displayName":"US probe start position anterior knee exam","title":"US probe start position anterior knee exam","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US probe start position anterior knee exam</div><div class=\"cntnt\"><img style=\"width:382px; height:708px;\" src=\"images/SM/104549_US_prb_strt_pst_antrr_kn_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To begin the ultrasound examination of the anterior knee, the&nbsp;transducer is placed in the transverse plane at mid-thigh.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104549 Version 2.0</div></div></div>"},"104550":{"type":"graphic_picture","displayName":"SFT with dedifferentiated (anaplastic) areas","title":"Histologic appearance of de-differentiated (anaplastic) solitary fibrous tumor (SFT), hematoxylin and eosin (H&E)-stained tissue section","html":"<div class=\"graphic\"><div style=\"width: 811px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of de-differentiated (anaplastic) solitary fibrous tumor (SFT), hematoxylin and eosin (H&amp;E)-stained tissue section</div><div class=\"cntnt\"><img style=\"width:791px; height:300px;\" src=\"images/ONC/104550_SFT_ddffrnt_anpls_ars.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Mosquera JM, Fletcher CD. Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component--is this dedifferentiated SFT? Am J Surg Pathol 2009; 33:1314. DOI: <a href=\"http://journals.lww.com/ajsp/pages/articleviewer.aspx?year=2009&amp;issue=09000&amp;article=00007&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/PAS.0b013e3181a6cd33</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2009 The Arthur Purdy Stout Society of Surgical Pathologists and The Gastrointestinal Pathology Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104550 Version 1.0</div></div></div>"},"104551":{"type":"graphic_diagnosticimage","displayName":"US distal femur quadriceps transverse view","title":"US distal femur quadriceps transverse view","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">US distal femur quadriceps transverse view</div><div class=\"cntnt\"><img style=\"width:710px; height:428px;\" src=\"images/SM/104551_US_dst_fmr_qdrcp_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the rectus femoris and vastus intermedius muscles in a transverse view (short-axis).</div><div class=\"graphic_footnotes\">RF: rectus femoris muscle; VI: vastus intermedius muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104551 Version 2.0</div></div></div>"},"104552":{"type":"graphic_diagnosticimage","displayName":"US distal femur vastus medialis transverse view","title":"US distal femur vastus medialis transverse view","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US distal femur vastus medialis transverse view</div><div class=\"cntnt\"><img style=\"width:715px; height:370px;\" src=\"images/SM/104552_US_dstl_fmr_vsts_mdl_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse plane (short axis) ultrasound image shows the rectus femoris and vastus medialis muscles.</div><div class=\"graphic_footnotes\">RF: rectus femoris muscle; VI: vastus intermedius muscle; VM: vastus medialis muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104552 Version 1.0</div></div></div>"},"104553":{"type":"graphic_diagnosticimage","displayName":"US distal femur vastus lateralis transverse view","title":"US distal femur vastus lateralis transverse view","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">US distal femur vastus lateralis transverse view</div><div class=\"cntnt\"><img style=\"width:712px; height:431px;\" src=\"images/SM/104553_US_dstl_fmr_vsts_ltrl_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse plane (short axis) ultrasound image shows the rectus femoris and vastus lateralis muscles.</div><div class=\"graphic_footnotes\">RF: Rectus femoris muscle; VI: vastus intermedius muscle; VL: vastus lateralis muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104553 Version 2.0</div></div></div>"},"104555":{"type":"graphic_diagnosticimage","displayName":"US distal anterior thigh merging of quadriceps tendons","title":"US distal anterior thigh merging of quadriceps tendons","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">US distal anterior thigh merging of quadriceps tendons</div><div class=\"cntnt\"><img style=\"width:783px; height:390px;\" src=\"images/SM/104555_US_dstl_antr_thg_mrg_qdrc_tnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows&nbsp;all three layers of the quadriceps tendon in the transverse plane&nbsp;(short-axis).</div><div class=\"graphic_footnotes\">SL: superficial layer; ML: middle layer; DL: deep layer; QFP: quadriceps fat pad; PFFP: prefemoral fat pad.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104555 Version 1.0</div></div></div>"},"104556":{"type":"graphic_diagnosticimage","displayName":"US quadriceps tendon insertion long axis view","title":"US quadriceps tendon insertion long axis view","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">US quadriceps tendon insertion long axis view</div><div class=\"cntnt\"><img style=\"width:788px; height:281px;\" src=\"images/SM/104556_US_qdrcp_tnd_insr_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound&nbsp;image shows&nbsp;the quadriceps tendon in the sagittal plane&nbsp;(long-axis).</div><div class=\"graphic_footnotes\">Arrowheads: quadriceps tendon; SL: superficial layer; ML: middle layer; DL: deep layer.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104556 Version 1.0</div></div></div>"},"104557":{"type":"graphic_picture","displayName":"Handheld Snellen chart","title":"Handheld Snellen chart","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Handheld Snellen chart</div><div class=\"cntnt\"><img style=\"width:515px; height:864px;\" src=\"images/EM/104557_Handheld_Snellen_chart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sample pocket near visual acuity testing card. Many different versions are available. The card should be held at the distance specified at the top of the card.</div><div class=\"graphic_reference\">Courtesy of Mathew Gardiner, MD and Ankoor Shah, MD.</div><div id=\"graphicVersion\">Graphic 104557 Version 1.0</div></div></div>"},"104558":{"type":"graphic_picture","displayName":"Irregular pupil after a closed globe injury","title":"IrregularÂ pupil after a closed globe injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irregular&nbsp;pupil after a closed globe injury</div><div class=\"cntnt\"><img style=\"width:415px; height:405px;\" src=\"images/EM/104558_Irregular_pupil_closed_globe_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Matthew F. Gardiner, MD and Ankoor Shah, MD, PhD</div><div id=\"graphicVersion\">Graphic 104558 Version 1.0</div></div></div>"},"104559":{"type":"graphic_table","displayName":"Spiritual domains and healthcare outcomes in serious illness","title":"Patient, family, faith community, and medical team spiritual domains and healthcare outcomes in serious illness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient, family, faith community, and medical team spiritual domains and healthcare outcomes in serious illness</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Spiritual domains within serious illness (independent variables)</td> </tr> <tr> <td class=\"subtitle2_single\">Patient spirituality domains</td> </tr> <tr> <td class=\"indent1\">Patient spirituality</td> </tr> <tr> <td class=\"indent1\">Patient religiousness</td> </tr> <tr> <td class=\"indent1\">Patient religious coping (positive and negative)</td> </tr> <tr> <td class=\"indent1\">Patient religious/spiritual goals and values</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Patient religious/spiritual practices</td> </tr> <tr> <td class=\"subtitle2_single\">Family spirituality domains</td> </tr> <tr> <td class=\"indent1\">Family spirituality </td> </tr> <tr> <td class=\"indent1\">Family religiousness</td> </tr> <tr> <td class=\"indent1\">Family religious coping (positive and negative)</td> </tr> <tr> <td class=\"indent1\">Family religious/spiritual goals and values</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Family religious/spiritual practices</td> </tr> <tr> <td class=\"subtitle2_single\">Faith community domains*</td> </tr> <tr> <td class=\"indent1\">Spiritual care provision to patients</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Religious/spiritual goals and values</td> </tr> <tr> <td class=\"subtitle2_single\">Medical team spirituality domains</td> </tr> <tr> <td class=\"indent1\">Spiritual care provision to patients</td> </tr> <tr> <td class=\"indent1\">Spiritual care training</td> </tr> <tr> <td class=\"indent1\">Spiritual care team structure</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Outcomes for patients, families, faith communities and healthcare practitioners (dependent variables)</td> </tr> <tr> <td class=\"subtitle2_single\">Patient-centered healthcare outcomes</td> </tr> <tr> <td class=\"indent1\">Quality of life (bio-psychosocial-spiritual)</td> </tr> <tr> <td class=\"indent1\">Medical care received</td> </tr> <tr> <td class=\"indent1\">Patient goal attainment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Patient satisfaction with medical care</td> </tr> <tr> <td class=\"subtitle2_single\">Family-centered healthcare outcomes</td> </tr> <tr> <td class=\"indent1\">Family quality of life</td> </tr> <tr> <td class=\"indent1\">Family bereavement</td> </tr> <tr> <td class=\"indent1\">Family end-of-life goal attainment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Family satisfaction with medical care</td> </tr> <tr> <td class=\"subtitle2_single\">Disparities in healthcare outcomes (patient and family)</td> </tr> <tr> <td class=\"subtitle2_single\">Faith community outcomes*</td> </tr> <tr> <td class=\"indent1\">Faith community engagement in patient/family medical care</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Faith community understanding of palliative and hospice care</td> </tr> <tr> <td class=\"subtitle2_single\">Medical team-centered healthcare outcomes</td> </tr> <tr> <td class=\"indent1\">Spiritual care competency (individual and team)</td> </tr> <tr> <td class=\"indent1\">Patient and family satisfaction with medical care</td> </tr> <tr> <td class=\"indent1\">Patient and family trust in medical practitioners</td> </tr> <tr> <td class=\"indent1\">Communication effectiveness</td> </tr> <tr> <td class=\"indent1\">Spiritual care provision to patients</td> </tr> <tr> <td class=\"indent1\">Caregiver burnout and well-being</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Faith community domains and outcomes relevant to the care of patients/families who desire a connection with their faith community within serious illness.</div><div id=\"graphicVersion\">Graphic 104559 Version 1.0</div></div></div>"},"104560":{"type":"graphic_diagnosticimage","displayName":"US suprapatellar region sagittal plane view","title":"US suprapatellar region sagittal plane view","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">US suprapatellar region sagittal plane view</div><div class=\"cntnt\"><img style=\"width:781px; height:403px;\" src=\"images/SM/104560_US_sprptllr_rgn_sgttl_pln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound&nbsp;image shows&nbsp;the suprapatellar recess and the quadriceps tendon in the sagittal plane.</div><div class=\"graphic_footnotes\">Arrows: suprapatellar recess; white outline: quadriceps tendon; SL: superficial layer; ML: middle layer; DL: deep layer; QFP: quadriceps fat pad; PFFP: prefemoral fat pad.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104560 Version 1.0</div></div></div>"},"104561":{"type":"graphic_diagnosticimage","displayName":"US patella sagittal plane","title":"US patella sagittal plane","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">US patella sagittal plane</div><div class=\"cntnt\"><img style=\"width:784px; height:283px;\" src=\"images/SM/104561_US_ptll_sgttl_pln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows&nbsp;the patella in the sagittal plane.</div><div class=\"graphic_footnotes\">Arrowheads: quadriceps tendon (long-axis).<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104561 Version 1.0</div></div></div>"},"104562":{"type":"graphic_diagnosticimage","displayName":"US patella transverse view","title":"US patella transverse view","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US patella transverse view</div><div class=\"cntnt\"><img style=\"width:787px; height:217px;\" src=\"images/SM/104562_US_ptll_trnsvrs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows the patella in the transverse plane.</div><div class=\"graphic_footnotes\">Arrowheads: quadriceps tendon (short-axis).<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104562 Version 1.0</div></div></div>"},"104564":{"type":"graphic_diagnosticimage","displayName":"US medial patellofemoral ligament","title":"US medial patellofemoral ligament","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US medial patellofemoral ligament</div><div class=\"cntnt\"><img style=\"width:787px; height:197px;\" src=\"images/SM/104564_US_mdl_ptllfmrl_lgm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the medial patellofemoral ligament in a long-axis view.</div><div class=\"graphic_footnotes\">Arrowheads: medial patellofemoral ligament; MFC: medial femoral condyle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104564 Version 1.0</div></div></div>"},"104565":{"type":"graphic_diagnosticimage","displayName":"US femoral condyles and trochlea transverse view","title":"US femoral condyles and trochlea transverse view","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">US femoral condyles and trochlea transverse view</div><div class=\"cntnt\"><img style=\"width:784px; height:331px;\" src=\"images/SM/104565_US_fml_cndl_trchl_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above is&nbsp;a transverse plane&nbsp;view of&nbsp;the cartilage of the femoral condyles and trochlea.<br />&nbsp;</div><div class=\"graphic_footnotes\">*: articular cartilage; LC: lateral femoral condyle; MC: medial femoral condyle.<br />Left side of image is&nbsp;lateral; right side of image is&nbsp;medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104565 Version 1.0</div></div></div>"},"104566":{"type":"graphic_picture","displayName":"US probe start position for infrapatellar examination","title":"US probe start position for infrapatellar examination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US probe start position for infrapatellar examination</div><div class=\"cntnt\"><img style=\"width:405px; height:708px;\" src=\"images/SM/104566_US_prb_strt_pst_infrptllr_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the position of the ultrasound&nbsp;transducer&nbsp;to evaluate the patellar tendon and begin the examination of the infrapatellar portion of the anterior knee.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104566 Version 1.0</div></div></div>"},"104567":{"type":"graphic_diagnosticimage","displayName":"US patellar tendon sagittal view","title":"US patellar tendon sagittal view","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">US patellar tendon sagittal view</div><div class=\"cntnt\"><img style=\"width:783px; height:248px;\" src=\"images/SM/104567_US_ptllr_tndn_sgttl_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound image provides an extended field view of the patellar tendon (outlined by arrows)&nbsp;in the sagittal plane&nbsp;(long-axis).</div><div class=\"graphic_footnotes\">TT: tibial tubercle; IPFP: infrapatellar fat pad.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104567 Version 1.0</div></div></div>"},"104568":{"type":"graphic_diagnosticimage","displayName":"US patellar tendon transverse view","title":"US patellar tendon transverse view","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US patellar tendon transverse view</div><div class=\"cntnt\"><img style=\"width:787px; height:397px;\" src=\"images/SM/104568_US_ptllr_tndn_trnsvr_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound&nbsp;image shows&nbsp;the patellar tendon in the transverse plane&nbsp;(short-axis).</div><div class=\"graphic_footnotes\">Arrowheads: patellar tendon; IPFP: infrapatellar fat pad.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104568 Version 1.0</div></div></div>"},"104569":{"type":"graphic_table","displayName":"Revised classification criteria for antiphospholipid syndrome","title":"Revised classification criteria for the antiphospholipid syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised classification criteria for the antiphospholipid syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antiphospholipid syndrome is present if at least one of the clinical criteria and one of the laboratory criteria that follow are met*</td> </tr> <tr> <td class=\"subtitle2_single\">Clinical criteria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>1. Vascular thrombosis<sup>&#182;</sup></p> One or more clinical episodes<sup>&#916;</sup>\u0002 of arterial, venous, or small vessel thrombosis<sup>&#9674;</sup>, in any tissue or organ. Thrombosis must be confirmed by objective validated criteria (ie, unequivocal findings of appropriate imaging studies or histopathology). For histopathologic confirmation, thrombosis should be present without significant evidence of inflammation in the vessel wall.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2. Pregnancy morbidity <p class=\"indent2\">a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation, with normal fetal morphology documented by ultrasound or by direct examination of the fetus; or</p> <p class=\"indent2\">b. One or more premature births of a morphologically normal neonate before the 34th week of gestation because of: (i) eclampsia or severe preeclampsia defined according to standard definitions, or (ii) recognized features of placental insufficiency<sup>&#167;</sup>; or</p> <p class=\"indent2\">c. Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded.</p> In studies of populations of patients who have more than one type of pregnancy morbidity, investigators are strongly encouraged to stratify groups of subjects according to a, b, or c above. </td> </tr> <tr> <td class=\"subtitle2_single\">Laboratory criteria<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1. LA present in plasma, on two or more occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Haemostasis (Scientific Subcommittee on LAs/phospholipid-dependent antibodies).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2. aCL&nbsp;of IgG and/or IgM isotype in serum or plasma, present in medium or high titer (ie, &#62;40 GPL or MPL, or &#62;the 99th percentile), on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA.</td> </tr> <tr> <td class=\"indent1\">3. Anti-beta-2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma (in titer &#62;the 99th percentile), present on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA, according to recommended procedures.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LA: lupus anticoagulant; aCL: anticardiolipin antibody; Ig: immunoglobulin; ELISA: enzyme-linked immunosorbent assay; APS: antiphospholipid syndrome; aPL: antiphospholipid antibodies; LDL: low-density lipoprotein; HDL: high-density lipoprotein; GFR: glomerular filtration rate.<br />* Classification of APS should be avoided if less than 12 weeks or more than&nbsp;five years separate the positive aPL test and the clinical manifestation.<br />Â¶ Coexisting inherited or acquired factors for thrombosis are not reasons for excluding patients from APS trials. However, two subgroups of APS patients should be recognized, according to: (a) the presence; and (b) the absence of additional risk factors for thrombosis. Indicative (but not exhaustive) cases include: age (&gt;55 in men and &gt;65 in women) and the presence of any of the established risk factors for cardiovascular disease (hypertension, diabetes mellitus, elevated LDL or low HDL cholesterol, cigarette smoking, family history of premature cardiovascular disease, body mass index â¥30 kg m<SUP>â2</SUP>, microalbuminuria, estimated GFR &lt;60 mL minute<SUP>â1</SUP>), inherited thrombophilias, oral contraceptives, nephrotic syndrome, malignancy, immobilization, and surgery. Thus, patients who fulfill criteria should be stratified according to contributing causes of thrombosis.<br />Î A thrombotic episode in the past could be considered as a clinical criterion, provided that thrombosis is proved by appropriate diagnostic means and that no alternative diagnosis or cause of thrombosis is found.<br /><FONT class=lozenge>â</FONT> Superficial venous thrombosis is not included in the clinical criteria.<br />Â§ Generally accepted features of placental insufficiency include: (i) abnormal or non-reassuring fetal surveillance test(s), eg, a non-reactive non-stress test, suggestive of fetal hypoxemia; (ii) abnormal Doppler flow velocimetry waveform analysis suggestive of fetal hypoxemia, eg, absent end-diastolic flow in the umbilical artery; (iii) oligohydramnios, eg, an amniotic fluid index of 5 cm or less; or (iv) a postnatal birth weight less than the 10th percentile for the gestational age.<br />Â¥ Investigators are strongly advised to classify APS patients in studies into one of the following categories: I, more than one laboratory criteria present (any combination); IIa, LA present alone; IIb, aCL antibody present alone; IIc, anti-beta-2 glycoprotein-I antibody present alone.</div><div class=\"graphic_reference\">From: Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2006.01753.x/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2006.01753.x/abstract</a>. Copyright &copy; 2006 International Society on Thrombosis and Haemostasis. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 104569 Version 2.0</div></div></div>"},"104570":{"type":"graphic_diagnosticimage","displayName":"Normal fetal corpus callosum","title":"Normal fetal corpus callosum","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Normal fetal corpus callosum</div><div class=\"cntnt\"><img style=\"width:542px; height:435px;\" src=\"images/OBGYN/104570_Nrml_ftl_crps_cllsm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Images show a normal corpus callosum at 24-weeks gestational age.<br />(A) Sagittal midline view shows the hypoechoic corpus callosum.<br />(B) Power Doppler shows flow in the normal pericallosal artery.<br />(C) Anatomy of corpus callosum: rostrum (R), genu (G), body (B), and splenium (S).</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 104570 Version 3.0</div></div></div>"},"104571":{"type":"graphic_diagnosticimage","displayName":"Agenesis of the corpus callosum in fetus","title":"Fetal ultrasound showing agenesis of the corpus callosum","html":"<div class=\"graphic\"><div style=\"width: 759px\" class=\"figure\"><div class=\"ttl\">Fetal ultrasound showing agenesis of the corpus callosum</div><div class=\"cntnt\"><img style=\"width:739px; height:525px;\" src=\"images/OBGYN/104571_Agns_crps_cllsm_fts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Agenesis of the corpus callosum at 21 1/7 weeks of gestation.<br />(B) Same fetus as (A)&nbsp;showing absence of the normal pericallosal artery.<br />(C) Normal corpus callosum, cingulate gyrus, and normal gyral pattern at 34 0/7 weeks of gestation.<br />(D) Agenesis of the corpus callosum in a third trimester fetus.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 104571 Version 1.0</div></div></div>"},"104572":{"type":"graphic_diagnosticimage","displayName":"3-D ultrasound image agenesis of the corpus callosum","title":"Three-dimensional ultrasound image showing agenesis of the corpus callosum in a fetus","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Three-dimensional ultrasound image showing agenesis of the corpus callosum in a fetus</div><div class=\"cntnt\"><img style=\"width:761px; height:544px;\" src=\"images/OBGYN/104572_3D_ultrsn_img_agns_crp_cllsm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal image shows the widely separated ventricles (arrows).<br />(B) Sagittal image shows absence of the corpus callosum.<br />(C) Oblique axial image shows the teardrop-shaped appearance of the lateral ventricles (colpocephaly).</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 104572 Version 1.0</div></div></div>"},"104573":{"type":"graphic_picture","displayName":"US probe position start lateral knee examination","title":"US probe position start lateral knee examination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US probe position start lateral knee examination</div><div class=\"cntnt\"><img style=\"width:277px; height:712px;\" src=\"images/SM/104573_US_prb_pst_strt_lt_kn_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the proper position of the ultrasound transducer to evaluate the distal iliotibial band in&nbsp;its long-axis and to begin the examination of the lateral knee. The probe is located at Gerdy's tubercle.</div><div class=\"graphic_footnotes\">Rectangle: probe position; arrow: direction probe is translated, from imaging patellar tendon in long-axis to imaging iliotibial band.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104573 Version 2.0</div></div></div>"},"104574":{"type":"graphic_diagnosticimage","displayName":"US distal iliotibial band Gerdys tubercle coronal view","title":"US distal iliotibial band Gerdys tubercle coronal view","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">US distal iliotibial band Gerdys tubercle coronal view</div><div class=\"cntnt\"><img style=\"width:786px; height:226px;\" src=\"images/SM/104574_US_dstl_iltbl_bnd_grd_tbrcl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound image above shows&nbsp;the distal iliotibial band (outlined by small arrowheads)&nbsp;in the coronal oblique plane (ie, long-axis) as it inserts onto Gerdy's tubercle at the proximal tibia.</div><div class=\"graphic_footnotes\">Small arrowheads: iliotibial band; large arrowheads: lateral knee joint line; arrows: lateral meniscus.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104574 Version 1.0</div></div></div>"},"104576":{"type":"graphic_diagnosticimage","displayName":"US distal ITB at lateral femoral condyle transverse view","title":"US distal ITB at lateral femoral condyle transverse view","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US distal ITB at lateral femoral condyle transverse view</div><div class=\"cntnt\"><img style=\"width:787px; height:270px;\" src=\"images/SM/104576_US_dst_ITB_lat_fem_cnd_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound&nbsp;umage shows the distal iliotibial band in the transverse plane&nbsp;(short-axis).</div><div class=\"graphic_footnotes\">Arrowheads: iliotibial band; LFC: lateral femoral condyle.<br />Left side of image: posterior; right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104576 Version 1.0</div></div></div>"},"104577":{"type":"graphic_picture","displayName":"Intraocular pressure measurement by applanation tonometry","title":"Intraocular pressure measurement by applanation tonometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraocular pressure measurement by applanation tonometry</div><div class=\"cntnt\"><img style=\"width:434px; height:340px;\" src=\"images/EM/104577_Intraocular_pressure_measurement.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mathew F. Gardiner, MD, and Ankoor Shah, MD, PhD</div><div id=\"graphicVersion\">Graphic 104577 Version 1.0</div></div></div>"},"104581":{"type":"graphic_table","displayName":"Rx EC IE (S to PCN and R to gent)","title":"Suggested regimens for therapy of native or prostheticÂ valve endocarditis due to enterococcal strains susceptible to penicillin and resistant to gentamicin*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested regimens for therapy of native or prosthetic&nbsp;valve endocarditis due to enterococcal strains susceptible to penicillin and resistant to gentamicin*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\">European Society of Cardiology (ESC)</td> <td class=\"subtitle1\">British Society for Antimicrobial Therapy (BSAC)</td> </tr> <tr> <td class=\"subtitle2\">Adult dose</td> <td class=\"subtitle2\">Pediatric dose</td> <td class=\"subtitle2\">Adult dose</td> <td class=\"subtitle2\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Aminoglycoside combination regimen<sup>&#182;</sup></td> <td class=\"subtitle2_left\">Aminoglycoside combination regimen<sup>&#182;</sup></td> <td class=\"subtitle2_left\">Aminoglycoside combination regimen<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Ampicillin 2 g IV every 4 hours for four to six weeks<sup>&#916;</sup></p> <p><strong>or</strong></p> <p>Aqueous penicillin G 18 to 30 million units per 24 hours continuously or in six divided doses for four to six weeks<sup>&#916;</sup></p> <p><strong>plus</strong></p> Streptomycin<sup>&#9674;</sup> 15 mg/kg per 24 hours IV or IM in two divided doses for four to six weeks<sup>&#916;</sup> </td> <td class=\"indent1\">Consultation with a pediatric infectious disease expert is recommended in all cases of enterococcal infective endocarditis</td> <td class=\"indent1\"> <p>Amoxicillin 200 mg/kg/day in four to six doses for four to six weeks<sup>&#916;</sup></p> <p><strong>or</strong></p> <p>Ampicillin 12 g per day (200 mg/kg per day) in four or six doses for four to six weeks<sup>&#916;</sup></p> <p><strong>plus</strong></p> Streptomycin<sup>&#9674;</sup> 15 mg/kg per 24 hours IV or IM in two divided doses for four to six weeks<sup>&#916;</sup></td> <td class=\"indent1\"> <p>Amoxicillin 2 g every 4 hours IV for&nbsp;four to six&nbsp;weeks<sup>&#916;</sup></p> <p><strong>with or without</strong></p> Streptomycin<sup>&#9674;</sup> 15 mg/kg per 24 hours IM in two divided doses for&nbsp;four to six&nbsp;weeks<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Beta-lactam combination regimen<sup>&#167;</sup></td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <p>Ceftriaxone 2 g IV every 12 hours for six weeks</p> <p><strong>plus</strong></p> Ampicillin 2 g IV every 4 hours for six weeks</td> <td> <p>Ceftriaxone 100 mg/kg per 24 hours IVâ in two divided doses or 80 mg/kg in one daily dose (maximum dose: 4 g per 24 hours; if dose is &#62;2 g per 24 hours, use divided dosing every 12 hours) for six weeks</p> <p><strong>plus</strong></p> <p><strong></strong>Ampicillin 200 to 300 mg/kg per 24 hours IV divided in four to six divided doses (maximum dose: 12 g per 24 hours) for six weeks</p> </td> <td class=\"indent1\"> <p>Ceftriaxone 2 g IV every 12 hours for six weeks</p> <p><strong>plus</strong></p> Ampicillin 2 g IV every 4 hours for six weeks</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; IV: intravenously; IM: intramuscularly; HLAR: high-level aminoglycoside resistance.<br />* Patients unable to tolerate beta-lactams should receive treatment as for infection due to isolates with intrinsic penicillin resistance. Refer to UpToDate table on treatment regimens for native or prosthetic valve endocarditis due to an enterococcal strain resistant to penicillin and susceptible to vancomycin and aminoglycosides.<br />Â¶ For treatment of infection due to isolates that are gentamicin resistant and streptomycin susceptible (growth inhibited by 1000 mcg/mL) in patients with creatinine clearance &gt;50 mL/minute. Although this regimen was used effectively before gentamicin was established as the preferred aminoglycoside, AHA 2015 guidelines discourage its use. This is because of general lack of physician familiarity with streptomycin, supply shortages, lack of readily available laboratory testing for serum concentration monitoring, and cranial nerve VIII toxicity (refer to&nbsp;text).<br />Î Patients with NVE and symptoms &lt;3 months may be treated for 4 weeks; patients with PVE or NVE with symptoms â¥3 months should be treated for at least 6 weeks.<br /><FONT class=lozenge>â</FONT> In adults, streptomycin is dosed based on ideal body weight. Dose should be adjusted to obtain serum peak concentration of 20 to 35 mcg/mL and a trough concentration of &lt;10 mcg/mL.<br />Â§ The beta-lactam combination regimen is active against <EM>Enterococcus faecalis</EM> strains with and without HLAR and is the combination of choice in patients with HLAR <EM>E. faecalis</EM> endocarditis; it is not bactericidally synergistic against <EM>Enterococcus faecium</EM>. This regimen is reasonable for patients with normal renal function (and preferred for patients with impaired renal function), abnormal cranial nerve VIII function, and generally in lieu of combination therapy with streptomycin.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</LI>&#xD;&#xA;<LI>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</LI>&#xD;&#xA;<LI>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</LI>&#xD;&#xA;<LI>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</LI></OL></div><div id=\"graphicVersion\">Graphic 104581 Version 3.0</div></div></div>"},"104582":{"type":"graphic_table","displayName":"Indications for surgery for IE","title":"Indications for surgery in left-sided valve infective endocarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for surgery in left-sided valve infective endocarditis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"61%\"></colgroup><colgroup span=\"3\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indications for surgery</td> <td class=\"subtitle1\">Timing*</td> <td class=\"subtitle1\">Class<sup>&#182;</sup></td> <td class=\"subtitle1\">Level<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">1. Heart failure</td> </tr> <tr> <td class=\"indent1\">Aortic or mitral NVE or PVE with severe acute regurgitation, obstruction or fistula causing refractory pulmonary oedema or cardiogenic shock</td> <td class=\"centered\">Emergency</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aortic or mitral NVE or PVE with severe regurgitation or obstruction causing symptoms of HF or echocardiographic signs of poor haemodynamic tolerance</td> <td class=\"centered\">Urgent</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">2. Uncontrolled infection</td> </tr> <tr> <td class=\"indent1\">Locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation)</td> <td class=\"centered\">Urgent</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Infection caused by fungi or multiresistant organisms</td> <td class=\"centered\">Urgent/elective</td> <td class=\"centered\">I</td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"indent1\">Persisting positive blood cultures despite appropriate antibiotic therapy and adequate control of septic metastatic foci</td> <td class=\"centered\">Urgent</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PVE caused by staphylococci or non-HACEK gram-negative bacteria</td> <td class=\"centered\">Urgent/elective</td> <td class=\"centered\">IIa</td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">3. Prevention of embolism</td> </tr> <tr> <td class=\"indent1\">Aortic or mitral NVE or PVE with persistent vegetations &#62;10 mm after one or more embolic episode despite appropriate antibiotic therapy</td> <td class=\"centered\">Urgent</td> <td class=\"centered\">I</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Aortic or mitral NVE with vegetations &#62;10 mm, associated with severe valve stenosis or regurgitation, and low operative risk</td> <td class=\"centered\">Urgent</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Aortic or mitral NVE or PVE with isolated very large vegetations (&#62;30 mm)</td> <td class=\"centered\">Urgent</td> <td class=\"centered\">IIa</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Aortic or mitral NVE or PVE with isolated large vegetations (&#62;15 mm) and no other indication for surgery<sup>&#9674;</sup></td> <td class=\"centered\">Urgent</td> <td class=\"centered\">IIb</td> <td class=\"centered\">C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HACEK:â <EM>Haemophilus parainfluenzae</EM>, <EM>Haemophilus aphrophilus</EM>, <EM>Haemophilus paraphrophilus</EM>, <EM>Haemophilus influenza</EM>, <EM>Actinobacillus actinomycetemcomitans</EM>, <EM>Cardiobacterium hominis</EM>,â <EM>ââEikenella corrodens</EM>, <EM>Kingella kingae</EM>, and <EM>Kingella denitrificans</EM>; HF: heart failure; IE: infective endocarditis; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis.ââââ<br />* Emergency surgery: surgery performed within 24 hours; urgent surgery: within a few days; elective surgery: after at least one to two weeks of antibiotic therapy.ââ<br />Â¶ Class of recommendation.â Class I: Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Class II: Conflicting evidence and/or divergence of opinion about the usefulness/efficacy of the given treatment or procedure. Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy. Class IIb: Usefulness/efficacy is less well established by evidence/opinion.<br />Î Level of evidence.â A: Data derived from multiple randomized clinical trials or meta-analyses. B: Data derived from a single randomized clinical trial or large non-randomized studies. C: Consensus of opinion of the experts and/or small studies, retrospective studies, registries.<br /><FONT class=lozenge>â</FONT> Surgery may be preferred if a procedure preserving the native valve is feasible.ââ</div><div class=\"graphic_reference\">Reproduced from: Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J 2015; 36(44):3036-7, by permission of Oxford University Press on behalf of The European Society of Cardiology. Copyright Â© 2015 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org</A>.</div><div id=\"graphicVersion\">Graphic 104582 Version 3.0</div></div></div>"},"104583":{"type":"graphic_table","displayName":"Management of PPH based on estimated blood loss","title":"Overview of management of postpartum hemorrhage based on estimated blood loss and hemodynamic stability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of management of postpartum hemorrhage based on estimated blood loss and hemodynamic stability</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">The obstetrical provider should initiate a sequence of nonoperative and operative interventions for control of PPH and promptly assess the success or failure of each measure. Intervention is based, in part, on the severity of hemorrhage.</span></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Quantify blood loss. </li> <li>Initiate additional measures to control bleeding based on severity of obstetric hemorrhage. <ul> <li>Blood loss &#62;500 mL and &#60;1000 mL at vaginal delivery or &#62;1000 mL and &#60;1500 mL at cesarean delivery with ongoing excessive bleeding and/or mild tachycardia and/or hypotension. <ul> <li>Get help and notify obstetric hemorrhage team. </li> <li>Continue to monitor vital signs and quantify blood loss. </li> <li>Ensure intravenous access with a large gauge catheter(s). </li> <li>Begin bimanual uterine massage. </li> <li>Increase oxytocin flow rate (avoid direct intravenous injection of undiluted oxytocin). </li> <li>Volume resuscitation, preferably with blood and blood products if bleeding is heavy and coagulopathy is imminent. </li> <li>Give a second uterotonic (eg, methylergonovine, carboprost tromethamine). </li> <li>Examine for lacerations, retained products of conception, uterine inversion, and other causes of bleeding. Consider bedside ultrasound of uterus. Treat as appropriate (eg, repair lacerations, curettage, reposition uterus, etc). </li> <li>If cesarean delivery: Apply conservative surgical interventions to control bleeding (eg, uterine artery/ovarian artery ligation, uterine compression sutures). </li> </ul> </li> <li>Blood loss &#62;1000 mL and &#60;1500 mL at vaginal delivery or &#62;1500 mL at cesarean delivery with ongoing excessive bleeding and/or hemodynamic instability. <ul> <li>Do all of the above. </li> <li>Draw blood for baseline labs (complete blood count, coagulation studies) and clot observation test. </li> <li>Insert intrauterine balloon for tamponade. </li> <li>Transfuse two units packed red cells and one to two units fresh frozen plasma. Activate a massive transfusion protocol if bleeding is heavy and transfusion of four or more units of blood is likely. </li> <li>If vaginal delivery: Move the patient to an operating room to perform conservative surgical interventions to control bleeding. </li> <li>Consider selective arterial embolization only if patient is hemodynamically stable. This should preferably be performed in an operating room or hybrid suite if available. Bleeding patients should only be moved to a radiology suite for embolization if they are hemodynamically stable and blood products are being replaced at a rate that can exceed that of the bleeding. Arterial embolization outside of an operating room is not an option in situations where there is catastrophic bleeding in a decompensating patient. </li> <li>If cesarean delivery: Continue to apply conservative surgical interventions to control bleeding (eg, uterine artery/ovarian artery ligation, uterine compression sutures). </li> </ul> </li> <li>Blood loss &#62;1500 mL, ongoing excessive bleeding, and hemodynamic instability despite initial therapy. <ul> <li>Initiate massive transfusion protocol (transfuse appropriate ratio of red cells, fresh frozen plasma/cryoprecipitate, and platelets). </li> <li>If conservative surgical interventions are not successful, perform hysterectomy. Hysterectomy should not be delayed in women who require prompt control of uterine hemorrhage to prevent death. </li> <li>Keep patient warm. </li> <li>Treat acidosis. </li> <li>Check ionized calcium and potassium levels every 15 minutes once a massive transfusion protocol has been initiated and treat hypocalcemia and hyperkalemia aggressively. Continue until the emergency has been contained and the protocol for massive transfusion has been stopped. </li> <li>Maintain oxygen saturation &#62;95%. </li> </ul> </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 104583 Version 2.0</div></div></div>"},"104587":{"type":"graphic_figure","displayName":"Differential diagnosis of the rash in roseola","title":"Differential diagnosis of the rash in roseola","html":"<div class=\"graphic\"><div style=\"width: 894px\" class=\"figure\"><div class=\"ttl\">Differential diagnosis of the rash in roseola</div><div class=\"cntnt\"><img style=\"width:874px; height:1964px;\" src=\"images/PEDS/104587_DDx_of_rash_in_roseola.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\"><strong>Roseola:</strong> Courtesy of Michael Brady, MD.<br /><strong>Rubella:</strong> Image from Centers for Disease Control and Prevention.<br /><strong>Rubeola:</strong> Copyright Dr. Michael Bennish; reproduced with his permission.<br /><strong>Enteroviral infection:</strong> Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.<br /><strong>Erythema infectiosum:</strong><br />(A) Courtesy of Moise L Levy, MD.<br />(B) Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.<br /><strong>Scarlet fever:</strong><br />(A) Reproduced with permission from: George A. Datto, III, MD.<br />(B) Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.<br />(C) Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.<br /><strong>Drug allergy:</strong> Courtesy of Andrew Samel, MD.</div><div id=\"graphicVersion\">Graphic 104587 Version 2.0</div></div></div>"},"104591":{"type":"graphic_figure","displayName":"Nerves of the upper extremity","title":"Nerves of the upper extremity","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Nerves of the upper extremity</div><div class=\"cntnt\"><img style=\"width:479px; height:667px;\" src=\"images/ANEST/104591_Nerves_of_the_upper_extremity.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">n.: nerve.</div><div id=\"graphicVersion\">Graphic 104591 Version 1.0</div></div></div>"},"104592":{"type":"graphic_figure","displayName":"Wrist blocks with cutaneous distribution","title":"Wrist blocks with cutaneous distribution","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Wrist blocks with cutaneous distribution</div><div class=\"cntnt\"><img style=\"width:541px; height:559px;\" src=\"images/ANEST/104592_Wrist_blocks_with_cutaneous_distribution.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The colored shading shows the cutaneous distribution of each nerve block at the wrist. </div><div id=\"graphicVersion\">Graphic 104592 Version 1.0</div></div></div>"},"104593":{"type":"graphic_figure","displayName":"Axillary blocks","title":"Axillary block","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Axillary block</div><div class=\"cntnt\"><img style=\"width:540px; height:454px;\" src=\"images/ANEST/104593_Axillary_blocks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axillary block anesthetizes the nerves of the brachial plexus at the level of the individual nerves (ie, median, radial, and ulnar), where they surround the axillary artery. The placement of the ultrasound probe is shown by the rectangle in this graphic. The injection point is shown by the white dot. A separate injection may be required to block the musculocutaneous nerve, which exits the brachial plexus sheath proximally.&nbsp;See text for a description of block technique.</div><div id=\"graphicVersion\">Graphic 104593 Version 1.0</div></div></div>"},"104594":{"type":"graphic_figure","displayName":"Intercostobrachial nerve block","title":"Intercostobrachial nerve block","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Intercostobrachial nerve block</div><div class=\"cntnt\"><img style=\"width:520px; height:410px;\" src=\"images/ANEST/104594_Intercostobrachial_nerve_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intercostobrachial nerve is blocked by raising a subcutaneous wheal of local anesthetic along the medial edge of the axillary crease. The path of injection is shown as a dotted line in this figure.</div><div id=\"graphicVersion\">Graphic 104594 Version 1.0</div></div></div>"},"104608":{"type":"graphic_figure","displayName":"Pomeroy tubal ligation","title":"Tubal ligation: Pomeroy method","html":"<div class=\"graphic\"><div style=\"width: 866px\" class=\"figure\"><div class=\"ttl\">Tubal ligation: Pomeroy method</div><div class=\"cntnt\"><img style=\"width:846px; height:338px;\" src=\"images/OBGYN/104608_Pomeroy_tubal_ligation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A loop of the isthmic portion of the tube is elevated and ligated at its base with one or two ties of no. 1 plain catgut suture. If performed through a minilaparotomy incision, these ties should be held long to prevent premature retraction of the tubal stumps into the abdomen when the loop of tube is transected.<br />(B) A fenestration is bluntly created through the mesentery within the tubal loop, and each limb of the tube on either side of this fenestration is individually cut. The cut ends of the tube are inspected for hemostasis and allowed to retract into the abdomen.</div><div class=\"graphic_reference\">Reproduced with permission from: Peterson HB, Warshaw JS, Pollack AE, Levy BS. Tubal sterilization. In: TeLinde's Operative Gynecology, 11th ed, Jones HW, Rock JA (eds), Lippincott Williams &amp; Wilkins, 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104608 Version 1.0</div></div></div>"},"104609":{"type":"graphic_diagnosticimage","displayName":"US popliteal tendon coronal view","title":"US popliteal tendon coronal view","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">US popliteal tendon coronal view</div><div class=\"cntnt\"><img style=\"width:785px; height:288px;\" src=\"images/SM/104609_US_ppltl_tndn_crnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows&nbsp;the popliteus tendon (asterisk)&nbsp;in the coronal plane&nbsp;(short-axis).</div><div class=\"graphic_footnotes\">*: popliteus tendon; FC: femoral condyle; arrows: cocave fossa of femoral condyle housing popliteus tendon; small arrowheads: lateral joint line; large arrowheads: iliotibial band.<br />Left side of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104609 Version 1.0</div></div></div>"},"104611":{"type":"graphic_figure","displayName":"Parkland tubal ligation method","title":"Tubal ligation: Parkland method","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Tubal ligation: Parkland method</div><div class=\"cntnt\"><img style=\"width:648px; height:618px;\" src=\"images/OBGYN/104611_Parkland_tubal_ligat_method.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 2- to 3-cm fenestration is made beneath the isthmic portion of tube either with scissors or bluntly with a hemostat.<br />(B) Ligation of the tube. Pulling up on the suture during ligation or during transection of the tube can shear the tube off the underlying mesentery, resulting in troublesome bleeding.<br />(C) Portion of tube removed.</div><div class=\"graphic_reference\">Reproduced with permission from: Peterson HB, Warshaw JS, Pollack AE, Levy BS. Tubal sterilization. In: TeLinde's Operative Gynecology, 11th ed, Jones HW, Rock JA (eds), Lippincott Williams &amp; Wilkins, 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104611 Version 1.0</div></div></div>"},"104612":{"type":"graphic_figure","displayName":"Irving tubal ligation","title":"Tubal ligation: Irving method","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Tubal ligation: Irving method</div><div class=\"cntnt\"><img style=\"width:616px; height:363px;\" src=\"images/OBGYN/104612_Irving_tubal_ligation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tying these sutures secures the cut end of the proximal tube deep in the myometrial pocket.</div><div class=\"graphic_reference\">Reproduced with permission from: Peterson HB, Warshaw JS, Pollack AE, Levy BS. Tubal sterilization. In: TeLinde's Operative Gynecology, 11th ed, Jones HW, Rock JA (eds), Lippincott Williams &amp; Wilkins, 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104612 Version 1.0</div></div></div>"},"104613":{"type":"graphic_figure","displayName":"Uchida tubal ligation","title":"Tubal ligation: Uchida method","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Tubal ligation: Uchida method</div><div class=\"cntnt\"><img style=\"width:544px; height:316px;\" src=\"images/OBGYN/104613_Uchida_tubal_ligation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mesosalpinx is closed. A purse-string stitch of the mesosalpinx around the exteriorized tubal stump secures it in a position open to the abdomen, whereas the ligated proximal stump is buried within the mesosalpinx. Once the purse-string suture is tied, the hemostat can be removed.</div><div class=\"graphic_reference\">Reproduced with permission from: Peterson HB, Warshaw JS, Pollack AE, Levy BS. Tubal sterilization. In: TeLinde's Operative Gynecology, 11th ed, Jones HW, Rock JA (eds), Lippincott Williams &amp; Wilkins, 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104613 Version 1.0</div></div></div>"},"104620":{"type":"graphic_diagnosticimage","displayName":"US popliteal tendon transverse view","title":"US popliteal tendon transverse view","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US popliteal tendon transverse view</div><div class=\"cntnt\"><img style=\"width:787px; height:327px;\" src=\"images/SM/104620_US_ppltl_tndn_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound&nbsp;image above&nbsp;shows the&nbsp;popliteus tendon in a transverse view&nbsp;(long-axis) as it inserts on the femur.</div><div class=\"graphic_footnotes\">Large arrowheads: popliteus tendon insertion; Small arrowheads: portion of popliteus tendon not well visualized (anisotropy); FC: femoral condyle.<br />Left side of image: cranial; right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104620 Version 1.0</div></div></div>"},"104621":{"type":"graphic_diagnosticimage","displayName":"US lateral knee extended field transverse view","title":"US lateral knee extended field transverse view","html":"<div class=\"graphic\"><div style=\"width: 810px\" class=\"figure\"><div class=\"ttl\">US lateral knee extended field transverse view</div><div class=\"cntnt\"><img style=\"width:790px; height:469px;\" src=\"images/SM/104621_US_lt_kn_extn_fld_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image provides an extended field of view of the lateral knee structures in the transverse plane.</div><div class=\"graphic_footnotes\">Small arrowheads: iliotibial band (short-axis); large arrowheads: musculotendinous junction of biceps femoris muscle (short-axis); dotted ellipse: peroneal nerve (short-axis).<br />Left side of image: posterior; right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104621 Version 1.0</div></div></div>"},"104622":{"type":"graphic_picture","displayName":"ICDs PI","title":"Implantable cardioverter-defibrillators","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Implantable cardioverter-defibrillators</div><div class=\"cntnt\"><img style=\"width:520px; height:647px;\" src=\"images/PI/104622_ICDs_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows several different examples of implantable cardioverter-defibrillators (ICDs).</div><div id=\"graphicVersion\">Graphic 104622 Version 1.0</div></div></div>"},"104623":{"type":"graphic_diagnosticimage","displayName":"US biceps femoris tendon division transverse view","title":"US biceps femoris tendon division transverse view","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">US biceps femoris tendon division transverse view</div><div class=\"cntnt\"><img style=\"width:785px; height:250px;\" src=\"images/SM/104623_US_bcp_fmr_tnd_dvsn_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse ultrasound&nbsp;image shows&nbsp;the fibular collateral ligament (short-axis) and deep and superficial layers of the biceps femoris tendon (short-axis).&nbsp;The distal portion of the tendon&nbsp;divides into these deep and superficial portions,&nbsp;which travel around the fibular collateral ligament.</div><div class=\"graphic_footnotes\">Open ellipse: superficial layer of biceps femoris tendon; dotted ellipse: deep layer of biceps femoris tendon; open rectangle: fibular collateral ligament; arrow: direction superficial layer (superficial to fibular collateral ligament) courses caudally; dashed arrow: direction deep layer (deep to fibular collateral ligament) courses distally.<br />Left side of image: posterior; right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104623 Version 1.0</div></div></div>"},"104624":{"type":"graphic_picture","displayName":"Pacemakers PI","title":"Pacemakers","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Pacemakers</div><div class=\"cntnt\"><img style=\"width:517px; height:502px;\" src=\"images/PI/104624_Pacemakers_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows several different examples of pacemakers.</div><div id=\"graphicVersion\">Graphic 104624 Version 1.0</div></div></div>"},"104625":{"type":"graphic_picture","displayName":"US probe position start medial knee examination","title":"US probe position start medial knee examination","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">US probe position start medial knee examination</div><div class=\"cntnt\"><img style=\"width:788px; height:405px;\" src=\"images/SM/104625_US_prb_pst_strt_mdl_kn_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To begin the ultrasound examination of the medial knee, the patient is positioned as in the photograph above with the knee and hip slightly flexed.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104625 Version 1.0</div></div></div>"},"104626":{"type":"graphic_diagnosticimage","displayName":"US medial collateral ligament coronal view","title":"US medial collateral ligament coronal view","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">US medial collateral ligament coronal view</div><div class=\"cntnt\"><img style=\"width:792px; height:266px;\" src=\"images/SM/104626_US_mdl_clltrl_lgm_crnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the medial collateral ligament (outlined by the arrows) in a coronal plane (long-axis).</div><div class=\"graphic_footnotes\">Arrows: superficial layer of medial collateral ligament (tibial collateral ligament); arrowheads: deep layer of medial collateral ligament (meniscotibial ligament); *: deep layer of medial collateral ligament (meniscofemoral ligament); MM: medial meniscus.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104626 Version 1.0</div></div></div>"},"104627":{"type":"graphic_diagnosticimage","displayName":"US pes anserine tendons coronal view","title":"US pes anserine tendons coronal view","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">US pes anserine tendons coronal view</div><div class=\"cntnt\"><img style=\"width:792px; height:193px;\" src=\"images/SM/104627_US_pes_ansrn_tndn_crnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows&nbsp;the pes anserine tendons in a coronal oblique plane. In this view, the tendons are adjacent to the tibial collateral ligament.</div><div class=\"graphic_footnotes\">Arrows: pes anserine tendons; arrowheads: tibial collateral ligament; dotted ellipses: genicular artery.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104627 Version 1.0</div></div></div>"},"104628":{"type":"graphic_picture","displayName":"US probe position medial hamstring tendon examination","title":"US probe position semimembranosus semitendinosus tendon examination","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">US probe position semimembranosus semitendinosus tendon examination</div><div class=\"cntnt\"><img style=\"width:483px; height:782px;\" src=\"images/SM/104628_US_prb_pst_mdl_hmstr_tnd_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above of the posterior thigh and knee shows the position of the transducer for the ultrasound examination of the distal semimembranosus and semitendinosus tendons.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104628 Version 1.0</div></div></div>"},"104629":{"type":"graphic_diagnosticimage","displayName":"US distal semimembranosus semitendinosus transverse view","title":"US distal semimembranosus semitendinosus transverse view","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">US distal semimembranosus semitendinosus transverse view</div><div class=\"cntnt\"><img style=\"width:792px; height:363px;\" src=\"images/SM/104629_US_dst_smmmbrn_smtndn_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows transverse views (short axis) of the semimembranosus muscle and semitendinosus tendon.</div><div class=\"graphic_footnotes\">ST: semitendinosus tendon; SM: semimembranosus muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104629 Version 2.0</div></div></div>"},"104630":{"type":"graphic_diagnosticimage","displayName":"US semimembranosus tendon insertion transverse view","title":"US semimembranosus tendon insertion transverse view","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">US semimembranosus tendon insertion transverse view</div><div class=\"cntnt\"><img style=\"width:792px; height:453px;\" src=\"images/SM/104630_US_smmmbrn_tndn_insrt_trnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the semimembranosus tendon (outlined by arrowheads)&nbsp;in a transverse view (short-axis), including its tibial insertion.</div><div class=\"graphic_footnotes\">Small arrowheads: semimembranosus tendon; asterisks (*): tendon of medial head of gastrocnemius; MHG: medial head of gastrocnemius muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104630 Version 2.0</div></div></div>"},"104635":{"type":"graphic_diagnosticimage","displayName":"US semimembranosus tendon insertion sagittal view","title":"US semimembranosus tendon insertion sagittal view","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">US semimembranosus tendon insertion sagittal view</div><div class=\"cntnt\"><img style=\"width:792px; height:453px;\" src=\"images/SM/104635_US_smbrn_tndn_insrt_sgt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows&nbsp;the semimembranosus tendon insertion onto the tibia&nbsp;in a sagittal oblique plane&nbsp;(long-axis).</div><div class=\"graphic_footnotes\">Arrowheads: semimembranosus tendon.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104635 Version 1.0</div></div></div>"},"104636":{"type":"graphic_diagnosticimage","displayName":"US location potential space popliteal Bakers cyst","title":"US location potential space popliteal Bakers cyst","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US location potential space popliteal Bakers cyst</div><div class=\"cntnt\"><img style=\"width:787px; height:237px;\" src=\"images/SM/104636_US_lct_ptnt_spc_pplt_bkr_cst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the&nbsp;semimembranosus tendon in a transverse view&nbsp;(short-axis)&nbsp;in the&nbsp;area that contains&nbsp;the&nbsp;potential space for the semimembranosus bursa (Baker's cyst). In image A, the&nbsp;transducer is perpendicular to the skin surface. In image B, the&nbsp;transducer is tilted cranially.</div><div class=\"graphic_footnotes\">Arrow: semimembranosus tendon; arrowhead: semitendinosus tendon; +: articular cartilage; *: tendon of medial head of gastrocnemius; MHG: medial head of gastrocnemius muscle.<br />Left side of each image: lateral; right side of each image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104636 Version 1.0</div></div></div>"},"104639":{"type":"graphic_diagnosticimage","displayName":"US medial head gastrocnemius sagittal view","title":"US medial head gastrocnemius sagittal view","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">US medial head gastrocnemius sagittal view</div><div class=\"cntnt\"><img style=\"width:792px; height:477px;\" src=\"images/SM/104639_US_mdl_hd_gstrcnm_sgtl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal ultrasound scan of the medial head of gastrocnemius muscle and soleus muscle (long-axis).</div><div class=\"graphic_footnotes\">MHG: medial head of gastrocnemius muscle; SO: soleus muscle; large arrowheads: medial head of gastrocnemius muscle insertion into distal aponeurosis; small arrowheads: soleus muscle insertion into distal aponeurosis; arrows: Achilles tendon.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104639 Version 1.0</div></div></div>"},"104640":{"type":"graphic_picture","displayName":"US probe position popliteal fossa examination","title":"US probe position popliteal fossa examination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US probe position popliteal fossa examination</div><div class=\"cntnt\"><img style=\"width:388px; height:712px;\" src=\"images/SM/104640_US_prb_pst_ppltl_fss_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As pictured above, the transducer is positioned in the transverse plane and placed in the posterior knee to examine the popliteal fossa.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104640 Version 1.0</div></div></div>"},"104641":{"type":"graphic_picture","displayName":"Pediculosis capitis louse and nit","title":"Pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:712px; height:467px;\" src=\"images/DERM/104641_Pdclscptslousnit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Louse and nit on hair shafts.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright Â© 2015 Scott Camazine, MD, PhD. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104641 Version 3.0</div></div></div>"},"104642":{"type":"graphic_picture","displayName":"Pediculosis capitis nits on hair shafts","title":"Pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:712px; height:474px;\" src=\"images/DERM/104642_Pdclscptsntshrshft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nits on hair shafts.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright Â© 2015 Scott Camazine, MD, PhD. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104642 Version 3.0</div></div></div>"},"104643":{"type":"graphic_picture","displayName":"Pediculosis capitis with lice and nits","title":"Pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104643_Pediculosis_capts_lice_nits_SRC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Live lice and nits on the hair.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104643 Version 2.0</div></div></div>"},"104647":{"type":"graphic_diagnosticimage","displayName":"US popliteal fossa transverse view with doppler","title":"US popliteal fossa transverse view with doppler","html":"<div class=\"graphic\"><div style=\"width: 813px\" class=\"figure\"><div class=\"ttl\">US popliteal fossa transverse view with doppler</div><div class=\"cntnt\"><img style=\"width:793px; height:346px;\" src=\"images/SM/104647_US_ppltl_fss_trnsv_vw_dp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows a transverse&nbsp;view of the&nbsp;popliteal fossa. Image A is a&nbsp;grey scale image, while image B is a&nbsp;color Doppler image that highlights blood flow in the tibial vessels.</div><div class=\"graphic_footnotes\">Arrow: tibial nerve (short-axis); V and blue color: tibial vein (short-axis); A and orange color: tibial artery (short-axis).<br />Left side of each image: lateral; right side of each image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104647 Version 2.0</div></div></div>"},"104648":{"type":"graphic_table","displayName":"Long-acting reversible contraception","title":"Long-acting reversible contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Long-acting reversible contraception</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">US trade name (manufacturer)</td> <td class=\"subtitle1\">Progestin (mg)*</td> <td class=\"subtitle1\">Estrogen (micrograms)<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Depo-Provera intramuscular (Pfizer)</td> <td>Medroxyprogesterone acetate (150 mg/mL)</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Depo-SubQ Provera 104 subcutaneous (Pfizer)</td> <td>Medroxyprogesterone acetate (104 mg/0.65 mL)</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Liletta 52 mg intrauterine device (Actavis)</td> <td>Levonorgestrel (releases 0.0186 mg/day, decreasing to approximately 0.0163 mg/day at 1 year, then decreasing to approximately 0.0143 mg/day at 2 years, and 0.0126 mg/day at 3 years)</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Mirena 52 mg intrauterine device (Bayer)</td> <td>Levonorgestrel (releases approximately 0.02 mg/day, decreasing progressively to 0.01 mg/day by 5 years)<sup>&#916;</sup></td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Skyla 13.5 mg intrauterine device (Bayer)</td> <td>Levonorgestrel (releases 0.014 mg/day, decreasing to approximately 0.01 mg/day after 60 days, then decreasing to approximately 0.005 mg/day after 3 years)</td> <td>None</td> </tr> <tr> <td>Nexplanon 68 mg subdermal implant (Organon)<sup>&#9674;</sup></td> <td>Etonogestrel (releases 0.06 to 0.07 mg/day in weeks 5 to 6, decreasing to approximately 0.035 to 0.045 mg/day by 1 year, then decreasing to approximately 0.03 to 0.04 mg/day by year 2, and then to 0.025 to 0.03 mg/day by end of year 3)</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Different progestins are not equivalent on a milligram basis.<br />&para; Ethinyl estradiol and mestranol are not equivalent on a milligram basis; the results of some studies indicate that 30 to 35 mcg of ethinyl estradiol is equivalent to 50 mcg of mestranol.<br />&Delta; Decreases to 0.01 mg/day by 5 years. Do not leave same system in place for &gt;5 years.<br /><span class=\"lozenge\">&loz;</span> Also contains radiopaque (barium sulfate 15 mg).</div><div class=\"graphic_reference\">Adapted with special permission from The Medical Letter on Drugs and Therapeutics, September 14, 2015; Vol. 57 (1477):e133-e134. <A href=\"http://www.medicalletter.org/\" target=_blank>www.medicalletter.org</A>.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>US Food &amp; Drug Administration Orange Book: Approved Drugs with Therapeutic Equivalence Equations. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm (Accessed on September 30, 2015).</LI>&#xD;&#xA;<LI>Lexicomp online. Copyright Â© 1978-2016 by Lexicomp, Inc. All rights reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 104648 Version 2.0</div></div></div>"},"104649":{"type":"graphic_diagnosticimage","displayName":"US popliteus muscle transverse oblique view","title":"US popliteus muscle transverse oblique view","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">US popliteus muscle transverse oblique view</div><div class=\"cntnt\"><img style=\"width:664px; height:400px;\" src=\"images/SM/104649_US_pplt_mscl_trnsvr_oblq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;ultrasound scan&nbsp;shows the&nbsp;popliteus muscle in the transverse-oblique plane&nbsp;(long-axis).</div><div class=\"graphic_footnotes\">Arrows: popliteus muscle.<br />Left side of image: lateral; right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104649 Version 1.0</div></div></div>"},"104650":{"type":"graphic_diagnosticimage","displayName":"US PCL attachment to tibia sagittal view","title":"US posterior cruciate ligament (PCL) attachment to tibia sagittal view","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">US posterior cruciate ligament (PCL) attachment to tibia sagittal view</div><div class=\"cntnt\"><img style=\"width:784px; height:484px;\" src=\"images/SM/104650_Figure_34_US_PCL_at_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows the&nbsp;posterior cruciate ligament (PCL)&nbsp;in the sagittal plane&nbsp;(long-axis) where it attaches to the tibia.</div><div class=\"graphic_footnotes\">Arrows: posterior cruciate ligament.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104650 Version 1.0</div></div></div>"},"104651":{"type":"graphic_diagnosticimage","displayName":"US posterior lateral meniscus posterior sagittal view","title":"US posterior lateral meniscus posterior sagittal view","html":"<div class=\"graphic\"><div style=\"width: 691px\" class=\"figure\"><div class=\"ttl\">US posterior lateral meniscus posterior sagittal view</div><div class=\"cntnt\"><img style=\"width:671px; height:249px;\" src=\"images/SM/104651_US_pstrr_ltr_mnsc_pstr_sgttl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;ultrasound&nbsp;image above shows the&nbsp;posterior lateral meniscus in the sagittal plane.</div><div class=\"graphic_footnotes\">LM: lateral meniscus; *: articular cartilage.<br />Left side of image: caudal; right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 104651 Version 1.0</div></div></div>"},"104657":{"type":"graphic_figure","displayName":"Postpartum sterilization minilap","title":"Postpartum sterilization: Infraumbilical minilaparotomy incision","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Postpartum sterilization: Infraumbilical minilaparotomy incision</div><div class=\"cntnt\"><img style=\"width:500px; height:611px;\" src=\"images/OBGYN/104657_Postpartum_sterilization_minilap.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 104657 Version 1.0</div></div></div>"},"104665":{"type":"graphic_picture","displayName":"Onychotillomania","title":"Habit-tic disorder (onychotillomania)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Habit-tic disorder (onychotillomania)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104665_Onychotillomania.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Absence of the cuticles; midline nail plate furrows; and welling, erythema, and scaling of the proximal and lateral nail folds are typically seen in patients with onychotillomania.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104665 Version 1.0</div></div></div>"},"104666":{"type":"graphic_picture","displayName":"Pachydermodactyly","title":"Pachydermodactyly","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Pachydermodactyly</div><div class=\"cntnt\"><img style=\"width:680px; height:545px;\" src=\"images/DERM/104666_Pachydermodactyly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft tissue swelling of the proximal interphalangeal joints due to repetitive trauma.</div><div class=\"graphic_reference\">From: Ye S, Chen SL, Dong YQ, et al. Pachydermodactyly: six new cases from China. J Clin Rheumatol 2005; 11:72. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2005 PANLAR. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104666 Version 1.0</div></div></div>"},"104667":{"type":"graphic_movie","displayName":"Quadriceps active test for PCL injury","title":"Quadriceps active test for posterior cruciate ligament (PCL) injury","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Quadriceps active test for posterior cruciate ligament (PCL) injury</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/104667_QuadricepstestPCLinjvid.mp4\" style=\"width:640px;height:368px\"></div><img style=\"width:576px; height:401px;\" src=\"images/SM/104667_QuadricepstestPCLinjimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As shown in the video, contraction of the quadriceps muscles against resistance in the PCL-deficient knee causes an anterior shift of the tibia.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 104667 Version 1.0</div></div></div>"},"104672":{"type":"graphic_picture","displayName":"Pinching the alae to stop a nosebleed","title":"Pinching the alae to stop a nosebleed","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Pinching the alae to stop a nosebleed</div><div class=\"cntnt\"><img style=\"width:715px; height:641px;\" src=\"images/EM/104672_Pnch_alae_stp_nsbld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial attempt to tamponade a nosebleed involves the patient exerting pressure by grasping the alae distally (below the bony nasal bridge) and pinching them tightly against the septum such that the mucosal surfaces are tightly apposed, as is shown in the photographs above. This position should be held <STRONG innerHtml>continuously</STRONG>&nbsp;(without releasing any pressure) for at least 10 minutes if the patient is attempting to stop a nosebleed at home. </div><div id=\"graphicVersion\">Graphic 104672 Version 2.0</div></div></div>"},"104673":{"type":"graphic_table","displayName":"Pediatric conditions altered ADH","title":"Conditions affecting antidiuretic hormone (ADH) release and action in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions affecting antidiuretic hormone (ADH) release and action in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Action</td> <td class=\"subtitle1\">Affect on urinary volume</td> <td class=\"subtitle1\">Condition or disease category</td> </tr> <tr class=\"divider_bottom\"> <td>Nonphysiologic or inappropriate ADH release</td> <td>Decrease in urinary volume</td> <td> <ul> <li>Postoperative state</li> <li>CNS disease &ndash; Meningitis, brain tumors, head injury</li> <li>Pulmonary disease &ndash; Pneumonia, bronchiolitis, asthma</li> <li>Immobilization</li> <li>Drugs <ul> <li>Antidepressants (eg, SSRI)</li> <li>Antipsychotics (eg, haloperidol)</li> <li>Seizure medications (eg, carbamazepine)</li> <li>Chemotherapeutic agents (eg, vincristine, cisplatin, vinblastine)</li> <li>Opiates</li> </ul> </li> <li>Response to pain, stress, or anxiety</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Enhanced renal ADH receptor response</td> <td>Decease in urinary volume</td> <td> <ul> <li>Nephrogenic SIADH &ndash; Gain of function mutations in the renal V2 receptor gene</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lack of adequate ADH release/central diabetes insipidus</td> <td>Increase in urinary volume</td> <td> <ul> <li>CNS tumors (eg, craniopharyngioma)</li> <li>Congenital brain abnormalities (eg, septo-optic dysplasia)</li> <li>Brain trauma or injury (eg, complication of brain surgery)</li> <li>Genetic diseases</li> <li>Anorexia nervosa</li> </ul> </td> </tr> <tr> <td>Lack of renal ADH receptor response/nephrogenic diabetes insipidus</td> <td>Increase in urinary volume</td> <td> <ul> <li>Congenital disorders (eg, loss of function mutation in renal V2 receptor gene, renal tubulopathy [Bartter syndrome])</li> <li>Drugs (eg, lithium toxicity, foscarnet, ifosfamide)</li> <li>Renal disorders (eg, bilateral urinary tract obstruction, sickle cell nephropathy)</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; SSRI: selective serotonin release inhibitors; SIADH: syndrome of inappropriate antidiuretic hormone secretion; V2: vasopress-2.</div><div id=\"graphicVersion\">Graphic 104673 Version 1.0</div></div></div>"},"104715":{"type":"graphic_form","displayName":"ESAS-r:Renal","title":"Edmonton Symptom Assessment System Revised:Renal (ESAS-r:Renal)","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Edmonton Symptom Assessment System Revised:Renal (ESAS-r:Renal)</div><div class=\"cntnt\"><img style=\"width:592px; height:1360px;\" src=\"images/NEPH/104715_ESASrrenalrev112016.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced and updated with permission from: Watanabe SM, Nekolaichuk C, Beaumont C, Johnson L, Myers J, Strasser F. A multi-centre comparison of two numerical versions of the Edmonton Symptom Assessment System in palliative care patients J Pain Symptom Manage 2011; 41:456-468. ESAS-r: Renal revised November 2016. Copyright &copy; 2016 Covenant Health Palliative Institute.</div><div id=\"graphicVersion\">Graphic 104715 Version 2.0</div></div></div>"},"104720":{"type":"graphic_picture","displayName":"Examples of cardiac pacemaker pulse generators","title":"Examples of cardiac pacemaker pulse generators","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Examples of cardiac pacemaker pulse generators</div><div class=\"cntnt\"><img style=\"width:517px; height:502px;\" src=\"images/CARD/104720_Examples_of_cardiac_pacemaker_pulse_generators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of cardiac pacemaker pulse generators commonly used in practice in 2015.</div><div id=\"graphicVersion\">Graphic 104720 Version 1.0</div></div></div>"},"104721":{"type":"graphic_picture","displayName":"Examples of transvenous ICD pulse generators","title":"Examples of transvenous ICD pulse generators","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Examples of transvenous ICD pulse generators</div><div class=\"cntnt\"><img style=\"width:520px; height:647px;\" src=\"images/CARD/104721_Examples_of_transvenous_ICD_pulse_generators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of implantable cardioverter-defibrillator pulse generators commonly used in practice in 2015.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.</div><div id=\"graphicVersion\">Graphic 104721 Version 2.0</div></div></div>"},"104722":{"type":"graphic_picture","displayName":"Subcutaneous ICD pulse generator ","title":"Subcutaneous ICD pulse generator ","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Subcutaneous ICD pulse generator </div><div class=\"cntnt\"><img style=\"width:517px; height:596px;\" src=\"images/CARD/104722_Subcutaneos_ICD_pulse_generator.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of subcutaneous implantable cardioverter-defibrillator pulse generator commonly used in practice in 2015.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.</div><div id=\"graphicVersion\">Graphic 104722 Version 3.0</div></div></div>"},"104723":{"type":"graphic_picture","displayName":"Comparison of transvenous and subcutaneous ICD pulse generators","title":"Comparison of transvenous and subcutaneous ICD pulse generators ","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Comparison of transvenous and subcutaneous ICD pulse generators </div><div class=\"cntnt\"><img style=\"width:517px; height:400px;\" src=\"images/CARD/104723_ComparisonoftransvenousandsubcutaneousICDpulsegenerators.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of four transvenous ICD pulse generators and one subcutaneous ICD pulse generator commonly used in practice in 2015. The term \"subcutaneous\" here refers to the ICD electrode positioning, which is subcutaneous rather than transvenous. Note the significantly larger size of the subcutaneous ICD pulse generator.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.</div><div id=\"graphicVersion\">Graphic 104723 Version 2.0</div></div></div>"},"104724":{"type":"graphic_picture","displayName":"Implantable loop recorder","title":"Implantable loop recorder for long-term electrocardiographic (ECG) monitoring","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Implantable loop recorder for long-term electrocardiographic (ECG) monitoring</div><div class=\"cntnt\"><img style=\"width:517px; height:405px;\" src=\"images/CARD/104724_Implantable_loop_monitor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph showing an implantable loop recorder used for long-term electrocardiographic (ECG) monitoring. The device is inserted under local anesthesia in the left anterior chest.</div><div id=\"graphicVersion\">Graphic 104724 Version 2.0</div></div></div>"},"104728":{"type":"graphic_table","displayName":"PLMS reporting","title":"Polysomnography reporting of periodic limb movements of sleep","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polysomnography reporting of periodic limb movements of sleep</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup width=\"95%\"></colgroup> <tbody> <tr> <td class=\"centered\">1</td> <td>Total number of PLMS</td> </tr> <tr> <td class=\"centered\">2</td> <td>Total number of PLMS associated with arousals</td> </tr> <tr> <td class=\"centered\">3</td> <td>PLMS index (PLMS x 60/total PSG sleep time)</td> </tr> <tr> <td class=\"centered\">4</td> <td>PLMS arousal index (PLMS associated with arousals x 60/total PSG sleep time)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PLMS: periodic limb movements of sleep; PSG: polysomnography.</div><div class=\"graphic_reference\"><EM>Berry RB, Brooks R, Gamaldo CE, et al. AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, 2.0.2, American Academy of Sleep Medicine, Darien, IL 2013.</EM></div><div id=\"graphicVersion\">Graphic 104728 Version 2.0</div></div></div>"},"104729":{"type":"graphic_table","displayName":"AASM scoring manual specifications for recording movements","title":"American Academy of Sleep Medicine (AASM) scoring manual: Technical and digital specifications for recording movements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Academy of Sleep Medicine (AASM) scoring manual: Technical and digital specifications for recording movements</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td rowspan=\"3\"><strong>EMG</strong></td> <td>Sampling rate range</td> <td colspan=\"2\">500 to 200 Hz</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Filter settings</td> <td>Low frequency</td> <td class=\"centered\">10 Hz</td> </tr> <tr class=\"divider_bottom\"> <td>High frequency</td> <td class=\"centered\">100 Hz</td> </tr> <tr> <td rowspan=\"2\"><strong>PSG recording software</strong></td> <td colspan=\"3\">Histogram with capability to record leg movement events with cursor capability to jump from page to page</td> </tr> <tr> <td colspan=\"3\">Recording video capacity with PSG synchronization at an accuracy of at least one video frame per second</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EMG: electromyography; PSG: polysomnography.</div><div class=\"graphic_reference\"><EM>Berry RB, Brooks R, Gamaldo CE, et al. AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, 2.0.2, American Academy of Sleep Medicine, Darien, IL 2013.</EM></div><div id=\"graphicVersion\">Graphic 104729 Version 2.0</div></div></div>"},"104732":{"type":"graphic_table","displayName":"Hemorrhoid treatments PI","title":"Common at-home treatments for hemorrhoids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common at-home treatments for hemorrhoids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of medicine</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Notes</td> </tr> <tr class=\"divider_bottom\"> <td>Stool softener</td> <td>Docusate sodium (sample brand names: Colace, Docu, Stool Softener)</td> <td> <p>Softens bowel movements</p> Helps avoid straining while sitting on toilet</td> </tr> <tr class=\"divider_bottom\"> <td>Bulk-forming laxatives and fiber supplements</td> <td> <p>Methylcellulose (sample brand names: Citrucel, Soluble Fiber Therapy)</p> <p>Polycarbophil (sample brand names: FiberCon, Konsyl Fiber)</p> <p>Psyllium (sample brand names: Metamucil, Konsyl)</p> Wheat dextrin (sample brand name: Benefiber)</td> <td> <p>Prevent hard dry stools which make hemorrhoids worse</p> <p>Might reduce bleeding and other hemorrhoid symptoms</p> <p>Needs to be taken with plenty of water (8 glasses of water a day)</p> Your doctor might suggest starting with a small dose and then increasing over time</td> </tr> <tr class=\"divider_bottom\"> <td>Pain relief</td> <td>Pramoxine rectal foam, ointment, or wipes (sample brand names: Proctofoam, Pramox)</td> <td> <p>Can help with pain and itching</p> Area must be gently cleaned and allowed to dry before using</td> </tr> <tr class=\"divider_bottom\"> <td>Medicines to dry or protect skin</td> <td> <p>Witch hazel (sample brand names: Tucks, Preparation H pads, Preparation H wipes)</p> Zinc oxide topical paste (sample brand names: Boudreaux's Butt Paste, Desitin)</td> <td> <p>May dry or tighten skin around the anus</p> <p>Zinc oxide also protects skin from irritation</p> <p>Area must be gently cleaned and allowed to dry before using</p> <p>Can apply after a sitz bath (soaking in warm, shallow water)</p> Witch hazel wipes or unscented baby wipes can be used to clean the anus after a bowel movement</td> </tr> <tr class=\"divider_bottom\"> <td>Steroid cream</td> <td>Hydrocortisone rectal cream (sample brand name: Preparation H hydrocortisone)</td> <td> <p>Reduces swelling, and pain caused by hemorrhoids</p> <p>Do <strong>not</strong> use for longer than a week</p> Do <strong>not</strong> use at all if you are pregnant unless your doctor or nurse tells you to</td> </tr> <tr class=\"divider_bottom\"> <td>Medicines to shrink hemorrhoids</td> <td>Phenylephrine ointment or suppository (sample brand names: Preparation H, Rectacaine)</td> <td> <p>Phenylephrine shrinks swollen hemorrhoids, and relieves itching and discomfort for a few hours</p> Area must be gently cleaned and allowed to dry before applying</td> </tr> <tr> <td>Numbing ointments</td> <td> <p>Benzocaine rectal ointment (sample brand name: Americaine)</p> <p>Dibucaine rectal ointment (sample brand name: Nupercainal)</p> Lidocaine rectal cream (sample brand name: RectiCare)</td> <td>Benzocaine, dibucaine, and lidocaine can help with pain and itching, but should not be used without talking to a doctor first. They should only be used once in a while, in small amounts.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>This table lists some examples of over-the-counter treatments for hemorrhoids. There are many more brand-name and generic versions available, too. Read all labels to make sure you're not using too much of one ingredient.</li>&#xD;&#xA;    <li>Do not use over-the-counter treatments for more than one week without speaking to your doctor. They can damage your skin.</li>&#xD;&#xA;    <li>Follow instructions carefully &ndash; for example, it's important to clean and dry your skin before using creams or ointments. You can use an unscented baby wipe to clean your anus after a bowel movement.</li>&#xD;&#xA;    <li>If you have rectal bleeding, or if your bowel movements look like tar, see your doctor or nurse. These problems could be caused by something other than hemorrhoids. You should also see your doctor or nurse if your hemorrhoid symptoms still bother you after you have tried taking care of them yourself.</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 104732 Version 7.0</div></div></div>"},"104733":{"type":"graphic_algorithm","displayName":"Algorithm for nipple discharge","title":"Algorithm for management of spontaneous nipple discharge (non-lactating)","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of spontaneous nipple discharge (non-lactating)</div><div class=\"cntnt\"><img style=\"width:490px; height:322px;\" src=\"images/SURG/104733_Algorithm_nipple_discharge.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Breast ultrasound is recommended for imaging all patients with nipple discharge. Mammograms are recommended for women &ge; age 30.</div><div class=\"graphic_reference\">Adapted from: CRICO/RMF Breast care management algorithm www.rmf.harvard.edu/bca.</div><div id=\"graphicVersion\">Graphic 104733 Version 1.0</div></div></div>"},"104734":{"type":"graphic_diagnosticimage","displayName":"Detecting a PFO with TEE","title":"Detecting a patent foramen ovale (PFO) with TEE","html":"<div class=\"graphic\"><div style=\"width: 819px\" class=\"figure\"><div class=\"ttl\">Detecting a patent foramen ovale (PFO) with TEE</div><div class=\"cntnt\"><img style=\"width:799px; height:304px;\" src=\"images/ANEST/104734_Detecting_a_PFO_with_TEE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midesophageal bicaval view in a patient with a PFO. The PFO was detected with Doppler color-flow imaging (panel A) showing blood flow from the LA into the RA at the fossa ovalis, where the septum secundum and septum primum have failed to fuse completely (arrow). The PFO was additionally verified by agitated saline contrast injection into the RA (panel B) that demonstrated transit of echo contrast from the RA into the LA (double arrow) through the PFO.&nbsp;Maintaining positive airway pressure for a short period of time and acutely releasing the airway pressure during the injection of echocontrast into the RA transiently increases the RA pressure in relation to the LA pressure to improve the likelihood of detecting a PFO using TEE.</div><div class=\"graphic_footnotes\">PFO: patent foramen ovale; TEE: transesophageal echocardiography; LA: left atrium; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 104734 Version 4.0</div></div></div>"},"104735":{"type":"graphic_diagnosticimage","displayName":"Cardiac output calculation with TEE","title":"Cardiac output calculation with TEE","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Cardiac output calculation with TEE</div><div class=\"cntnt\"><img style=\"width:796px; height:604px;\" src=\"images/ANEST/104735_Crdc_otpt_clcltn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Steps for CO calculation:<br /><STRONG>(A)</STRONG> Midesophageal AV long-axis view with AV open in systole is used to measure the LVOT diameter. (Note that the LVOT radius is Â½ the LVOT diameter.)<br /><STRONG>(B)</STRONG> Deep transgastric view through the LVOT and AV is used to measure the LVOT VTI. The pulsed-wave Doppler sample volume is positioned in the LVOT 1 cm proximal to the AV annulus.<br /><STRONG>(C)</STRONG> The LVOT VTI is measured by tracing the pulsed-wave Doppler spectral waveform.<br /><STRONG>(D)</STRONG> Machine-derived calculations of the SV and CO from the SV and HR.<br />Echocardiography systems commonly include software packages incorporating these formulas to automatically calculate CO from the measured parameters.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; CO: cardiac output; HR: heart rate; AV: aortic valve; bpm: beats per minute; LVOT: left ventricular outflow tract; VTI: velocity time integral; Vmax: maximum velocity in the LVOT; Vmean: mean velocity in the LVOT; PG: pressure gradient; SV: stroke volume; CO: cardiac output.</div><div id=\"graphicVersion\">Graphic 104735 Version 3.0</div></div></div>"},"104736":{"type":"graphic_diagnosticimage","displayName":"TEE view of renal cell tumor in the IVC","title":"TEE view of renal cell tumor in the inferior vena cava","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TEE view of renal cell tumor in the inferior vena cava</div><div class=\"cntnt\"><img style=\"width:320px; height:240px;\" src=\"images/ANEST/104736_Rnl_cell_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transgastric long-axis view of the intrahepatic IVC demonstrating a renal cell tumor within the IVC near the junction of the hepatic veins.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; IVC: inferior vena cava.</div><div id=\"graphicVersion\">Graphic 104736 Version 2.0</div></div></div>"},"104743":{"type":"graphic_picture","displayName":"Partial labial adhesion in a prepubertal girl","title":"Partial labial adhesion in a prepubertal girl","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Partial labial adhesion in a prepubertal girl</div><div class=\"cntnt\"><img style=\"width:503px; height:612px;\" src=\"images/EM/104743_Part_labial_adhsn_prepb_grl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows fused labia minora (arrowheads) and a residual vaginal opening (arrow) in a prepubertal girl with labial adhesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ. Vulvovaginal problems in the prepubertal child. In: Emans, Laufer, and Goldstein's Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 104743 Version 1.0</div></div></div>"},"104748":{"type":"graphic_form","displayName":"Immune globulin treatment record","title":"Immune globulin treatment record","html":"<div class=\"graphic\"><div style=\"width: 798px\" class=\"figure\"><div class=\"ttl\">Immune globulin treatment record</div><div class=\"cntnt\"><img style=\"width:778px; height:596px;\" src=\"images/ALLRG/104748_Immune_globulin_tx_record.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The purpose of this chart is to help your clinician determine the correct dose of immune globulin for you. When you have a blood level of immune globulin measured, find the corresponding number on the far left and follow it across the graph to the correct week or month. Record the value with a dark circle. For some people, the levels should be checked regularly, while for others, a level may be needed only infrequently. Ask your clinician what is appropriate for you. When you get sick, record what kind of infection you have with a letter in a circle. Bring this chart to every appointment with your clinician.</div><div id=\"graphicVersion\">Graphic 104748 Version 2.0</div></div></div>"},"104750":{"type":"graphic_form","displayName":"Example of immune globulin treatment record","title":"Example of immune globulin treatment record","html":"<div class=\"graphic\"><div style=\"width: 798px\" class=\"figure\"><div class=\"ttl\">Example of immune globulin treatment record</div><div class=\"cntnt\"><img style=\"width:778px; height:586px;\" src=\"images/ALLRG/104750_Ex_immune_globulin_tx_recrd.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The purpose of this chart is to help your&nbsp;clinician determine the correct dose of immune globulin for you. When you have a blood level of immune globulin measured, find the corresponding number on the far left and follow it across the graph to the correct week or month. Record the value with a dark circle. For some people, the levels should be checked regularly, while for others, a level may be needed only infrequently. Ask your&nbsp;clinician what is appropriate for you. When you get sick, record what kind of infection you have with a letter in a circle. Bring this chart to every appointment with your clinician. This is an example of how someone might fill out the chart. Your chart may look very different.</div><div id=\"graphicVersion\">Graphic 104750 Version 1.0</div></div></div>"},"104764":{"type":"graphic_algorithm","displayName":"Diagnostic algorithm bone mets in patients with CA and back pain","title":"Diagnostic imaging algorithm for the detection of osseous metastases in patients with known or suspected cancer andÂ vertebral back pain","html":"<div class=\"graphic\"><div style=\"width: 880px\" class=\"figure\"><div class=\"ttl\">Diagnostic imaging algorithm for the detection of osseous metastases in patients with known or suspected cancer and&nbsp;vertebral back pain</div><div class=\"cntnt\"><img style=\"width:860px; height:1172px;\" src=\"images/ONC/104764_Diagnst_bone_mets_back_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; PET: positron emission tomography; CT: computed tomography; POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome; FDG-PET: 18-F fluorodeoxyglucose positron emission tomography.<br />* Following surgery, the patient will need a comprehensive skeletal survey to assess for other metastases.<br />Â¶ For example, in a patient with a monoclonal (M) protein (which can be detected by protein electrophoresis of the serum [SPEP] and/or of an aliquot of urine [UPEP] from a 24-hour collection combined with immunofixation of the serum and urine), hypercalcemia, abnormal immunoelectropheresis, anemia, or&nbsp;renal failure.<br />âÎ The presence of multiple skeletal lesions influences choice of therapy.<br /><FONT class=lozenge>â</FONT> The vast majority of patients without an unstable spine or evidence of a cord compression do not require surgery. For very highly selected patients who present with or develop a vertebral bone lesion as the only focus of cancer beyond the primary site, resection of the metastasis may optimize local tumor control, provide durable pain relief, and possibly prolong patient survival.<br />Â§ A negative repeat biopsy should prompt reevaluation of the original MRI result.</div><div id=\"graphicVersion\">Graphic 104764 Version 3.0</div></div></div>"},"104765":{"type":"graphic_table","displayName":"FTT causes by age of onset","title":"Potential factors contributing to failure to thrive by age of onset","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential factors contributing to failure to thrive by age of onset</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age of onset</td> <td class=\"subtitle1\">Potential contributing factors</td> </tr> <tr class=\"divider_bottom\"> <td>Prenatal</td> <td> <ul> <li>Intrauterine growth restriction </li> <li>Prematurity </li> <li>Prenatal infection </li> <li>Congenital syndrome (metabolic or chromosomal) </li> <li>Teratogenic exposure (eg, alcohol, anticonvulsant, tobacco smoke, caffeine) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Birth to 6 months</td> <td> <ul> <li>Poor quality of suck (whether breast- or bottle-fed) </li> <li>Improper formula preparation </li> <li>Breastfeeding problems </li> <li>Inadequate number of feedings </li> <li>Poor feeding interactions (eg, infant gags or vomits during feeding, mother misreads signals of hunger or satiety) </li> <li>Child neglect </li> <li>Parental mental illness </li> <li>Metabolic, chromosomal, or anatomic abnormalities </li> <li>Underfeeding (possibly related to poverty) </li> <li>Milk protein intolerance </li> <li>Oral motor dysfunction </li> <li>Cystic fibrosis </li> <li>Congenital heart disease </li> <li>Gastroesophageal reflux disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>7 to 12 months</td> <td> <ul> <li>Feeding problems, for example: <ul> <li>Autonomy struggles, particularly if caretaker is unduly anxious about intake or cleanliness </li> <li>Oral motor dysfunction that interferes with adaptation to more textured foods </li> <li>Delayed introduction of solid foods </li> <li>Refusal to eat new foods when first offered so caretaker no longer offers </li> <li>Caretaker does not offer adequate quantity or variety of solid foods </li> </ul> </li> <li>Intestinal parasites </li> <li>Food allergies </li> </ul> </td> </tr> <tr> <td>&#62;12 months</td> <td> <ul> <li>Coercive feeding </li> <li>Picky eater </li> <li>Highly distractible child </li> <li>Distracting environment </li> <li>Acquired illness </li> <li>Social factors (eg, underfeeding related to fear of overfeeding, poverty) </li> <li>New psychosocial stressor (eg, divorce, job loss, new sibling, etc) </li> <li>Sensory-based feeding disorders in children with developmental disorders (eg, autism spectrum disorder) </li> <li>Chewing or swallowing dysfunction </li> <li>Excessive milk or juice intake </li> <li>Caretaker does not offer enough quantity or combination of healthy foods </li> <li>Celiac disease </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cardona Cano S, Hoek HW, Bryant-Waugh R. Picky eating: The current state of research. Curr Opin Psychiatry 2015; 28:448.</LI>&#xD;&#xA;<LI>Emond A, Drewett R, Blair P, Emmett P. Postnatal factors associated with failure to thrive in term infants in the Avon Longitudinal Study of Parents and Children. Arch Dis Child 2007; 92:115.</LI>&#xD;&#xA;<LI>Frank D, Silva M, Needlman R. Failure to thrive: Mystery, myth and method. Contemp Pediatr 1993; 10:114.</LI>&#xD;&#xA;<LI>McDougall P, Drewett RF, Hungin AP, Wright CM. The detection of early weight faltering at the 6-8-week check and its association with family factors, feeding and behavioural development. Arch Dis Child 2009; 94:549.</LI>&#xD;&#xA;<LI>Olsen EM, Skovgaard AM, Weile B, et al. Risk factors for weight faltering in infancy according to age at onset. Paediatr Perinat Epidemiol 2010; 24:370. </LI></OL></div><div id=\"graphicVersion\">Graphic 104765 Version 3.0</div></div></div>"},"104766":{"type":"graphic_figure","displayName":"Operating room layout during robotic surgery","title":"Operating room layout during robotic surgery","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Operating room layout during robotic surgery</div><div class=\"cntnt\"><img style=\"width:577px; height:724px;\" src=\"images/ANEST/104766_Oprtngrmlytroboticsrgry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The most commonly used robotic system occupies a lot of operating room space. This graphic shows one configuration, with the robotic cart positioned at the patient's head. The cart may be placed at the patient's side (eg, for kidney surgery), and is often placed between the patient's legs in the lithotomy position for gynecologic and urologic surgery.</div><div class=\"graphic_reference\">Reproduced with permission from: Horgan S, Sedrak MF. Robotic surgery. In: Fischer's Mastery of Surgery, 6th ed, Fischer JE, Jones DB, Pomposelli FB, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104766 Version 2.0</div></div></div>"},"104767":{"type":"graphic_figure","displayName":"Hans and Tally methods DLBCL","title":"Hans and Tally methods for determining cell of origin in diffuse large B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hans and Tally methods for determining cell of origin in diffuse large B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:380px; height:345px;\" src=\"images/HEME/104767_Hans_Tally_mthd_DLBCL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Hans algorithm and Tally method use immunohistochemical stains to predict the cell of origin (GCB versus ABC or non-GCB) for cases of diffuse large B cell lymphoma. Each is approximately 80% concordant with gene expression profile results.</div><div class=\"graphic_footnotes\">DLBCL: diffuse large B cell lymphoma; GCB: germinal center B cell; ABC: activated B cell.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275.</li>&#xD;&#xA;    <li>Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B cell lymphoma treated with rituximab. J Clin Oncol 2011; 29:200.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 104767 Version 1.0</div></div></div>"},"104769":{"type":"graphic_picture","displayName":"Macromastia with bra strap grooves","title":"Macromastia with bra strap grooves","html":"<div class=\"graphic\"><div style=\"width: 863px\" class=\"figure\"><div class=\"ttl\">Macromastia with bra strap grooves</div><div class=\"cntnt\"><img style=\"width:843px; height:329px;\" src=\"images/SURG/104769_Mcrmst_bra_strp_grv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photos demonstrate deep bra strap grooves of the shoulders in&nbsp;a patient with macromastia.</div><div id=\"graphicVersion\">Graphic 104769 Version 1.0</div></div></div>"},"104770":{"type":"graphic_picture","displayName":"Macromastia with postural problems","title":"Macromastia with postural problemsâ","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Macromastia with postural problemsâ</div><div class=\"cntnt\"><img style=\"width:726px; height:302px;\" src=\"images/SURG/104770_Mcrmst_pst_prblm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photos demonstrate the typical posture seen in patients with macromastia.</div><div id=\"graphicVersion\">Graphic 104770 Version 1.0</div></div></div>"},"104771":{"type":"graphic_picture","displayName":"Chronic inframammary rash","title":"Chronic inframammary rash","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Chronic inframammary rash</div><div class=\"cntnt\"><img style=\"width:712px; height:533px;\" src=\"images/SURG/104771_Chrnc_infrm_rsh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows a chronic rash in the inframammary crease of&nbsp;the right breast.</div><div id=\"graphicVersion\">Graphic 104771 Version 1.0</div></div></div>"},"104772":{"type":"graphic_picture","displayName":"Inferior pedicle breast reduction","title":"Inferior pedicle breast reduction","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Inferior pedicle breast reduction</div><div class=\"cntnt\"><img style=\"width:728px; height:246px;\" src=\"images/SURG/104772_Infrr_pdcl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Intraoperative design of inferior pedicle, shown deepithelialized.<br />(B) Excess glandular tissues are excised. Uniform mastectomy flap shown behind the inferior pedicle.</div><div id=\"graphicVersion\">Graphic 104772 Version 1.0</div></div></div>"},"104773":{"type":"graphic_picture","displayName":"Medial pedicle breast reduction","title":"Medial pedicle breast reduction","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Medial pedicle breast reduction</div><div class=\"cntnt\"><img style=\"width:729px; height:246px;\" src=\"images/SURG/104773_Mdl_pdcl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Intraoperative design of medial pedicle, shown deepithelialized.<br />(B) The deepithelialized medial pedicle is elevated showing its base.</div><div id=\"graphicVersion\">Graphic 104773 Version 1.0</div></div></div>"},"104774":{"type":"graphic_picture","displayName":"Pre- and postoperative medial pedicle breast reduction","title":"Pre- and postoperative medial pedicle breast reduction","html":"<div class=\"graphic\"><div style=\"width: 813px\" class=\"figure\"><div class=\"ttl\">Pre- and postoperative medial pedicle breast reduction</div><div class=\"cntnt\"><img style=\"width:793px; height:604px;\" src=\"images/SURG/104774_Pre_pstop_med_pdcl_brst_rdc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative (A,C) and postoperative (B,D) photos after breast reduction using a medial pedicle technique with resection weights of 358 grams from the left breast and 340 grams from the right breast.</div><div id=\"graphicVersion\">Graphic 104774 Version 1.0</div></div></div>"},"104775":{"type":"graphic_picture","displayName":"Breast reduction in gigantomastia patient","title":"Breast reduction in gigantomastia patient","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Breast reduction in gigantomastia patient</div><div class=\"cntnt\"><img style=\"width:766px; height:538px;\" src=\"images/SURG/104775_Breast_rdctn_gigantomastia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative (A,C) and postoperative (B,D) photos in a patient with gigantomastia. Bilateral breast reduction was performed using a free nipple graft technique with resection weights of 1202 grams from the right breast and 1066 grams from the left breast.</div><div id=\"graphicVersion\">Graphic 104775 Version 2.0</div></div></div>"},"104777":{"type":"graphic_picture","displayName":"Wise pattern skin resection scars in breast reduction","title":"Wise pattern skin resection scars in breast reduction","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Wise pattern skin resection scars in breast reduction</div><div class=\"cntnt\"><img style=\"width:715px; height:450px;\" src=\"images/SURG/104777_Ws_pttrn_skn_rsctn_scr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wise pattern skin resection used in breast reduction&nbsp;leaves periareolar, vertical, and inframammary scars.</div><div id=\"graphicVersion\">Graphic 104777 Version 1.0</div></div></div>"},"104778":{"type":"graphic_picture","displayName":"Verticle short scar technique","title":"Verticle short scar technique","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Verticle short scar technique</div><div class=\"cntnt\"><img style=\"width:797px; height:320px;\" src=\"images/SURG/104778_Vrtcl_shrt_scr_tchnq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative and postoperative views of vertical short scar technique which avoids the scar along the inframammary fold.</div><div id=\"graphicVersion\">Graphic 104778 Version 1.0</div></div></div>"},"104779":{"type":"graphic_table","displayName":"ACMG criteria for expanded prenatal genetic screening","title":"American College of Medical Genetics (ACMG) criteria for expanded prenatal genetic screening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Medical Genetics (ACMG) criteria for expanded prenatal genetic screening</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">American College of Medical Genetics criteria for inclusion of disorders in expanded prenatal carrier screening</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Most carriers of the disorder would consider having prenatal diagnosis to facilitate making decisions about reproduction. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Individuals undergoing screening understand whether symptoms of the disorder have adult or pediatric onset, and the personal and family implications of preconception/prenatal identification of adult-onset disorders. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The causative gene(s), mutations, and mutation frequencies are known in the population being tested, so screen-negative individuals can be given meaningful residual risk estimates. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The clinical association between the mutation(s) detected and the severity of the disorder has been validated. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The laboratory performing the test is in compliance with the American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, including quality control and proficiency testing. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med 2013; 15:482.</div><div id=\"graphicVersion\">Graphic 104779 Version 1.0</div></div></div>"},"104781":{"type":"graphic_movie","displayName":"Physiologic splitting of S2","title":"Physiological splitting of the second heart sound","html":"<div class=\"graphic normal\"><div style=\"width: 1640px\" class=\"figure\"><div class=\"ttl\">Physiological splitting of the second heart sound</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104781_PhysiologicsplittngS2vid.mp4\" style=\"width:1620px;height:800px\"></div><img style=\"width:498px; height:162px;\" src=\"images/PEDS/104781_PhysiologicsplittngS2img.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left upper sternal border in a healthy child showing physiological splitting of the second heart sound (S<sub>2</sub>) that varies with the respiratory cycle. S<sub>2</sub> is split in inspiration and single in expiration.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound; A<sub>2</sub>: aortic valve closure sound; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104781 Version 1.0</div></div></div>"},"104782":{"type":"graphic_movie","displayName":"S2 splitting in RBBB","title":"Splitting of the second heart sound with right bundle branch block","html":"<div class=\"graphic normal\"><div style=\"width: 1614px\" class=\"figure\"><div class=\"ttl\">Splitting of the second heart sound with right bundle branch block</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104782_S2splittingRBBBvid.mp4\" style=\"width:1594px;height:800px\"></div><img style=\"width:528px; height:162px;\" src=\"images/PEDS/104782_S2splittingRBBBimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left upper sternal border in a patient with right bundle branch block. S<sub>2</sub> is persistently split but still varies with the respiratory cycle, being more widely split in inspiration than expiration.</div><div class=\"graphic_footnotes\">S<sub>2</sub>: second heart sound; RBBB: right bundle branch block; S<sub>1</sub>: first heart sound; A<sub>2</sub>: aortic valve closure sound; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104782 Version 1.0</div></div></div>"},"104783":{"type":"graphic_movie","displayName":"ASD murmur with fixed split S2","title":"Systolic murmur and fixed split S<sub>2</sub> in a child with an atrial septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 1640px\" class=\"figure\"><div class=\"ttl\">Systolic murmur and fixed split S<sub>2</sub> in a child with an atrial septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104783_ASDmurmurfxdsplitS2vid.mp4\" style=\"width:1620px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104783_ASDmurmurfxdsplitS2img.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left upper sternal border in a five-year-old patient with a 12 mm secundum atrial septal defect. There is a fixed split S<SUB>2</SUB> (0.075 seconds). There is a systolic ejection murmur created by the increased right ventricular stroke volume.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; A<sub>2</sub>: aortic valve closure sound; SM: systolic murmur; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104783 Version 2.0</div></div></div>"},"104784":{"type":"graphic_algorithm","displayName":"Diagnostic algorithm non-vertebral bone pain in cancer patients","title":"Diagnostic imaging algorithm for evaluation of non-vertebral bone pain in patients with known or suspected cancer","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Diagnostic imaging algorithm for evaluation of non-vertebral bone pain in patients with known or suspected cancer</div><div class=\"cntnt\"><img style=\"width:798px; height:1268px;\" src=\"images/ONC/104784_Diag_algo_nonvertebral_bone.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; FDG-PET: 18-F fluorodeoxyglucose positron emission tomography; MRI: magnetic resonance imaging; POEMS: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome; EFT: Ewings sarcoma family of tumors.<br />* Indications for urgent surgery: displaced pathologic fracture, severe pain due to pathologic fracture.<br />&para; Following surgery, the patient will need a comprehensive skeletal evaluation to assess for other metasteses.<br />&Delta; For example, in a patient with a monoclonal (M) protein (which can be detected by protein electrophoresis of the serum [SPEP] and/or of an aliquot of urine [UPEP] from a 24-hour collection combined with immunofixation of the serum and urine), hypercalcemia, abnormal immunoelectropheresis, anemia, renal failure.<br /><span class=\"lozenge\">&loz;</span> The majority of patients without an impending or completed fracture do not require surgery. For highly selected patients who present with or develop a bone lesion as the only focus of cancer beyond the primary site, en bloc resection of the metastasis may optimize local tumor control, provide durable pain relief and possibly prolong patient survival.<br />&sect; A negative repeat biopsy should prompt reevaluation of the original imaging and need for integrated FDG-PET/CT.</div><div id=\"graphicVersion\">Graphic 104784 Version 2.0</div></div></div>"},"104785":{"type":"graphic_movie","displayName":"Single and loud S2 in PAH","title":"Single and loud S2 in a child with pulmonary artery hypertension","html":"<div class=\"graphic normal\"><div style=\"width: 1642px\" class=\"figure\"><div class=\"ttl\">Single and loud S2 in a child with pulmonary artery hypertension</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104785_SingleloudS2PAHvid.mp4\" style=\"width:1622px;height:800px\"></div><img style=\"width:416px; height:148px;\" src=\"images/PEDS/104785_SingleloudS2PAHimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left upper sternal border in a child with systemic level pulmonary artery hypertension. S2 is single and loud with a prominent pulmonary component.</div><div class=\"graphic_footnotes\">S2: second heart sound; S1: first heart sound; A2: aortic valve closure sound; P2: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104785 Version 2.0</div></div></div>"},"104786":{"type":"graphic_movie","displayName":"S3 in healthy child","title":"S<sub>3</sub> gallop in a healthy child","html":"<div class=\"graphic normal\"><div style=\"width: 1638px\" class=\"figure\"><div class=\"ttl\">S<sub>3</sub> gallop in a healthy child</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104786_S3healthychildvid.mp4\" style=\"width:1618px;height:800px\"></div><img style=\"width:708px; height:367px;\" src=\"images/PEDS/104786_S3healthychildimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the apex in a 12-year-old patient showing a S<sub>3</sub>. The S<sub>3</sub> occurs between the T wave and P wave in the electrocardiogram during the rapid filling phase in diastole. An echocardiogram demonstrated normal cardiac anatomy and function in this patient.</div><div class=\"graphic_footnotes\">S<SUB>1</SUB>: first heart sound; S<SUB>2</SUB>: second heart sound; S<SUB>3</SUB>: third heart sound.</div><div id=\"graphicVersion\">Graphic 104786 Version 1.0</div></div></div>"},"104787":{"type":"graphic_movie","displayName":"S4 gallop due to HTN and LV dysfunction","title":"S<sub>4</sub> gallop in a patient with severe hypertension and left ventricular dysfunction","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">S<sub>4</sub> gallop in a patient with severe hypertension and left ventricular dysfunction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104787_S4gallopHTNLVdysfunvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104787_S4gallopHTNLVdysfunimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the apex in a 20-year-old patient with Takayasu's aortitis associated with severe systemic hypertension and severe left ventricular dysfunction (ejection fraction 23 percent). In the recording a fourth heart sound (S<sub>4</sub>) is heard coincident with the P wave on the electrocardiogram during the period of atrial contraction.</div><div class=\"graphic_footnotes\">S1: first heart sound; S<SUB>2</SUB>: second heart sound; S<SUB>4</SUB>: fourth heart sound.</div><div id=\"graphicVersion\">Graphic 104787 Version 1.0</div></div></div>"},"104788":{"type":"graphic_movie","displayName":"S4 gallop due to prolonged SVT","title":"S<sub>4</sub> gallop in a neonate following a prolonged period of supraventricular tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">S<sub>4</sub> gallop in a neonate following a prolonged period of supraventricular tachycardia</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104788_S4gallopprolongedSVTvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104788_S4gallopprolongedSVTimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the apex in 17-day-old neonate with severe left ventricular dysfunction secondary to a prolonged episode of supraventricular tachycardia. The electrocardiogram demonstrates Wolff-Parkinson-White syndrome with a prominent delta wave. In the recording a fourth heart sound (S<sub>4</sub>) is heard coincident with the P wave on the electrocardiogram during the period of atrial contraction.</div><div class=\"graphic_footnotes\">S1: first heart sound; S<SUB>2</SUB>: second heart sound; S<SUB>4</SUB>: fourth heart sound.</div><div id=\"graphicVersion\">Graphic 104788 Version 1.0</div></div></div>"},"104789":{"type":"graphic_movie","displayName":"Rheumatic mitral stenosis","title":"Phonocardiogram of a patient with rheumatic mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Phonocardiogram of a patient with rheumatic mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104789_Rheumaticmitralstenosvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104789_Rheumaticmitralstenosimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the apex in a 20-year-old patient with rheumatic mitral stenosis. An echocardiogram documented a 13 mmHg peak and 6 mmHg mean gradient across the mitral valve. In diastole, there is an opening snap (OS) and a diastolic murmur (DM) that has presystolic accentuation.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound; OS: opening snap; DM: diastolic murmur.</div><div id=\"graphicVersion\">Graphic 104789 Version 1.0</div></div></div>"},"104790":{"type":"graphic_movie","displayName":"Ejection click in bicuspid AV","title":"Ejection click in an adolescent with bicuspid aortic valves","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Ejection click in an adolescent with bicuspid aortic valves</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104790_EjectclickbicuspidAVvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104790_EjectclickbicuspidAVimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the apex in an adolescent with bicuspid aortic valve demonstrating an early, constant systolic ejection click (EC) that occurs shortly after S<sub>1</sub>.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound.</div><div id=\"graphicVersion\">Graphic 104790 Version 1.0</div></div></div>"},"104791":{"type":"graphic_movie","displayName":"Valvar PS SM and EC","title":"Phonocardiogram of a child with valvar pulmonic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Phonocardiogram of a child with valvar pulmonic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104791_ValvarPSSMECvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104791_ValvarPSSMECimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at left upper sternal border in a four-year-old child with a 45 mmHg peak systolic gradient across the pulmonary valve. The early systolic ejection click that precedes the murmur is more prominent in expiration than in inspiration.</div><div class=\"graphic_footnotes\">EC: ejection click; SM: systolic murmur; S<sub>2</sub>: second heart sound.</div><div id=\"graphicVersion\">Graphic 104791 Version 1.0</div></div></div>"},"104792":{"type":"graphic_movie","displayName":"PDA murmur","title":"Phonocardiogram of a patient with a restrictive patent ductus arteriosus","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Phonocardiogram of a patient with a restrictive patent ductus arteriosus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104792_PDAmurmurvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:626px; height:194px;\" src=\"images/PEDS/104792_PDAmurmurimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left upper sternal border in a patient with a restrictive patent ductus arteriosus. There are multiple systolic ejection clicks along with a continuous murmur.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; C: click; S<sub>2</sub>: second heart sound; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104792 Version 1.0</div></div></div>"},"104793":{"type":"graphic_movie","displayName":"Pericardial friction rub in a child","title":"Pericardial friction rub in a child following cardiac surgery","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Pericardial friction rub in a child following cardiac surgery</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104793_Pericardfricrubchildvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:604px; height:120px;\" src=\"images/PEDS/104793_Pericardfricrubchildimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded along left sternal border one day after cardiac surgery in an eight-year-old child. There is a pericardial friction rub present in both systole and diastole.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound.</div><div id=\"graphicVersion\">Graphic 104793 Version 1.0</div></div></div>"},"104794":{"type":"graphic_movie","displayName":"ASD diastolic murmur","title":"Diastolic murmur in a child with an atrial septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Diastolic murmur in a child with an atrial septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104794_ASDdiastolicmurmurvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:548px; height:120px;\" src=\"images/PEDS/104794_ASDdiastolicmurmurimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram obtained at the left lower sternal border in a five-year-old child with a 12 mm diameter secundum atrial septal defect associated with right ventricular volume overload. There is a diastolic murmur consistent with \"relative\" tricuspid stenosis. Auscultation at the left upper sternal border in this patient revealed a wide fixed split S<sub>2</sub> (Refer to separate UpToDate phonocardiogram [\"Systolic murmur and fixed split S<sub>2</sub> in a child with an atrial septal defect\"]).</div><div class=\"graphic_footnotes\">ASD: atrial septal defect; TS: tricuspid stenosis; S<SUB>1</SUB>: first heart sound; S<SUB>2</SUB>: second heart sound; A<SUB>2</SUB>: aortic valve closure sound; P<SUB>2</SUB>: pulmonic valve closure.</div><div id=\"graphicVersion\">Graphic 104794 Version 1.0</div></div></div>"},"104795":{"type":"graphic_movie","displayName":"Valvar AS murmur","title":"Systolic and diastolic murmurs in a patient with valvar aortic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Systolic and diastolic murmurs in a patient with valvar aortic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104795_ValvarASmurmurvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:500px; height:206px;\" src=\"images/PEDS/104795_ValvarASmurmurimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the right upper sternal border in a patient with bicuspid aortic valve, mild-moderate aortic stenosis (peak systolic Doppler gradient 35 to 40 mmHg from the apical view) and moderate aortic regurgitation. There is a systolic ejection murmur of aortic stenosis and diastolic blowing murmur of aortic regurgitation.</div><div class=\"graphic_footnotes\">AS: aortic stenosis; AR: aortic regurgitation; S<sub>1</sub>: first heart sound; EC: ejection click; A<sub>2</sub>: aortic valve closure sound; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104795 Version 1.0</div></div></div>"},"104796":{"type":"graphic_movie","displayName":"Valvar PS SM and DM","title":"Systolic and diastolic murmurs in a child with mild valvar pulmonic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 1568px\" class=\"figure\"><div class=\"ttl\">Systolic and diastolic murmurs in a child with mild valvar pulmonic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104796_ValvarPSSMDMvid.mp4\" style=\"width:1548px;height:800px\"></div><img style=\"width:498px; height:206px;\" src=\"images/PEDS/104796_ValvarPSSMDMimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left upper sternal border in a three-year-old child with mild valvar pulmonary stenosis (peak Doppler systolic gradient 15 mmHg) and mild pulmonary regurgitation. There is a variable soft early ejection click, systolic murmur and diastolic murmur.</div><div class=\"graphic_footnotes\">PS: pulmonic stenosis; PR: pulmonic regurgitation; S<sub>1</sub>: first heart sound; EC: ejection click; A<sub>2</sub>: aortic valve closure sound; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104796 Version 1.0</div></div></div>"},"104797":{"type":"graphic_movie","displayName":"Membranous VSD murmur","title":"Holosystolic murmur in a child with a membranous ventricular septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Holosystolic murmur in a child with a membranous ventricular septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104797_MembranousVSDmurmurvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104797_MembranousVSDmurmurimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left lower sternal border in a 12-year-old child with a restrictive membranous ventricular septal defect. The systolic murmur (SM) is holosystolic and extends from S<sub>1</sub> to S<sub>2</sub>.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound; SM: systolic murmur.</div><div id=\"graphicVersion\">Graphic 104797 Version 1.0</div></div></div>"},"104798":{"type":"graphic_table","displayName":"Differential diagnosis narcolepsy in children","title":"Differential diagnosis of narcolepsy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of narcolepsy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Insufficient nocturnal sleep</strong></td> <td>Inadequate sleep hygiene</td> <td>Inconsistent bedtime and morning wake-up times; abuse of caffeine, alcohol, nicotine, or an illicit substance; use of electronic media around bedtime or at night</td> <td>Detailed history about sleep-wake schedules and habits; sleep logs, actigraphy and urine drug screen</td> </tr> <tr class=\"divider_bottom\"> <td>Delayed sleep-wake phase disorder</td> <td>Teenager with inability to fall asleep prior to midnight to 2 a.m., relatively well organized and normal sleep quality, inability to awaken fully prior to mid-morning; male predominance</td> <td>Actigraphy and sleep logs show characteristic delayed sleep onset and offset times</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fragmented nocturnal sleep</strong></td> <td>Obstructive sleep apnea</td> <td>Habitual snoring, mouth breathing, daytime sleepiness, obesity, narrow nasal passages or oropharynx</td> <td>PSG: obstructive apneas and hypopneas, oxygen desaturations associated with apneas</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Other central disorders of hypersomnolence</strong></td> <td>Idiopathic hypersomnia</td> <td>Chronic hypersomnolence with onset in the teenage years, slightly more common in girls, relatively normal nocturnal sleep architecture</td> <td> <p>PSG: relatively normal sleep architecture, without sleep-disordered breathing or sleep-onset REM periods</p> MSLT: shortened mean sleep latency (&#60;8 min), but absence of two or more sleep-onset REM periods</td> </tr> <tr class=\"divider_bottom\"> <td>Kleine-Levin syndrome</td> <td>Teenager with periods of hypersomnia lasting 10 to 14 days and occurring two to three times per year; normal sleep-wake function in intervening periods; male predominance; hyperphagia, anorexia, feelings of depersonalization</td> <td>Clinical diagnosis. There are no reliable PSG or MSLT findings, although suppression of N3 sleep and increased sleep fragmentation may be seen in some cases in the early stages</td> </tr> <tr> <td><strong>Psychiatric disorders</strong></td> <td>Depression</td> <td>Daytime somnolence and fatigue, apathy, may have anorexia or increased appetite, mood disturbance, suicidal ideation, and disrupted nocturnal sleep</td> <td>Clinical diagnosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PSG: polysomnography; REM: rapid eye movement; MSLT: multiple sleep latency test.</div><div id=\"graphicVersion\">Graphic 104798 Version 1.0</div></div></div>"},"104799":{"type":"graphic_movie","displayName":"Small muscular VSD murmur","title":"Short systolic murmur in a child with a small muscular ventricular septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Short systolic murmur in a child with a small muscular ventricular septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104799_SmallmuscularVSDmrmrvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104799_SmallmuscularVSDmrmrimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the left lower sternal border in a six-year-old child with a small apical muscular ventricular septal defect. The systolic murmur (SM) is short and does not extend to S<SUB>2</SUB>.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound; SM: systolic murmur.</div><div id=\"graphicVersion\">Graphic 104799 Version 1.0</div></div></div>"},"104800":{"type":"graphic_movie","displayName":"Aortic stenosis SEM","title":"Systolic ejection murmur in a patient with moderate aortic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Systolic ejection murmur in a patient with moderate aortic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104800_AorticstenosisSEMvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:709px; height:378px;\" src=\"images/PEDS/104800_AorticstenosisSEMimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the right upper sternal border in a patient with moderate aortic stenosis. There is a systolic ejection murmur (SM) with a diamond-shaped form.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; SM: systolic murmur; S<sub>2</sub>: second heart sound.</div><div id=\"graphicVersion\">Graphic 104800 Version 1.0</div></div></div>"},"104801":{"type":"graphic_table","displayName":"Treatment of daytime sleepiness in children with narcolepsy","title":"Medications used to treat daytime sleepiness in children<SUP>*</SUP> with narcolepsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used to treat daytime sleepiness in children<SUP>*</SUP> with narcolepsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Usual effective dose range</td> <td class=\"subtitle1\">Common side effects</td> <td class=\"subtitle1\">Serious side effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Stimulants</td> </tr> <tr> <td class=\"indent1\">Methylphenidate immediate release</td> <td>5 mg twice daily (before breakfast and before lunch)</td> <td>10 to 60 mg/day in two to three divided doses</td> <td class=\"divider_bottom\" rowspan=\"7\">Anorexia, poor growth or weight loss, sleep disturbance, jitteriness, emotional lability, tics</td> <td class=\"divider_bottom\" rowspan=\"7\">Psychosis, mania, seizures, cardiovascular effects<sup>&#182;</sup>, priapism, diversion or misuse</td> </tr> <tr> <td class=\"indent1\">Methylphenidate ER or SR</td> <td>10 mg every morning</td> <td>20 to 60 mg every morning</td> </tr> <tr> <td class=\"indent1\">Methylphenidate (Concerta)</td> <td>18 mg every morning</td> <td>18 to 54 mg every morning</td> </tr> <tr> <td class=\"indent1\">Methylphenidate patch</td> <td>10 mg patch every morning</td> <td>10 to 30 mg every morning</td> </tr> <tr> <td class=\"indent1\">Dextroamphetamine immediate release</td> <td>5 mg every morning</td> <td>5 to 40 mg/day in one to&nbsp;two divided doses</td> </tr> <tr> <td class=\"indent1\">Amphetamine/dextroamphetamine immediate release</td> <td>5&nbsp;mg every morning</td> <td>10 to 40 mg/day in one to two divided doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lisdexamfetamine</td> <td>20 mg every morning</td> <td>30 to 70 mg every morning</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Wake-promoting agents</td> </tr> <tr> <td class=\"indent1\">Modafinil</td> <td>50 mg every morning</td> <td>50 to 200 mg/day in one to two divided doses</td> <td class=\"divider_bottom\" rowspan=\"2\">Headache, nervousness, nausea, insomnia</td> <td class=\"divider_bottom\" rowspan=\"2\">Severe rash, severe psychiatric events</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Armodafinil</td> <td>50 mg every morning</td> <td>50 to 250 mg/day in one to two divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Others</td> </tr> <tr> <td class=\"indent1\">Sodium oxybate<sup>&#9674;</sup></td> <td>2 grams in&nbsp;two divided doses at night</td> <td>2 to 8 grams in two divided doses at night</td> <td>Morning sedation, nausea, weight loss, dizziness, enuresis, sleepwalking, tremor, constipation, worsening of OSA</td> <td>Confusion, severe sedation, coma<sup>&#9674;</sup>, diversion or misuse</td> </tr> <tr> <td class=\"indent1\">Atomoxetine</td> <td>0.5 mg/kg/day (maximum 40 mg/day)</td> <td>0.5 to 1.2 mg/kg/day in one to two divided doses (maximum 100 mg/day)</td> <td>Weight loss, abdominal pain, nausea, anorexia, headache</td> <td>Suicidal ideation, psychosis, mania, cardiovascular events, priapism, hepatotoxicity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ER: extended release; OSA: obstructive sleep apnea; SR: sustained release.<br />* Doses listed in table are appropriate for children â¥6 years and adolescents.<br />Â¶ For additional information refer to topic review of&nbsp;pharmacology&nbsp;of drugs used to treat&nbsp;attention deficit hyperactivity disorder children and adolescents, section on adverse effects.<br />â Not recommended in children with narcolepsy type 2 (narcolepsy without cataplexy). Combined use with alcohol, sedatives, or hypnotics is specifically contraindicated in US licensing information.</div><div id=\"graphicVersion\">Graphic 104801 Version 1.0</div></div></div>"},"104802":{"type":"graphic_movie","displayName":"AR diastolic murmur","title":"Diastolic murmur in a patient with aortic regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Diastolic murmur in a patient with aortic regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104802_ARdiastolicmurmurvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:582px; height:148px;\" src=\"images/PEDS/104802_ARdiastolicmurmurimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram obtained at the left upper sternal border demonstrating a diastolic murmur of aortic regurgitation.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound; A<sub>2</sub>: aortic valve closure sound; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104802 Version 3.0</div></div></div>"},"104803":{"type":"graphic_table","displayName":"Treatment of cataplexy in children with narcolepsy","title":"Medications used to treat cataplexy in children* with narcolepsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used to treat cataplexy in children* with narcolepsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Starting dose</td> <td class=\"subtitle1\">Usual effective dose range</td> <td class=\"subtitle1\">Common side effects</td> <td class=\"subtitle1\">Rare but serious side effects</td> </tr> <tr class=\"divider_bottom\"> <td>Sodium oxybate<sup>&#182;</sup></td> <td>2 grams in two divided doses at night</td> <td>2 to 8 grams in two divided doses at night</td> <td>Morning sedation, nausea, weight loss, dizziness, enuresis, sleepwalking, tremor, constipation, worsening of OSA</td> <td>Confusion, severe sedation, coma<sup>&#182;</sup>, diversion or misuse</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tricyclic antidepressants</td> </tr> <tr> <td class=\"indent1\">Clomipramine<sup>&#916;</sup></td> <td>25 mg at bedtime</td> <td>25 to 100 mg/day at bedtime</td> <td class=\"divider_bottom\" rowspan=\"3\">Dry mouth, constipation, sweating, blurry vision, somnolence, weight gain, orthostatic hypotension</td> <td class=\"divider_bottom\" rowspan=\"3\">Cardiotoxicity, seizures, suicidal ideation, bone marrow suppression, serotonin syndrome</td> </tr> <tr> <td class=\"indent1\">Imipramine</td> <td>25 mg once daily</td> <td>25 to 75 mg/day in one to two divided doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Protriptyline<sup>&#916;</sup></td> <td>5 mg once daily</td> <td>5 to 10 mg/day in one to two divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Selective serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>5 to 10 mg once daily</td> <td>10 to 30 mg once daily</td> <td class=\"divider_bottom\" rowspan=\"3\">Nausea, insomnia, tremor</td> <td class=\"divider_bottom\" rowspan=\"3\">Suicidal ideation, prolongation of QT interval, serotonin syndrome</td> </tr> <tr> <td class=\"indent1\">Sertraline</td> <td>12.5 to 25 mg once daily</td> <td>25 to 200 mg once daily</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Citalopram</td> <td>10 mg once daily</td> <td>10 to 40 mg once daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Serotonin norepinephrine reuptake inhibitors</td> </tr> <tr> <td class=\"indent1\">Venlafaxine</td> <td>&nbsp;25 mg once daily</td> <td>37.5 to 75 mg once daily</td> <td>Nausea, weight loss, dizziness, headache, constipation, insomnia, somnolence, tremor</td> <td>Suicidal ideation, prolongation of QT interval, serotonin syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OSA: obstructive sleep apnea.<br />* Doses listed in table are appropriate for children â¥6 years and adolescents (except as noted).<br />Â¶ âCombined use with alcohol, sedatives, or hypnotics is specifically contraindicated in US licensing information.<br />Î Dosing shown for children â¥10 years and adolescents.</div><div id=\"graphicVersion\">Graphic 104803 Version 2.0</div></div></div>"},"104804":{"type":"graphic_movie","displayName":"Coronary artery fistula murmur","title":"Continuous murmur in a newborn with patient with a coronary artery fistula","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Continuous murmur in a newborn with patient with a coronary artery fistula</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104804_Coronaryarteryfistulavid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:548px; height:180px;\" src=\"images/PEDS/104804_Coronaryarteryfistulaimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram obtained in a four-day-old infant with a coronary artery fistula from the left main coronary artery to the left atrial appendage. The recording was made at the left midsternal border and demonstrates a continuous murmur.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound; P<sub>2</sub>: pulmonic valve closure sound.</div><div id=\"graphicVersion\">Graphic 104804 Version 1.0</div></div></div>"},"104805":{"type":"graphic_movie","displayName":"Benign venous hum","title":"Benign venous hum","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Benign venous hum</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104805_Benignvenoushumvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:516px; height:144px;\" src=\"images/PEDS/104805_Benignvenoushumimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded in a three-year-old child with a benign venous hum. The recording was made in the supraclavicular region with the patient sitting with head extended. There is a continuous murmur which softened or resolved&nbsp;with flexion of the head, application of pressure over the cervical triangle, or when the patient was placed in the supine position.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound.</div><div id=\"graphicVersion\">Graphic 104805 Version 1.0</div></div></div>"},"104806":{"type":"graphic_movie","displayName":"Innocent Still's murmur","title":"Innocent Still's murmur","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Innocent Still's murmur</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104806_InnocentStillsmurmurvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:532px; height:144px;\" src=\"images/PEDS/104806_InnocentStillsmurmurimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram obtained in a four-year-old child with an innocent Still's murmur. The recording was made in the supine position between the left lower sternal border and apex. There is a characteristic vibratory quality to the murmur.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound.</div><div id=\"graphicVersion\">Graphic 104806 Version 1.0</div></div></div>"},"104807":{"type":"graphic_movie","displayName":"MR murmur","title":"Systolic murmur in mitral regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Systolic murmur in mitral regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/104807_MRmurmurvid.mp4\" style=\"width:1544px;height:800px\"></div><img style=\"width:578px; height:144px;\" src=\"images/PEDS/104807_MRmurmurimg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phonocardiogram recorded at the apex in a patient with mitral regurgitation showing the characteristic holosystolic murmur.</div><div class=\"graphic_footnotes\">S<sub>1</sub>: first heart sound; S<sub>2</sub>: second heart sound.</div><div id=\"graphicVersion\">Graphic 104807 Version 1.0</div></div></div>"},"104812":{"type":"graphic_table","displayName":"ABPA diagnostic criteria","title":"International Society for Human and Animal Mycology (ISHAM) working group diagnostic criteria for allergic bronchopulmonary aspergillosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International Society for Human and Animal Mycology (ISHAM) working group diagnostic criteria for allergic bronchopulmonary aspergillosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Predisposing conditions (one must be present):</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"subtitle1_single\">Obligatory criteria (both must be present):</td> </tr> <tr> <td class=\"indent1\"><em>Aspergillus</em> skin test positivity or elevated IgE levels against <em>Aspergillus fumigatus</em></td> </tr> <tr> <td class=\"indent1\">Elevated total IgE concentration (typically &#62;1000 IU/mL, but if the patient meets all other criteria, an IgE value &#60;1000 IU/mL may be acceptable)</td> </tr> <tr> <td class=\"subtitle1_single\">Other criteria (at least two must be present):</td> </tr> <tr> <td class=\"indent1\">Precipitating serum antibodies to <em>A. fumigatus</em> or elevated serum <em>Aspergillus</em> IgG by immunoassay</td> </tr> <tr> <td class=\"indent1\">Radiographic pulmonary opacities consistent with ABPA</td> </tr> <tr> <td class=\"indent1\">Total eosinophil count &#62;500 cells/microL in glucocorticoid-na&#239;ve patients (may be historical)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; ABPA: Allergic bronchopulmonary aspergillosis.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>âAgarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43:850.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 104812 Version 1.0</div></div></div>"},"104813":{"type":"graphic_table","displayName":"Diagnostic model for impending death in CA patients","title":"Diagnostic model for impending death in cancer patients based upon Palliative Performance Scale and drooping of the nasolabial folds","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic model for impending death in cancer patients based upon Palliative Performance Scale and drooping of the nasolabial folds</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">PPS</td> <td class=\"subtitle1\">Drooping of nasolabial fold, present/absent</td> <td class=\"subtitle1\">3-day mortality rate (%)</td> </tr> <tr> <td>&#8804;20%</td> <td>present</td> <td>94</td> </tr> <tr> <td>&#8804;20%</td> <td>absent</td> <td>42</td> </tr> <tr> <td>30 to 60%</td> <td>&nbsp;</td> <td>16</td> </tr> <tr> <td>&#8805;70%</td> <td>&nbsp;</td> <td>3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPS: Palliative performance scale.</div><div class=\"graphic_reference\">Data from: Hui D, Hess K, dos Santos R, et al. A diagnostic model for impending death in cancer patients: preliminary report. Cancer 2015; 3914.</div><div id=\"graphicVersion\">Graphic 104813 Version 1.0</div></div></div>"},"104814":{"type":"graphic_diagnosticimage","displayName":"Extrabronchial tumor","title":"Extrabronchial tumor not suitable for photodynamic therapy","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Extrabronchial tumor not suitable for photodynamic therapy</div><div class=\"cntnt\"><img style=\"width:711px; height:521px;\" src=\"images/PULM/104814_Extrabronchial_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan of a right-sided tumor that involves the airway in a minimal capacity, but has a significant proportion of disease outside the airway wall and invades the lobar pulmonary artery and vein. Patients with tumors such as these are not candidates for bronchoscopic photodynamic therapy.</div><div id=\"graphicVersion\">Graphic 104814 Version 1.0</div></div></div>"},"104815":{"type":"graphic_picture","displayName":"Diode laser","title":"Diode laser light source for photodynamic therapy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diode laser light source for photodynamic therapy</div><div class=\"cntnt\"><img style=\"width:340px; height:506px;\" src=\"images/PULM/104815_Diode_laser.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative image of the most commonly used light source for bronchoscopic photodynamic therapy, the diode laser.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Pinnacle Biologics, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104815 Version 1.0</div></div></div>"},"104816":{"type":"graphic_picture","displayName":"Pendant reservoir cannula","title":"Pendant reservoir cannula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pendant reservoir cannula</div><div class=\"cntnt\"><img style=\"width:374px; height:497px;\" src=\"images/PULM/104816_Pendant_rsrvr_cnnl.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 104816 Version 1.0</div></div></div>"},"104817":{"type":"graphic_table","displayName":"Conditions associated with chronic dyspnea","title":"Conditions associated with chronic dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with chronic dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Upper airway</td> </tr> <tr> <td class=\"indent1\">Laryngeal mass</td> </tr> <tr> <td class=\"indent1\">Vocal cord paralysis</td> </tr> <tr> <td class=\"indent1\">Paradoxical vocal&nbsp;cord dysfunction</td> </tr> <tr> <td class=\"indent1\">Goiter</td> </tr> <tr> <td class=\"indent1\">Neck mass compressing airway</td> </tr> <tr> <td class=\"subtitle1_single\">Chest/abdominal wall</td> </tr> <tr> <td class=\"indent1\">Diaphragmatic paralysis</td> </tr> <tr> <td class=\"indent1\">Kyphoscoliosis</td> </tr> <tr> <td class=\"indent1\">Late pregnancy</td> </tr> <tr> <td class=\"indent1\">Massive obesity</td> </tr> <tr> <td class=\"indent1\">Ventral hernia</td> </tr> <tr> <td class=\"indent1\">Ascites</td> </tr> <tr> <td class=\"indent1\">Intra-abdominal process</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis</td> </tr> <tr> <td class=\"indent1\">COPD/emphysema</td> </tr> <tr> <td class=\"indent1\">Chronic thromboembolic disease</td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Lung mass compressing or occluding airway</td> </tr> <tr> <td class=\"indent1\">Pleural effusion</td> </tr> <tr> <td class=\"indent1\">Pulmonary right-to-left shunt</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypertension</td> </tr> <tr> <td class=\"indent1\">Trapped lung</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Arrhythmia</td> </tr> <tr> <td class=\"indent1\">Constrictive pericarditis, pericardial effusion</td> </tr> <tr> <td class=\"indent1\">Coronary heart disease</td> </tr> <tr> <td class=\"indent1\">Deconditioning</td> </tr> <tr> <td class=\"indent1\">Heart failure (systolic or diastolic dysfunction)</td> </tr> <tr> <td class=\"indent1\">Intracardiac shunt</td> </tr> <tr> <td class=\"indent1\">Restrictive cardiomyopathy </td> </tr> <tr> <td class=\"indent1\">Valvular dysfunction</td> </tr> <tr> <td class=\"subtitle1_single\">Neuromuscular disease</td> </tr> <tr> <td class=\"indent1\">Amyotrophic lateral sclerosis</td> </tr> <tr> <td class=\"indent1\">Phrenic nerve disease/dysfunction</td> </tr> <tr> <td class=\"indent1\">Glycolytic enzyme defects (eg, McArdle)</td> </tr> <tr> <td class=\"indent1\">Mitochondrial diseases</td> </tr> <tr> <td class=\"indent1\">Polymyositis/dermatomyositis</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic/metabolic/systemic</td> </tr> <tr> <td class=\"indent1\">Anemia</td> </tr> <tr> <td class=\"indent1\">Metabolic acidosis </td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"indent1\">Thyroid disease</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Anxiety</td> </tr> <tr> <td class=\"indent1\">Early pregnancy (effect of progesterone)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 104817 Version 3.0</div></div></div>"},"104818":{"type":"graphic_table","displayName":"Evaluation of dyspnea: Initial testing","title":"Evaluation of dyspnea: Initial testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of dyspnea: Initial testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle2\" colspan=\"2\">Tests are selected based on clinical likelihood. As examples, a patient under age 40 with suspected asthma might just need spirometry pre/post bronchodilator; a young patient without suspicion for heart failure or pulmonary hypertension might not need an ECG or plasma BNP; and a patient with suspected heart failure might not need spirometry. However, some patients will need all tests in this section.</td> </tr> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Rationale/indications</td> </tr> <tr> <td>Hemoglobin/hematocrit</td> <td>Anemia can present as dyspnea or reduced exercise tolerance.</td> </tr> <tr> <td>Glucose, blood urea nitrogen, creatinine, electrolytes, phosphate, calcium</td> <td>For adults with other comorbidities or over age 40, screen for metabolic causes of dyspnea.</td> </tr> <tr> <td>Thyroid stimulating hormone (TSH)</td> <td>Hyper and hypothyroidism can present as dyspnea or reduced exercise tolerance.</td> </tr> <tr> <td>Spirometry pre/post bronchodilator with or without lung volumes and DLCO</td> <td> <p>Depending on the likelihood of asthma or COPD and difficulties of travel and scheduling, spirometry pre/post&nbsp;bronchodilator may be ordered initially without full PFTs. Alternatively, full testing (spirometry pre and post bronchodilator, lung volumes, DLCO, ambulatory oximetry) may be more expeditious.</p> Refer to UpToDate table on follow-up testing based on initial results.</td> </tr> <tr> <td>Assess SpO<sub>2</sub> (eg, walking &#8805;200 feet and two flights of stairs)*</td> <td> <p>Hypoxemia at rest or desaturation with exertion indicates the need to pursue definitive diagnosis. Obtain full PFTs, CXR, BNP, ECG, and possibly echocardiogram.</p> Refer to UpToDate table on follow-up testing based on initial results.</td> </tr> <tr> <td>Chest radiograph</td> <td>Indicated for most dyspneic patients, particularly those who are over age 40, have suspected heart failure or interstitial disease, or abnormal PFTs. Not needed in routine evaluation of asthma.</td> </tr> <tr> <td>ECG</td> <td> <p>Indicated for most dyspneic patients over age 40. Not needed in young patients with clear diagnosis of asthma and response to treatment.</p> Refer to UpToDate table on follow-up testing based on initial results.</td> </tr> <tr> <td>Plasma BNP or NT-pro BNP</td> <td>Useful screening test for HF although not entirely specific; dyspnea due to HF is associated with plasma BNP &#62;400 pg/mL; high negative predictive value for BNP &#60;100 pg/mL, although BNP increases with age.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DLCO: diffusing capacity of the lungs for carbon monoxide; COPD: chronic obstructive pulmonary disease; PFTs: pulmonary function tests; SpO<SUB>2</SUB>: pulse oxygen saturation; CXR: chest radiograph; BNP: brain natriuretic peptide; ECG: electrocardiogram; HF: heart failure.<br />* Stop exertion if SpO<SUB>2</SUB> decreases to 90 percent or patient becomes symptomatic.</div><div id=\"graphicVersion\">Graphic 104818 Version 2.0</div></div></div>"},"104821":{"type":"graphic_table","displayName":"Pulmonary function testing in the evaluation of chronic dyspnea","title":"Pulmonary function testing in the evaluation of chronic dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary function testing in the evaluation of chronic dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Pulmonary function tests</td> </tr> <tr> <td class=\"subtitle2\">Abnormality</td> <td class=\"subtitle2\">Interpretation</td> <td class=\"subtitle2\">Further testing</td> </tr> <tr class=\"divider_bottom\"> <td>Airflow obstruction with complete reversibility following inhaled bronchodilator</td> <td>Likely asthma: Institute therapy based on severity of obstruction according to current guidelines.</td> <td>Reassess dyspnea and spirometry after treatment trial.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Airflow obstruction that is irreversible or incompletely reversible following bronchodilator</td> <td class=\"divider_bottom\" rowspan=\"2\">Likely COPD, especially in smokers. Chronic/severe asthma can cause airflow limitation that is incompletely reversible with bronchodilator, but may improve over time with inhaled or oral glucocorticoid therapy. Less commonly bronchiolitis or bronchiectasis.</td> <td>Reassess dyspnea and spirometry after treatment trial/pulmonary rehabilitation/smoking cessation/removal of allergen exposure.</td> </tr> <tr class=\"divider_bottom\"> <td>Bronchiolitis should be suspected in patients with poor response to therapy for asthma/COPD or with the combination of airflow limitation and impaired gas transfer, may need HRCT to look for radiographic evidence of bronchiolitis or bronchiectasis.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Normal (expiratory) spirometry</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Normal spirometry does not exclude asthma or upper airway obstruction.</p> Depending on clinical suspicion: <ul class=\"decimal_heading\"> <li>Review inspiratory and expiratory flow volume loop for upper airway flow limitation </li> <li>Obtain bronchoprovocation challenge (eg, methacholine, mannitol, exercise) </li> <li>Obtain lung volumes, DLCO, SpO<sub>2</sub> with exercise (if not already done) </li> </ul> </td> <td>Positive bronchoprovocation: Asthma is likely cause of dyspnea. Reassess after treatment trial.</td> </tr> <tr> <td>Bronchoprovocation negative but flow volume loop has slowing on inspiratory phase suggesting possible upper airway obstruction; direct visualization needed to confirm.</td> </tr> <tr class=\"divider_bottom\"> <td>Refer to \"Lung volumes normal but DLCO reduced and/or SpO<sub>2</sub> &#60;95% or decreases by &#62;4% with exertion\" below.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Reduced FVC with normal FEV<sub>1</sub>/FVC</td> <td class=\"divider_bottom\" rowspan=\"3\">Evaluate for restrictive process (pleural, chest wall, or neuromuscular), interstitial lung disease, or air trapping. <ul class=\"decimal_heading\"> <li>Obtain/review lung volumes and DLCO </li> <li>Examine CXR re: pleural effusion, kyphoscoliosis, or hemidiaphragm elevation </li> </ul> </td> <td>Lung volumes (FVC and TLC) confirm restrictive pattern, DLCO normal or slightly low: Consider pleural, chest wall, and neuromuscular disease. <ul class=\"decimal_heading\"> <li>Obtain MEP, MIP, MVV </li> <li>Review imaging </li> <li>Consider fluoroscopy for diaphragm dysfunction </li> </ul> </td> </tr> <tr> <td>Reduced DLCO and lung volumes suggest interstitial lung disease or emphysema: Consider HRCT.</td> </tr> <tr class=\"divider_bottom\"> <td>Increased RV or FRC suggests airtrapping (eg, due to emphysema, LAM, bronchiolitis) as a cause of low FVC. HRCT can identify emphysema, cystic changes of LAM, mosaic pattern suggestive of bronchiolitis.</td> </tr> <tr class=\"divider_bottom\"> <td>Lung volumes normal but DLCO reduced and/or SpO<sub>2</sub> &#60;95% or decreases by &#62;4% with exertion</td> <td>Possibilities include early ILD and pulmonary vascular disease: Obtain HRCT, BNP, and echocardiogram with Doppler assessment of PA pressures.</td> <td>If no ILD on HRCT and BNP and echocardiogram suggest pulmonary hypertension, may need PA catheterization.</td> </tr> <tr> <td>Normal flow volume loop, lung volumes, DLCO, ambulatory SpO<sub>2</sub>, and bronchoprovocation</td> <td>Increasing likelihood of preload dependent or nonrespiratory cause of dyspnea.</td> <td>Obtain/review CXR, echocardiogram. May need CPET.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; HRCT: high resolution computed tomography; DLCO: diffusing capacity of the lungs for carbon monoxide; SpO<SUB>2</SUB>: pulse oxygen saturation; FVC: forced vital capacity; FEV<SUB>1</SUB>: forced expiratory volume in one second; CXR: chest radiograph; TLC: total lung capacity; MEP: maximal expiratory pressure; MIP: maximal inspiratory pressure; MVV: maximal voluntary ventilation; RV: right ventricular; FRC: functional residual capacity; LAM: lymphangioleiomyomatosis; ILD: interstitial lung disease; BNP: brain natriuretic peptide; PA: pulmonary artery; CPET: cardiopulmonary exercise test.</div><div id=\"graphicVersion\">Graphic 104821 Version 2.0</div></div></div>"},"104824":{"type":"graphic_table","displayName":"Evaluation of dyspnea: Advanced testing","title":"Evaluation of dyspnea: Advanced testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of dyspnea: Advanced testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle2\" colspan=\"3\">Patients who require this level of testing for undiagnosed dyspnea may benefit from referral to a pulmonary or cardiology specialist</td> </tr> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Rationale</td> <td class=\"subtitle1\">Further testing</td> </tr> <tr> <td>Revisit description of dyspnea; Consider upper airway contribution (including nasal obstruction), muscle weakness, or fatigue being interpreted as dyspnea</td> <td>Conditioning program with reassessment of symptoms and PFTs at 6 to 12 month intervals.</td> <td>Further testing as described below if no response to conditioning program or patient prefers more immediate answers.</td> </tr> <tr> <td>Exercise echocardiography</td> <td>Wall motion and Doppler parameters are monitored during treadmill or cycle exercise to elicit exercise related PH, identify segmental wall motion abnormalities suggestive of CAD, or unmask mitral or aortic valvular disease that is hemodynamically significant during exercise.</td> <td> <p>Exercise-related pulmonary hypertension may need further evaluation with invasive CPET, if clinically significant dyspnea.</p> CAD and valvular disease will need appropriate evaluation and treatment.</td> </tr> <tr> <td>Obtain CPET</td> <td>CPET can help identify nonrespiratory causes of exercise limitation, mitochondrial disease, and can help distinguish whether cardiac or respiratory problems are causing the patient's limitation in cases in which more than one disease is present.</td> <td>Patients with normal testing including a normal CPET are likely to have deconditioning or a perceptual or psychological cause for dyspnea.</td> </tr> <tr> <td>Serum lactate (rest and exercise)</td> <td>Plasma lactate level at rest and fasting &#62;2.5 mmol/L may suggest mitochondrial disease.</td> <td>Further correlation needed with CPET, creatine kinase, and possibly muscle biopsy.</td> </tr> <tr> <td>Invasive CPET (with arterial line and/or pulmonary artery catheter in place)</td> <td>Depending on the level of suspicion and availability of testing, iCPET may be performed directly or based on exercise echocardiogram findings.</td> <td>iCPET is largely used to identify or exclude exercise-related PH, HFpEF, and preload dependent limitations to cardiac output.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFTs: pulmonary function tests; CPET: cardiopulmonary exercise test; PH: pulmonary hypertension; CAD: coronary artery disease; iCPET: invasive CPET; HFpEF: heart failure with preserved ejection fraction.</div><div id=\"graphicVersion\">Graphic 104824 Version 1.0</div></div></div>"},"104825":{"type":"graphic_figure","displayName":"PSG electrode positioning","title":"Positioning of electrodes for polysomnography","html":"<div class=\"graphic\"><div style=\"width: 930px\" class=\"figure\"><div class=\"ttl\">Positioning of electrodes for polysomnography</div><div class=\"cntnt\"><img style=\"width:910px; height:541px;\" src=\"images/SLEEP/104825_PSG_electrodes_ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the position of the electrodes for the EEG, EOG, chin and leg EMG, and ECG on a standard sleep study with video monitoring. The EEG is used to detect brain wave activity, EOG is used to capture eye movement, EMG is used to detect muscle activity and movement, and ECG captures electrical activity of the heart.</div><div class=\"graphic_footnotes\">PSG: polysomnography; EEG: electroencephalography; EOG: electrooculography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104825 Version 3.0</div></div></div>"},"104826":{"type":"graphic_waveform","displayName":"Muscle artifact on PSG","title":"Muscle artifact on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Muscle artifact on polysomnography</div><div class=\"cntnt\"><img style=\"width:784px; height:510px;\" src=\"images/SLEEP/104826_Muscle_artfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure highlights typical characteristics of muscle artifact on PSG (dashed boxes): high amplitude and high frequency signals and EMG muscle artifacts superimposed upon EEG activity.</div><div class=\"graphic_footnotes\">PSG: polysomnography; EMG: electromyography; EEG: electroencephalography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104826 Version 1.0</div></div></div>"},"104827":{"type":"graphic_figure","displayName":"Survival in DLBCL by IPI","title":"Survival in diffuse large B cell lymphomaÂ by International Prognostic Index (IPI)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival in diffuse large B cell lymphoma&nbsp;by International Prognostic Index (IPI)</div><div class=\"cntnt\"><img style=\"width:404px; height:986px;\" src=\"images/HEME/104827_Survival_DLBCL_IPI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Event-free survival (EFS), progression-free survival (PFS), and overall survival (OS), according to International Prognostic Index (IPI) score in rituximab-treated patients with diffuse large B cell lymphoma (DLBCL)&nbsp;from the MabThera International Trial (MInT;&nbsp;â¤60 years, age-adjusted IPI [aaIPI] 0, 1; n = 380); MegaCHOEP (dose-escalated regimen of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) trial (â¤60 years, aaIPI 1-3; n = 72); RICOVER-60 (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab for patients older than age 60 years) trial (&gt;60 years, all IPI groups; n = 610); and all trials (18 to 80 years of age, all IPI groups; n = 1,062).</div><div class=\"graphic_reference\">From: Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28(14):2373-80. Reprinted with permission. Copyright &copy; 2010 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104827 Version 2.0</div></div></div>"},"104828":{"type":"graphic_figure","displayName":"Survival in double hit and double expressor DLBCL","title":"Survival in double hit and double expressor diffuse large B cell lymphoma ","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Survival in double hit and double expressor diffuse large B cell lymphoma </div><div class=\"cntnt\"><img style=\"width:552px; height:428px;\" src=\"images/HEME/104828_Suvvl_hit_vrs_dbl_exprs_DLBCL.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival in 307 patients with diffuse large B cell lymphoma according to molecular subtype. Double hit lymphoma (DHIT) were those that had translocations of MYC and BCL2. The MYC+/BCL2+ lymphoma subgroup included those that expressed both MYC and BCL2 on immunohistochemistry and excluded those meeting the requirements for DHIT. Four DHIT patient cases had no MYC protein expression; one had a missing value for BCL2 protein expression.</div><div class=\"graphic_reference\">From: Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30(28):3452-9. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104828 Version 2.0</div></div></div>"},"104829":{"type":"graphic_figure","displayName":"Survival in DLBCL by cell of origin","title":"Survival in DLBCL by cell of origin","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Survival in DLBCL by cell of origin</div><div class=\"cntnt\"><img style=\"width:487px; height:763px;\" src=\"images/HEME/104829_SrvvlDLBCLcllorgn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Progression-free survival and overall survival of 52 patients with diffuse large B cell lymphoma (DLBCL)&nbsp;diagnosed between 2002 and 2005 and with gene expression profiling data available according to molecular subtype (GCB versus ABC) profile.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117:4836; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 104829 Version 3.0</div></div></div>"},"104831":{"type":"graphic_table","displayName":"MDS clinical criteria for PD","title":"Movement Disorder Society clinical diagnostic criteria for Parkinson Disease â Executive summary/completion form","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Movement Disorder Society clinical diagnostic criteria for Parkinson Disease &mdash; Executive summary/completion form</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">The first essential criterion is parkinsonism, which is defined as bradykinesia, in combination with at least one of rest tremor or rigidity. Examination of all cardinal manifestations should be carried out as described in the MDS-Unified Parkinson Disease Rating Scale.<sup>[1]</sup> Once parkinsonism has been diagnosed:</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diagnosis of clinically established PD requires:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ol> <li>Absence of absolute exclusion criteria</li> <li>At least two supportive criteria, and</li> <li>No red flags</li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diagnosis of clinically probable PD requires:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ol> <li>Absence of absolute exclusion criteria</li> <li>Presence of red flags counterbalanced by supportive criteria<br /> If one red flag is present, there must also be at least one supportive criterion<br /> If two red flags, at least two supportive criteria are needed<br /> No more than two red flags are allowed for this category</li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Supportive criteria (check box if criteria met)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <p><span class=\"primarybox_left\">&nbsp;</span> 1. Clear and dramatic beneficial response to dopaminergic therapy. During initial treatment, patient returned to normal or near-normal level of function. In the absence of clear documentation of initial response a dramatic response can be classified as:</p> <p class=\"indent2\">a. Marked improvement with dose increases or marked worsening with dose decreases. Mild changes do not qualify. Document this either objectively (&#62;30% in UPDRS III with change in treatment), or subjectively (clearly-documented history of marked changes from a reliable patient or caregiver)</p> <p class=\"indent2\">b. Unequivocal and marked on/off fluctuations, which must have at some point included predictable end-of-dose wearing off</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 2. Presence of levodopa-induced dyskinesia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 3. Rest tremor of a limb, documented on clinical examination (in past, or on current examination)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span>4. The presence of either olfactory loss or cardiac sympathetic denervation on MIBG scintigraphy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"3\">Absolute exclusion criteria: The presence of any of these features rules out PD:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span>1. Unequivocal cerebellar abnormalities, such as cerebellar gait, limb ataxia, or cerebellar oculomotor abnormalities (eg, sustained gaze evoked nystagmus, macro square wave jerks, hypermetric saccades)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 2. Downward vertical supranuclear gaze palsy, or selective slowing of downward vertical saccades</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span>3. Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia, defined according to consensus criteria<sup>[2]</sup> within the first five years of disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 4. Parkinsonian features restricted to the lower limbs for more than three years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 5. Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and time-course consistent with drug-induced parkinsonism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 6. Absence of observable response to high-dose levodopa despite at least moderate severity of disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 7. Unequivocal cortical sensory loss (ie, graphesthesia, stereognosis with intact primary sensory modalities), clear limb ideomotor apraxia, or progressive aphasia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 8. Normal functional neuroimaging of the presynaptic dopaminergic system</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 9. Documentation of an alternative condition known to produce parkinsonism and plausibly connected to the patient's symptoms, or, the expert evaluating physician, based on the full diagnostic assessment feels that an alternative syndrome is more likely than PD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Red flags</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 1. Rapid progression of gait impairment requiring regular use of wheelchair within five years of onset</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 2. A complete absence of progression of motor symptoms or signs over five or more years unless stability is related to treatment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 3. Early bulbar dysfunction: severe dysphonia or dysarthria (speech unintelligible most of the time) or severe dysphagia (requiring soft food, NG tube, or gastrostomy feeding) within first five years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 4. Inspiratory respiratory dysfunction: either diurnal or nocturnal inspiratory stridor or frequent inspiratory sighs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <p><span class=\"primarybox_left\">&nbsp;</span> 5. Severe autonomic failure in the first five years of disease. This can include:</p> <p class=\"indent2\">a. Orthostatic hypotension<sup>[3]</sup>-orthostatic decrease of blood pressure within three minutes of standing by at least 30 mmHg systolic or 15 mmHg diastolic, in the absence of dehydration, medication, or other diseases that could plausibly explain autonomic dysfunction, or</p> <p class=\"indent2\">b. Severe urinary retention or urinary incontinence in the first five years of disease (excluding long-standing or small amount stress incontinence in women), that is not simply functional incontinence. In men, urinary retention must not be attributable to prostate disease, and must be associated with erectile dysfunction</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 6. Recurrent (&#62;1/year) falls because of impaired balance within three years of onset</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 7. Disproportionate anterocollis (dystonic) or contractures of hand or feet within the first 10 years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 8. Absence of any of the common nonmotor features of disease despite five years disease duration. These include sleep dysfunction (sleep-maintenance insomnia, excessive daytime somnolence, symptoms of REM sleep behavior disorder), autonomic dysfunction (constipation, daytime urinary urgency, symptomatic orthostasis), hyposmia, or psychiatric dysfunction (depression, anxiety, or hallucinations)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 9. Otherwise-unexplained pyramidal tract signs, defined as pyramidal weakness or clear pathologic hyperreflexia (excluding mild reflex asymmetry and isolated extensor plantar response)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><span class=\"primarybox_left\">&nbsp;</span> 10. Bilateral symmetric parkinsonism. The patient or caregiver reports bilateral symptom onset with no side predominance, and no side predominance is observed on objective examination</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Criteria application:</td> </tr> <tr> <td class=\"indent1\">1. Does the patient have parkinsonism, as defined by the MDS criteria?</td> <td class=\"divider_bottom\" rowspan=\"2\">Yes <span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"divider_bottom\" rowspan=\"2\">No <span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">If no, <em>neither</em> probable PD nor clinically established PD can be diagnosed. <em>If yes</em>:</td> </tr> <tr> <td class=\"indent1\">2. Are any absolute exclusion criteria present?</td> <td class=\"divider_bottom\" rowspan=\"2\">Yes <span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"divider_bottom\" rowspan=\"2\">No <span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">If yes, <em>neither</em> probable PD nor clinically established PD can be diagnosed. <em>If no</em>:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">3. Number of red flags present ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">4. Number of supportive criteria present ______</td> </tr> <tr> <td class=\"indent1\">5. Are there at least two supportive criteria and no red flags?</td> <td class=\"divider_bottom\" rowspan=\"2\">Yes <span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"divider_bottom\" rowspan=\"2\">No <span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">If yes, patient meets criteira for clinically established PD. <em>If no</em>:</td> </tr> <tr> </tr> <tr> <td class=\"indent1\">6. Are there more than two red flags?</td> <td class=\"divider_bottom\" rowspan=\"2\">Yes <span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"divider_bottom\" rowspan=\"2\">No <span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">If yes, probable PD <em>cannot</em> be diagnosed. <em>If no</em>:</td> </tr> <tr> </tr> <tr> <td class=\"indent1\">7. Is the number of red flags equal to, or less than, the number of supportive criteria?</td> <td rowspan=\"2\">Yes <span class=\"primarybox_left\">&nbsp;</span></td> <td rowspan=\"2\">No <span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\">If yes, patient meets criteria for probable PD</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDS: Movement Disorder Society; PD: Parkinson disease; MIBG: metaiodobenzylguanidine; REM: rapid eye movement.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23:2129.</LI>&#xD;&#xA;<LI>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134:2456.</LI>&#xD;&#xA;<LI>Gilman S, Lost D, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.</LI></OL>From: Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30:1591. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/doi/10.1002/mds.26424/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1002/mds.26424/abstract</A>. Copyright Â© 2015 International Parkinson and Movement Disorder Society. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://www.onlinelibrary.wiley.com/\" target=_blank>www.onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 104831 Version 1.0</div></div></div>"},"104832":{"type":"graphic_table","displayName":"Evaluation of DAH in SLE","title":"Evaluation of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General tests for most patients</td> </tr> <tr> <td class=\"indent1\">Complete blood count and differential</td> </tr> <tr> <td class=\"indent1\">International normalized ratio, prothrombin time, partial thromboplastin time</td> </tr> <tr> <td class=\"indent1\">BUN, creatinine</td> </tr> <tr> <td class=\"indent1\">Urinalysis including examination for red cell casts</td> </tr> <tr> <td class=\"indent1\">Blood cultures and testing for influenza</td> </tr> <tr> <td class=\"indent1\">BNP or N-terminal pro-BNP</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bronchoalveolar lavage (visible hemorrhage, hemosiderin-laden macrophages, eosinophils, microbiologic cultures/immunoassays, cytology)</td> </tr> <tr> <td class=\"subtitle1_single\">Tests for immune-mediated diseases</td> </tr> <tr> <td class=\"indent1\">ANCA</td> </tr> <tr> <td class=\"indent1\">Anti-GBM antibodies</td> </tr> <tr> <td class=\"indent1\">ANA, anti-double-stranded DNA, CH50, C3, C4</td> </tr> <tr> <td class=\"indent1\">CPK</td> </tr> <tr> <td class=\"indent1\">Anticardiolipin antibodies, anti-beta-2-glycoprotein I, and/or a lupus anticoagulant</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rheumatoid factor</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous tests based on clinical evaluation</td> </tr> <tr> <td class=\"indent1\">Antihistone antibodies</td> </tr> <tr> <td class=\"indent1\">Antistreptococcal antibodies</td> </tr> <tr> <td class=\"indent1\">Drug screen for cocaine</td> </tr> <tr> <td class=\"indent1\">Serologic test for leptospirosis, if clinically appropriate</td> </tr> <tr> <td class=\"indent1\">Skin biopsy</td> </tr> <tr> <td class=\"indent1\">Lung biopsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen; BNP: brain natriuretic peptide; ANCA: antineutrophil cytoplasmic antibodies; GBM: glomerular basement membrane; ANA: antinuclear antibody; CH50: total hemolytic complement; C3: complement component 3; C4: complement component 4; CPK: creatinine phosphokinase.</div><div id=\"graphicVersion\">Graphic 104832 Version 1.0</div></div></div>"},"104833":{"type":"graphic_picture","displayName":"Young adult with full fragile X mutation","title":"Young adult with full fragile X mutation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Young adult with full fragile X mutation</div><div class=\"cntnt\"><img style=\"width:284px; height:354px;\" src=\"images/ALLRG/104833_Yng_adlt_fll_frgl_X_mut.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Facial phenotype of a young male adult with fragile X syndrome. Note the elongated face with prominent chin and the pale blue eyes.</div><div class=\"graphic_reference\">Courtesy of Hilde Van Esch, MD, PhD.</div><div id=\"graphicVersion\">Graphic 104833 Version 1.0</div></div></div>"},"104836":{"type":"graphic_waveform","displayName":"Periodic limb movements of sleep on PSG","title":"Periodic limb movements of sleep on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Periodic limb movements of sleep on polysomnography</div><div class=\"cntnt\"><img style=\"width:772px; height:503px;\" src=\"images/SLEEP/104836_Prdc_lmb_mv_slp_plysmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG depicting PLMS in&nbsp;the right and left leg channels. The minimum duration of a limb movement event is 0.5 seconds, and the maximum duration of a limb movement is 10 seconds. The minimum amplitude is 8 microvolts above the resting EMG level, and the minimum period length between PLMS is 5 seconds (measured from onset of former leg to onset of latter leg) with a maximum period length of 90 seconds.</div><div class=\"graphic_footnotes\">PSG: polysomnography; PLMS: periodic limb movements of sleep; EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104836 Version 2.0</div></div></div>"},"104838":{"type":"graphic_waveform","displayName":"Periodic limb movements of sleep without arousal on PSG","title":"Periodic limb movements of sleep without arousal on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Periodic limb movements of sleep without arousal on polysomnography</div><div class=\"cntnt\"><img style=\"width:801px; height:372px;\" src=\"images/SLEEP/104838_Prdc_lmb_mv_slp_wthout_arsl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG demonstrating PLMS that are not associated with an arousal. While PLMS can be observed during N1 sleep and N2 sleep, they are typically reduced in N3 sleep and are generally absent during REM sleep.</div><div class=\"graphic_footnotes\">PSG: polysomnography; PLMS: periodic limb movements of sleep; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography; REM: rapid eye movement.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104838 Version 2.0</div></div></div>"},"104839":{"type":"graphic_waveform","displayName":"Periodic limb movements of sleep with arousal on PSG","title":"Periodic limb movements of sleep with arousal on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Periodic limb movements of sleep with arousal on polysomnography</div><div class=\"cntnt\"><img style=\"width:784px; height:350px;\" src=\"images/SLEEP/104839_Prdc_lmb_mv_slp_arsl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG with PLMS associated with an arousal. Specifically, K complexes, K-alpha complexes, brief bursts of alpha activity, or other cortical/subcortical arousals are examples of EEG activity that may be observed in association with PLMS.</div><div class=\"graphic_footnotes\">PSG: polysomnography; PLMS: periodic limb movements of sleep; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104839 Version 2.0</div></div></div>"},"104840":{"type":"graphic_table","displayName":"Echo grading severity of pulmonic regurgitation","title":"Echocardiographic parameters for grading the severity of pulmonic regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic parameters for grading the severity of pulmonic regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td>Pulmonic valve</td> <td>Normal</td> <td>Normal or abnormal</td> <td>Abnormal</td> </tr> <tr> <td>Right ventricular&nbsp;size</td> <td>Normal*</td> <td>Normal or dilated</td> <td>Dilated**</td> </tr> <tr> <td>Regurgitant jet width by color Doppler<sup>&#182;</sup></td> <td>Thin (usually &#60;10 mm in length) with a narrow origin</td> <td>Intermediate (&#60;50 percent of pulmonic valve annulus)</td> <td>Usually large (&#62;50 percent of pulmonic valve annulus), with a wide origin; may be brief in duration</td> </tr> <tr> <td>Jet density and deceleration rate by CW<sup>&#916;</sup></td> <td>Soft; slow deceleration</td> <td>Dense; variable deceleration</td> <td>Dense; steep deceleration with early termination of diastolic flow</td> </tr> <tr> <td>Pulmonic/systemic stroke volume ratio&nbsp;by PW<sup>&#9674;</sup></td> <td>Slightly increased</td> <td>Intermediate</td> <td>Significantly&nbsp;increased</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CW: continuous wave Doppler; PW: pulsed wave Doppler.<br />* Unless there are other reasons for RV enlargement. Normal 2D measurements from the apical four-chamber view; RV basal diameter â¤4.1 cm, RV end-diastolic area indexed to BSA is&nbsp; â¤12.6 cm<SUP innerHtml>2</SUP>/m<SUP>2</SUP> in men and â¤11.5 cm<SUP innerHtml>2</SUP>/m<SUP>2</SUP> in women <SUP>[1]</SUP>.<br />** Exception: acute pulmonic regurgitation<br />Â¶ At a Nyquist limit of 50 to 60 cm/s.<br />Î Steep deceleration is not specific for severe PR.<br /><FONT class=lozenge>â</FONT> Cut-off values for regurgitant volume and fraction are not well validated.</div><div class=\"graphic_reference\">Original figure modified for this publication. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777. Table used with the permission of Elsevier Inc. All rights reserved.<br />Updated with data from:<br /><OL>&#xD;&#xA;<LI>Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 104840 Version 1.0</div></div></div>"},"104841":{"type":"graphic_waveform","displayName":"Long leg movements on PSG","title":"Leg movements on polysomnography that are too long to qualify as periodic limb movements of sleep (PLMS)","html":"<div class=\"graphic\"><div style=\"width: 798px\" class=\"figure\"><div class=\"ttl\">Leg movements on polysomnography that are too long to qualify as periodic limb movements of sleep (PLMS)</div><div class=\"cntnt\"><img style=\"width:778px; height:518px;\" src=\"images/SLEEP/104841_Too_lng_leg_kck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a two-minute&nbsp;epoch of a PSG depicting leg movements lasting about 15 seconds, and therefore \"too long\" to be considered periodic leg movements of sleep (PLMS). The&nbsp;maximum duration of PLMS is 10 seconds.</div><div class=\"graphic_footnotes\">PSG: polysomnography; PLMS: periodic limb movements of sleep; EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104841 Version 3.0</div></div></div>"},"104843":{"type":"graphic_waveform","displayName":"Brief leg movements on PSG","title":"Brief legÂ movements on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Brief leg&nbsp;movements on polysomnography</div><div class=\"cntnt\"><img style=\"width:792px; height:526px;\" src=\"images/SLEEP/104843_Too_shrt_leg_kck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG demonstrating 0.2 to 0.3&nbsp;second leg movements in the left leg EMG&nbsp;that do not qualify as PLMS, as they&nbsp;are shorter than the minimum 0.5 second duration criteria.</div><div class=\"graphic_footnotes\">PSG: polysomnography; PLMS: periodic limb movements of sleep; EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104843 Version 3.0</div></div></div>"},"104844":{"type":"graphic_waveform","displayName":"Periodic limb movements of sleep with sleep apnea on PSG","title":"Periodic limb movementsÂ of sleep with sleep apnea on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Periodic limb movements&nbsp;of sleep with sleep apnea on polysomnography</div><div class=\"cntnt\"><img style=\"width:766px; height:531px;\" src=\"images/SLEEP/104844_Prdc_lmb_mvmnt_slp_apn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG depicting&nbsp;periodic limb movements of sleep&nbsp;(PLMS) with comorbid&nbsp;sleep apnea.</div><div class=\"graphic_footnotes\">PSG: polysomnography; PLMS: periodic limb movements of sleep; EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104844 Version 2.0</div></div></div>"},"104845":{"type":"graphic_waveform","displayName":"Leg cramps on PSG","title":"Leg cramps on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Leg cramps on polysomnography</div><div class=\"cntnt\"><img style=\"width:772px; height:496px;\" src=\"images/SLEEP/104845_Leg_cramp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG&nbsp;in a&nbsp;patient with sleep-related leg cramps. Sleep-related leg cramps can occur in any sleep stage. Leg cramps are briefer than periodic limb movements of sleep and are defined by the actual spasm or hardening of the muscle during sleep, with pain typically relieved by forcefully stretching the muscle.</div><div class=\"graphic_footnotes\">PSG: polysomnography; PLMS: periodic limb movements of sleep; EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104845 Version 2.0</div></div></div>"},"104846":{"type":"graphic_figure","displayName":"Two-host ixodid tick life cycle","title":"Two-host ixodid tick life cycle","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Two-host ixodid tick life cycle</div><div class=\"cntnt\"><img style=\"width:564px; height:468px;\" src=\"images/ID/104846_Two_host_ixodid_tick_life.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The adult is considered the diagnostic stage, as identification to the species level is best achieved with adults. An example of an ixodid tick of public health concern with this life cycle is <em>Hyalomma marginatum</em>, a vector of Crimean-Congo viral hemorrhagic fever.</div><div class=\"graphic_footnotes\">Two-host ixodid ticks have a life cycle that usually spans over two years. Gravid females drop off the second host after feeding to lay eggs <strong>(1)</strong>, usually in the fall. Eggs hatch into six-legged larvae <strong>(2)</strong> and overwinter in this stage. The following spring, the larvae seek out and attach to the first host <strong>(3)</strong>, usually a rodent or lagomorph. The larvae molt into nymphs on the first host <strong>(3a-3b)</strong>. Engorged nymphs drop off the first host, usually in the late summer or fall <strong>(4)</strong> and overwinter in the nymphal stage. Nymphs molt into adults the following spring <strong>(5)</strong> and seek out the second host <strong>(6)</strong>, which is usually a larger herbivore (bovids, cervids, etc). Adults feed on the second host during the summer and mate. In the fall, females drop off the second host to continue the cycle. Females may reattach and feed multiple times. Humans may serve as first or second hosts for ticks with this life cycle. Also, the second host does not necessarily have to be a separate species or even a separate individual as the first host.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Ticks. Available at: <a href=\"http://www.cdc.gov/dpdx/ticks/\" target=\"_blank\">http://www.cdc.gov/dpdx/ticks/</a> (Accessed on October 22, 2015).</div><div id=\"graphicVersion\">Graphic 104846 Version 1.0</div></div></div>"},"104847":{"type":"graphic_figure","displayName":"Crimean-Congo distribution map","title":"Crimean-Congo hemorrhagic fever distribution map","html":"<div class=\"graphic\"><div style=\"width: 729px\" class=\"figure\"><div class=\"ttl\">Crimean-Congo hemorrhagic fever distribution map</div><div class=\"cntnt\"><img style=\"width:709px; height:535px;\" src=\"images/ID/104847_Crmn_cng_dstrbt_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Crimean-Congo Hemorrhagic Fever (CCHF). Available at: <a href=\"http://www.cdc.gov/vhf/crimean-congo/index.html\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/vhf/crimean-congo/index.html</a> (Accessed on October 22, 2015).</div><div id=\"graphicVersion\">Graphic 104847 Version 1.0</div></div></div>"},"104848":{"type":"graphic_waveform","displayName":"Sleep-related bruxism on PSG","title":"Sleep-related bruxism on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Sleep-related bruxism on polysomnography</div><div class=\"cntnt\"><img style=\"width:754px; height:434px;\" src=\"images/SLEEP/104848_Sleep_rlt_brxsm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG&nbsp;with prominent&nbsp;sleep-related bruxism (dashed box). The clear arousal sequence of sleep-related bruxism can be seen in the EEG leads of the PSG.</div><div class=\"graphic_footnotes\">PSG: polysomnography; EEG: electroencephalography; EOG: electrooculography; EMG: electromyography; ECG: electrocardiography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104848 Version 2.0</div></div></div>"},"104849":{"type":"graphic_figure","displayName":"Body rocking illustration","title":"Body rocking","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Body rocking</div><div class=\"cntnt\"><img style=\"width:607px; height:682px;\" src=\"images/SLEEP/104849_Body_rock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the distinct morphological feature of body rocking.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104849 Version 1.0</div></div></div>"},"104850":{"type":"graphic_figure","displayName":"Head banging and head rolling illustration","title":"Head banging and head rolling","html":"<div class=\"graphic\"><div style=\"width: 813px\" class=\"figure\"><div class=\"ttl\">Head banging and head rolling</div><div class=\"cntnt\"><img style=\"width:793px; height:384px;\" src=\"images/SLEEP/104850_Hd_bng_hd_rll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the distinct morphological features of sleep-related rhythmic movements: (A) head banging and (B) head rolling.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104850 Version 1.0</div></div></div>"},"104851":{"type":"graphic_waveform","displayName":"Chewing artifact on PSG","title":"Chewing artifact on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Chewing artifact on polysomnography</div><div class=\"cntnt\"><img style=\"width:768px; height:493px;\" src=\"images/SLEEP/104851_Chew_artfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a PSG&nbsp;with chewing artifact, characterized by rhythmic bursts of muscles activity in the high frequency range of 50 to 100 Hz, usually with shorter onset times than the EEG bursts (dashed boxes).</div><div class=\"graphic_footnotes\">EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography; PSG: polysomnography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104851 Version 1.0</div></div></div>"},"104852":{"type":"graphic_waveform","displayName":"Sleep-related rhythmic movement disorder on PSG","title":"Sleep-related rhythmic movement disorder (head banging) on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Sleep-related rhythmic movement disorder (head banging) on polysomnography</div><div class=\"cntnt\"><img style=\"width:764px; height:421px;\" src=\"images/SLEEP/104852_Slp_rlt_rhth_mv_dsr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a PSG of sleep-related rhythmic movement disorder, which includes head banging, body rocking, and head rolling. In this PSG, the rhythmic movement is head rolling. The frequency range for&nbsp;rhythmic movement disorder&nbsp;is 0.5 to 2.0 Hz with at least four defined movements representing a \"cluster\" of rhythmic movements (dashed boxes).</div><div class=\"graphic_footnotes\">EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography; PSG: polysomnography; RMD: rhythmic movement disorder.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104852 Version 2.0</div></div></div>"},"104853":{"type":"graphic_waveform","displayName":"Propriospinal myoclonus at sleep onset on PSG","title":"Propriospinal myoclonus at sleep onset on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 789px\" class=\"figure\"><div class=\"ttl\">Propriospinal myoclonus at sleep onset on polysomnography</div><div class=\"cntnt\"><img style=\"width:769px; height:497px;\" src=\"images/SLEEP/104853_Prprspnl_mycln_slp_onst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a PSG demonstrating propriospinal myoclonus at sleep onset (prominent EMG bursts in the right and left leg leads).</div><div class=\"graphic_footnotes\">EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography; PSG: polysomnography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104853 Version 1.0</div></div></div>"},"104854":{"type":"graphic_waveform","displayName":"Excessive fragmentary myoclonus on PSG","title":"Excessive fragmentary myoclonus on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 798px\" class=\"figure\"><div class=\"ttl\">Excessive fragmentary myoclonus on polysomnography</div><div class=\"cntnt\"><img style=\"width:778px; height:494px;\" src=\"images/SLEEP/104854_Excs_frgmntry_mycln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG in a patient with excessive fragmentary myoclonus (dashed box). Each burst is at least 150 milliseconds long, and there are at least five EMG bursts per minute. Excessive fragmentary myoclonus&nbsp;is typically evident during NREM sleep.</div><div class=\"graphic_footnotes\">EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography; PSG: polysomnography; NREM: non-rapid eye movement.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104854 Version 2.0</div></div></div>"},"104855":{"type":"graphic_waveform","displayName":"Alternating leg muscle activation on PSG","title":"Alternating leg muscle activation on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 765px\" class=\"figure\"><div class=\"ttl\">Alternating leg muscle activation on polysomnography</div><div class=\"cntnt\"><img style=\"width:745px; height:488px;\" src=\"images/SLEEP/104855_Altrnt_lg_mscl_actvt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second epoch of a PSG in a patient with alternating leg muscle activation (ALMA). The PSG shows that ALMA duration is between 100 to 500 milliseconds (dashed box), with an EMG burst frequency range of 0.5 to 3.0 Hz. A single ALMA episode represents four movements that alternate between the legs.</div><div class=\"graphic_footnotes\">EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography; PSG: polysomnography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104855 Version 3.0</div></div></div>"},"104856":{"type":"graphic_waveform","displayName":"Hypnagogic foot tremor on PSG","title":"Hypnagogic foot tremor on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Hypnagogic foot tremor on polysomnography</div><div class=\"cntnt\"><img style=\"width:766px; height:494px;\" src=\"images/SLEEP/104856_Hypnggc_foot_trmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a 30-second&nbsp;epoch of a PSG&nbsp;with hypnogogic foot tremor. The PSG shows&nbsp;a series of&nbsp;EMG bursts in the leg channels that are 250 to 1000 milliseconds long with frequencies between 0.3 Hz and 4.0 Hz (dashed box), and the EEG shows drowsiness or sleep patterns consistent with stage N1.</div><div class=\"graphic_footnotes\">EOG: electrooculography; EEG: electroencephalography; electromyography; ECG: electrocardiography; PSG: polysomnography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104856 Version 2.0</div></div></div>"},"104857":{"type":"graphic_figure","displayName":"Hypnic jerks illustration","title":"Hypnic jerks (sleep starts)","html":"<div class=\"graphic\"><div style=\"width: 680px\" class=\"figure\"><div class=\"ttl\">Hypnic jerks (sleep starts)</div><div class=\"cntnt\"><img style=\"width:660px; height:588px;\" src=\"images/SLEEP/104857_Hypnc_jrk_illstrtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates a patient experiencing hypnic jerks, which are sudden, brief contractions of the body or one or more body segments occurring at sleep onset.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104857 Version 1.0</div></div></div>"},"104858":{"type":"graphic_waveform","displayName":"Hypnic jerk on PSG","title":"Hypnic jerk on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Hypnic jerk on polysomnography</div><div class=\"cntnt\"><img style=\"width:784px; height:523px;\" src=\"images/SLEEP/104858_Hypnic_jerk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a PSG of a patient with hypnic jerks. Hypnic jerks are short body contractions that affect the body asymmetrically during sleep onset. EMG shows that the involved muscles have, singly or in succession, brief high amplitude potentials that are generally 75 to 250 milliseconds in duration. EEG shows that stage N1 sleep patterns may occur with hypnic jerks.</div><div class=\"graphic_footnotes\">EOG: electrooculography; EEG: electroencephalography; EMG: electromyography; ECG: electrocardiography; PSG: polysomnography.</div><div class=\"graphic_reference\">Illustrated by Seulah Rebecca Choi. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 104858 Version 2.0</div></div></div>"},"104862":{"type":"graphic_table","displayName":"Vision screening for amblyopia","title":"Vision screening in infants and children: Findings indicative of amblyopia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vision screening in infants and children: Findings indicative of amblyopia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Screening test</td> <td class=\"subtitle1\">Finding</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Preverbal children</td> </tr> <tr> <td class=\"indent1\">Fixation reflex*</td> <td>Failure to initiate or maintain fixation</td> </tr> <tr> <td class=\"indent1\">Occlusion objection<sup>&#182;</sup></td> <td>Asymmetric objection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vertical prism test<sup>&#916;</sup></td> <td>Fixation preference or inability to maintain fixation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Older children</td> </tr> <tr> <td class=\"indent1\">Best-corrected VA</td> <td>Unilateral amblyopia: <ul class=\"decimal_heading\"> <li>&#8805;2-line difference between eyes </li> </ul> Bilateral amblyopia: <ul class=\"decimal_heading\"> <li>Age &#8804;3 years: VA worse than 20/50 in either eye </li> <li>Age &#8805;4 years: VA worse than 20/40 in either eye </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VA: visual acuity.<br />* Testing of the fixation reflex involves moving a visual target to and fro in the child's visual space. Each eye is tested separately by occluding the nontested eye. Accuracy is improved if the test is repeated several times. Refer to the UpToDate topic on&nbsp;evaluation of amblyopia in children for further details.<br />Â¶ The occlusion objection test involves monitoring the child's response to alternate occlusion of the eyes. Children with equal vision should respond equally, or not at all, to alternate occlusion. Children with moderate-to-severe visual impairment in one eye typically become irritable when the eye with better vision is occluded. Refer to the UpToDate topic on&nbsp;evaluation of amblyopia in children for further details.<br />Î The vertical prism test is performed using a 10- to 14-diopter vertical prism held (with the base down) in front of one eye and then the other. Amblyopia should be suspected if the child is unable to maintain fixation or demonstrates preference for the displaced image (ie, the eye moves upward). Refer to the UpToDate topic on&nbsp;evaluation of amblyopia in children for further details.</div><div class=\"graphic_reference\">American Academy of Ophthalmology Pediatric Ophthalmology/Strabismus Panel. Preferred Practice Pattern Guidelines. Amblyopia. American Academy of Ophthalmology, San Francisco, CA: American Academy of Ophthalmology; 2012. Available at: http://www.aao.org/preferred-practice-pattern/amblyopia-ppp--september-2012 (Accessed on August 05, 2015).</div><div id=\"graphicVersion\">Graphic 104862 Version 3.0</div></div></div>"},"104863":{"type":"graphic_figure","displayName":"Colorectal cancer risk associated with a first-degree relative","title":"Risk of colorectal cancer associated with a first-degree relative with colorectal cancer, by patient age","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Risk of colorectal cancer associated with a first-degree relative with colorectal cancer, by patient age</div><div class=\"cntnt\"><img style=\"width:652px; height:473px;\" src=\"images/PC/104863_Clrct_cncr_rsk_assct_frst_dgr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Data extrapolated from: Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331:1669.<br />Numbers indicate point estimate reported for each age group.</div><div class=\"graphic_reference\">Reproduced from: Doubeni CA, Fletcher RH. Family history of colorectal cancer: It is time to rethink screening recommendations. Gastroenterology 2015; S0016-5085:01386. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104863 Version 1.0</div></div></div>"},"104864":{"type":"graphic_table","displayName":"Differential diagnosis of amblyopia in children","title":"Nonamblyopic conditions associated with reduced visual acuity in childhood*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonamblyopic conditions associated with reduced visual acuity in childhood*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disorders of the visual pathway</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Retinal lesions</strong></td> </tr> <tr> <td class=\"indent2\">Chorioretinitis</td> <td> <ul> <li>Inflammatory changes in choroid and retina </li> <li>Associated with congenital TORCH infections, especially toxoplasmosis and cytomegalovirus </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Retinoblastoma</td> <td> <ul> <li>Typically presents as leukocoria* </li> <li>Strabismus, nystagmus, and a red eye also present </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Retinopathy of prematurity</td> <td> <ul> <li>Abnormal retinal vascular proliferation </li> <li>Occurs in preterm infants (most commonly in infants born at &#60;30 weeks gestation or birth weight &#8804;1500 grams) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Traumatic retinal injury</td> <td> <ul> <li>A clear history of preceding trauma may not be given in cases of nonaccidental trauma </li> <li>Patients may complain of flashes and floaters </li> <li>Retinal hemorrhages or tears may be seen on funduscopic exam </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Macular scarring</td> <td> <ul> <li>Can result from congenital infections (especially toxoplasmosis and cytomegalovirus), retinal injury, or retinal dystrophies </li> </ul> </td> </tr> <tr> <td class=\"indent2\"><a href=\"http://omim.org/entry/248200\" target=\"_blank\">Stargardt disease</a></td> <td> <ul> <li>Inherited disorder that causes macular degeneration in childhood </li> <li>Onset is typically at age 7 to 12 years </li> </ul> </td> </tr> <tr> <td class=\"indent2\"><a href=\"http://omim.org/entry/300216\" target=\"_blank\">Coats disease</a></td> <td> <ul> <li>Exudative retinal vascular disorder characterized by retinal telangiectasias and subretinal exudation leading to serous retinal detachment </li> <li>Occurs mainly in boys and is almost always unilateral </li> <li>Presents with leukocoria that is yellowish in color </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Retinal dystrophies (eg, <a href=\"http://omim.org/entry/216900\" target=\"_blank\">achromatopsia</a>, <a href=\"http://omim.org/entry/120970\" target=\"_blank\">cone-rod dystrophy</a>, <a href=\"http://omim.org/entry/203100\" target=\"_blank\">albinism</a>)</td> <td> <ul> <li>In addition to reduced visual acuity, patients may have photophobia and abnormal color vision </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Optic nerve lesions</strong></td> <td>The optic nerve lesions are generally associated with: <ul class=\"decimal_heading\"> <li>Afferent pupillary defect </li> <li>Abnormal color vision (dyschromatopsia) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Optic nerve hypoplasia</td> <td> <ul> <li>Optic disc is small and pale and often surrounded by a yellowish halo bordered by a ring of pigmentation </li> <li>Bilateral involvement is more common than is unilateral </li> <li>Associated with a variety of CNS and endocrine abnormalities (eg, septo-optic dysplasia) </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Optic neuropathy/atrophy</td> <td> <ul> <li>Optic disc is pale or whitish </li> <li>Some causes are associated with eye pain </li> <li>Can be caused by injury to the optic disc (eg, from ischemia, compression, inflammation, or increased intracranial pressure) or it may be hereditary </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Optic neuritis</td> <td> <ul> <li>Optic disc appears swollen with blurring of disc margins </li> <li>Usually unilateral </li> <li>Eye pain is common </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Myelinated nerve fibers</td> <td> <ul> <li>Characteristic finding is a white optic disc with feathery borders </li> <li>May be inherited in an autosomal dominant fashion or a component of the Gorlin syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Optic disc coloboma</td> <td> <ul> <li>Appears as a sharply defined, white, inferiorly decentered excavation of the optic disc </li> <li>Occur unilaterally or bilaterally with equal frequency </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Brain lesions</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Craniopharyngioma</td> <td> <ul> <li>Often associated with headaches and endocrine abnormalities </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Psychogenic causes</td> </tr> <tr> <td class=\"indent1\">Conversion disorder</td> <td rowspan=\"2\"> <ul> <li>May occur in children with underlying mental health disorders </li> <li>Often associated with other somatic complaints including headache, photophobia, or diplopia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Malingering</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TORCH: toxoplasmosis, other (syphilis), rubella, cytomegalovirus, herpes simplex virus; CNS: central nervous system.<br />* Nonamblyopic conditions associated with reduced visual acuity in children are presented in this table. Conditions that are associated with amblyopia or risk of amblyopia include strabismus, refractive errors, and structural obstructions of the visual pathway (eg, cataract, ptosis, corneal abnormalities). These conditions are reviewed separately. Refer to UpToDate topics on amblyopia, strabismus, refractive errors in children, and the approach to the child with leukocoria for further information.</div><div id=\"graphicVersion\">Graphic 104864 Version 3.0</div></div></div>"},"104869":{"type":"graphic_table","displayName":"Clinical features NREM parasomnias in adults","title":"Clinical features of non-rapid eye movement (NREM) parasomnias in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of non-rapid eye movement (NREM) parasomnias in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Confusional arousals</td> <td class=\"subtitle1\">Sleep terrors</td> <td class=\"subtitle1\">Sleepwalking</td> <td class=\"subtitle1\">Sleep-related abnormal sexual behavior</td> <td class=\"subtitle1\">Sleep-related eating disorder</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Timing at night</strong></td> <td>First third of the major sleep period, less commonly in the morning during transition from sleep to wakefulness or during light NREM sleep</td> <td>First third of the major sleep period</td> <td>First third of the major sleep period</td> <td>First third of the major sleep period</td> <td>First third of the major sleep period</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gender distribution</strong></td> <td>Equal</td> <td>Equal</td> <td>Equal</td> <td>Males &#62; females</td> <td>Females &#62; males</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Event semiology</strong></td> <td>Confusion and disorientation during an arousal from sleep; slow speech devoid of content</td> <td>Screaming, agitation, intense fear, facial flushing, sweating; inconsolable, difficult to arouse</td> <td>Slow and quiet ambulation, occasionally with more agitated behaviors</td> <td>Abnormal sexual behaviors without awareness</td> <td>Involuntary eating associated with diminished level of consciousness during an arousal from sleep</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Event duration</strong></td> <td>3 to 15 minutes</td> <td>3 to 15 minutes</td> <td>3 to 15 minutes</td> <td>3 to 15 minutes</td> <td>3 to 15 minutes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Event recall</strong></td> <td>Typically none</td> <td>May have partial dream recollection after event</td> <td>Typically none</td> <td>Typically none</td> <td>May have partial awareness during event or recall after event</td> </tr> <tr> <td><strong>PSG characteristics</strong></td> <td>Slow wave sleep, with rhythmic theta or delta activity</td> <td>Slow wave sleep, with rhythmic theta or delta activity; prominent tachycardia, increase in EMG tone</td> <td>Slow wave sleep, with rhythmic theta or delta activity</td> <td>Slow wave sleep, with rhythmic theta or delta activity</td> <td>Slow wave sleep, with rhythmic theta or delta activity; rhythmic masticatory muscle activity on EMG</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EMG: electromyography; NREM: non-rapid eye movement; PSG: polysomnography.</div><div id=\"graphicVersion\">Graphic 104869 Version 1.0</div></div></div>"},"104870":{"type":"graphic_table","displayName":"Management NREM parasomnias in adults","title":"Management of non-rapid eye movement (NREM) parasomnias in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of non-rapid eye movement (NREM) parasomnias in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Confusional arousals</td> <td class=\"subtitle1\">Sleep terrors</td> <td class=\"subtitle1\">Sleepwalking</td> <td class=\"subtitle1\">Sleep-related abnormal sexual behavior</td> <td class=\"subtitle1\">Sleep-related eating disorder</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Environmental safety</strong></td> <td colspan=\"5\"> <ul> <li>Pad nearby furniture </li> <li>Lower mattress to the floor and/or use a ground-floor bedroom </li> <li>Secure doors and windows (locks, alarms, barriers) </li> <li>Remove sharp and dangerous objects from bedroom, including firearms </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Behavioral management</strong></td> <td colspan=\"5\"> <ul> <li>Avoid sleep deprivation </li> <li>Maintain consistent and regular sleep-wake cycles </li> <li>Identify and eliminate potential triggers, including medications* and alcohol </li> <li>Treat comorbid sleep disorders<sup>&#182;</sup> </li> <li>Educate patients, bed partners, and bystanders </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Scheduled awakenings</strong></td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Pharmacotherapy</strong></td> <td>Clonazepam</td> <td>Clonazepam</td> <td>Clonazepam</td> <td> <p>Clonazepam</p> SSRI</td> <td> <p>Clonazepam</p> <p>SSRI</p> <p>Topiramate</p> Dopamine agonist<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NREM: non-rapid eye movement; SSRI: selective serotonin reuptake inhibitor.<br />* A variety of drugs may precipitate NREM arousal parasomnias, including sedative-hypnotic drugs, especially nonbenzodiazepine benzodiazepine receptor agonists (eg, zolpidem), anticholinergics, antipsychotics, and&nbsp;lithium.<br />Â¶ Most commonly implicated sleep disorders are obstructive sleep apnea, restless legs syndrome/Willis-Ekbom disease (especially for sleep-related eating disorder), and periodic limb movement disorder.<br />Î For sleep-related eating disorder associated with restless legs syndrome/Willis-Ekbom disease.</div><div id=\"graphicVersion\">Graphic 104870 Version 1.0</div></div></div>"},"104872":{"type":"graphic_table","displayName":"Follow-up for clinically localized renal neoplasms: AUA","title":"Follow-up for clinically localized renal neoplasms: American Urological Association guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Follow-up for clinically localized renal neoplasms: American Urological Association guidelines</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"10\">AUA T1NX/0</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\" colspan=\"2\">Modality</td> <td class=\"subtitle2\" colspan=\"8\">Months post-operatively</td> </tr> <tr> <td class=\"subtitle3\">6</td> <td class=\"subtitle3\">12</td> <td class=\"subtitle3\">18</td> <td class=\"subtitle3\">24</td> <td class=\"subtitle3\">30</td> <td class=\"subtitle3\">36</td> <td class=\"subtitle3\">48</td> <td class=\"subtitle3\">60</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">History and physical*</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Laboratories<sup>&#182;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Chest CXR</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Abdomen imaging<br /> (CT/MRI/US)<sup>&#916;</sup></td> <td class=\"divider_bottom\">Partial nephrectomy</td> <td class=\"centered divider_bottom\">X</td> <td class=\"centered divider_bottom\">X</td> <td class=\"centered divider_bottom\">&nbsp;</td> <td class=\"centered divider_bottom\">X</td> <td class=\"centered divider_bottom\">&nbsp;</td> <td class=\"centered divider_bottom\">X</td> <td class=\"centered divider_bottom\">&nbsp;</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td>Radical nephrectomy%</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"9\">AUA T2-4NX/0, TanyN1</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Modality</td> <td class=\"subtitle2\" colspan=\"8\">Months post-operatively</td> </tr> <tr> <td class=\"subtitle3\">6</td> <td class=\"subtitle3\">12</td> <td class=\"subtitle3\">18</td> <td class=\"subtitle3\">24</td> <td class=\"subtitle3\">30</td> <td class=\"subtitle3\">36</td> <td class=\"subtitle3\">48</td> <td class=\"subtitle3\">60</td> </tr> <tr class=\"divider_bottom\"> <td>History and physical*</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td>Laboratories</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td>Chest CT/chest radiograph<sup>&#9674;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Abdomen imaging<br /> (CT/MRI/US)<sup>&#9674;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CXR: chest radiograph; CT: computed tomography; MRI: magnetic resonance imaging; US: ultrasound; CNS: central nervous system; BUN: blood urea nitrogen.<br />* Imaging as indicated based on clinical suspicion including CNS and bone imaging.<br />Â¶ Laboratory values other than BUN/creatinine and urinanalysis to be used at the discretion of the clinician.<br />Î CT/MRI recommended initially, after which CT/MRI/US use acceptable for abdominal imaging.<br /><FONT class=lozenge>â</FONT> CT recommended initially, after which CT/CXR use acceptable for chest imaging.</div><div class=\"graphic_reference\">Data from: Donat SM, Diaz M, Bishoff JT, et al. Follow-up for clinically localized renal neoplasms: AUA Guideline. J Urol 2013, 190:407.</div><div id=\"graphicVersion\">Graphic 104872 Version 1.0</div></div></div>"},"104874":{"type":"graphic_table","displayName":"Renal cell carcinoma: 2015 NCCN recommendations","title":"Renal cell carcinoma: 2015 National Comprehensive Cancer Network guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal cell carcinoma: 2015 National Comprehensive Cancer Network guidelines</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"9\">NCCN stage I</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\" colspan=\"2\">Modality</td> <td class=\"subtitle2\" colspan=\"7\">Months post-operatively</td> </tr> <tr> <td class=\"subtitle3\">6</td> <td class=\"subtitle3\">12</td> <td class=\"subtitle3\">18</td> <td class=\"subtitle3\">24</td> <td class=\"subtitle3\">36</td> <td class=\"subtitle3\">48</td> <td class=\"subtitle3\">60</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">History and physical*</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Laboratories</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Chest CXR or chest CT</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Abdomen imaging<br /> (CT/MRI/US)<sup>&#182;</sup></td> <td class=\"divider_bottom\">Partial nephrectomy</td> <td class=\"centered divider_bottom\" colspan=\"2\">X<sup>&#916;</sup></td> <td class=\"centered divider_bottom\">&nbsp;</td> <td class=\"centered divider_bottom\">X</td> <td class=\"centered divider_bottom\">X</td> <td class=\"centered divider_bottom\">&nbsp;</td> <td class=\"centered divider_bottom\">&nbsp;</td> </tr> <tr> <td>Radical nephrectomy</td> <td class=\"centered\" colspan=\"2\">X<sup>&#916;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup width=\"15%\"></colgroup><colgroup span=\"10\" width=\"8%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"11\">NCCN stage II/III</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Modality</td> <td class=\"subtitle2\" colspan=\"10\">Months post-operatively</td> </tr> <tr> <td class=\"subtitle3\">3<sup>&#167;</sup></td> <td class=\"subtitle3\">6<sup>&#167;</sup></td> <td class=\"subtitle3\">9<sup>&#167;</sup></td> <td class=\"subtitle3\">12<sup>&#167;</sup></td> <td class=\"subtitle3\">18<sup>&#167;</sup></td> <td class=\"subtitle3\">24<sup>&#167;</sup></td> <td class=\"subtitle3\">30<sup>&#167;</sup></td> <td class=\"subtitle3\">36<sup>&#167;</sup></td> <td class=\"subtitle3\">48</td> <td class=\"subtitle3\">60</td> </tr> <tr class=\"divider_bottom\"> <td>History and physical*</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td>Laboratories</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td>Chest CT</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Abdomen imaging<br /> (CT/MRI)<sup>&#9674;</sup></td> <td class=\"centered\" colspan=\"2\">X<sup>&#167;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CXR: chest radiograph; CT: computed tomography; MRI: magnetic resonance imaging; US: ultrasound; CNS: central nervous system.<br />* Imaging as indicated based on clinical suspicion including CNS and bone imaging.<br />Â¶ Pelvic imaging as clinically indicated.<br />Î Imaging performed anywhere within 3 and 12 months of surgery.<br /><FONT class=lozenge>â</FONT> Pelvic imaging as clinically indicated, US Class 2B recommendations for stage II.<br />Â§ Guidelines recommend three to six month intervals for the first three years. For simplicity, we kept&nbsp;every three&nbsp;months for the first year and every six months for the second/third years.</div><div class=\"graphic_reference\">Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2015. J Natl Compr Canc Netw 2015; 13:151.</div><div id=\"graphicVersion\">Graphic 104874 Version 1.0</div></div></div>"},"104878":{"type":"graphic_figure","displayName":"Estimation of diffusive clearance","title":"Estimation of diffusive clearance","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Estimation of diffusive clearance</div><div class=\"cntnt\"><img style=\"width:473px; height:204px;\" src=\"images/NEPH/104878_Estimation_diffus_clearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">K<sub>D</sub>: diffusive component; K<sub>o</sub>A: solute-specific dialyzer mass transfer area coefficient; Q<sub>be</sub>: effective blood flow rate; Q<sub>d</sub>: dialysis fluid flow rate.</div><div id=\"graphicVersion\">Graphic 104878 Version 1.0</div></div></div>"},"104879":{"type":"graphic_figure","displayName":"Prediction of post-rebound or equilibrated concentration","title":"Prediction of post-rebound or equilibrated concentration","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Prediction of post-rebound or equilibrated concentration</div><div class=\"cntnt\"><img style=\"width:459px; height:183px;\" src=\"images/NEPH/104879_Pred_post_reb_equil_concen.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">C<SUB>eq</SUB>: post-rebound or equilibrated concentration; C<SUB>pre</SUB>:&nbsp;predialysis beta-2 microglobulin concentration in blood; C<SUB>post</SUB>: immediate postdialysis beta-2 microglobulin concentration in blood; t<SUB>d</SUB>: time difference in minutes between C<SUB>pre</SUB> and C<SUB>post</SUB> samples; t<SUB>p</SUB>: solute-specific patient equilibrium time.</div><div id=\"graphicVersion\">Graphic 104879 Version 1.0</div></div></div>"},"104882":{"type":"graphic_table","displayName":"WHO clinical staging HIV pediatric","title":"WHO clinical staging of HIV/AIDS for children with confirmed HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO clinical staging of HIV/AIDS for children with confirmed HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical stage 1</td> </tr> <tr> <td class=\"indent1\">Asymptomatic</td> </tr> <tr> <td class=\"indent1\">Persistent generalized lymphadenopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical stage 2</td> </tr> <tr> <td class=\"indent1\">Unexplained persistent hepatosplenomegaly</td> </tr> <tr> <td class=\"indent1\">Papular pruritic eruptions</td> </tr> <tr> <td class=\"indent1\">Fungal nail infection</td> </tr> <tr> <td class=\"indent1\">Angular cheilitis</td> </tr> <tr> <td class=\"indent1\">Lineal gingival erythema</td> </tr> <tr> <td class=\"indent1\">Extensive wart virus infection</td> </tr> <tr> <td class=\"indent1\">Extensive molluscum contagiosum</td> </tr> <tr> <td class=\"indent1\">Recurrent oral ulcerations</td> </tr> <tr> <td class=\"indent1\">Unexplained persistent parotid enlargement</td> </tr> <tr> <td class=\"indent1\">Herpes zoster</td> </tr> <tr> <td class=\"indent1\">Recurrent or chronic upper respiratory tract infections (otitis media, otorrhea, sinusitis or tonsillitis)</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical stage 3</td> </tr> <tr> <td class=\"indent1\">Unexplained* moderate malnutrition or wasting not adequately responding to standard therapy</td> </tr> <tr> <td class=\"indent1\">Unexplained persistent diarrhea (14 days or more)</td> </tr> <tr> <td class=\"indent1\">Unexplained persistent fever (above 37.5&#176;C intermittent or constant, for longer than one month)</td> </tr> <tr> <td class=\"indent1\">Persistent oral candidiasis (after first 6 to 8 weeks of life)</td> </tr> <tr> <td class=\"indent1\">Oral hairy leukoplakia</td> </tr> <tr> <td class=\"indent1\">Acute necrotizing ulcerative gingivitis or periodontitis</td> </tr> <tr> <td class=\"indent1\">Lymph node tuberculosis</td> </tr> <tr> <td class=\"indent1\">Pulmonary tuberculosis</td> </tr> <tr> <td class=\"indent1\">Severe recurrent bacterial pneumonia</td> </tr> <tr> <td class=\"indent1\">Symptomatic lymphoid interstitial pneumonitis</td> </tr> <tr> <td class=\"indent1\">Chronic HIV-associated lung disease including bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Unexplained anaemia (Hgb &#60;8 g/dL), neutropenia (ANC &#60;500 cells/microL (&#60;0.5 &times; 10<sup>9</sup>/L)) and or chronic thrombocytopenia (PLT &#60;50,000 cells/micoL (&#60;50 &times; 10<sup>9</sup> per litre))</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical stage 4<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Unexplained severe wasting, stunting or severe malnutrition not responding to standard therapy</td> </tr> <tr> <td class=\"indent1\">Pneumocystis pneumonia</td> </tr> <tr> <td class=\"indent1\">Recurrent severe bacterial infections (such as empyema, pyomyositis, bone or joint infection or meningitis but excluding pneumonia)</td> </tr> <tr> <td class=\"indent1\">Chronic herpes simplex infection (orolabial or cutaneous of more than one month's duration or visceral at any site)</td> </tr> <tr> <td class=\"indent1\">Esophageal candidiasis (or candidiasis of trachea, bronchi or lungs)</td> </tr> <tr> <td class=\"indent1\">Extrapulmonary tuberculosis</td> </tr> <tr> <td class=\"indent1\">Kaposi sarcoma</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus infection: retinitis or cytomegalovirus infection affecting another organ, with onset at age older than one month</td> </tr> <tr> <td class=\"indent1\">Central nervous system toxoplasmosis (after one month of life)</td> </tr> <tr> <td class=\"indent1\">Extrapulmonary cryptococcosis (including meningitis)</td> </tr> <tr> <td class=\"indent1\">HIV encephalopathy</td> </tr> <tr> <td class=\"indent1\">Disseminated endemic mycosis (coccidiomycosis or histoplasmosis)</td> </tr> <tr> <td class=\"indent1\">Disseminated non-tuberculous mycobacterial infection</td> </tr> <tr> <td class=\"indent1\">Chronic cryptosporidiosis (with diarrhea)</td> </tr> <tr> <td class=\"indent1\">Chronic isosporiasis</td> </tr> <tr> <td class=\"indent1\">Cerebral or B-cell non-Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"indent1\">Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hgb: Hemoglobin; ANC: absolute neutrophil count; PLT: platelet count; WHO: World Health Organization.</div><div class=\"graphic_footnotes\">* Unexplained refers to where the condition is not explained by other causes.<br />&para; Some additional specific conditions can also be included in regional classifications (such as reactivation of American trypanosomiasis [meningoencephalitis and/or myocarditis] in the WHO Region of the Americas, disseminated penicilliosis in Asia and HIV-associated rectovaginal fistula in Africa).</div><div class=\"graphic_reference\">Reprinted from: WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization, Geneva, Switzerland, 2007. Copyright &copy; 2007 World Health Organization.</div><div id=\"graphicVersion\">Graphic 104882 Version 1.0</div></div></div>"},"104888":{"type":"graphic_table","displayName":"COVADIS diagnostic criteria for vasospastic angina","title":"COVADIS diagnostic criteria for vasospastic angina*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">COVADIS diagnostic criteria for vasospastic angina*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Vasospastic angina diagnostic criteria elements</td> </tr> <tr> <td class=\"indent1\">1. Nitrate-responsive angina (during spontaneous episode, with at least one of the following):</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Rest angina, especially between night and early morning </li> <li>Marked diurnal variation in exercise tolerance, reduced in morning </li> <li>Hyperventilation can precipitate an episode </li> <li>Calcium channel blockers (but not beta blockers) suppress episodes </li> </ul> </td> </tr> <tr> <td class=\"indent1\">2. Transient ischemic ECG changes (during spontaneous episode, including any of the following in at least two contiguous leads):</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>ST segment elevation &#8805;0.1 mV </li> <li>ST segment depression &#8805;0.1 mV </li> <li>New negative U waves </li> </ul> </td> </tr> <tr> <td class=\"indent1\">3. Coronary artery spasm: Defined as transient total or subtotal coronary artery occlusion (&#62;90% constriction) with angina and ischemic ECG changes either spontaneously or in response to a provocative stimulus (typically acetylcholine, ergot, or hyperventilation)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: Electrocardiogram.<br />* \"Definitive vasospastic angina\" is diagnosed if nitrate-responsive angina is evident during spontaneous episodes and either the transient ischemic ECG changes during the spontaneous episodes or coronary artery spasm criteria are fulfilled. \"Suspected vasospastic angina\" is diagnosed if nitrate-responsive angina is evident during spontaneous episodes but transient ischaemic ECG changes are equivocal or unavailable and coronary artery spasm criteria are equivocal.</div><div class=\"graphic_reference\">Reproduced from: Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J 2015, by permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright Â© 2015 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 104888 Version 3.0</div></div></div>"},"104902":{"type":"graphic_table","displayName":"CMAS scoring sheet","title":"Childhood Myositis Assessment Scale (CMAS) scoring sheet","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Childhood Myositis Assessment Scale (CMAS) scoring sheet</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">1. Head elevation (neck flexion): </td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable</p> <p>1 = 1 to 9 seconds</p> <p>2 = 10 to 29 seconds</p> <p>3 = 30 to 59 seconds</p> <p>4 = 60 to 119 seconds</p> <p>5 = &#8805;2 minutes</p> Number of seconds ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_left\">2. Leg raise/touch object:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable to lift leg off table.</p> <p>1 = Able to clear table, but cannot touch object.</p> 2 = Able to lift leg high enough to touch object.</td> </tr> <tr> <td class=\"subtitle1_left\">3. Straight leg lift/duration:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable</p> <p>1 = 1 to 9 seconds</p> <p>2 = 10 to 29 seconds</p> <p>3 = 30 to 59 seconds</p> <p>4 = 60 to 119 seconds</p> <p>5 = &#8805;2 minutes</p> Number of seconds ______</td> </tr> <tr> <td class=\"subtitle1_left\">4. Supine to prone:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable. Has difficulty even turning onto side; able to pull arms under torso only slightly or not at all.</p> <p>1 = Turns onto side fairly easily, but cannot fully free arms and is not able to fully assume a prone position.</p> 2 = Easily turns onto side; has some difficulty freeing arms, but fully frees them and fully assumes a prone position.</td> </tr> <tr> <td class=\"subtitle1_left\">5. Sit-ups:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>For each type of sit-up enter either \"0\" (unable) or \"1\" (able). Then enter the total subscore.</p> (maximum possible item score 6.)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <p>Hands on thighs, with counterbalance ______</p> <p>Hands across chest, with counterbalance ______</p> <p>Hands behind head, with counterbalance ______</p> <p>Hands on thighs, without counterbalance ______</p> <p>Hands across chest, without counterbalance ______</p> Hands behind head, without counterbalance ______</td> </tr> <tr> <td class=\"subtitle1_left\">6. Supine to sit:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable by self.</p> <p>1 = Much difficulty. Very slow, struggles greatly, barely makes it. Almost unable.</p> <p>2 = Some difficulty. Able, but is somewhat slow, struggles some.</p> 3 = No difficulty.</td> </tr> <tr> <td class=\"subtitle1_left\">7. Arm raise/straighten:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Cannot raise wrists.</p> <p>1 = Can raise wrists at least up to the level of the acromioclavicular joint, but not above top of head.</p> <p>2 = Can raise wrists above top of head, but cannot raise arms straight above head so that elbows are in full extension.</p> 3 = Can raise arms straight above head so that elbows are in full extension.</td> </tr> <tr> <td class=\"subtitle1_left\">8. Arm raise/duration:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Can maintain wrists above top of head for:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <p>0 = Unable</p> <p>1 = 1 to 9 seconds</p> <p>2 = 10 to 29 seconds</p> <p>3 = 30 to 59 seconds</p> <p>4 = 60 to 119 seconds</p> <p>5 = &#8805;120 seconds</p> Number of seconds ______</td> </tr> <tr> <td class=\"subtitle1_left\">9. Floor sit:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Going from a standing position to a sitting position on the floor.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <p>0 = Unable. Afraid to even try, even if allowed to use a chair for support. Child fears that he/she will collapse, fall into a sit, or harm self.</p> <p>1 = Much difficulty. Able, but needs to hold onto a chair for support during descent. (Unable or unwilling to try if not able to use a chair for support.)</p> <p>2 = Some difficulty. Can go from stand to sit without using a chair for support, but has at least some difficulty during descent. Descends somewhat slowly and/or apprehensively; may not have full control or balance as maneuvers into a sit.</p> 3 = No difficulty. Requires no compensatory maneuvering.</td> </tr> <tr> <td class=\"subtitle1_left\">10. All-fours maneuver:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable to go from a prone to an all-fours position.</p> <p>1 = Barely able to assume and maintain an all-fours position.</p> <p>2 = Can maintain all-fours position with straight back and head raised (so as to look straight ahead). But, cannot creep (crawl) forward.</p> <p>3 = Can maintain all-fours, look straight ahead, and creep (crawl) forward.</p> 4 = Maintains balance while lifting and extending leg.</td> </tr> <tr> <td class=\"subtitle1_left\">11. Floor rise:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Going from a kneeling position on the floor to a standing position.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <p>0 = Unable, even if allowed to use a chair for support.</p> <p>1 = Much difficulty. Able, but needs to use a chair for support. Unable if not allowed to use a chair.</p> <p>2 = Moderate difficulty. Able to get up without using a chair for support, but needs to place one or both hands on thighs/knees or floor. Unable without using hands.</p> <p>3 = Mild difficulty. Does not need to place hands on knees, thighs, or floor, but has at least some difficulty during ascent.</p> 4 = No difficulty.</td> </tr> <tr> <td class=\"subtitle1_left\">12. Chair rise:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable to rise from chair, even if allowed to place hands on sides of chair seat.</p> <p>1 = Much difficulty. Able, but needs to place hands on sides of seat. Unable if not allowed to place hands on knees/thighs.</p> <p>2 = Moderate difficulty. Able, but needs to place hands on knees/thighs. Does not need to place hands on side of seat.</p> 3 = Mild difficulty. Able; does not need to use hands at all, but has at least some difficulty.</td> </tr> <tr> <td class=\"subtitle1_left\">13. Stool step:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable.</p> <p>1 = Much difficulty. Able, but needs to place one hand on exam table or examiner's hand.</p> <p>2 = Some difficulty. Able; does not need to use exam table for support, but needs to use hand(s) on knee/thigh.</p> 3 = Able. Does not need to use exam table or hand(s) on knee/thigh.</td> </tr> <tr> <td class=\"subtitle1_left\">14. Pick up:</td> <td class=\"subtitle1_left\">Item score ______</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <p>0 = Unable to bend over and pick up pencil off floor.</p> <p>1 = Much difficulty. Able, but relies heavily on support gained by placing hand(s) on knees/thighs.</p> <p>2 = Some difficulty. Needs to at least minimally and briefly place hand(s) on knees/thighs for support and is somewhat slow.</p> 3 = No difficulty. No compensatory maneuver necessary.</td> </tr> <tr> <td colspan=\"2\"><strong>Total score (maximum possible score 51) ______</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damange indices for the juvenile idiopathic inflammatory myopathies. II. The Childhoold Myositis Assessment Scale (CMAS): A quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42:2213. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/doi/10.1002/1529-0131(199910)42:10%3C2213::AID-ANR25%3E3.0.CO;2-8/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1002/1529-0131(199910)42:10%3C2213::AID-ANR25%3E3.0.CO;2-8/abstract</A>. Copyright Â© 1999 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://www.onlinelibrary.wiley.com/\" target=_blank>www.onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 104902 Version 1.0</div></div></div>"},"104908":{"type":"graphic_figure","displayName":"Sawtooth waves on PSG","title":"Sawtooth waves on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 809px\" class=\"figure\"><div class=\"ttl\">Sawtooth waves on polysomnography</div><div class=\"cntnt\"><img style=\"width:789px; height:406px;\" src=\"images/SLEEP/104908_Swtth_wave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 30-second epoch, referential montage. Sawtooth waves in REM sleep (box), a normal variant.</div><div class=\"graphic_footnotes\">PSG: polysomnography; REM: rapid eye movement.</div><div id=\"graphicVersion\">Graphic 104908 Version 1.0</div></div></div>"},"104910":{"type":"graphic_figure","displayName":"Hypnagogic hypersynchrony on EEG","title":"Hypnagogic hypersynchrony on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Hypnagogic hypersynchrony on electroencephalography</div><div class=\"cntnt\"><img style=\"width:772px; height:504px;\" src=\"images/SLEEP/104910_Hpnggc_hprsnchrny.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">10-second epoch, referential montage.&nbsp;Hypnagogic hypersynchrony is a&nbsp;normal physiologic variant of medium to high amplitude synchronous rhythmic theta frequencies seen in light NREM sleep.</div><div class=\"graphic_footnotes\">NREM: non-rapid eye movement.</div><div id=\"graphicVersion\">Graphic 104910 Version 1.0</div></div></div>"},"104911":{"type":"graphic_figure","displayName":"Onset of confusional arousal on EEG","title":"Onset of confusional arousal on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 835px\" class=\"figure\"><div class=\"ttl\">Onset of confusional arousal on electroencephalography</div><div class=\"cntnt\"><img style=\"width:815px; height:447px;\" src=\"images/SLEEP/104911_Cnfsnl_arsl_prsmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EEG 30-second epoch, longitudinal bipolar montage. This epoch shows a confusional arousal during N3 sleep, with&nbsp;increased beta/spindle activity due to benzodiazepine use. Arrow: Arousal when nurse entered the room. Patient quickly sat up in bed and appeared scared and confused.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; NREM: non-rapid eye movement.</div><div id=\"graphicVersion\">Graphic 104911 Version 1.0</div></div></div>"},"104912":{"type":"graphic_figure","displayName":"Continuation of confusional arousal on EEG","title":"Continuation of confusional arousal on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 837px\" class=\"figure\"><div class=\"ttl\">Continuation of confusional arousal on electroencephalography</div><div class=\"cntnt\"><img style=\"width:817px; height:420px;\" src=\"images/SLEEP/104912_Cnfsnl_arsl_cntntn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EEG 30-second epoch, longitudinal bipolar montage. When asked his location, the patient replied \"We are on the ship,\" and continued to&nbsp;refer to the ship on subsequent questioning. EEG demonstrates incomplete awakening, with intermixed theta, alpha, and delta frequencies.</div><div class=\"graphic_footnotes\">EEG: electroencephalography.</div><div id=\"graphicVersion\">Graphic 104912 Version 1.0</div></div></div>"},"104913":{"type":"graphic_figure","displayName":"EEG after confusional arousal termination","title":"Electroencephalography after confusional arousal termination","html":"<div class=\"graphic\"><div style=\"width: 837px\" class=\"figure\"><div class=\"ttl\">Electroencephalography after confusional arousal termination</div><div class=\"cntnt\"><img style=\"width:817px; height:419px;\" src=\"images/SLEEP/104913_EEG_aftr_cnfs_arsl_trm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EEG 30-second epoch, longitudinal bipolar montage, after confusional arousal termination. Within a few minutes, the patient returned to baseline, his responses became appropriate, and he remembered the code phrase given to him during the middle of the episode but was amnestic to conversations early in the spell. EEG demonstrates intermixed alpha and beta frequencies, his usual waking baseline.</div><div class=\"graphic_footnotes\">EEG: electroencephalography.</div><div id=\"graphicVersion\">Graphic 104913 Version 1.0</div></div></div>"},"104914":{"type":"graphic_figure","displayName":"Normal REM sleep on PSG","title":"Normal rapid eye movement sleep on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 883px\" class=\"figure\"><div class=\"ttl\">Normal rapid eye movement sleep on polysomnography</div><div class=\"cntnt\"><img style=\"width:863px; height:578px;\" src=\"images/SLEEP/104914_Nrml_REM_slp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 30-second epoch. Note the rapid eye movements in the EOG derivations (arrows) and atonia in the chin (EMG) and leg EMG derivations.</div><div class=\"graphic_footnotes\">REM: rapid eye movement; PSG: polysomnography; EOG: electrooculography; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 104914 Version 1.0</div></div></div>"},"104915":{"type":"graphic_figure","displayName":"REM sleep behavior disorder on PSG","title":"Rapid eye movement sleep behavior disorder on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 887px\" class=\"figure\"><div class=\"ttl\">Rapid eye movement sleep behavior disorder on polysomnography</div><div class=\"cntnt\"><img style=\"width:867px; height:585px;\" src=\"images/SLEEP/104915_REM_slp_bhv_dsrd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 30-second epoch. Note the rapid eye movements in the EOG derivations (box) and lack of atonia in the chin and leg EMG derivations (arrows) for &gt;5 three-second mini-epochs.</div><div class=\"graphic_footnotes\">REM: rapid eye movement; PSG: polysomnography; EOG: electrooculography; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 104915 Version 1.0</div></div></div>"},"104916":{"type":"graphic_figure","displayName":"REM sleep behavior disorder on PSG (cont)","title":"Rapid eye movement sleep behavior disorder on polysomnography (continued)","html":"<div class=\"graphic\"><div style=\"width: 964px\" class=\"figure\"><div class=\"ttl\">Rapid eye movement sleep behavior disorder on polysomnography (continued)</div><div class=\"cntnt\"><img style=\"width:944px; height:673px;\" src=\"images/SLEEP/104916_REM_slp_bhvr_dsrd_cnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 30-second epoch. Continued complex motor behaviors during a partial arousal in the same patient with REM sleep behavior disorder. At the bottom right hand corner of the epoch, the technologist notes that the patient is reaching out with his right hand.</div><div class=\"graphic_footnotes\">REM: rapid eye movement; PSG: polysomnography; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 104916 Version 2.0</div></div></div>"},"104917":{"type":"graphic_figure","displayName":"Focal interictal epileptiform discharges, 30-second epoch","title":"Focal interictal epileptiform discharges, 30-second epoch","html":"<div class=\"graphic\"><div style=\"width: 819px\" class=\"figure\"><div class=\"ttl\">Focal interictal epileptiform discharges, 30-second epoch</div><div class=\"cntnt\"><img style=\"width:799px; height:513px;\" src=\"images/SLEEP/104917_Fcl_intrc_eplf_dschr_30_scn_epc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EEG 30-second epoch, longitudinal bipolar montage. Arrow: Interictal one second burst of 3.5 Hz rhythmic spike and slow wave discharges, localized to T6 electrode based on the phase reversal of the discharges.</div><div class=\"graphic_footnotes\">EEG: electroencephalography.</div><div id=\"graphicVersion\">Graphic 104917 Version 2.0</div></div></div>"},"104918":{"type":"graphic_figure","displayName":"Focal interictal epileptiform discharges, 10-second epoch","title":"Focal interictal epileptiform discharges, 10-second epoch","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Focal interictal epileptiform discharges, 10-second epoch</div><div class=\"cntnt\"><img style=\"width:800px; height:515px;\" src=\"images/SLEEP/104918_Fcl_intrc_eplpt_dsch_10_scnd_epc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EEG 10-second epoch, longitudinal bipolar montage. Arrow: The same interictal one second burst of 3.5 Hz rhythmic spike and slow wave discharges as seen on the 30-second epoch, now on a 10-second epoch. Note the field includes T6, T4, FT10 and C4.</div><div class=\"graphic_footnotes\">EEG: electroencephalography.</div><div id=\"graphicVersion\">Graphic 104918 Version 2.0</div></div></div>"},"104919":{"type":"graphic_figure","displayName":"Suspicious EEG, 30-second epoch","title":"Suspicious electroencephalography, 30-second epoch","html":"<div class=\"graphic\"><div style=\"width: 719px\" class=\"figure\"><div class=\"ttl\">Suspicious electroencephalography, 30-second epoch</div><div class=\"cntnt\"><img style=\"width:699px; height:408px;\" src=\"images/SLEEP/104919_Sspcs_EEG_30_scnd_epch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 30-second epoch, average montage including both mastoid electrodes. Circled discharges are suspicious for epileptiform activity intermixed with theta and delta frequencies.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; PSG: polysomnography.</div><div id=\"graphicVersion\">Graphic 104919 Version 1.0</div></div></div>"},"104920":{"type":"graphic_figure","displayName":"Suspicious EEG, 10-second epoch","title":"Suspicious electroencephalography, 10-second epoch","html":"<div class=\"graphic\"><div style=\"width: 718px\" class=\"figure\"><div class=\"ttl\">Suspicious electroencephalography, 10-second epoch</div><div class=\"cntnt\"><img style=\"width:698px; height:412px;\" src=\"images/SLEEP/104920_Sspc_EEG_10scnd_epch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 10-second epoch, average montage including both mastoid electrodes. The same suspicious discharges as seen in the 30-second epoch,&nbsp;now in a 10-second epoch.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; PSG: polysomnography.</div><div id=\"graphicVersion\">Graphic 104920 Version 1.0</div></div></div>"},"104922":{"type":"graphic_figure","displayName":"Suspicious EEG, 30-second epoch, adjusted average montage","title":"Suspicious electroencephalography, 30-second epoch, adjusted average montage without A1, A2 mastoid electrodes","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Suspicious electroencephalography, 30-second epoch, adjusted average montage without A1, A2 mastoid electrodes</div><div class=\"cntnt\"><img style=\"width:690px; height:425px;\" src=\"images/SLEEP/104922_Sspc_EEG_30scnd_adjs_mntg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 30-second epoch, average montage without A1, A2 mastoid electrodes. Suspicious discharges are not present. EEG demonstrates intermixed theta and delta frequencies.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; PSG: polysomnography.</div><div id=\"graphicVersion\">Graphic 104922 Version 1.0</div></div></div>"},"104923":{"type":"graphic_figure","displayName":"Suspicious EEG, 10-second epoch, adjusted average montage","title":"Suspicious electroencephalography, 10-second epoch, adjusted average montage without A1, A2 mastoid electrodes","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Suspicious electroencephalography, 10-second epoch, adjusted average montage without A1, A2 mastoid electrodes</div><div class=\"cntnt\"><img style=\"width:690px; height:420px;\" src=\"images/SLEEP/104923_Sspc_EEG_10scnd_adjs_mtg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSG 10-second epoch, average montage without A1, A2 mastoid electrodes. Suspicious discharges are not present. EEG demonstrates intermixed theta and delta frequencies.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; PSG: polysomnography.</div><div id=\"graphicVersion\">Graphic 104923 Version 1.0</div></div></div>"},"104924":{"type":"graphic_waveform","displayName":"60 Hz artifact with notch filter","title":"60 Hz artifact with notch filter","html":"<div class=\"graphic\"><div style=\"width: 891px\" class=\"figure\"><div class=\"ttl\">60 Hz artifact with notch filter</div><div class=\"cntnt\"><img style=\"width:871px; height:543px;\" src=\"images/SLEEP/104924_60Hz_artfct_ntch_fltr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography (EEG) with 60 Hz artifact from a charging cell phone that is filtered out with the notch filter. Low frequency filter (LFF) 1 Hz, high frequency filter (HFF) 70 Hz, sensitivity 7 microV, timebase 30 mm/second, 60 Hz notch filter on.</div><div class=\"graphic_footnotes\">ECG: electrocardiography.</div><div id=\"graphicVersion\">Graphic 104924 Version 2.0</div></div></div>"},"104925":{"type":"graphic_waveform","displayName":"60 Hz artifact without notch filter","title":"60 Hz artifact without notch filter","html":"<div class=\"graphic\"><div style=\"width: 890px\" class=\"figure\"><div class=\"ttl\">60 Hz artifact without notch filter</div><div class=\"cntnt\"><img style=\"width:870px; height:388px;\" src=\"images/SLEEP/104925_60Hz_artfct_wtht_ntch_fltr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography (EEG) with 60 Hz artifact from a charging cell phone that obscures all derivations. Low frequency filter (LFF) 1 Hz, high frequency filter (HFF) 70 Hz, sensitivity 30 microV, timebase 30 mm/second, 60 Hz notch filter off.</div><div class=\"graphic_footnotes\">ECG: electrocardiography.</div><div id=\"graphicVersion\">Graphic 104925 Version 2.0</div></div></div>"},"104926":{"type":"graphic_figure","displayName":"ECG artifact on EEG","title":"Electrocardiogram (ECG) artifact on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 883px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) artifact on electroencephalography</div><div class=\"cntnt\"><img style=\"width:863px; height:578px;\" src=\"images/SLEEP/104926_ECG_artifact.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography demonstrating electrocardiogram (ECG) artifact. Note the diffuse ECG artifacts time-locked with the QRS waves in the ECG derivation.</div><div id=\"graphicVersion\">Graphic 104926 Version 1.0</div></div></div>"},"104927":{"type":"graphic_figure","displayName":"Electrode pop artifact on EEG","title":"Electrode pop artifact on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 884px\" class=\"figure\"><div class=\"ttl\">Electrode pop artifact on electroencephalography</div><div class=\"cntnt\"><img style=\"width:864px; height:551px;\" src=\"images/SLEEP/104927_Elctrd_pop_artfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography demonstrating electrode pop artifact. Electrode pops are seen in FT9 and F3 (arrows).</div><div id=\"graphicVersion\">Graphic 104927 Version 1.0</div></div></div>"},"104928":{"type":"graphic_figure","displayName":"Eyelid myoclonus on EEG","title":"Eyelid myoclonus on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 862px\" class=\"figure\"><div class=\"ttl\">Eyelid myoclonus on electroencephalography</div><div class=\"cntnt\"><img style=\"width:842px; height:523px;\" src=\"images/SLEEP/104928_Eyelid_myoclonus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography demonstrating myogenic artifact in the bilateral frontal regions due to eyelid myoclonus (boxes).</div><div id=\"graphicVersion\">Graphic 104928 Version 1.0</div></div></div>"},"104929":{"type":"graphic_figure","displayName":"Generalized epileptiform discharges arising from stage N2 sleep","title":"Generalized epileptiform discharges arising from stage N2 sleep","html":"<div class=\"graphic\"><div style=\"width: 880px\" class=\"figure\"><div class=\"ttl\">Generalized epileptiform discharges arising from stage N2 sleep</div><div class=\"cntnt\"><img style=\"width:860px; height:575px;\" src=\"images/SLEEP/104929_Gn_eplpt_dschr_ars_stg_N2_slp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography in an 18-year-old female showing N2 sleep with a 2.5-second burst of 2.5 Hz generalized rhythmic polyspike and slow wave discharges (box) resulting in subsequent arousal.</div><div id=\"graphicVersion\">Graphic 104929 Version 1.0</div></div></div>"},"104930":{"type":"graphic_figure","displayName":"Generalized seizure arising from stage N2 sleep","title":"Generalized seizure arising from stage N2 sleep","html":"<div class=\"graphic\"><div style=\"width: 882px\" class=\"figure\"><div class=\"ttl\">Generalized seizure arising from stage N2 sleep</div><div class=\"cntnt\"><img style=\"width:862px; height:435px;\" src=\"images/SLEEP/104930_Gnrlz_szr_ars_stg_N2_slp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography in a 22-year-old male demonstrating stage N2 sleep, then a sudden background change evolving to generalized low amplitude fast activity (box), then medium amplitude rhythmic sharp theta activity.</div><div id=\"graphicVersion\">Graphic 104930 Version 1.0</div></div></div>"},"104931":{"type":"graphic_figure","displayName":"Lambda waves on EEG","title":"Lambda waves on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 891px\" class=\"figure\"><div class=\"ttl\">Lambda waves on electroencephalography</div><div class=\"cntnt\"><img style=\"width:871px; height:519px;\" src=\"images/SLEEP/104931_Lambda_wave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography showing lambda waves (box), a benign variant, in the bioccipital regions in a 34-year-old woman during reading. Note the saccadic lateral eye movements in F7 and F8 (arrows), which are normal physiologic eye movement artifacts.</div><div id=\"graphicVersion\">Graphic 104931 Version 2.0</div></div></div>"},"104932":{"type":"graphic_figure","displayName":"Movement artifact on EEG","title":"Movement artifact on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 881px\" class=\"figure\"><div class=\"ttl\">Movement artifact on electroencephalography</div><div class=\"cntnt\"><img style=\"width:861px; height:542px;\" src=\"images/SLEEP/104932_Movement_artfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography with high-frequency movement artifact, maximal in the bifrontotemporal regions, which begins as the patient starts to talk (arrow).</div><div id=\"graphicVersion\">Graphic 104932 Version 1.0</div></div></div>"},"104933":{"type":"graphic_figure","displayName":"Pulse artifact on EEG","title":"Pulse artifact on electroencephalography","html":"<div class=\"graphic\"><div style=\"width: 824px\" class=\"figure\"><div class=\"ttl\">Pulse artifact on electroencephalography</div><div class=\"cntnt\"><img style=\"width:804px; height:532px;\" src=\"images/SLEEP/104933_Pulse_artfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography with prominent pulse artifact. Note the slow waves in T5 following the QRS complex in the electrocardiogram (ECG) derivation (boxes).</div><div id=\"graphicVersion\">Graphic 104933 Version 1.0</div></div></div>"},"104934":{"type":"graphic_figure","displayName":"Right temporal lobe seizure from stage N2 sleep (continuation)","title":"Right temporal lobe seizure from stage N2 sleep (continuation)","html":"<div class=\"graphic\"><div style=\"width: 863px\" class=\"figure\"><div class=\"ttl\">Right temporal lobe seizure from stage N2 sleep (continuation)</div><div class=\"cntnt\"><img style=\"width:843px; height:446px;\" src=\"images/SLEEP/104934_Rght_tmp_lb_sz_stg_N2_slp_cnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuation of a right temporal lobe seizure from stage N2 sleep. Electroencephalography demonstrates evolution into a 2.5 to 3 Hz rhythmic sharp ictal pattern over the right temporal lobe (box). Time base 30 mm/second.</div><div id=\"graphicVersion\">Graphic 104934 Version 1.0</div></div></div>"},"104935":{"type":"graphic_figure","displayName":"Right temporal lobe seizure from stage N2 sleep (onset)","title":"Right temporal lobe seizure from stage N2 sleep (onset)","html":"<div class=\"graphic\"><div style=\"width: 855px\" class=\"figure\"><div class=\"ttl\">Right temporal lobe seizure from stage N2 sleep (onset)</div><div class=\"cntnt\"><img style=\"width:835px; height:443px;\" src=\"images/SLEEP/104935_Rght_tmp_lb_sz_stg_N2_slp_onst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During stage N2 sleep, sharply contoured discharges are seen at T6 (open arrows) that broaden to the right temporal region (solid arrow). Time base 30 mm/second.</div><div id=\"graphicVersion\">Graphic 104935 Version 1.0</div></div></div>"},"104936":{"type":"graphic_figure","displayName":"Sweat artifact on PSG","title":"Sweat artifact on polysomnography","html":"<div class=\"graphic\"><div style=\"width: 929px\" class=\"figure\"><div class=\"ttl\">Sweat artifact on polysomnography</div><div class=\"cntnt\"><img style=\"width:909px; height:400px;\" src=\"images/SLEEP/104936_Sweat_artfct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polysomnography with prominent sweat artifact. Note the high amplitude slowing in the electrooculography (EOG) and electroencephalography (EEG) derivations due to sweat artifact. 60-second epoch.</div><div id=\"graphicVersion\">Graphic 104936 Version 1.0</div></div></div>"},"104937":{"type":"graphic_figure","displayName":"Vertex sharp waves during stage N1 sleep","title":"Vertex sharp waves during stage N1 sleep","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Vertex sharp waves during stage N1 sleep</div><div class=\"cntnt\"><img style=\"width:634px; height:405px;\" src=\"images/SLEEP/104937_Vrtx_shrp_wv_stg_N1_slp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electroencephalography showing a run of vertex sharp waves during stage N1 sleep (box). The vertex sharp waves have a phase reversal at Cz with a field involving the bilateral paracentral regions.</div><div id=\"graphicVersion\">Graphic 104937 Version 1.0</div></div></div>"},"104938":{"type":"graphic_table","displayName":"Extended EEG montages during video polysomnography","title":"Suggested electroencephalography (EEG)Â montages during video polysomnography with extended EEG*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested electroencephalography (EEG)&nbsp;montages during video polysomnography with extended EEG*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"24%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Derivation</td> <td class=\"subtitle1\">Longitudinal bipolar</td> <td class=\"subtitle1\">Transverse bipolar</td> <td class=\"subtitle1\">Referential</td> </tr> <tr> <td>1</td> <td>Fp1-F7</td> <td>F7-Fp1</td> <td>F7-M1</td> </tr> <tr> <td>2</td> <td>F7-T3</td> <td>Fp1-Fp2</td> <td>T3-M1</td> </tr> <tr> <td>3</td> <td>T3-T5</td> <td>Fp2-F8</td> <td>T5-M1</td> </tr> <tr> <td>4</td> <td>T5-O1</td> <td>F7-F3</td> <td>Fp1-M1</td> </tr> <tr> <td>5</td> <td>Fp1-F3</td> <td>F3-Fz</td> <td>F3-M1</td> </tr> <tr> <td>6</td> <td>F3-C3</td> <td>Fz-F4</td> <td>C3-M1</td> </tr> <tr> <td>7</td> <td>C3-P3</td> <td>F4-F8</td> <td>P3-M1</td> </tr> <tr> <td>8</td> <td>P3-O1</td> <td>T3-C3</td> <td>O1-M1</td> </tr> <tr> <td>9</td> <td>Fz-Cz</td> <td>C3-Cz</td> <td>Fz-M1</td> </tr> <tr> <td>10</td> <td>Cz-Pz</td> <td>Cz-C4</td> <td>Pz-M2</td> </tr> <tr> <td>11</td> <td>Fp2-F4</td> <td>C4-T4</td> <td>Fp2-M2</td> </tr> <tr> <td>12</td> <td>F4-C4</td> <td>T5-P3</td> <td>F4-M2</td> </tr> <tr> <td>13</td> <td>C4-P4</td> <td>P3-Pz</td> <td>C4-M2</td> </tr> <tr> <td>14</td> <td>P4-O2</td> <td>Pz-P4</td> <td>P4-M2</td> </tr> <tr> <td>15</td> <td>Fp2-F8</td> <td>P4-T6</td> <td>O2-M2</td> </tr> <tr> <td>16</td> <td>F8-T4</td> <td>T5-O1</td> <td>F8-M2</td> </tr> <tr> <td>17</td> <td>T4-T6</td> <td>O1-O2</td> <td>T4-M2</td> </tr> <tr> <td>18</td> <td>T6-O2</td> <td>O2-T6</td> <td>T6-M2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG:electroencephalography; C: central; F: frontal; Fp: frontopolar; M: mastoid; O: occipital; P: parietal; T: temporal; z: midline.<br />* Based on International 10-20 System of Electrode Placement.</div><div class=\"graphic_reference\">Data from: American Clinical Neurophysiology Society. Guideline 6: A proposal for standard montages to be used in clinical EEG. J Clin Neurophysiol 2006;23:111.</div><div id=\"graphicVersion\">Graphic 104938 Version 1.0</div></div></div>"},"104939":{"type":"graphic_picture","displayName":"CCHF petechiae","title":"Crimean-Congo hemorrhagic fever: Petechiae","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Crimean-Congo hemorrhagic fever: Petechiae</div><div class=\"cntnt\"><img style=\"width:708px; height:530px;\" src=\"images/ID/104939_CCHF_petechiae.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Hakan Leblebicioglu, MD.</div><div id=\"graphicVersion\">Graphic 104939 Version 1.0</div></div></div>"},"104940":{"type":"graphic_picture","displayName":"CCHF ecchymosis tick","title":"Crimean-Congo hemorrhagic fever: Ecchymosis at tick bite area","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Crimean-Congo hemorrhagic fever: Ecchymosis at tick bite area</div><div class=\"cntnt\"><img style=\"width:710px; height:532px;\" src=\"images/ID/104940_CCHF_ecchymosis_tick.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Hakan Leblebicioglu, MD.</div><div id=\"graphicVersion\">Graphic 104940 Version 1.0</div></div></div>"},"104941":{"type":"graphic_picture","displayName":"CCHF ecchymosis injection","title":"Crimean-Congo hemorrhagic fever: Ecchymosis at injection site","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Crimean-Congo hemorrhagic fever: Ecchymosis at injection site</div><div class=\"cntnt\"><img style=\"width:532px; height:710px;\" src=\"images/ID/104941_CCHF_ecchymosis_inject.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Hakan Leblebicioglu, MD.</div><div id=\"graphicVersion\">Graphic 104941 Version 1.0</div></div></div>"},"104942":{"type":"graphic_picture","displayName":"CCHF gum bleeding","title":"Crimean-Congo hemorrhagic fever: Gum bleeding","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Crimean-Congo hemorrhagic fever: Gum bleeding</div><div class=\"cntnt\"><img style=\"width:712px; height:472px;\" src=\"images/ID/104942_CCHF_gum_bleed.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Hakan Leblebicioglu, MD.</div><div id=\"graphicVersion\">Graphic 104942 Version 1.0</div></div></div>"},"104943":{"type":"graphic_picture","displayName":"Hydroa vacciniforme-like lymphoma","title":"Hydroa vacciniforme-like lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hydroa vacciniforme-like lymphoma</div><div class=\"cntnt\"><img style=\"width:289px; height:797px;\" src=\"images/DERM/104943_Hydr_vccnfrm_lk_lmphm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Facial edema and ulcerated lesions and scars on the face of a child with hydroa vacciniforme-like lymphoma.<br />(B) Less marked facial edema and several small ulcerated lesions with some scars.<br />(C) Infiltrated edematous lesions on the face. Both arms show similar lesions with prominent scarring.</div><div class=\"graphic_reference\">From: Maga&ntilde;a M, Massone C, Maga&ntilde;a P, Cerroni L. Clinicopathologic features of hydroa vacciniforme-like lymphoma: A series of 9 patients. Am J Dermatopathol 2016; 38:20. DOI: <a href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2016&amp;issue=01000&amp;article=00002&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/DAD.0000000000000385</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2016 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 104943 Version 1.0</div></div></div>"},"104945":{"type":"graphic_table","displayName":"Obstetric management of imminent delivery of periviable neonates","title":"Obstetric management of threatened or imminent delivery of pregnancies at a periviable gestational age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obstetric management of threatened or imminent delivery of pregnancies at a periviable gestational age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"6\">Recommendations for periviable birth</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"4\">Recommendations</td> <td class=\"subtitle2\" colspan=\"2\">Grade of recommendations</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Based on anticipated neonatal or maternal complications, antepartum transport to a center with advanced levels of neonatal or maternal care is recommended when feasible and appropriate.</td> <td colspan=\"2\">Best practice</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Prenatal and postnatal counseling regarding anticipated short-term and long-term neonatal outcome should take into consideration anticipated gestational age at delivery, as well as other variables that may alter the likelihood of survival and adverse newborn outcomes (eg, fetal sex, multiple gestation, the presence of suspected major fetal malformations, antenatal corticosteroid administration, birth weight, and response to initial newborn resuscitation).</td> <td colspan=\"2\">Best practice</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Family counseling should be provided by a multidisciplinary team that includes obstetrician-gynecologists and other obstetric providers, maternal-fetal medicine specialists, if available, and neonatologists who can address their individual and shared considerations and perspectives. Maternal and neonatal outcomes should be considered. Follow-up counseling should be provided when there is relevant new information about the maternal and fetal status or the newborn's evolving condition.</td> <td colspan=\"2\">Best practice</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">A predelivery plan, made with the parents, family, or both, should be recognized as a general plan of approach, which may be modified as the neonate's condition and response is evaluated by the neonatal providers. A recommendation regarding assessment for resuscitation is not meant to indicate that resuscitation should always either be undertaken or deferred, or that every possible intervention need be offered. A stepwise approach concordant with neonatal circumstances and condition and with parental wishes is appropriate. Care should be reevaluated regularly and potentially redirected based on the evolution of the clinical situation.</td> <td colspan=\"2\">Best practice</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\">Recommendations regarding specific interventions, tailored to gestational age and other clinical data, and taking into account individual family preferences and values, are summarized below.</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"6\">General guidance regarding obstetric interventions for threatened and imminent periviable birth by best estimate of gestational age*</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">20<sup>0/7</sup> weeks to 21<sup>6/7</sup> weeks</td> <td class=\"subtitle2\">22<sup>0/7</sup> weeks to 22<sup>6/7</sup> weeks</td> <td class=\"subtitle2\">23<sup>0/7</sup> weeks to 23<sup>6/7</sup> weeks</td> <td class=\"subtitle2\">24<sup>0/7</sup> weeks to 24<sup>6/7</sup> weeks</td> <td class=\"subtitle2\">25<sup>0/7</sup> weeks to 25<sup>6/7</sup> weeks</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neonatal assessment for resuscitation*</strong></td> <td>Not recommended 1A</td> <td>Consider 2B</td> <td>Consider 2B</td> <td>Recommended 1B</td> <td>Recommended 1B</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antenatal corticosteroids</strong></td> <td>Not recommended 1A</td> <td>Not recommended 1A</td> <td>Consider 2B</td> <td>Recommended 1B</td> <td>Recommended 1B</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tocolysis for preterm labor to allow for antenatal corticosteroid administration</strong></td> <td>Not recommended 1A</td> <td>Not recommended 1A</td> <td>Consider 2B</td> <td>Recommended 1B</td> <td>Recommended 1B</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Magnesium sulfate for neuroprotection</strong></td> <td>Not recommended 1A</td> <td>Not recommended 1A</td> <td>Consider 2B</td> <td>Recommended 1B</td> <td>Recommended 1B</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Antibiotics to prolong latency during expectant management of preterm PROM if delivery is not considered imminent</strong>t</td> <td>Consider 2C</td> <td>Consider 2C</td> <td>Consider 2B</td> <td>Recommended 1B</td> <td>Recommended 1B</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Intrapartum antibiotics for group B streptococci prophylaxis<sup>&#182;</sup></strong></td> <td>Not recommended 1A</td> <td>Not recommended 1A</td> <td>Consider 2B</td> <td>Recommended 1B</td> <td>Recommended 1B</td> </tr> <tr> <td><strong>Cesarean delivery for fetal indication<sup>&#916;</sup></strong></td> <td>Not recommended 1A</td> <td>Not recommended 1A</td> <td>Consider 2B</td> <td>Consider 1B</td> <td>Recommended 1B</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PROM: premature rupture of membranes.<br />* Survival of infants born in the periviable period is dependent on resuscitation and support. Between 22 weeks and 25 weeks of gestation, there may be factors in addition to gestational age that will affect the potential for survival and the determination of viability. Importantly, some families, concordant with their values and preferences, may choose to forgo such resuscitation and support. Many of the other decisions on this table will be linked to decisions regarding resuscitation and support and should be considered in that context.<br />Â¶ Group B streptococci carrier, or carrier status unknown.<br />Î For example, persistently abnormal fetal heart rate patterns or biophysical testing, malpresentation.</div><div class=\"graphic_reference\">Reproduced from: American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 4: Periviable Birth. Am J Obstet Gynecol 2016. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104945 Version 2.0</div></div></div>"},"104946":{"type":"graphic_algorithm","displayName":"Non-Rh(D) alloimmunization algorithm","title":"Algorithm for non-Rh(D) alloimmunized pregnancy","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Algorithm for non-Rh(D) alloimmunized pregnancy</div><div class=\"cntnt\"><img style=\"width:568px; height:734px;\" src=\"images/HEME/104946_NonRhD_alloimmunization_alg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate content on non-Rh(D) alloimmunization in pregnancy for further details.</div><div class=\"graphic_footnotes\">HDFN: hemolytic disease of the fetus and newborn; RBC: red blood cell; MCA-PSV: middle cerebral artery peak systolic velocity.<br />* In many countries including the United Sates, cell-free DNA testing for red blood cell antigens other than Rh(D) is not routinely available. In countries where cell-free testing is available, it is usually only done for for Kell, Rh(c), and Rh(E). If cell-free DNA testing is not available, serial maternal antibody titers are obtained and amniocentesis is performed to determine fetal antigen status from amniocytes if/when the critical titer is reached.</div><div id=\"graphicVersion\">Graphic 104946 Version 1.0</div></div></div>"},"104967":{"type":"graphic_table","displayName":"Causes of hypoventilation","title":"Causes of hypoventilation in pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypoventilation in pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Brain</strong></td> <td> <p>Congenital central hypoventilation syndrome (CCHS)</p> <p>Late onset central hypoventilation syndrome (LO-CHS)</p> <p>ROHHAD</p> <p>Asphyxia</p> <p>Tumor</p> <p>Chiari II malformation (Arnold-Chiari)</p> Head trauma</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Spinal cord</strong></td> <td> <p>Spinal muscular atrophy</p> Spinal cord injury</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Nerves</strong></td> <td> <p>Guillain-Barr&#233; syndrome</p> Phrenic nerve injury</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neuromuscular junction</strong></td> <td>Myasthenia gravis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Muscles</strong></td> <td> <p>Muscular dystrophy</p> Myopathy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lung</strong></td> <td> <p>Pneumonia</p> <p>Aspiration</p> <p>Lung hypoplasia</p> <p>Malformation</p> Chronic lung disease</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Airway</strong></td> <td> <p>Laryngomalacia</p> Obstructive sleep apnea</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Developmental</strong></td> <td>Prematurity</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Systemic</strong></td> <td> <p>Metabolic alkalosis</p> <p>Sepsis</p> <p>Obesity</p> <p>CNS infection</p> <p>Inborn errors of metabolism</p> CNS depressant drugs</td> </tr> <tr> <td><strong>Multisite</strong></td> <td> <p>Prader-Willi syndrome</p> <p>Achondroplasia</p> Trisomy 21</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CCHS: congenital central hypoventilation syndrome; LO-CHS: late onset central hypoventilation syndrome; ROHHAD: rapid onset obesity, hypothalamic dysfunction, hypoventilation and autonomic dysregulation (also known as rapid onset obesity with hypothalamic dysfunction, hypoventilation,&nbsp;and neural crest tumors; ROHHADNET); CNS: central nervous system.</div><div class=\"graphic_reference\">Courtesy of Dr. Robert Brouillette.</div><div id=\"graphicVersion\">Graphic 104967 Version 1.0</div></div></div>"},"104971":{"type":"graphic_waveform","displayName":"Polysomnogram in CCHS","title":"Polysomnographic findings in congenital central hypoventilation syndrome (CCHS)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Polysomnographic findings in congenital central hypoventilation syndrome (CCHS)</div><div class=\"cntnt\"><img style=\"width:700px; height:636px;\" src=\"images/SLEEP/104971_Polysomnogram_in_CCHS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This tracing from a 2.5-year-old girl shows the typical breathing pattern during NREM (stage N) sleep in congenital central hypoventilation syndrome (CCHS). Note the regular shallow breathing. The tidal volume is abnormally low, at 2.9 cc/kg (normal is approximately 5-6 cc/kg), and respiratory rate is stable at 22 breaths/minute, resulting in a minute ventilation of only 64 cc/kg/minute. The patient also displays hypercapnia (end-tidal PaCO<sub>2</sub> is 71 mmHg; normal is &lt;50) and hypoxemia (SaO<sub>2</sub> 69%; normal is &gt;95%). The failure of hypoxemia and hypercapnia to stimulate ventilation and/or arousal during sleep is diagnostic of a central control of breathing disorder and characteristic of CCHS. Decreased heart rate variability, characteristic of CCHS, is also present.</div><div class=\"graphic_footnotes\">Flow: airflow measured with a pneumotachograph; INSP: inspiration upward on the Flow and Tidal volume channels; PACO<sub>2</sub>: partial pressure of carbon dioxide; mmHg: millimeters of mercury; ECG: electrocardiogram; BPM: beats per minute; SaO<sub>2</sub>: oxygen saturation (by pulse oximetry); NREM: non-rapid eye movement.</div><div class=\"graphic_reference\">Reproduced from: Hunt CE, Brouillette RT. Disorders of breathing during sleep. In: Chernick V, Boat TF, Eds. Kendig's Disorders of the Respiratory Tract in Children, 6th Ed. W.B. Saunders Inc, 1998. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 104971 Version 1.0</div></div></div>"},"104974":{"type":"graphic_table","displayName":"PHOX2B mutations and comorbid disorders","title":"Severity and complications of CCHS, by PHOX2B genotype","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity and complications of CCHS, by PHOX2B genotype</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Phenotype</td> <td class=\"subtitle1\" colspan=\"2\"> <p>Proportion of CCHS patients affected</p> n (%)</td> </tr> <tr> <td class=\"subtitle2\">PARM</td> <td class=\"subtitle2\">NPARM</td> </tr> <tr> <td>Continuous ventilatory support</td> <td class=\"centered\">111/314 (35%)</td> <td class=\"centered\">38/57 (67%)</td> </tr> <tr> <td>Hirschsprung disease</td> <td class=\"centered\">95/493 (19%)</td> <td class=\"centered\">53/66 (80%)</td> </tr> <tr> <td>Neural crest tumor*</td> <td class=\"centered\">4/344 (1%)</td> <td class=\"centered\">11/27 (41%)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Phenotype of&nbsp;congenital central hypoventilation syndrome (CCHS) with paired-like homeobox 2B gene (<EM>PHOX2B)</EM> polyalanine repeat expansion mutations (PARMs)<EM>,&nbsp;</EM>compared with&nbsp;those with <EM>PHOX2B</EM>&nbsp;nonpolyalanine repeat expansion mutations (NPARMs). These data represent all known cases of CCHS reported in the world literature as of 2010. </div><div class=\"graphic_footnotes\">* Information on neural crest tumors was derived from cases in which the child had survived at least the first year of life. All PARM cases with tumors had large (29 to 33 repeat) PARMs.</div><div class=\"graphic_reference\">Data from: Weese-Mayer DE, Berry-Kravis EM, Ceccherini I, et al. An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. Am J Respir Crit Care Med 2010; 181:626.</div><div id=\"graphicVersion\">Graphic 104974 Version 2.0</div></div></div>"},"104976":{"type":"graphic_algorithm","displayName":"Dx Wilson disease","title":"Approach to the diagnosis of Wilson disease","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of Wilson disease</div><div class=\"cntnt\"><img style=\"width:800px; height:390px;\" src=\"images/GAST/104976_Dx_Wilson_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The serum copper concentration should also be determined. It is decreased in proportion to the reduction in serum ceruloplasmin and can be used to monitor therapy.<br />Â¶ If the serum ceruloplasmin is â¥20 mg/dL (200 mg/L) and Kayser-Fleischer rings are present, a liver biopsy or molecular genetic testing is required regardless of the 24-hour urine copper. <br />Î Ensure adequate urine collection.<br /><FONT class=lozenge>â</FONT> For patients with neurologic disease but no evidence of liver disease, molecular genetic testing should be done first; for patients with liver disease, either molecular genetic testing or liver biopsy may be done first.&nbsp;If molecular genetic testing is positive, the diagnosis is confirmed. If negative, liver biopsy should be performed. On liver biopsy,&nbsp;a diagnosis of Wilson disease is established if the hepatic copper concentration is â¥250 mcg/g dry weight; a diagnosis is excluded if the hepatic copper concentration is &lt;50 mcg/g dry weight; if the hepatic copper concentration is â¥50 and &lt;250 mcg/g dry weight, molecular genetic testing for mutations in ATP7B should be performed (if not already done)&nbsp;to establish or exclude the diagnosis.<br />Â§ Most patients with Wilson disease are compound heterozygotes. The identification of one mutation supports the diagnosis, and the identification of two mutations confirms the diagnosis. Refer to UpToDate topics on the diagnosis of Wilson disease for additional discussion of genetic testing.</div><div id=\"graphicVersion\">Graphic 104976 Version 2.0</div></div></div>"},"104979":{"type":"graphic_table","displayName":"Clinical features of CCHS","title":"Clinical features of congenital central hypoventilation syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of congenital central hypoventilation syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Respiratory</td> </tr> <tr> <td class=\"indent1\">Alveolar hypoventilation, with increased PCO<sub>2 </sub>and<sub>&nbsp;</sub>hypoxemia. Low tidal volume and/or respiratory rate</td> </tr> <tr> <td class=\"indent1\">Lack of normal ventilatory and arousal responses to hypercarbia and hypoxemia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Limited breath-to-breath variability</td> </tr> <tr> <td class=\"subtitle2_left\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Decreased beat-to-beat variability of heart rate</td> </tr> <tr> <td class=\"indent1\">Attenuated&nbsp;hear&nbsp;rate&nbsp;response to exercise</td> </tr> <tr> <td class=\"indent1\">Orthostatic hypotension</td> </tr> <tr> <td class=\"indent1\">Attenuation of normal sleep-related blood pressure decrement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Prolonged sinus pauses</td> </tr> <tr> <td class=\"subtitle2_left\">Facial features</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Box-shaped face (shorter and flatter), with inferior reflection of the lateral segment of the vermillion border on the upper lip</td> </tr> <tr> <td class=\"subtitle2_left\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Hirschsprung disease (16 to 20 percent)</td> </tr> <tr> <td class=\"indent1\">Severe constipation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Esophageal dysmotility; dysphagia</td> </tr> <tr> <td class=\"subtitle2_left\">Neural crest tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">eg, neuroblastoma, ganglioneuroblastoma, or ganglioneuroma</td> </tr> <tr> <td class=\"subtitle2_left\">Ophthalmologic</td> </tr> <tr> <td class=\"indent1\">Pupillary abnormalities (meiosis; altered pupillary response to light)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Altered accommodation (with accommodative strabismus)</td> </tr> <tr> <td class=\"subtitle2_left\">Neuropsychological</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Decreased perception of anxiety</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cognitive delays&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Sudomotor</td> </tr> <tr> <td class=\"indent1\">Sporadic profuse sweating</td> </tr> <tr> <td class=\"indent1\">Decreased basal body temperature</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCO<SUB innerHtml>2</SUB>: partial pressure of carbon dioxide.</div><div class=\"graphic_reference\">Modified from: Weese-Mayer DE, Marazita ML, Rand CM, et al. Congenital Central Hypoventilation Syndrome. 2004 Jan 28 [Updated 2014 Jan 30]. In: Pagon RA, Adam MP, Ardinger HH, et al (Eds). GeneReviews&reg; [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1427/\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK1427/</a> (Accessed on November 4, 2015).</div><div id=\"graphicVersion\">Graphic 104979 Version 2.0</div></div></div>"},"104981":{"type":"graphic_diagnosticimage","displayName":"Lateral pulsed-tissue Doppler mitral annular velocities","title":"Lateral pulsed-tissue Doppler mitral annular velocities","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Lateral pulsed-tissue Doppler mitral annular velocities</div><div class=\"cntnt\"><img style=\"width:688px; height:467px;\" src=\"images/CARD/104981_Lat_pls_tss_Dp_mtrl_ann_vlc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of lateral pulsed-tissue Doppler mitral annular velocities used to differentiate constriction from restriction. Patient A has constrictive pericarditis and elevated early diastolic velocities, and Patient B has restrictive cardiomyopathy from amyloidosis and depressed early diastolic velocities.</div><div class=\"graphic_footnotes\">e': early diastolic mitral annular velocity; a': atrial mitral annular velocity.</div><div id=\"graphicVersion\">Graphic 104981 Version 1.0</div></div></div>"},"104990":{"type":"graphic_table","displayName":"Causes of small bowel bleeding","title":"Causes of small bowel bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of small bowel bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Common causes</td> <td class=\"subtitle1\">Rare causes</td> </tr> <tr> <td class=\"subtitle2\">Under age 40 years</td> <td class=\"subtitle2\">Over age 40 years</td> <td class=\"subtitle2\">Henoch-Schoenlein purpura</td> </tr> <tr> <td>Inflammatory bowel disease</td> <td>Angioectasia</td> <td>Small bowel varices and/or portal hypertensive enteropathy</td> </tr> <tr> <td>Dieulafoy lesions</td> <td>Dieulafoy lesions</td> <td>Amyloidosis</td> </tr> <tr> <td>Neoplasia</td> <td>Neoplasia</td> <td>Blue rubber bleb nevus syndrome</td> </tr> <tr> <td>Meckel diverticulum</td> <td>NSAID ulcers</td> <td>Pseudoxanthoma elasticum</td> </tr> <tr> <td>Polyposis syndromes</td> <td>&nbsp;</td> <td>Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Kaposi sarcoma with AIDS</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Plummer-Vinson syndrome</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Ehlers-Danlos syndrome</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Inherited polyposis syndromes (FAP, Peutz-Jeghers)</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Malignant atrophic papulosis</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Hematobilia</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Aortoenteric fistula</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>Hemosuccus entericus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FAP: familial adenomatous polyposis; NSAID: nonsteroidal anti-inflammatory drug.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Gerson LB, Fidler JL, Cave DR, Leighton JA. ACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding. Am J Gastroenterol 2015; 110:1265. Copyright &copy; 2015. <a href=\"http://www.nature.com/ajg\" spellcheck=\"true\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 104990 Version 1.0</div></div></div>"},"104992":{"type":"graphic_picture","displayName":"Eruptive xanthomas close view","title":"Eruptive xanthomas","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Eruptive xanthomas</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/104992_Erptv_xnthms_cls_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-red papules.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104992 Version 1.0</div></div></div>"},"104993":{"type":"graphic_picture","displayName":"Eruptive xanthomas on legs","title":"Eruptive xanthomas","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Eruptive xanthomas</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104993_Erptv_xnthm_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-red papules on the legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104993 Version 1.0</div></div></div>"},"104994":{"type":"graphic_picture","displayName":"Eruptive xanthomas on extremity","title":"Eruptive xanthomas","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Eruptive xanthomas</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104994_Erptv_xnthms_extrmty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-red papules.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104994 Version 1.0</div></div></div>"},"104995":{"type":"graphic_picture","displayName":"Tuberous xanthomas on knee","title":"Tuberous xanthomas","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tuberous xanthomas</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104995_Tbrs_xnthms_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nodules on the knee.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104995 Version 1.0</div></div></div>"},"104996":{"type":"graphic_picture","displayName":"Tuberous xanthomas on elbow","title":"Tuberous xanthomas","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tuberous xanthomas</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104996_Tbrs_xnthms_elbw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-orange and erythematous papules and nodules near the elbow.</div><div class=\"graphic_reference\">Reproduced with permission from <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104996 Version 1.0</div></div></div>"},"104997":{"type":"graphic_picture","displayName":"Tendinous xanthomas","title":"Tendinous xanthomas","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tendinous xanthomas</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/104997_Tndns_xnthm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple skin-colored nodules on the dorsal hands.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104997 Version 1.0</div></div></div>"},"104998":{"type":"graphic_picture","displayName":"Plane xanthoma axilla","title":"Plane xanthoma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Plane xanthoma</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/104998_Pln_xnthm_axll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin, yellow plaque surrounding the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104998 Version 1.0</div></div></div>"},"104999":{"type":"graphic_picture","displayName":"Xanthoma striatum palmaris","title":"Xanthoma striatum palmaris (palmar xanthomas)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Xanthoma striatum palmaris (palmar xanthomas)</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/104999_Xnthm_strtm_plmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-red papules in the creases of the palms.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 104999 Version 1.0</div></div></div>"}};